




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 217/22, 401/12, 403/12, A61K 31/435	A2	(11) International Publication Number: WO 00/05214 (43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/IB99/01289 (22) International Filing Date: 15 July 1999 (15.07.99) (30) Priority Data: 9816228.2 24 July 1998 (24.07.98) GB 9908829.6 16 April 1999 (16.04.99) GB (71) Applicant (for all designated States except GB US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BARBER, Christopher, Gordon [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DICKINSON, Roger, Peter [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). FISH, Paul, Vincent [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (74) Agents: WOOD, David, J. et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ISOQUINOLINES AS UROKINASE INHIBITORS <div style="text-align: center;">  </div> <div style="text-align: right; margin-top: 10px;"> (1) </div>		
(57) Abstract Isoquinolinylguanidine compounds of formula (I): wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ISOQUINOLINES AS UROKINASE INHIBITORS

This invention relates to certain isoquinolines useful as urokinase inhibitors, and in particular to isoquinolinylguanidines useful as urokinase inhibitors.

5

Urokinase (urinary-type plasminogen activator or uPA; International Union of Biochemistry classification number EC.3.4.21.31) is a serine protease produced by a large variety of cell types (smooth muscle cells, fibroblasts, endothelial cells, macrophages and tumour cells). It has been implicated as playing a key role in cellular invasion and tissue remodelling. A principal substrate for uPA is plasminogen which is converted by cell surface-bound uPA to yield the serine protease plasmin. Locally produced high plasmin concentrations mediate cell invasion by breaking down the extracellular matrix. Important processes involving cellular invasion and tissue remodelling include wound repair, bone remodelling, angiogenesis, tumour invasiveness and spread of metastases.

10

Beneficial effects of urokinase inhibitors have been reported using anti-urokinase monoclonal antibodies and certain other known urokinase inhibitors. For instance, anti-urokinase monoclonal antibodies have been reported to block tumour cell invasiveness *in vitro* (W.Hollas, et al, *Cancer Res.* 51:3690; A.Meissauer, et al, *Exp.Cell Res.* 192:453 (1991); tumour metastases and invasion *in vivo* (L.Ossowski, *J.Cell Biol.* 107:2437 (1988)); L.Ossowski, et al, *Cancer Res.* 51:274 (1991)) and angiogenesis *in vivo* (J.A.Jerdan et al, *J.Cell Biol.* 115[3 Pt 2]:402a (1991). Also, Amiloride™, a known urokinase inhibitor of only moderate potency, has been reported to inhibit tumour metastasis *in vivo* (J.A.Kellen et al, *Anticancer Res.*, 8:1373 (1988)) and angiogenesis / capillary network formation *in vitro* (M.A.Alliegro et al, *J.Cell Biol.* 115[3 Pt 2]:402a).

20

Conditions of particular interest for treatment by urokinase inhibitors include chronic dermal ulcers (including venous ulcers, diabetic ulcers and pressure sores), which are a major cause of morbidity in the ageing population and cause a significant economic burden on healthcare systems. Chronic dermal ulcers are characterised by excessive uncontrolled proteolytic degradation resulting in ulcer extension, loss of functional matrix molecules (e.g. fibronectin) and retardation of epithelisation and ulcer healing. A number of groups have investigated the enzymes responsible for the excessive degradation in the wound environment, and the role of plasminogen activators has been highlighted (M.C. Stacey et al., *Br. J. Surgery*, 80, 596; M. Palolahti et al., *Exp. Dermatol.*, 2, 29, 1993; A.A. Rogers et al., *Wound Repair and Regen.*, 3, 273, 1995). Urokinase activity has also been implicated

30

as a factor in psoriasis : Jensen & Lavker (1996) Cell Growth Diff. 7, 1793-1804 Baker BS and Fry L (1992). Br J Dermatol, 126(1), 1-9.2; Spiers EM, et al (1994). J Invest Dermatol, 102(3), 333-338.3. Grondahl-Hansen J, et al (1987). J Invest Dermatol, 88(1), 28-32. Gissler H, et al (1993). Br J Dermatol, 128(6), 612-8; Venning VA, et al (1993). Clin Exp Dermatol, 18(2), 119-23.

5

Normal human skin demonstrates low levels of plasminogen activators which are localised to blood vessels and identified as tissue type plasminogen activator (tPA). In marked contrast, chronic ulcers demonstrate high levels of urokinase type plasminogen activator (uPA) localised diffusely throughout the ulcer periphery and the lesion, and readily detectable in wound fluids.

10

uPA could affect wound healing in several ways. Plasmin, produced by activation of plasminogen, can produce breakdown of extracellular matrix by both indirect (via activation of matrix metalloproteases) and direct means. Plasmin has been shown to degrade several extracellular matrix components, including gelatin, fibronectin, proteoglycan core proteins as well as its major substrate, fibrin. Whilst activation of matrix metalloproteases (MMPs) can be performed by a number of inflammatory cell proteases (e.g. elastase and cathepsin G), the uPA/plasmin cascade has been implicated in the activation of MMPs *in situ*, providing a broad capacity for degrading all components of the extracellular matrix. Furthermore, in addition to its effect on production of plasmin, uPA has been shown to catalyse direct cleavage of fibronectin yielding antiproliferative peptides. Thus, over-expression of uPA in the wound environment has the potential to promote uncontrolled matrix degradation and inhibition of tissue repair. Inhibitors of the enzyme thus have the potential to promote healing of chronic wounds.

20

Several related enzymes such as tPA, which also acts via production of plasmin, play a key role in the fibrinolytic cascade. Because of this it is important that an inhibitor has adequate potency and selectivity for uPA relative to both tPA and plasmin to avoid the possibility of anti-fibrinolytic side effects.

25


The utility of such potent and selective urokinase inhibitors is highlighted by the broad range of invasive biological processes and conditions mediated by urokinase. These processes and conditions include, but are not limited to, wound healing, angiogenesis-dependent conditions such as retinopathy, bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, psoriasis, tissue remodelling during wound repair

30

and organ differentiation, fibrosis, local invasion of tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and tissue destruction in arthritis.

Various aromatic amidines have been reported to inhibit uPA (J.D. Geratz, M.C.-F. Cheng, *Thromb. Diathes. haemorrh. (Stuttg.)*, **33**, 230, 1975; J. Stürzebecher, F. Markwardt, *Pharmazie*, **33**, 599, 1978; J.D. Geratz et al., *Thromb. Res.*, **24**, 73, 1981). The compounds reported in these publications are generally relatively weak and/or non-selective for uPA relative to other related serine proteases. EP 0 568 289 A2 discloses a series of benzo[*b*]thiophene-2-carboxamidines with significantly greater potency and selectivity with respect to tPA and plasmin (see also M.J. Towle et al., *Cancer Res.*, **53**, 2553, 1993; A.J. Bridges et al., *Bioorg. Med. Chem.*, **1**, 403, 1993).

There are few reports of guanidine derivatives as uPA inhibitors. AmilorideTM (see below) is a weak but selective inhibitor of uPA (J.-D. Vassalli, D. Belin, *FEBS Letters*, **214**, 187, 1987), and various substituted phenylguanidines are reported to have a similar level of potency (H. Yang et al., *J. Med. Chem.*, **33**, 2956, 1990).




The compounds described herein are potent reversibly-competitive inhibitors of urokinase enzymatic activity, with selectivity for urokinase relative to certain other important proteases, including the fibrinolytic enzymes tissue-type plasminogen activator (tPA) and plasmin.

The selectivity of the instantly-claimed compounds for inhibition of urokinase over inhibition of other proteases such as tPA and plasmin, and the fact that they inhibit reversibly, prevents them from having thrombogenic properties.

Thus, according to the present invention, there are provided isoquinolinyguanidine compounds of formula (I) :-

4



(I)

and the pharmaceutically acceptable salts thereof, wherein:

G is $\text{N}=\text{C}(\text{NH})_2$ or $\text{NHC}(=\text{NH})\text{NH}_2$;

5

R^1 is H or halo;

X is CO, CH_2 or SO_2 ;

10 R^2 is H, aryl, heteroaryl, C_{3-7} cycloalkyl or C_{1-6} alkyl each of which C_{3-7} cycloalkyl and C_{1-6} alkyl is optionally substituted by one or more substituents independently selected from halo, aryl, het, C_{3-7} cycloalkyl, C_{5-7} cycloalkenyl, OH, C_{1-6} alkoxy, O-het¹, C_{1-3} alkyl, CO_2R^7 and NR^4R^5 ;

15 X^1 is arylene, C_{1-6} alkylene optionally substituted by one or more R^6 group, or cyclo(C_{4-7})alkylene optionally substituted by R^6 , which cyclo(C_{4-7})alkylene ring can optionally contain a hetero moiety selected from O, $\text{S}(\text{O})_p$ or NR^7 ;

or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring;


20

R^3 is CO_2R^7 , CH_2OH , CONR^8R^9 or $\text{CH}_2\text{NR}^8\text{R}^9$;


or, when X^1 is taken independently from R^2 and is methylene optionally substituted by one or more R^6 group, or is a 1,1-cyclo(C_{4-7})alkylene optionally containing a hetero moiety selected from O, $\text{S}(\text{O})_p$,

25 or NR^7 and optionally substituted by R^6 ,

then R^2 and R^3 can be taken together with the N and X^1 groups to which they are attached, as a group of formula (IA) or (IB):



(IA)



(IB)

wherein X^2 is ethylene, n-propylene or n-butylene;

R^4 and R^5 are each independently H, aryl or C_{1-6} alkyl optionally substituted by aryl;

R^6 is halo, OH, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{3-7} cycloalkyl, SH, aryl, CO_2R^7 , $CONHR^8$, or C_{1-6} alkyl optionally substituted by aryl, C_{1-6} alkoxy, CO_2H , OH, $CONR^8R^9$ or by NR^8R^9 ;

R^7 is H or C_{1-6} alkyl;

R^8 and R^9 are either each independently H, or C_{1-6} alkyl optionally substituted by OH, CO_2R^7 , C_{1-6} alkoxy or by NR^4R^5 ;

or R^8 and R^9 can be taken together with the N atom to which they are attached, to form a 4- to 7-membered ring optionally incorporating an additional hetero- group selected from O, S and NR^7 ;

p is 0, 1 or 2;

“aryl” is phenyl optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, or halo;

“het” is a saturated or partly or fully unsaturated 5- to 7-membered heterocycle containing up to 3 hetero-atoms independently selected from O, N and S, and which is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, CO_2R^7 or halo;

“heteroaryl” is a fully unsaturated 5- to 7-membered heterocycle containing up to 3 hetero-atoms independently selected from O, N and S, and which is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, CO_2R^7 or halo;

"het¹" is tetrahydropyran-2-yl (2-THP);

and "arylene" is phenylene optionally substituted by one or more substituents independently selected
5 from C₁₋₆ alkyl, C₁₋₆ alkoxy, CO₂R⁷ or halo.

"Alkyl" groups can be straight or branched chain. "Halo" in the definitions above refers to F, Cl or Br.

10 "Cycloalkylene" groups in the definition of the X¹ linker moiety which optionally contains a hetero moiety selected from O, S(O)_p or NR⁷ and is optionally substituted by R⁶, can be linked via any available atoms. "1,1-Cycloalkylene" groups in the definition of the X¹ linker moiety which optionally contains a hetero moiety selected from O, S(O)_p or NR⁷ and is optionally substituted by R⁶, means the linkage is via a common quaternary centre at one position in the ring, viz. for example:
15 1,1-cyclobutylene and 4,4-tetrahydropyranylene are to be regarded as both belonging to the same genus of "1,1-cycloalkylene" groups optionally containing a hetero moiety selected from O, S(O)_p or NR⁷ and optionally substituted by R⁶.

The two definitions given for the "G" moiety in compounds of formula (I) are of course tautomeric.

20 The skilled man will realise that in certain circumstances one tautomer will prevail, and in other circumstances a mixture of tautomers will be present. It is to be understood that the invention encompasses all tautomeric forms of the substances and mixtures thereof.

Pharmaceutically-acceptable salts are well known to those skilled in the art, and for example include
25 those mentioned by Berge et al, in *J.Pharm.Sci.*, 66, 1-19 (1977). Suitable acid addition salts are formed from acids which form non-toxic salts and include the hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate, bisulphate, phosphate, hydrogenphosphate, acetate, trifluoroacetate, gluconate, lactate, salicylate, citrate, tartrate, ascorbate, succinate, maleate, fumarate, gluconate, formate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate and p-
30 toluenesulphonate salts.

When one or more of the substituents on the compound of formula (I) contains an acidic moiety, suitable pharmaceutically acceptable base addition salts can be formed from bases which form non-

toxic salts and include the aluminium, calcium, lithium, magnesium, potassium, sodium, zinc, and pharmaceutically-active amines such as diethanolamine, salts.

Certain of the compounds of formula (I) which have an acidic moiety can exist as one or more
5 zwitterions. It is to be understood that all such zwitterions are included within the scope of the invention.

Certain of the compounds of the formula (I) may exist as geometric isomers. The compounds of the formula (I) may possess one or more asymmetric centres and so exist in two or more stereoisomeric
10 forms. The present invention includes all the individual stereoisomers and geometric isomers of the compounds of formula (I) and mixtures thereof.

Another aspect of the invention is a pharmaceutical composition comprising a compound or salt according to the above definitions and a pharmaceutically-acceptable adjuvant, diluent or carrier.
15

Yet another aspect of the invention is a compound or salt according to the above definitions for use as a medicament.

A further aspect of the invention is the use of a compound or salt according to the above definitions
20 for the manufacture of a medicament for the treatment of a condition or process mediated by uPA, such as angiogenesis (neo-vascularization), bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, psoriasis, tissue remodelling during wound repair and organ differentiation, fibrosis, local invasion of tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and tissue
25 destruction in arthritis.

Yet another aspect of the invention is a method of treatment of a condition mediated by uPA, such as angiogenesis (neo-vascularization), bone restructuring, embryo implantation in the uterus, infiltration of immune cells into inflammatory sites, ovulation, spermatogenesis, psoriasis, tissue remodelling
30 during wound repair and organ differentiation, fibrosis, local invasion of tumours into adjacent areas, metastatic spread of tumour cells from primary to secondary sites, and tissue destruction in arthritis, comprising administering a therapeutic amount of a compound or salt or composition according to the above definitions.

It is to be appreciated that reference to treatment includes prophylaxis as well as the alleviation of established symptoms of uPA-mediated conditions and processes.

5 Preferably G is $N=C(NH)_2$.

Preferably R^1 is halo.

More preferably R^1 is chloro or bromo.

Most preferably R^1 is chloro.

10

Preferably X is SO_2 .

Preferably R^2 is H, C_{3-7} cycloalkyl or C_{1-6} alkyl each of which C_{3-7} cycloalkyl and C_{1-6} alkyl is optionally substituted by aryl, het, C_{3-7} cycloalkyl, OH, $OHet^1$, C_{1-6} alkoxy, CO_2H , $CO_2(C_{1-6}$ alkyl) or
15 by NR^4R^5 , or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.

More preferably R^2 is H, C_{1-3} alkyl optionally substituted by aryl or by optionally substituted pyridyl or by NR^4R^5 or by HO or by $OHet^1$, or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.

20 Further more preferably R^2 is H, $CH_2CH_2N(CH_3)_2$, CH_3 , CH_2CH_2OH , $CH_2CH_2O(2-THP)$, pyridinylmethyl, benzyl or methoxybenzyl, or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R^3 moiety via the 2-position of said ring.

Most preferably R^2 is H, $CH_2CH_2N(CH_3)_2$, CH_3 , CH_2CH_2OH , $CH_2CH_2O(2-THP)$ or R^2 and X^1 are
25 taken together with the N atom to which they are attached to form a pyrrolidine ring linked to the R^3 moiety via the 2-position.

Preferably X^1 is phenylene optionally substituted by one or two substituents independently selected from methoxy and halo,

30 or is C_{1-3} alkylene optionally substituted by one or more group selected from aryl or (C_{1-6} alkyl optionally substituted by aryl, C_{1-6} alkoxy, CO_2H , OH, NH_2 or $CONH_2$), or is cyclo(C_{4-7})alkylene optionally contain a hetero moiety selected from O or NR^7 , which ring is optionally substituted by R^6 ,

or is taken together with R^2 and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.

More preferably, X^1 is methylene optionally substituted by one or more group selected from aryl or (C_{1-4} alkyl optionally substituted by OH, NH_2 or $CONH_2$),

- 5 or is cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, tetrahydropyranylene, piperidinylene substituted by R^7 ,

or is taken together with R^2 and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.


- Yet more preferably X^1 is $C(CH_3)_2$, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, CH_2 , $CH(CH(CH_3)_2)$, $CH(CH_2)_4NH_2$, $CH(CH_2)_3NH_2$, $CH(CH_2)CONH_2$, 1,1-cyclobutylene, 1,1-cyclopentylene, 1,1-cyclohexylene, 1,1-cycloheptylene, *N*-methyl-4,4-piperidinylene, 4,4-tetrahydropyranylene, or is taken together with R^2 and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R^3 moiety via the 2-position.

- 15 Most preferably X^1 is $C(CH_3)_2$, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, or is taken together with R^2 and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine ring linked to the R^3 moiety via the 2-position.


Preferably R^3 is CO_2R^7 or $CONR^8R^9$.

- 20 More preferably R^3 is CO_2H , $CONH_2$, $CON(CH_3)(CH_2)_2OH$, $CON(CH_3)(CH_2)_2NHCH_3$, $CO_2(C_{1-3}alkyl)$, $CONH(CH_2)_2OH$, $CONH(CH_2)_2OCH_3$, (morpholino)CO or (4-methylpiperazino)CO.
Most preferably R^3 is CO_2H .

- A preferred group of substances (a) are the compounds where X is SO_2 in which the $R^3-X^1-NR^2$ - moiety is, where X^1 is taken independently from R^2 and is methylene optionally substituted by one or more R^6 group, or is a 1,1-cyclo(C_{4-7})alkylene optionally containing a hetero moiety selected from O, $S(O)_p$, or NR^7 and optionally substituted by R^6 ,
25 and R^2 and R^3 can be taken together with the N and X^1 groups to which they are attached, as a group of formula (IA) or (IB):



(IA)



(IB)

wherein X^2 is ethylene, n-propylene or n-butylene.

In this group of substances (a) X^1 is preferably $C(CH_3)_2$, 1,1-cyclobutylene, 1,1-cyclopentylene, 1,1-cyclohexylene, 4,4-tetrahydropyranylene or *N*-methyl-4,4-piperidinylene, most preferably 1,1-cyclopentylene.

- 5 In this group of substances (a) X^2 is preferably ethylene.

A preferred group of substances are the compounds in which the substituent R^1 has the values as described by the Examples below, and the salts thereof.

- 10 A preferred group of substances are the compounds in which the substituent X has the values as described by the Examples below, and the salts thereof.

A preferred group of substances are the compounds in which the substituent R^2 has the values as described by the Examples below, and the salts thereof.

15

A preferred group of substances are the compounds in which the substituent X^1 has the values as described by the Examples below, and the salts thereof.

- 20 A preferred group of substances are the compounds in which the substituent R^3 has the values as described by the Examples below, and the salts thereof.

Another preferred group of substances are the compounds in which each of the substituents R^1 , X , R^2 , X^1 and R^3 have the values as described by the Examples below, and the salts thereof.

- 25 A preferred group of substances are the compounds where R^1 is chloro or bromo; X is SO_2 ; R^2 is H, $CH_2CH_2N(CH_3)_2$, CH_3 , CH_2CH_2OH , $CH_2CH_2O(2-THP)$, pyridinylmethyl, benzyl or methoxybenzyl, or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R^3 moiety via the 2-position of said ring;
- 30 X^1 is $C(CH_3)_2$, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, CH_2 , $CH(CH(CH_3)_2)$, $CH(CH_2)_4NH_2$, $CH(CH_2)_3NH_2$, $CH(CH_2)CONH_2$, 1,1-cyclobutylene, 1,1-cyclopentylene, 1,1-cyclohexylene, 1,1-cycloheptylene, *N*-methyl-4,4-piperidinylene, 4,4-tetrahydropyranylene, or is taken together with R^2 and with the N atom to which they are attached to

form an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R³ moiety via the 2-position.;

R³ is CO₂H, CONH₂, CON(CH₃)(CH₂)₂OH, CON(CH₃)(CH₂)₂NHCH₃, CO₂(C₁₋₃alkyl), CONH(CH₂)₂OH, CONH(CH₂)₂OCH₃, (morpholino)CO or (4-methylpiperazino)CO;

5 and the salts thereof.

Another preferred group of substances are those in which R¹ is chloro; X is SO₂;

R² is H, CH₂CH₂N(CH₃)₂, CH₃, CH₂CH₂OH, CH₂CH₂O(2-THP) or R² and X¹ are taken together with the N atom to which they are attached to form a pyrrolidine ring linked to the R³ moiety via the 2-

10 position;

X¹ is C(CH₃)₂, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, or is taken together with R² and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine ring linked to the R³ moiety via the 2-position;

and R³ is CO₂H;

15 and the salts thereof.

Another preferred group of substances are the compounds of the Examples below and the salts thereof. More preferred within this group are the compounds of Examples 32(b), 34(b), 36(b), 37(b), 38, 39(a and b), 41(b), 43(b), 44(b), 71, 75, 76, 78, 79, 84(b), and 87(b and c) and the salts thereof.

20

The invention further provides Methods for the production of substances of the invention, which are described below and in the Examples. The skilled man will appreciate that the substances of the invention could be made by methods other than those herein described, by adaptation of the methods herein described in the sections below and/or adaptation thereof, and of methods known in the art.

25


In the Methods below, unless otherwise specified, the substituents are as defined above with reference to the compounds of formula (I) above.

Method 1

30

Compounds of formula (I) can be obtained from the corresponding 1-aminoisoquinoline derivative (II):

12



- by reaction with cyanamide (NH_2CN) or a reagent which acts as a " $\text{NHC}^+=\text{NH}$ " synthon such as carboxamidine derivatives, e.g. 1H-pyrazole-1-carboxamidine (M. S. Bernatowicz, Y. Wu, G. R. Matsueda, *J. Org. Chem.*, 1992, 57, 2497), the 3,5-dimethylpyrazole analogue thereof (M.A.Brimble et al, *J.Chem.Soc.Perkin Trans.I* (1990)311), simple O-alkylthiouronium salts or S-alkylisothiouronium salts such as O-methylisothiurea (F.El-Fehail et al, *J.Med.Chem.*(1986), 29, 984), S-methylisothiouronium sulphate (S.Botros et al, *J.Med.Chem.*(1986)29,874; P. S. Chauhan et al, *Ind. J. Chem.*, 1993, 32B, 858) or S-ethylisothiouronium bromide (M.L.Pedersen et al, *J.Org.Chem.*(1993) 58, 6966). Alternatively aminoiminomethanesulphinic acid, or aminoiminomethanesulphonic acid may be used (A.E.Miller et al, *Synthesis* (1986) 777; K.Kim et al, *Tet.Lett.*(1988) 29,3183).

- Other methods for this transformation are known to those skilled in the art (see for example, "Comprehensive Organic Functional Group Transformations", 1995, Pergamon Press, Vol 6 p639, T. L. Gilchrist (Ed.); Patai's "Chemistry of Functional Groups", Vol. 2. "The Chemistry of Amidines and Imidates", 1991, 488).

- Aminoisoquinolines (II) may be prepared by standard published methods (see for example, "The Chemistry of Heterocyclic Compounds" Vol. 38 Pt. 2 John Wiley & Sons, Ed. F. G. Kathawala, G. M. Coppolq, H. F. Schuster) including, for example, by rearrangement from the corresponding carboxy-derivative (Hoffmann, Curtius, Lossen, Schmidt-type rearrangements) and subsequent deprotection.

- Aminoisoquinolines (II) may alternatively be prepared by direct displacement of a leaving group such as Cl or Br with a nitrogen nucleophile such as azide (followed by reduction), or by ammonia, or through Pd-catalysis with a suitable protected amine (such as benzylamine) followed by deprotection using standard conditions well-known in the art.


Haloisoquinolines are commercially available or can alternatively be prepared by various methods, for example those described in : Goldschmidt, Chem.Ber.(1895)28,1532; Brown and Plasz, J.Het.Chem.(1971)6,303; US Patent 3,930,837; Hall et al, Can.J.Chem.(1966)44,2473; White, J.Org.Chem.(1967)32,2689; and Ban, Chem.Pharm.Bull.(1964)12,1296.

1,4-(Dichloro- or dibromo)isoquinolines can be prepared by the method described by M.Robison et al in J.Org.Chem.(1958)23,1071, by reaction of the corresponding isocarbostyryl compound with PCl_5 or PBr_5 .

10

Method 2

Compounds of formula (I) can be obtained from the corresponding aminoisoquinoline derivative (II) as defined in Method 1 above, via reaction with a reagent which acts as a protected amidine(2+) synthon (III),



such as a compound $\text{PNHC}(=\text{X})\text{NHP}_1$, $\text{PN}=\text{CXNHP}_1$ or $\text{PNHCX}=\text{NP}_1$, where X is a leaving group such as Cl, Br, I, mesylate, tosylate, alkyloxy, etc., and where P and P_1 may be the same or different and are N-protecting groups such as are well-known in the art, such as t-butoxycarbonyl, benzyloxycarbonyl, arylsulphonyl such as toluenesulphonyl, nitro, etc.


Examples of reagents that act as synthons (III) include N, N'-protected-S-alkylthiuronium derivatives such as N, N'-bis(t-butoxycarbonyl)-S-Me-isothiurea, N, N'-bis(benzyloxycarbonyl)-S-methylisothiurea, or sulphonic acid derivatives of these (J. Org. Chem. 1986, 51, 1882), or S-arylthiuronium derivatives such as N, N'-bis(t-butoxycarbonyl)-S-(2,4-dinitrobenzene) (S. G. Lammin, B. L. Pedgrift, A. J. Ratcliffe, Tet. Lett. 1996, 37, 6815), or mono-protected analogues such as [(4-methoxy-2,3,6-trimethylphenyl)sulphonyl]-carbamimidothioic acid methyl ester or the corresponding 2,2,5,7,8-pentamethylchroman-6-sulphonyl analogue (D. R. Kent, W. L. Cody, A. M. Doherty, Tet. Lett., 1996, 37, 8711), or S-methyl-N-nitroisothiurea (L.Fishbein et al,

- J. Am. Chem. Soc. (1954) 76, 1877) or various substituted thioureas such as N, N'-bis(t-butoxycarbonyl)thiourea (C. Levallet, J. Lerpiniere, S. Y. Ko, Tet. 1997, 53, 5291) with or without the presence of a promoter such as a Mukaiyama's reagent (Yong, Y.F.; Kowalski, J.A.; Lipton, M.A. J. Org. Chem., 1997, 62, 1540), or copper, mercury or silver salts, particularly with mercury (II) chloride. Suitably N-protected O-alkylisoureas may also be used such as O-methyl-N-nitroisourea (N. Heyboer et al, Rec. Chim. Trav. Pays-Bas (1962) 81, 69). Alternatively other guanylation agents known to those skilled in the art such as 1-H-pyrazole-1-[N,N'-bis(t-butoxycarbonyl)]carboxamidine, the corresponding bis-Cbz derivative (M. S. Bernatowicz, Y. Wu, G. R. Matsueda, Tet. Lett. 1993, 34, 3389) or monoBoc or mono-Cbz derivatives may be used (B. Drake.. Synthesis, 1994, 579, M. S. Bernatowicz.. Tet. Lett. 1993, 34, 3389). Similarly, 3,5-dimethyl-1-nitroguanylpurazole may be used (T. Wakayama et al, Tet. Lett. (1986) 29, 2143).

The reaction can conveniently be carried out using a suitable solvent such as dichloromethane, N,N-dimethylformamide (DMF), methanol.

15

The reaction is also conveniently carried out by adding mercury (II) chloride to a mixture of the aminoisoquinoline (II) and a thiourea derivative of type (III) in a suitable base / solvent mixture such as triethylamine / dichloromethane.



(IV)

20

The product of this reaction is the protected isoquinolinylguanidine (IV), where G¹ is a protected guanidine moiety N=C(NHP)(NHP₁) or tautomer thereof, where P and P₁ are nitrogen-protecting groups such as t-butoxycarbonyl ("Boc"), benzyl, benzyloxycarbonyl, etc., which can conveniently be deprotected to give (I) or a salt thereof.

25

For example, if the protecting group P and/or P₁ is t-butoxycarbonyl, conveniently the deprotection is carried out using an acid such as trifluoroacetic acid (TFA) or hydrochloric acid, in a suitable solvent such as dichloromethane, to give the bistrifluoroacetate salt of (I).

- 5 If P and/or P₁ is a hydrogenolysable group, such as benzyloxycarbonyl, the deprotection could be performed by hydrogenolysis.

Other protection / deprotection regimes include : nitro (K.Suzuki et al, Chem.Pharm.Bull.

(1985)33,1528, Nencioni et al, J.Med.Chem.(1991)34,3373, B.T.Golding et al,


- 10 J.C.S.Chem.Comm.(1994)2613; p-toluenesulphonyl (J.F.Callaghan et al, Tetrahedron (1993) 49 3479; mesitylsulphonyl (Shiori et al, Chem.Pharm.Bull.(1987)35,2698, *ibid.*(1987)35,2561, *ibid.*, (1989)37,3432, *ibid.*, (1987)35,3880, *ibid.*, (1987)35,1076; 2-adamantoyloxycarbonyl (Iuchi et al, *ibid.*, (1987) 35, 4307; and methylsulphonylethoxycarbonyl (Filippov et al, Syn.Lett.(1994)922)

- 15 It will be apparent to those skilled in the art that other protection and subsequent deprotection regimes during synthesis of a compound of the invention may be achieved by various other conventional techniques, for example as described in "Protective Groups in Organic Synthesis" by T W Greene and P G M Wuts, John Wiley and Sons Inc. (1991), and by P.J.Kocienski, in "Protecting Groups", Georg Thieme Verlag (1994).

20

Method 3

Compounds of the formula (I) can be obtained from compounds of formula (V)



- 25 where Z is a suitable leaving group such as Cl, Br or OPh, by displacement of the leaving group by the free base of guanidine.

Compounds of formula (V) are available as mentioned above in the section on preparation of compounds of formula (II) in Method 1, and routine variation thereof.

The free base of guanidine may conveniently be generated in situ from a suitable salt, such as the hydrochloride, carbonate, nitrate, or sulphate with a suitable base such as sodium hydride, potassium hydride, or another alkali metal base, preferably in a dry non-protic solvent such as tetrahydrofuran (THF), DMSO, N,N-dimethylformamide (DMF), ethylene glycol dimethyl ether (DME), N,N-dimethyl acetamide (DMA), toluene or mixtures thereof. Alternatively it can be generated from a suitable salt using an alkoxide in an alcohol solvent such as potassium t-butoxide in t-butanol, or in a non-protic solvent as above.

The thus formed free guanidine can be combined with the 1-isoquinoline derivative (V), and the reaction to form compounds of formula (I) can be carried out at from room temperature to 200°C, preferably from about 50°C to 150°C, preferably for between 4 hours and 6 days.

It will be clear to those skilled in the art, that some of the functionality in the R³, R² and/or X¹ groups may need to be either protected and released subsequent to guanylation or added, or generated after the guanidine moiety had been added to the substrate.

For example, an acid group could be carried through the guanylation stage while protected as an ester and subsequently hydrolysed. Base-catalysed hydrolysis of an ethyl ester and acid-catalysed hydrolysis of a t-butyl ester are two such suitable examples of this. In another example, an alcohol may be protected with groups well documented in the literature such as a 2-tetrahydropyranyl ether (2-THP) and subsequently removed by treatment with acid.

The addition of new functionality after the guanidine moiety has been installed is also encompassed by the invention. For example, alkylation of the sulphonamido NH (i.e. "X-NR²" is SO₂NH) with an alkyl halide may be performed in the presence of a base such as potassium carbonate and optionally in the presence of a promoter such as KI. In another example, an acid group may be converted to an amide through a range of coupling conditions known to those skilled in the art, or conveniently though the acid chloride while in the presence of a free or protected guanidine. Alternatively an ester group can be directly reacted with an amine to generate an amide; if this occurs in an intramolecular process, a lactam may be formed. Using similar methodology esters and lactones may be prepared.

Additional functionality could have been present in a protected form at this stage and subsequently revealed - such as an amino group which could be protected by groups well documented in the literature, e.g. a Boc group and subsequently removed under standard conditions, such as treatment with a strong base such as HCl or TFA.

5

Method 4

Compounds of the invention where one or more substituent is or contains a carboxylic acid group or carbamoyl group can be made from the corresponding compound where the corresponding
10 substituent is a nitrile by full or partial hydrolysis. Compounds of the invention where one or more substituent is or contains a carboxylic acid group can be made from the corresponding compound where the corresponding substituent is a carbamoyl moiety, by hydrolysis.

The hydrolysis can be carried out by methods well-known in the art, for example those mentioned in
15 "Advanced Organic Chemistry" by J. March, 3rd edition (Wiley-Interscience) chapter 6-5, and references therein. Conveniently the hydrolysis is carried out using concentrated hydrochloric acid, at elevated temperatures, and the product forms the hydrochloride salt.

Method 5

20

Where desired or necessary the compound of formula (I) is converted into a pharmaceutically acceptable salt thereof. A pharmaceutically acceptable salt of a compound of formula (I) may be conveniently be prepared by mixing together solutions of a compound of formula (I) and the desired acid or base, as appropriate. The salt may be precipitated from solution and collected by filtration, or
25 may be collected by other means such as by evaporation of the solvent.

Other Methods

Compounds of the formula (I) where one or more substituent is or contains Cl or Br may be
30 dehalogenated to give the corresponding hydrido compounds of formula (I) by hydrogenolysis, suitably using a palladium on charcoal catalyst, in a suitable solvent such as ethanol at about 20°C and at elevated pressure.

Compounds of formula (I) where one or more substituent is or contains a carboxy group may be prepared from a compound with a group hydrolysable to give a carboxy moiety, for example a corresponding nitrile or ester, by hydrolysis, for example by acidic hydrolysis with e.g. conc. aq. HCl at reflux. Other hydrolysis methods are well known in the art.

5

Compounds of formula (I) in which one or more substituent is or contains an amide moiety may be made via reaction of an optionally protected corresponding carboxy compound, either by direct coupling with the amine of choice, or via initial formation of the corresponding acid chloride or mixed anhydride, and subsequent reaction with the amine, followed by deprotection if appropriate.

10

Such transformations are well-known in the art.

Certain of the compounds of formula (I) which have an electrophilic group attached to an aromatic ring can be made by reaction of the corresponding hydrido compound with an electrophilic reagent. For example sulphonylation of the aromatic ring using standard reagents and methods, such as

15

fuming sulphuric acid, gives a corresponding sulphonic acid. This can then be optionally converted into the corresponding sulphonamide by methods known in the art, for example by firstly converting to the acid chloride followed by reaction with an amine.

20

Certain of the compounds of the invention can be made by cross-coupling techniques such as by reaction of a compound containing a bromo-substituent attached to e.g. an aromatic ring, with e.g. a boronic acid derivative, an olefin or a tin derivative by methods well-known in the art, for example by the methods described in certain of the Preparations below.

25

Certain of the compounds of the invention having an electrophilic substituent can be made via halogen/metal exchange followed by reaction with an electrophilic reagent. For example a bromo-substituent may react with a lithiating reagent such as n-butyllithium and subsequently an electrophilic reagent such as CO₂, an aldehyde or ketone, to give respectively an acid or an alcohol.

30

Compounds of the invention are available by either the methods described herein in the Methods and Examples or suitable adaptation thereof using methods known in the art. It is to be understood that the synthetic transformation methods mentioned herein may be carried out in various different sequences in order that the desired compounds can be efficiently assembled. The skilled chemist will

exercise his judgement and skill as to the most efficient sequence of reactions for synthesis of a given target compound.

5 It will be apparent to those skilled in the art that sensitive functional groups may need to be protected and deprotected during synthesis of a compound of the invention. This may be achieved by conventional techniques, for example as described in "Protective Groups in Organic Synthesis" by T W Greene and P G M Wuts, John Wiley and Sons Inc. (1991), and by P.J.Kocienski, in "Protecting Groups", Georg Thieme Verlag (1994).

10 It is possible during some of the reactions described herein that any stereocentres present could, under certain conditions, be racemised, for example if a base is used in a reaction with a substrate having an optical centre comprising a base-sensitive group. This is possible during e.g. a guanylation step. It should be possible to circumvent potential problems such as this by choice of reaction sequence, conditions, reagents, protection/deprotection regimes, etc. as is well-known in the art.

15

The compounds and salts of the invention may be separated and purified by conventional methods.

Separation of diastereomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of a compound of formula
20 (I) or a suitable salt or derivative thereof. An individual enantiomer of a compound of formula (I) may also be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereomeric salts formed by reaction of the corresponding racemate with a suitably optically active acid or base.

25

For human use, the compounds of formula (I) or their salts can be administered alone, but will generally be administered in admixture with a pharmaceutically acceptable diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they can be administered orally, including sublingually, in the form of tablets containing
30 such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents. They can be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous

solution or suspension which may contain other substances, for example, enough salt or glucose to make the solution isotonic with blood. They can be administered topically, in the form of sterile creams, gels, suspensions, lotions, ointments, dusting powders, sprays, drug-incorporated dressings or via a skin patch. For example they can be incorporated into a cream consisting of an aqueous or
5 oily emulsion of polyethylene glycols or liquid paraffin, or they can be incorporated into an ointment consisting of a white wax soft paraffin base, or as hydrogel with cellulose or polyacrylate derivatives or other viscosity modifiers, or as a dry powder or liquid spray or aerosol with butane/propane, HFA or CFC propellants, or as a drug-incorporated dressing either as a tulle dressing, with white soft paraffin or polyethylene glycols impregnated gauze dressings or with hydrogel, hydrocolloid,
10 alginate or film dressings. The compound or salt could also be administered intraocularly as an eye drop with appropriate buffers, viscosity modifiers (e.g. cellulose derivatives), preservatives (e.g. benzalkonium chloride (BZK)) and agents to adjust tenicity (e.g. sodium chloride).

All such formulations may also contain appropriate stabilisers and preservatives.

15

For oral and parenteral administration to human patients, the daily dosage level of the compounds of formula (I) or their salts will be from 0.001 to 20, preferably from 0.01 to 20, more preferably from 0.1 to 10, and most preferably from 0.5 to 5 mg/kg (in single or divided doses). Thus tablets or capsules of the compounds will contain from 0.1 to 500, preferably from 50 to 200, mg of active
20 compound for administration singly or two or more at a time as appropriate.

The physician in any event will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. the above dosages are exemplary of the average case; there can of course be individual instances where
25 higher or lower dosage ranges are merited, and such are within the scope of this invention.

It is to be appreciated that reference to treatment includes prophylaxis as well as the alleviation of established symptoms of the condition to be treated.

Test Methods

Compounds were tested for their ability to inhibit human urokinase, human tPA and human plasmin, using substantially the same methods as described by Yang, et al, *J. Med. Chem.*, (1990) 33, 2961. The urokinase assay was carried out using S-2444 (Quadragech 820357) as substrate and the urokinase used was HMWT Human Urokinase (Calbiochem 672081). The tPA assay was carried out using S-2288 (Quadragech 820832) tPA substrate, Quadragech 321116 as tPA stimulator, and the tPA used was Human tPA (Quadragech 881157). The plasmin assay was carried out using human plasmin (Quadragech 810665) acting on Chromozym-PL (Boehringer 378461) as substrate.

The compounds of Examples 32(b), 34(b), 36(b), 37(b), 38, 39(a and b), 41(b), 43(b), 44(b), 71, 75, 76, 78, 79, 84(b), and 87(b and c) all had K_i values of 20nM or less vs. urokinase.

The invention is illustrated by the following Examples.

EXPERIMENTAL SECTION

GENERAL DETAILS

- 5 Melting points (mp) were determined using either Gallenkamp or Electrothermal melting point apparatus and are uncorrected. Proton nuclear magnetic resonance (^1H NMR) data were obtained using a Varian Unity 300 or a Varian Inova 400. Low resolution mass spectral (LRMS) data were recorded on a Fisons Instruments Trio 1000 (thermaspray) or a Finnigan Mat. TSQ 7000 (APCI). Elemental combustion analyses (Anal.) were determined by Exeter
10 Analytical UK. Ltd.

Column chromatography was performed using Merck silica gel 60 (0.040-0.063 mm).

Reverse phase column chromatography was performed using Mitsubishi MCI gel (CHP 20P).

- 15 The following abbreviations were used: ammonia solution sp. gr. 0.880 (0.880NH_3); diethyl azodicarboxylate (DEAD); 1,2-dimethoxyethane (DME); *N,N*-dimethylacetamide (DMA); *N,N*-dimethylformamide (DMF); dimethylsulphoxide (DMSO); tetrahydrofuran (THF); trifluoroacetic acid (TFA); toluene (PhMe); methanol (MeOH); ethyl acetate (EtOAc) propanol (PrOH). Other abbreviations are used according to standard chemical practice.

20


Some nomenclature has been allocated using the IUPAC NamePro software available from Advanced Chemical Development Inc. It was noted following some preparations involving guanylation of intermediates containing a quaternary centre adjacent to a base-sensitive group e.g. an ester, that some racemisation had occurred, so in such cases there may be a

- 25 mixture of enantiomers produced.

EXAMPLES

Example 1:

- 30 (a) *tert*-Butyl 2-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]benzoate
(b) 2-[[[4-Chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]benzoic acid
hydrochloride



Guanidine hydrochloride (60 mg, 0.63 mmol) was added in one portion to a suspension of NaH (18 mg, 80% dispersion by wt in mineral oil, 0.6 mmol) in DMSO (3.0 mL) and the mixture was heated at 60 °C under N₂ for 30 min. *tert*-Butyl 2-[[[1,4-dichloro-7-isoquinolinyl]sulphonyl]amino]benzoate (110 mg, 0.24 mmol) was added and the mixture heated at 100 °C for 24 h. The cooled mixture was poured into water and extracted with EtOAc (x3) and the combined organic phase was then washed with brine and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3 to 95:5:0.5) as eluant to give a yellow resin (36 mg). This resin was suspended in water and extracted with ether (x3). The combined organic phase was washed with brine and evaporated *in vacuo* to give *tert*-butyl 2-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]benzoate (30 mg, 0.063 mmol) as a brown solid.

TLC R_f 0.60 (CH₂Cl₂-MeOH-0.880NH₃, 90:10:1).

¹H (CD₃OD, 400 MHz) δ 1.4 (9H, s), 7.1 (1H, dd), 7.5 (1H, dd), 7.7 (1H, d), 7.8 (1H, d), 7.9 (1H, d), 8.0 (1H, d), 8.1 (1H, s), 9.1 (1H, s) ppm.

LRMS 475 (MH⁺).

The silica gel column was then eluted with MeOH and the combined washings were concentrated *in vacuo* to give an off-white solid. This was dissolved in a solution of EtOH saturated with HCl gas and the mixture stirred at room temperature. The solvents were evaporated *in vacuo* and the residue was then dissolved in EtOAc-MeOH, filtered and again evaporated *in vacuo*. The solid was triturated with water and then dried to give 2-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]benzoic acid hydrochloride (11.8 mg, 0.02 mmol) as a pale yellow solid.

mp >280 °C (dec).

¹H (CD₃OD, 400 MHz) δ 7.0 (1H, dd), 7.3 (1H, dd), 7.65 (1H, d), 7.8 (1H, d), 8.1 (1H, d), 8.2 (1H, d), 8.3 (1H, s), 8.9 (1H, s) ppm.


LRMS 420, 422 (M⁺), 421 (MH⁺).

5

Anal. Found: C, 43.58; H, 3.37; N, 14.65. Calc for C₁₇H₁₄ClN₅O₄S•1.0HCl•0.7H₂O: C, 43.54; H, 3.53; N, 14.94.

Example 2:

- 10 (a) *tert*-Butyl 3-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]benzoate
 (b) 3-[[[4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]benzoic acid
 trifluoroacetate



15

- Guanidine hydrochloride (140 mg, 1.47 mmol) was added in one portion to a suspension of NaH (44 mg, 80% dispersion by wt in mineral oil, 1.47 mmol) in DMSO (4.0 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *tert*-butyl 3-[[[4-chloro-7-isoquinoliny]sulphonyl]amino]benzoate (280 mg, 0.59 mmol) in DMSO (2.0 mL) was added and the mixture heated at 90 °C for 18 h. The cooled mixture was poured into water (50 mL), extracted with EtOAc (x3) and the combined organic phase was then evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3 to 95:5:0.5) as eluant to give *tert*-butyl 3-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]benzoate (64 mg, 0.13 mmol) as a tan solid.

25

mp >142 °C (dec).

¹H (CD₃OD, 400 MHz) δ 1.5 (9H, s), 7.25-7.35 (2H, m), 7.65-7.7 (2H, m), 7.95 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 9.1 (1H, s) ppm.

30

LRMS 475 (MH⁺).

Anal. Found: C, 51.07; H, 4.55; N, 13.94. Calc for $C_{21}H_{22}ClN_5O_4S \cdot 0.23CH_2Cl_2$: C, 51.46; H, 4.57; N, 14.13.

tert-Butyl 3-[[[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]benzoate (30 mg, 0.063 mmol) was dissolved in CF_3CO_2H (1.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo*. The residue was triturated with Et_2O and then azeotroped with CH_2Cl_2 to give 3-[[[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]-benzoic acid trifluoroacetate (29 mg, 0.055 mmol) as an off-white solid.

mp >180 °C (dec).

1H (CD_3OD , 400 MHz) δ 7.2-7.35 (2H, m), 7.55 (1H, d), 7.65 (1H, s), 8.15 (1H, d), 8.3 (1H, d), 8.35 (1H, s), 8.85 (1H, s) ppm.


LRMS 419, 421 (MH^+).

Anal. Found: C, 42.51; H, 3.07; N, 13.19. Calc for $C_{17}H_{14}ClN_5O_4S \cdot 1.0CF_3CO_2H$: C, 42.75; H, 2.83; N, 13.12.

Example 3:

(a) Methyl 3-[[[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoate

(b) 3-[[[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoic acid hydrochloride



Guanidine hydrochloride (179.8 mg, 1.88 mmol) was added in one portion to a suspension of NaH (54.9 mg, 80% dispersion by wt in mineral oil, 1.83 mmol) in DMSO (10 mL) and the mixture was heated at 60 °C under N_2 for 20 min. Methyl 3-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoate (238.6 mg, 0.541 mmol) was added and

the mixture heated at 90 °C for 24 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3 to 90:10:1) as eluant to give methyl 3-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoate (203.2 mg, 0.43 mmol) as a pale yellow solid.

mp 134-137 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 3.45 (3H, s), 3.8 (3H, s), 6.95 (1H, d), 7.05-7.4 (4H, br s), 7.7 (1H, d), 7.8 (1H, s), 8.0 (2H, s), 8.1 (1H, s), 9.05 (1H, s), 9.9 (1H, br s) ppm.

LRMS 464, 466 (MH⁺).

Anal. Found: C, 48.37; H, 3.81; N, 14.75. Calc for C₁₉H₁₈ClN₅O₅S•0.15CH₂Cl₂: C, 48.26; H, 3.87; N, 14.69.

An aqueous solution of NaOH (0.7 mL, 1.0 M, 0.7 mmol) was added slowly to a stirred solution of methyl 3-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoate (52.2 mg, 0.113 mmol) in dioxane (2.5 mL) and the mixture stirred at room temperature for 1.5 h, and then at 70 °C for 3 h. The mixture was cooled to room temperature, dilute HCl (2 mL, 2 N) was added, the solvents were evaporated *in vacuo* and the residue was dried by azeotroping with *i*-PrOH (x3). The solid was extracted with hot *i*-PrOH (x4), the combined organic extracts were filtered, and the solvents were evaporated *in vacuo*. The residue was triturated with Et₂O to give 3-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoic acid hydrochloride (29 mg, 0.055 mmol) as a solid.

mp 258 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 3.45 (3H, s), 6.95 (1H, d), 7.7 (1H, d), 7.8 (1H, s), 8.3-8.7 (4H, br s), 8.3 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.9 (1H, s), 10.05 (1H, br s), 10.9 (1H, br s), 12.75 (1H, br s) ppm.

LRMS 450 (MH⁺).


Anal. Found: C, 44.50; H, 4.60; N, 12.17. Calc for

$C_{18}H_{16}ClN_5O_5S \cdot 1.0HCl \cdot 1.0(CH_3)_2CHOH \cdot 1.0H_2O$: C, 44.69; H, 4.82; N, 12.41.

Example 4:

- 5 (a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester hydrochloride

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]glycine trifluoroacetate



10

- NaH (29 mg, 80% dispersion by wt in mineral oil, 0.97 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (146 mg, 1.52 mmol) in DMSO (2.0 mL) and the mixture was heated at 60 °C under N_2 for 30 min. *N*-[(1,4-Dichloro-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester (150 mg, 0.38 mmol) was added and the mixture heated at 90 °C for 9 h. The cooled mixture was diluted with water (30 mL), extracted with EtOAc (4x20 mL) and the combined organic extracts were washed with water, brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was dissolved in Et_2O and a solution of HCl in Et_2O (1 M) was added to give a sticky precipitate. The Et_2O was decanted and the residue triturated with EtOAc to give a white solid. Filtration with EtOAc and Et_2O washing gave *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester hydrochloride (68 mg, 0.14 mmol).
- 15
- 20

mp 172-175 °C.

- 25 1H (DMSO- d_6 , 300 MHz) δ 1.2 (9H, s), 3.75 (2H, s), 8.3 (1H, d), 8.35-8.4 (2H, m), 8.5 (1H, s), 8.5-8.9 (4H, br), 9.1 (1H, s), 11.3 (1H, br s) ppm.

LRMS 414, 416 (MH^+).

- 30 Anal. Found: C, 42.45; H, 4.92; N, 14.76. Calc for $C_{16}H_{20}ClN_5O_4S \cdot 1.0HCl \cdot 0.33H_2O \cdot 0.2EtOAc$: C, 42.58; H, 4.95; N, 14.78.

N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]glycine *t*-butyl ester hydrochloride (50 mg, 0.11 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 1.5 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo*. The residue was triturated with Et₂O and EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]glycine trifluoroacetate (36 mg, 0.073 mmol) as a white powder.

¹H (CF₃CO₂D, 400 MHz) δ 4.1 (2H, s), 8.25 (1H, d), 8.3 (1H, s), 8.55 (1H, d), 9.0 (1H, s) ppm.


LRMS 358 (MH⁺), 715 (M₂H⁺).

Anal. Found: C, 36.25; H, 2.86; N, 14.28. Calc for C₁₂H₁₂ClN₅O₄S•1.0CF₃CO₂H•0.2EtOAc: C, 36.32; H, 3.01; N, 14.31.

Example 5:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-β-alanine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-β-alanine trifluoroacetate



Guanidine hydrochloride (140 mg, 1.46 mmol) was added in one portion to a stirred suspension of NaH (35 mg, 80% dispersion by wt in mineral oil, 1.17 mmol) in DME (8.0 mL) and the mixture was heated at 30 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-β-alanine *t*-butyl ester (150 mg, 0.37 mmol) was added and the mixture heated at 90 °C for 18 h. The cooled mixture was diluted with EtOAc, washed with water, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3 to 95:5:0.5) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-β-alanine *t*-butyl ester (75 mg, 0.175 mmol) as a yellow foam

mp >180 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 1.35 (9H, s), 2.3 (2H, t), 2.9 (2H, dt), 7.1-7.4 (4H, br), 7.8 (1H, br t), 8.05 (2H, s), 8.1 (1H, s), 9.1 (1H, s) ppm.

LRMS 428 (MH⁺).

5

Anal. Found: C, 47.32; H, 5.24; N, 16.02. Calc for C₁₇H₂₂ClN₅O₄S•0.2H₂O: C, 47.32; H, 5.23; N, 16.23.

N-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-β-alanine *t*-butyl ester (30 mg, 0.07 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was evaporated *in vacuo*, azeotroping with PhMe, MeOH and then CH₂Cl₂, to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-β-alanine trifluoroacetate (32 mg, 0.066 mmol) as a white solid.

15 mp >200 °C (dec).

¹H (DMSO-*d*₆ + D₂O, 400 MHz) δ 2.35 (2H, t), 3.0 (2H, t), 8.2 (1H, d), 8.3 (1H, d), 8.4 (1H, s), 9.1 (1H, s) ppm.


20 LRMS 372 (MH⁺).

Anal. Found: C, 37.38; H, 3.11; N, 14.52. Calc for C₁₃H₁₄ClN₅O₄S•1.0CF₃CO₂H: C, 37.08; H, 3.11; N, 14.42.

25 Example 6:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-methylglycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-methylglycine bis(trifluoroacetate)



30

Guanidine hydrochloride (286 mg, 2.99 mmol) was added in one portion to a stirred suspension of NaH (77.5 mg, 80% dispersion by wt in mineral oil, 2.58 mmol) in DME (2.0 mL) and the mixture was heated at 50 °C under N₂ for 20 min. A solution of *N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-*N*-methylglycine *t*-butyl ester (393 mg, 0.97 mmol) in
5 DME (10 mL) was added and the mixture heated at 90 °C for 2 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-methylglycine *t*-butyl ester (260 mg, 0.607 mmol) as an off-white foam

10 mp 84 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.3 (9H, s), 2.85 (3H, s), 3.95 (2H, s), 7.0-7.5 (4H, br), 8.0 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 9.05 (1H, s) ppm.

15 LRMS 427 (MH⁺), 855 (M₂H⁺).

Anal. Found: C, 47.92; H, 5.38; N, 15.07. Calc for C₁₇H₂₂ClN₅O₄S: C, 47.72; H, 5.18; N, 16.37.

20 *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-methylglycine *t*-butyl ester (255 mg, 5.96 mmol) was dissolved in CF₃CO₂H (4.0 mL) and CH₂Cl₂ (2.0 mL), and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo* to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-
25 methylglycine bis(trifluoroacetate) (349 mg, 0.56 mmol) as a white powder.

mp 240-242 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 2.9 (3H, s), 4.05 (2H, s), 8.3 (1H, d), 8.4 (1H, d), 8.4-8.7 (4H, br),
30 8.5 (1H, s), 8.9 (1H, s) ppm.


LRMS 372, 374 (MH⁺), 744 (M₂H⁺).

Anal. Found: C, 36.26; H, 3.10; N, 11.04. Calc for C₁₃H₁₄ClN₅O₄S•2.0CF₃CO₂H•0.3PhMe: C, 36.56; H, 2.96; N, 11.16.

35

Example 7:(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-phenylglycine *t*-butyl ester(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-phenylglycine

5 trifluoroacetate



NaH (32 mg, 80% dispersion by wt in mineral oil, 1.07 mmol) was added in one portion to a stirred suspension of guanidine hydrochloride (164 mg, 1.71 mmol) in DME (5.0 mL) and the mixture was heated at 60 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-*N*-phenylglycine *t*-butyl ester (200 mg, 0.43 mmol) was added and the mixture heated at 95 °C for 6 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3 to 95:5:0.5) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-phenylglycine *t*-butyl ester (28 mg, 0.057 mmol) as a yellow resin.

¹H (DMSO-*d*₆, 300 MHz) δ 1.3 (9H, s), 4.45 (2H, s), 7.2-7.3 (2H, m), 7.2-7.4 (4H, br), 7.3-7.4 (3H, m), 7.9 (1H, d), 8.0 (1H, d), 8.1 (1H, s), 8.95 (1H, s) ppm.

LRMS 490, 492 (MH⁺), 981 (M₂H⁺).

N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-phenylglycine *t*-butyl ester (25 mg, 0.05 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 2 h. The mixture was concentrated *in vacuo*, azeotroping with PhMe, and the residue triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-phenylglycine trifluoroacetate (13 mg, 0.23 mmol) as a pale yellow powder.

mp 218-223 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 4.5 (2H, s), 7.1-7.2 (2H, d), 7.25-7.4 (3H, m), 7.8-8.4 (4H, br), 8.0 (1H, d), 8.2 (1H, d), 8.35 (1H, s), 8.9 (1H, s) ppm.

LRMS 434, 436 (MH⁺), 744 (M₂H⁺).


Anal. Found: C, 42.55; H, 3.39; N, 11.90. Calc for

5 C₁₈H₁₆ClN₅O₄S•1.0CF₃CO₂H•H₂O•0.2Et₂O: C, 42.74; H, 3.52; N, 12.22.

Example 8:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-(cyclopentylmethyl)-glycine *t*-butyl ester

10 (b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-(cyclopentylmethyl)glycine



Guanidine hydrochloride (96 mg, 1.00 mmol) was added in one portion to a stirred
 15 suspension of NaH (19 mg, 80% dispersion by wt in mineral oil, 0.63 mmol) in DME (5.0 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-(cyclopentylmethyl)glycine *t*-butyl ester (120 mg, 0.25 mmol) in DME (5.0 mL) was added and the mixture heated at 90 °C for 3 h. The solvents were evaporated *in vacuo*, the residue was dissolved with EtOAc (200 mL), and
 20 washed with aqueous NH₄Cl (150 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 40:60) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-(cyclopentylmethyl)-glycine *t*-butyl ester (60 mg, 0.12 mmol).

25 ¹H (CDCl₃, 400 MHz) δ 1.1-1.25 (2H, m), 1.35 (9H, s), 1.45-1.7 (4H, m), 1.7-1.8 (2H, m), 2.1 (1H, m), 3.25 (2H, d), 4.0 (2H, s), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.2 (1H, s) ppm.

LRMS 496 (MH⁺).

30

Anal. Found: C, 52.99; H, 6.07; N, 13.82. Calc for C₂₂H₃₀ClN₅O₄S: C, 53.38; H, 5.90; N, 14.15.

A solution of HCl (2 mL, 2 M, 4 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(cyclopentylmethyl)glycine *t*-butyl ester (50 mg, 0.10 mmol) in dioxane (4.0 mL) and the mixture was heated at 60 °C for 24 h. The solvents were evaporated
 5 *in vacuo*, and the residue triturated with dichloromethane to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(cyclopentylmethyl)glycine hydrochloride (40 mg, 0.080 mmol) as a white solid.

mp 139-142 °C.

10

¹H (CD₃OD, 400 MHz) δ 1.2-1.3 (2H, m), 1.5-1.7 (4H, m), 1.7-1.8 (2H, m), 2.2 (1H, m), 3.65 (2H, d), 4.2 (2H, s), 8.35 (1H, d), 8.45 (1H, s), 8.45 (1H, d), 8.9 (1H, s) ppm.

LRMS 440 (MH⁺).

15

Anal. Found: C, 43.48; H, 5.32; N, 12.91. Calc for

C₁₈H₂₂ClN₅O₄S•1.0HCl•1.0H₂O•0.05CH₂Cl₂•0.05 dioxane: C, 43.17; H, 5.11; N, 13.92.


Example 9:

20

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(cyclohexylmethyl)glycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(cyclohexylmethyl)glycine hydrochloride

25



30

Guanidine hydrochloride (125 mg, 1.31 mmol) was added in one portion to a stirred suspension of NaH (25 mg, 80% dispersion by wt in mineral oil, 0.82 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-*N*-(cyclohexylmethyl)-glycine *t*-butyl ester (160 mg, 0.33 mmol) was added and the mixture heated at 80-90 °C for 2.5 h. The solvents were evaporated *in vacuo*, the residue was dissolved with EtOAc (200 mL), and washed with aqueous NH₄Cl

(150 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 40:60) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(cyclohexylmethyl)glycine *t*-butyl ester (65 mg, 0.127 mmol) as an off-white foam.

5

¹H (CDCl₃, 400 MHz) δ 0.8-0.95 (2H, m), 1.1-1.25 (3H, m), 1.3 (9H, s), 1.6-1.8 (6H, m), 3.1 (2H, d), 4.0 (2H, s), 8.0 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.2 (1H, s) ppm.

LRMS 510 (MH⁺).

10

Anal. Found: C, 54.21; H, 6.46; N, 13.46. Calc for C₂₃H₃₂ClN₅O₄S: C, 54.16; H, 6.32; N, 13.73.

A solution of HCl (2 mL, 2 M, 4 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(cyclohexylmethyl)glycine *t*-butyl ester (53 mg, 0.10 mmol) in dioxane (4.0 mL). The mixture was stirred at 23 °C for 18 h and then heated at 50-60 °C for 16 h. On cooling, a white precipitate crashed out of solution. The solid was collected by filtration, triturated with EtOAc and then dried under vacuum to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(cyclohexylmethyl)glycine hydrochloride (26 mg, 0.057 mmol).

20

¹H (CDCl₃, 400 MHz) δ 0.8-1.0 (2H, m), 1.1-1.3 (3H, m), 1.55-1.8 (6H, m), 3.2 (2H, d), 4.15 (2H, s), 8.3 (1H, d), 8.45 (1H, d), 8.45 (1H, s), 8.9 (1H, s) ppm.


25 LRMS 454, 456 (MH⁺).

Anal. Found: C, 44.70; H, 5.15; N, 13.56. Calc for C₂₃H₃₂ClN₅O₄S•HCl•H₂O: C, 44.89; H, 5.36; N, 13.77.

30 **Example 10:**

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-benzylglycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-benzylglycine trifluoroacetate



Guanidine hydrochloride (180 mg, 1.88 mmol) was added in one portion to a suspension of NaH (45 mg, 80% dispersion by wt in mineral oil, 1.5 mmol) in DME (11 mL) and the mixture was heated at 60 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-*N*-benzylglycine *t*-butyl ester (225 mg, 0.467 mmol) was added and the mixture heated at 90 °C for 18 h. The cooled mixture was poured into water, extracted with EtOAc (x3) and the combined organic phase was then washed with water, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-benzylglycine *t*-butyl ester (172 mg, 0.34 mmol) as a yellow foam.

mp >150 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 1.2 (9H, s), 3.8 (2H, s), 4.45 (2H, s), 7.1-7.4 (4H, br), 7.2-7.35 (5H, m), 8.0 (1H, d), 8.1 (1H, d), 8.1 (s, 1H), 9.1 (1H, s) ppm.

LRMS 504, 506 (MH⁺).

Anal. Found: C, 55.19; H, 5.55; N, 13.23. Calc for C₂₃H₂₆ClN₅O₄S•0.1C₆H₁₄: C, 55.30; H, 5.39; N, 13.66.

N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-benzylglycine *t*-butyl ester (50 mg, 0.10 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo*. The residue was azeotroped with PhMe and then CH₂Cl₂ to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-benzylglycine trifluoroacetate (52 mg, 0.10 mmol) as a white solid.

mp 274 °C (dec).

^1H (DMSO- d_6 , 400 MHz) δ 3.95 (2H, s), 4.5 (2H, s), 7.2-7.35 (5H, m), 8.3 (1H, d), 8.35 (1H, d), 8.4-8.6 (4H, br), 8.45 (1H, s), 8.9 (1H, s), 10.6 (1H, br), 12.7 (1H, br) ppm.

LRMS 448, 450 (MH^+), 497 (M_2H^+).


5

Anal. Found: C, 43.96; H, 3.39; N, 11.87. Calc for $\text{C}_{19}\text{H}_{18}\text{ClN}_5\text{O}_4\text{S} \cdot 1.0\text{CF}_3\text{CO}_2\text{H} \cdot 0.5\text{H}_2\text{O}$: C, 44.18; H, 3.53; N, 12.27.

Example 11:

10 (a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(2-methylbenzyl)glycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(2-methylbenzyl)glycine trifluoroacetate



Guanidine hydrochloride (120 mg, 1.26 mmol) was added in one portion to a suspension of NaH (32 mg, 80% dispersion by wt in mineral oil, 1.06 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N_2 for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-*N*-(2-methylbenzyl)glycine *t*-butyl ester (200 mg, 0.405 mmol) was added and the mixture heated at 90 °C for 2 h. The cooled mixture was diluted with EtOAc, washed with water, brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane- CH_2Cl_2 (50:50), then CH_2Cl_2 , and finally CH_2Cl_2 -MeOH-0.880 NH_3 (95:5:0.5) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(2-methylbenzyl)glycine *t*-butyl ester (94 mg, 0.18 mmol) as an off-white solid.

mp >110 °C (dec).

30 ^1H (CDCl_3 , 400 MHz) δ 1.25 (9H, s), 2.3 (3H, s), 3.8 (2H, s), 4.6 (2H, s), 7.1-7.2 (4H, m), 8.05 (1H, d), 8.1 (1H, d), 8.15 (s, 1H), 9.3 (1H, s) ppm.

LRMS 518, 520 (MH⁺).

Anal. Found: C, 56.21; H, 5.83; N, 12.57. Calc for C₂₄H₂₈ClN₅O₄S•0.3H₂O•0.25C₆H₁₄: C, 56.20; H, 5.94; N, 12.85.

5

N-[(4-Chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-*N*-(2-methylbenzyl)glycine *t*-butyl ester (30 mg, 0.058 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo*. The residue was azeotroped with PhMe and then Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-*N*-(2-methylbenzyl)glycine trifluoroacetate (29 mg, 0.05 mmol) as an off-white solid.

10

mp >150 °C (dec).

¹H (CD₃OD, 400 MHz) δ 2.3 (3H, s), 3.95 (2H, s), 4.7 (2H, s), 7.05-7.2 (4H, m), 8.35 (1H, d), 8.45 (1H, s), 8.45 (1H, d), 8.9 (1H, s) ppm.

15

LRMS 462, 464 (MH⁺).

Anal. Found: C, 45.51; H, 3.95; N, 11.36. Calc for C₂₀H₂₀ClN₅O₄S•1.0CF₃CO₂H•1.0H₂O•0.1PhMe: C, 45.20; H, 3.98; N, 11.61.


20

Example 12:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-*N*-(2-methoxybenzyl)glycine *t*-butyl ester trifluoroacetate

25

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-*N*-(2-methoxybenzyl)glycine trifluoroacetate



30

Guanidine hydrochloride (225 mg, 2.36 mmol) was added in one portion to a stirred suspension of NaH (44 mg, 80% dispersion by wt in mineral oil, 1.47 mmol) in DME (20

mL) and the mixture was heated at 60 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N*-(2-methoxybenzyl)glycine *t*-butyl ester (300 mg, 0.59 mmol) was added and the mixture heated at 90 °C for 2 h. The cooled mixture was poured into water and extracted with EtOAc (x3). The combined organic extracts were then washed with water,
5 brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20), and then CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 90:10:1) as eluant to give the product as a yellow semi-solid. This semi-solid was dissolved in EtOAc, a solution of TFA (35 µL) in EtOAc (25 mL) was added and the solvents were evaporated *in vacuo*, azeotroping with PhMe. The residue was
10 triturated with *i*-Pr₂O, the resulting white solid was collected by filtration, and then dried to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-(2-methoxybenzyl)glycine *t*-butyl ester trifluoroacetate (219 mg, 0.338 mmol).

mp >197 °C (dec).

15

¹H (DMSO-*d*₆, 400 MHz) δ 1.25 (9H, s), 3.6 (3H, s), 4.0 (2H, s), 4.45 (2H, s), 6.8-6.9 (2H, m), 7.1-7.2 (2H, m), 8.3 (2H, s), 8.4-8.6 (4H, br s), 8.5 (s, 1H), 8.8 (1H, s) ppm.

LRMS 534, 536 (MH⁺).

20

Anal. Found: C, 48.33; H, 4.55; N, 10.52. Calc for C₂₄H₂₈ClN₅O₅S•1.0CF₃CO₂H: C, 48.18; H, 4.51; N, 10.81.

N-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-(2-methoxybenzyl)glycine *t*-butyl ester trifluoroacetate (150 mg, 0.231 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 40 min. The mixture was diluted with PhMe, concentrated *in vacuo*, azeotroping with PhMe, and the residue triturated with *i*-Pr₂O to give
25 *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-(2-methoxybenzyl)glycine trifluoroacetate (122 mg, 0.206 mmol) as a white solid.

30

mp >165 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 3.6 (3H, s), 4.0 (2H, s), 4.5 (2H, s), 6.8 (1H, d), 6.85 (1H, dd), 7.1-7.2 (2H, m), 8.3 (2H, s), 8.35-8.5 (4H, br s), 8.5 (s, 1H), 8.8 (1H, s) ppm.

35

LRMS 478, 480 (MH⁺).

Anal. Found: C, 44.64; H, 3.58; N, 11.83. Calc for C₂₀H₂₀ClN₃O₃S•1.0CF₃CO₂H: C, 44.69; H, 3.68; N, 11.63.


5

Example 13:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-(3-methoxybenzyl)glycine *t*-butyl ester hydrochloride

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-(3-methoxybenzyl)glycine

10



Guanidine hydrochloride (149 mg, 1.55 mmol) was added in one portion to a suspension of NaH (35 mg, 80% dispersion by wt in mineral oil, 1.16 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-(3-methoxybenzyl)glycine *t*-butyl ester (200 mg, 0.39 mmol) was added and the mixture heated at 90 °C for 2 h. The cooled mixture was poured into water, extracted with EtOAc (x3), and the combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was dissolved in Et₂O-EtOAc and a solution of HCl in Et₂O (0.5 M) was added to give a precipitate. The solid was collected by filtration, triturated with EtOAc and then dried to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-(3-methoxybenzyl)glycine *t*-butyl ester hydrochloride (124 mg, 0.21 mmol) as a white solid.

mp 203-205 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.2 (9H, s), 3.65 (3H, s), 4.05 (2H, s), 4.5 (2H, s), 6.7 (1H, s), 6.75-6.85 (2H, m), 7.2 (1H, dd), 8.3 (1H, d), 8.35 (1H, d), 8.5 (s, 1H), 9.3 (1H, s), 11.6 (1H, br s) ppm.

30

LRMS 534, 536 (MH⁺), 1069 (M₂H⁺).

Anal. Found: C, 50.22; H, 5.11; N, 12.23. Calc for $C_{24}H_{28}ClN_5O_5S \cdot 1.0HCl$: C, 56.52; H, 5.12; N, 12.28.

N-[(4-Chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(3-methoxybenzyl)glycine *t*-butyl ester hydrochloride (95 mg, 0.167 mmol) was dissolved in CF_3CO_2H (1.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo*. The residue was dissolved in EtOAc and stirred at room temperature for 1 h. The resulting precipitate was collected by filtration, washed with Et_2O and dried to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(3-methoxybenzyl)glycine (65 mg, 0.128 mmol) as a white powder.

mp 290 °C (dec).


1H (CF_3CO_2D , 400 MHz) δ 3.9 (3H, s), 4.3 (2H, s), 4.6 (2H, s), 6.9-7.0 (3H, m), 7.3 (1H, dd), 8.35 (1H, d), 8.45 (1H, s), 8.6 (1H, d), 8.95 (1H, s) ppm.

LRMS 477, 479 (MH^+), 955 (M_2H^+).

Anal. Found: C, 48.67; H, 4.09; N, 13.88. Calc for $C_{20}H_{20}ClN_5O_5S \cdot 0.25CF_3CO_2H$: C, 48.62; H, 4.03; N, 13.83.

Example 14:

- (a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(3-chlorobenzyl)glycine *t*-butyl ester hydrochloride
- (b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(3-chlorobenzyl)glycine trifluoroacetate



NaH (35 mg, 80% dispersion by wt in mineral oil, 1.16 mmol) was added in one portion to a suspension of guanidine hydrochloride (150 mg, 1.55 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N_2 for 30 min. *N*-[(1,4-Dichloro-7-

isoquinolinyl)sulphonyl]-*N*-(3-chlorobenzyl)glycine *t*-butyl ester (185 mg, 0.36 mmol) was added and the mixture heated at 90 °C for 5 h. The cooled mixture was diluted with Et₂O, washed with water, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was dissolved in Et₂O and a solution of HCl in Et₂O (1 M) was added to give a precipitate. The solvents were
5 evaporated *in vacuo*, and the white solid triturated with EtOAc and then dried to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-chlorobenzyl)glycine *t*-butyl ester hydrochloride (85 mg, 0.145 mmol).

mp 203-205 °C.

10

¹H (DMSO-*d*₆, 300 MHz) δ 1.2 (9H, s), 4.1 (2H, s), 4.55 (2H, s), 7.2-7.35 (4H, m), 8.3 (1H, d), 8.35 (1H, d), 8.5 (s, 1H), 9.3 (1H, s), 11.55 (1H, br s) ppm.

LRMS 538, 540 (MH⁺), 1076 (M₂H⁺).

15

Anal. Found: C, 47.04; H, 4.53; N, 11.82. Calc for C₂₂H₂₂Cl₂N₅O₄S•1.0HCl•0.5H₂O: C, 47.31; H, 4.66; N, 11.99.

N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-chlorobenzyl)glycine *t*-butyl ester hydrochloride (60 mg, 0.104 mmol) was dissolved in CF₃CO₂H (0.5 mL) and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe and the solvents were evaporated *in vacuo*. The residue was dissolved in Et₂O and stirred at room temperature for 1 h. The resulting precipitate was collected by filtration, washed with Et₂O and dried to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-
25 chlorobenzyl)glycine trifluoroacetate (31 mg, 0.052 mmol) as a white solid.

mp 306-308 °C.

¹H (CF₃CO₂D, 400 MHz) δ 4.3 (2H, s), 4.55 (2H, s), 7.0-7.1 (2H, m), 7.1-7.15 (2H, m), 8.25
30 (1H, d), 8.4 (1H, s), 8.5 (1H, d), 8.8 (1H, s) ppm.


LRMS 482, 484 (MH⁺), 496, 498 (MH⁺ of corresponding methyl ester).

Anal. Found: C, 42.60; H, 3.04; N, 12.03. Calc for C₁₉H₁₇Cl₂N₅O₄S•1.0CF₃CO₂H: C, 42.29;
35 H, 3.04; N, 11.74.

Example 15:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester hydrochloride

5 (b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-methoxybenzyl)glycine



Guanidine hydrochloride (118 mg, 1.24 mmol) was added in one portion to a stirred
 10 suspension of NaH (23 mg, 80% dispersion by wt in mineral oil, 0.78 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester (155 mg, 0.31 mmol) was added and the mixture heated at 90 °C for 1 h. The cooled mixture was poured into water and extracted with EtOAc (x3). The combined organic extracts were then washed with water,
 15 brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20), and then CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 90:10:1) as eluant to give a yellow gum. Trituration with *i*-Pr₂O gave *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester (80 mg, 0.15 mmol) as a sticky yellow solid. A small sample (10-15 mg) was dissolved
 20 in EtOAc, a solution of HCl in Et₂O was added and the solvents were evaporated *in vacuo*, to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester hydrochloride (18 mg) as a solid. (All characterisation data is for the HCl salt).

mp >192 °C (dec).

25

¹H (DMSO-*d*₆, 400 MHz) δ 1.2 (9H, s), 3.7 (3H, s), 4.0 (2H, s), 4.4 (2H, s), 6.8 (2H, d), 7.1 (2H, d), 8.3 (1H, d), 8.3 (1H, d), 8.4-8.9 (4H, br s), 8.5 (s, 1H), 8.2 (1H, s) ppm.

LRMS 534, 536 (MH⁺).

30

Anal. Found: C, 51.36; H, 5.53; N, 11.23. Calc for C₂₄H₂₈ClN₅O₅S•1.0HCl•0.28*i*-Pr₂O: C, 51.48; H, 5.54; N, 11.69.

N-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester (65 mg, 0.122 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 40 min. The mixture was diluted with PhMe, concentrated *in vacuo*, and the residue purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (83:15:3) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(4-methoxybenzyl)glycine (11 mg, 0.023 mmol) as a white solid.

mp >293 °C (dec).


¹H (DMSO-*d*₆, 400 MHz) δ 3.7 (3H, s), 3.8 (2H, s), 4.4 (2H, s), 6.85 (2H, d), 7.15 (2H, d), 7.2-7.5 (4H, br s), 8.0 (1H, d), 8.1 (1H, d), 8.15 (s, 1H), 9.1 (1H, s) ppm.

Anal. Found: C, 48.44; H, 4.47; N, 14.12. Calc for C₂₀H₂₀ClN₅O₅S•1.0H₂O: C, 48.34; H, 4.27; N, 14.28.

Example 16:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(2-pyridylmethyl)glycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]-*N*-(2-pyridylmethyl)glycine dihydrochloride



Guanidine hydrochloride (293 mg, 3.07 mmol) was added in one portion to a stirred suspension of NaH (57 mg, 80% dispersion by wt in mineral oil, 1.92 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *N*-[(1,4-dichloro-7-isoquinoliny)l)sulphonyl]-*N*-(2-pyridylmethyl)glycine *t*-butyl ester (370 mg, 0.78 mmol) in DME (10 mL) was added and the mixture heated at 90 °C for 1 h. The solvents were evaporated *in vacuo*, the residue was dissolved with EtOAc (200 mL), and washed with aqueous NH₄Cl (150 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 20:80) as eluant

to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(2-pyridylmethyl)glycine *t*-butyl ester (120 mg, 0.24 mmol) as a pale yellow foam.

¹H (CDCl₃, 400 MHz) δ 1.3 (9H, s), 4.1 (2H, s), 4.65 (2H, s), 7.2 (1H, m), 7.5 (1H, d), 7.65
5 (1H, dd), 8.05 (1H, d), 8.1 (1H, d), 8.1 (1H, s), 8.45 (1H, d), 9.25 (1H, s) ppm.

LRMS 505 (MH⁺).

Anal. Found: C, 51.93; H, 5.03; N, 15.45. Calc for C₂₂H₂₅ClN₆O₄S•0.1H₂O•0.2EtOAc: C,
10 52.24; H, 5.18; N, 15.89.

A solution of HCl (3 mL, 2 M, 6 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(2-pyridylmethyl)glycine *t*-butyl ester (115 mg, 0.23 mmol) in dioxane (5.0 mL) and the mixture was heated at 60 °C for 18 h. The solvents were evaporated
15 *in vacuo* and the residue triturated with hot EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(2-pyridylmethyl)glycine dihydrochloride (95 mg, 0.167 mmol) as an off-white solid.

mp 216-220 °C.

20


¹H (CD₃OD, 400 MHz) δ 4.4 (2H, s), 5.1 (2H, s), 8.05 (1H, m), 8.3 (1H, d), 8.4 (1H, d), 8.5
(1H, s), 8.5 (1H, d), 8.6 (1H, dd), 8.85 (1H, d), 9.3 (1H, s) ppm.

Anal. Found: C, 39.01; H, 4.01; N, 14.14. Calc for
25 C₁₈H₁₇ClN₆O₄S•2.0HCl•2.0H₂O•0.12dioxane: C, 39.05; H, 4.25; N, 14.78.

Example 17:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-pyridylmethyl)glycine *t*-butyl ester

30 (b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-pyridylmethyl)glycine dihydrochloride



Guanidine hydrochloride (317 mg, 3.32 mmol) was added in one portion to a stirred suspension of NaH (62.3 mg, 80% dispersion by wt in mineral oil, 2.08 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*-(3-pyridylmethyl)glycine *t*-butyl ester (400 mg, 0.83 mmol) in DME (10 mL) was added and the mixture heated at 80 °C for 4 h. The solvents were evaporated *in vacuo*, the residue was dissolved with EtOAc (200 mL), and washed with aqueous NH₄Cl (200 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using (i) pentane-EtOAc (70:30 to 50:50) and then (ii) CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 90:10:1) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-pyridylmethyl)glycine *t*-butyl ester (104 mg, 0.21 mmol) as a pale yellow solid.

¹H (CDCl₃, 400 MHz) δ 1.3 (9H, s), 3.8 (2H, s), 4.5 (2H, s), 6.4-6.8 (4H, br), 7.2 (1H, m), 7.6 (1H, d), 8.0 (1H, d), 8.05 (1H, s), 8.05 (1H, d), 8.4 (1H, s), 8.5 (1H, d), 9.3 (1H, s) ppm.

LRMS 505, 507 (MH⁺).

Anal. Found: C, 51.95; H, 5.02; N, 16.25. Calc for C₂₂H₂₅ClN₆O₄S: C, 52.33; H, 4.99; N, 16.64.

CF₃CO₂H (1.0 mL) was added to a stirred solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-pyridylmethyl)glycine *t*-butyl ester (100 mg, 0.20 mmol) in CH₂Cl₂ (1.0 mL) and the mixture was stirred at 23 °C for 3.5 h. The solvents were evaporated *in vacuo*, azeotroping with PhMe and CH₂Cl₂. The oily residue was dissolved in EtOAc and a solution of EtOAc saturated with HCl (3.0 mL) was added which gave a precipitate. The white solid was collected by filtration and dried to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(3-pyridylmethyl)glycine dihydrochloride (48 mg, 0.086 mmol).

¹H (CD₃OD, 400 MHz) δ 4.25 (2H, s), 4.9 (2H, s), 8.05 (1H, dd), 8.4 (1H, d), 8.45 (1H, s), 8.5 (1H, d), 8.7 (1H, d), 8.8 (1H, d), 9.0 (1H, s), 9.2 (1H, s) ppm.

Anal. Found: C, 39.32; H, 4.07; N, 15.07. Calc for


$C_{18}H_{17}ClN_6O_4S \cdot 2.0HCl \cdot 1.5H_2O \cdot 0.05EtOAc \cdot 0.05CH_2Cl_2$: C, 39.19; H, 3.72; N, 14.64.

5 **Example 18:**

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-pyridylmethyl)glycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-pyridylmethyl)glycine dihydrochloride

10



Guanidine hydrochloride (300 mg, 3.14 mmol) was added in one portion to a stirred suspension of NaH (59 mg, 80% dispersion by wt in mineral oil, 1.97 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N_2 for 30 min. A solution of *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*-(4-pyridylmethyl)glycine *t*-butyl ester (379 mg, 0.79 mmol) in DME (10 mL) was added and the mixture heated at 80 °C for 4 h. The solvents were evaporated *in vacuo*, the residue was dissolved with EtOAc (200 mL), and washed with aqueous NH_4Cl (150 mL), dried ($MgSO_4$) and evaporated *in vacuo*. The residue was purified by repeated column chromatography upon silica gel using (i) pentane-EtOAc (70:30 to 50:50) and then with (ii) CH_2Cl_2 -MeOH-0.880 NH_3 (95:5:0.5 to 90:10:1) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-pyridylmethyl)glycine *t*-butyl ester (96 mg, 0.19 mmol).

25 1H ($CDCl_3$, 400 MHz) δ 1.3 (9H, s), 3.9 (2H, s), 4.55 (2H, s), 7.25 (2H, d), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 8.6 (2H, d), 9.3 (1H, s) ppm.

LRMS 505, 507 (MH^+).

30 Anal. Found: C, 52.63; H, 5.09; N, 16.18. Calc for $C_{22}H_{23}ClN_6O_4S$: C, 52.33; H, 4.99; N, 16.64.

CF₃CO₂H (1.0 mL) was added to a stirred solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-pyridylmethyl)glycine *t*-butyl ester (88 mg, 0.17 mmol) in CH₂Cl₂ (1.0 mL) and the mixture was stirred at 23 °C for 3.5 h. The solvents were evaporated *in vacuo*, azeotroping with CH₂Cl₂. The oily residue was dissolved in CH₂Cl₂-MeOH (1.0 mL, 9:1) and a solution of EtOAc saturated with HCl (3.0 mL) was added which gave a precipitate. The white solid was collected by filtration and dried to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-(4-pyridylmethyl)glycine dihydrochloride (18 mg, 0.033 mmol).


¹H (CD₃OD, 400 MHz) δ 4.3 (2H, s), 5.0 (2H, s), 8.2 (2H, d), 8.4 (1H, d), 8.5 (1H, s), 8.55 (1H, d), 8.8 (2H, d), 9.1 (1H, s) ppm.

Anal. Found: C, 39.57; H, 4.12; N, 14.85. Calc for C₁₈H₁₇ClN₆O₄S•2.0HCl•1.5H₂O: C, 39.39; H, 4.04; N, 15.39.

Example 19:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine hydrochloride



NaH (30 mg, 80% dispersion by wt in mineral oil, 1.01 mmol) was added in one portion to a stirred suspension of guanidine hydrochloride (154 mg, 1.61 mmol) in DME (6.0 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester (200 mg, 0.40 mmol) in DME (3.0 mL) was added and the mixture heated at 95 °C for 5 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using pentane-EtOAc (50:50 to 33:66) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester (125 mg, 0.23 mmol) as pale yellow foam after repeated evaporation from CH₂Cl₂.

mp 106-111 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.2 (9H, s), 1.3 (3H, d), 3.7 (1H, d), 3.95 (1H, d), 5.05 (1H, q), 7.1-7.4 (4H, br), 7.2-7.3 (5H, m), 8.0 (1H, d), 8.1 (1H, s), 8.2 (1H, d), 9.15 (1H, s) ppm.

5

LRMS 518, 520 (MH⁺), 1035 (M₂H⁺).

Anal. Found: C, 55.15; H, 5.55; N, 12.84. Calc for C₂₄H₂₈ClN₅O₄S•0.2EtOAc•0.1CH₂Cl₂: C, 54.96; H, 5.52; N, 12.87.

10

N-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester (100 mg, 0.19 mmol) was dissolved in a solution of EtOAc saturated with HCl (7.0 mL) and the mixture stirred at room temperature for 4 h. The mixture was concentrated *in vacuo* and the residue triturated with EtOAc to give *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine hydrochloride (75 mg, 0.14 mmol) as a white powder.

15

mp 185-190 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.35 (3H, d), 3.85 (1H, d), 4.15 (1H, d), 5.3 (1H, q), 7.15 (5H, br s), 8.3 (1H, d), 8.4-8.8 (4H, br), 8.4 (1H, d), 8.5 (1H, s), 9.1 (1H, s), 11.3 (1H, br), 12.5 (1H, br) ppm.

20

Anal. Found: C, 47.42; H, 4.40; N, 13.54. Calc for

C₂₀H₂₀ClN₅O₄S•1.0HCl•0.5H₂O•0.2EtOAc: C, 47.59; H, 4.53; N, 13.34.


25

Example 20:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester

30

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine hydrochloride



NaH (30 mg, 80% dispersion by wt in mineral oil, 1.01 mmol) was added in one portion to a stirred suspension of guanidine hydrochloride (154 mg, 1.61 mmol) in DME (6.0 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester (200 mg, 0.40 mmol) in DME (3.0 mL) was added and the mixture heated at 95 °C for 5 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using pentane-EtOAc (50:50 to 33:66) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester (128 mg, 0.23 mmol) as pale yellow foam after repeated evaporation from CH₂Cl₂.

mp 109-115 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.2 (9H, s), 1.3 (3H, d), 3.7 (1H, d), 3.95 (1H, d), 5.05 (1H, q), 7.1-7.45 (4H, br), 7.2-7.3 (5H, m), 8.0 (1H, d), 8.1 (1H, s), 8.2 (1H, d), 9.15 (1H, s) ppm.

LRMS 518, 520 (MH⁺), 1035 (M₂H⁺).

Anal. Found: C, 55.26; H, 5.56; N, 12.86. Calc for C₂₄H₂₈ClN₅O₄S•0.1EtOAc•0.05CH₂Cl₂: C, 55.28; H, 5.54; N, 12.97.

N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester (100 mg, 0.19 mmol) was dissolved in a solution of EtOAc saturated with HCl (4.0 mL) and the mixture stirred at room temperature for 4 h. The mixture was concentrated *in vacuo* and the residue triturated with EtOAc to give *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine hydrochloride (72 mg, 0.14 mmol) as a white powder.


mp 196-200 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.35 (3H, d), 3.85 (1H, d), 4.15 (1H, d), 5.3 (1H, q), 7.15 (5H, br s), 8.3 (1H, d), 8.4-8.8 (4H, br), 8.4 (1H, d), 8.5 (1H, s), 9.1 (1H, s), 11.3 (1H, br), 12.4 (1H, br) ppm.

5 Anal. Found: C, 47.42; H, 4.30; N, 13.51. Calc for
C₂₀H₂₀ClN₅O₄S•1.0HCl•1.0H₂O•0.1EtOAc: C, 47.47; H, 4.45; N, 13.57.

Example 21:

- (a) *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-L-alanine *t*-butyl ester
10 ester
(b) *N*-Benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-L-alanine hydrochloride



15

NaH (30 mg, 80% dispersion by wt in mineral oil, 1.01 mmol) was added in one portion to a stirred suspension of guanidine hydrochloride (154 mg, 1.61 mmol) in DME (5.0 mL) and the mixture was heated at 60 °C under N₂ for 45 min. A solution of *N*-benzyl-*N*-[(1,4-
20 dichloro-7-isoquinoliny)sulphonyl]-L-alanine *t*-butyl ester (200 mg, 0.40 mmol) in DME (2.0 mL) was added and the mixture heated at 95 °C for 4 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using pentane-EtOAc (50:50 to 20:80) as eluant to give *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-
isoquinoliny)sulphonyl]-L-alanine *t*-butyl ester (120 mg, 0.225 mmol) as pale yellow foam
25 after repeated evaporation from CH₂Cl₂.

¹H (DMSO-*d*₆, 300 MHz) δ 1.1 (9H, s), 1.15 (3H, d), 4.35 (1H, d), 4.5 (1H, q), 4.7 (1H, d), 7.1-7.45 (4H, br), 7.2-7.4 (5H, m), 8.0 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.1 (1H, s) ppm.

30 LRMS 518, 520 (MH⁺).

Anal. Found: C, 55.33; H, 5.55; N, 12.82. Calc for $C_{24}H_{28}ClN_3O_4S \cdot 0.1EtOAc + 0.05CH_2Cl_2$: C, 55.30; H, 5.48; N, 13.19.

N-Benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-L-alanine *t*-butyl ester (100 mg, 0.19 mmol) was dissolved in a solution of EtOAc saturated with HCl (5.0 mL) and the mixture stirred at room temperature for 18 h. The mixture was concentrated *in vacuo*, azeotroping with EtOAc, to give *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-L-alanine hydrochloride (77 mg, 0.15 mmol) as a white powder.

mp 256-262 °C.

1H (DMSO- d_6 , 300 MHz) δ 1.2 (3H, d), 4.35 (1H, d), 4.7 (1H, q), 4.8 (1H, d), 7.1-7.4 (5H, m), 8.3 (2H, s), 8.4-8.7 (4H, br), 8.5 (1H, s), 9.05 (1H, s), 11.2 (1H, br), 12.7 (1H, br) ppm.


LRMS 461, 463 (MH^+).

Anal. Found: C, 48.02; H, 4.38; N, 13.33. Calc for $C_{20}H_{20}ClN_3O_4S \cdot 1.0HCl + 0.25H_2O + 0.1EtOAc$: C, 47.88; H, 4.39; N, 13.69.

Example 22:

(a) *N*-(*t*-butoxycarbonylmethyl)-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]glycine *t*-butyl ester

(b) *N*-(Carboxymethyl)-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]glycine hydrochloride



Anhydrous K_2CO_3 (88 mg, 0.64 mmol) and then *t*-butyl bromoacetate (56 μ L, 0.38 mmol) were added to a stirred solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]glycine *t*-butyl ester (132 mg, 0.33 mmol) in DMF (2.0 mL) and the mixture was stirred at 23 °C for 18 h. The mixture was diluted with EtOAc (300 mL), washed with brine (150 mL), water (200 mL), dried ($MgSO_4$) and evaporated *in vacuo*. The residue

was purified by column chromatography upon silica gel using pentane-EtOAc (80:20 to 50:50) as eluant to give *N*-[(*t*-butoxycarbonylmethyl)-*N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester (101 mg, 0.19 mmol) as a pale yellow foam.

- 5 ¹H (CDCl₃, 400 MHz) δ 1.4 (18H, s), 4.1 (4H, s), 8.0 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.25 (1H, s) ppm.

LRMS 528 (MH⁺).

- 10 Anal. Found: C, 49.57; H, 5.78; N, 12.73. Calc for C₂₂H₃₀ClN₅O₆S•0.1H₂O•0.1EtOAc: C, 49.95; H, 5.80; N, 13.00.

- A solution of HCl (3 mL, 2 M, 6 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-*N*-(*t*-butoxycarbonylmethyl)glycine *t*-butyl ester (90 mg, 0.17 mmol) in dioxane (4.0 mL). The mixture was stirred at 23 °C for 18 h and then heated at 70 °C. The solvents were evaporated *in vacuo* and the residue dried to give *N*-(carboxymethyl)-*N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]glycine hydrochloride (61 mg, 0.127 mmol) as a white solid.


- 20 mp 296-300 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 4.05 (4H, s), 7.9-8.3 (4H, br), 8.2 (1H, d), 8.25 (1H, d), 8.35 (1H, s), 9.0 (1H, s) ppm.

- 25 Anal. Found: C, 38.29; H, 3.58; N, 14.13. Calc for C₁₄H₁₄ClN₅O₆S•1.0HCl•0.1H₂O•0.3dioxane: C, 37.99; H, 3.69; N, 14.57.

Example 23:

- (a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-alanine *t*-butyl ester
30 (b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-alanine trifluoroacetate



NaH (37 mg, 80% dispersion by wt in mineral oil, 1.23 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (189 mg, 1.97 mmol) in DME (6 mL) and the mixture was heated at 60 °C under N₂ for 30 min. 1-[[[1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino]-L-alanine *t*-butyl ester (200 mg, 0.49 mmol) was added and the mixture heated at 90 °C for 7 h. The cooled mixture was concentrated *in vacuo*, the residue suspended in water and extracted with EtOAc (3x30 mL). The combined organic extracts were dried (MgSO₄) and the solvents evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-alanine *t*-butyl ester (160 mg, 0.37 mmol) as a white powder.

¹H (DMSO-*d*₆, 300 MHz) δ 1.1 (9H, s), 1.15 (3H, d), 3.8 (1H, dq), 7.1-7.4 (4H, br), 8.0 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 8.3 (1H, d), 9.05 (1H, s) ppm.

CF₃CO₂H (1.0 mL) was added to a stirred solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-alanine *t*-butyl ester (ca. 150 mg, 0.35 mmol) in CH₂Cl₂ (3.0 mL) and the mixture stirred at room temperature for 2 h. The mixture was evaporated *in vacuo*, azeotroping with PhMe and CH₂Cl₂, and then triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-alanine trifluoroacetate (62 mg, 0.126 mmol) as a white powder.

mp >250 °C.

¹H (CD₃OD + TFA-*d*, 300 MHz) δ 1.35 (3H, d), 4.05 (1H, q), 8.3 (1H, d), 8.4 (1H, s), 8.45 (1H, d), 8.9 (1H, s) ppm.


LRMS 389, 391 (MNH₄⁺).

Anal. Found: C, 36.66; H, 3.11; N, 14.00. Calc for C₁₃H₁₄ClN₅O₄S•1.0CF₃CO₂H•0.3H₂O: C, 36.64; H, 3.21; N, 14.24.

Example 24:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-alanine methyl ester

(b) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-alanine hydrochloride



- NaH (35 mg, 80% dispersion by wt in mineral oil, 1.17 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (179 mg, 1.87 mmol) in DMSO (5 mL) and the mixture was heated at 60 °C under N₂ for 45 min. 1-[[[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino]-D-alanine methyl ester (170 mg, 0.47 mmol) was added and the mixture heated at 90 °C for 4 h. The cooled mixture was poured into water and extracted with EtOAc (3x30 mL). The combined organic extracts were dried (MgSO₄) and the solvents evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (66:33 to 0:100) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-alanine methyl ester (22 mg, 0.057 mmol) as a yellow foam/oil.

¹H (CD₃OD, 300 MHz) δ 1.3 (3H, d), 3.4 (3H, s), 4.1 (1H, q), 8.1 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.1 (1H, s) ppm.

- LRMS 386, 388 (MH⁺).


- A solution of NaOH (1 mL, 2 M, 2 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-alanine methyl ester (17 mg, 0.044 mmol) in MeOH (3 mL) and the mixture was heated at 60 °C for 18 h. The cooled mixture was neutralised with dilute HCl (2 M), the MeOH was evaporated *in vacuo*, and the residue triturated with water (10 mL). The solid was collected by filtration, with water washing, and dried under high vacuum to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-alanine hydrochloride (9 mg, 0.021 mmol) as an off-white powder.

- ¹H (DMSO-*d*₆, 300 MHz) δ 1.2 (3H, d), 3.8 (1H, dq), 7.2-7.6 (4H, br), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 8.2 (1H, m), 9.1 (1H, s) ppm.

Anal. Found: C, 37.56; H, 3.98; N, 15.74. Calc for C₁₃H₁₄ClN₅O₄S•1.0HCl•0.5H₂O: C, 37.42; H, 3.86; N, 16.78.

Example 25:

(a) 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-L-valine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*L*-valine trifluoroacetate

NaH (35 mg, 80% dispersion by wt in mineral oil, 1.17 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (176 mg, 1.84 mmol) in DMA (4 mL) under N₂ and the mixture was heated at 60 °C for 30 min. 1-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]amino)-*L*-valine *t*-butyl ester (161 mg, 0.43 mmol) was added in one portion and the mixture heated at 80 °C for 18 h. The cooled mixture was poured into water (50 mL), extracted with EtOAc (2x20 mL) and the combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was dissolved Et₂O and a solution of HCl in Et₂O (1 M) was added which gave a white precipitate. The Et₂O was decanted and the solid residue dissolved in MeCN and the solution cooled to ca. 0 °C which gave a precipitate. This solid was collected by filtration and then dried to give 1-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]amino)-*L*-valine *t*-butyl ester hydrochloride (36 mg, 0.072 mmol) as a white solid. Evaporation of the combined organic mother liquors gave a gum which was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant to give 1-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]amino)-*L*-valine *t*-butyl ester (104 mg, 0.228 mmol). (The sample was characterised as the hydrochloride salt.)

mp 192-194 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 0.8 (3H, d), 0.85 (3H, d), 1.05 (9H, s), 2.0 (1H, sept), 3.7 (1H, dd), 8.3 (1H, d), 8.4 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.5-8.7 (4H, br), 9.05 (1H, s), 11.3 (1H, br), ppm.

LRMS 456, 458 (MH⁺).

Anal. Found: C, 45.67; H, 5.54; N, 13.97. Calc for C₁₉H₂₆ClN₅O₄S•1.0HCl•0.5H₂O: C, 45.51; H, 5.63; N, 13.97.

1-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-L-valine *t*-butyl ester (104 mg, 0.228 mmol) was dissolved in CF₃CO₂H (1.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was diluted with PhMe (25 mL) and concentrated *in vacuo*. The residue was crystallised with Et₂O containing a small amount of EtOAc to give a white solid. This solid was then triturated with water and dried to give 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-L-valine trifluoroacetate (39 mg, 0.084 mmol).

mp >300 °C.


¹H (TFA-*d*, 400 MHz) δ 0.95 (3H, d), 1.0 (3H, d), 2.25 (1H, sept), 4.0 (1H, d), 8.3 (1H, d), 8.4 (1H, s), 8.55 (1H, d), 9.0 (1H, s) ppm.

LRMS 400, 402 (MH⁺).

Anal. Found: C, 41.29; H, 4.37; N, 14.99. Calc for C₁₅H₁₈ClN₅O₄S•0.5CF₃CO₂H•0.3H₂O: C, 41.57; H, 4.16; N, 15.15.

Example 26:

- (a) 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-D-valine *t*-butyl ester hydrochloride
 (b) *N*-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-valine hydrochloride



- NaH (35 mg, 80% dispersion by wt in mineral oil, 1.17 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (176 mg, 1.84 mmol) in DMSO (2.5 mL) under N₂ and the mixture was heated at 23 °C for 30 min. 1-[[[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino]-D-valine *t*-butyl ester (200 mg, 0.46 mmol) was added in one portion and the mixture heated at 90 °C for 3 h. The cooled mixture was poured into water, extracted with EtOAc and the combined organic extracts were washed with brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was dissolved Et₂O and a solution of HCl in Et₂O (0.5 mL, 1 M) was added which gave a white precipitate. Purification by column

chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880NH₃ (95:5:0.5) as eluant furnished the product which was again treated with a solution of HCl in Et₂O (1 M) to give 1-
5 {{{(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}-D-valine *t*-butyl ester hydrochloride (76.6 mg, 0.151 mmol).

mp 124-125 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 0.8 (3H, d), 0.85 (3H, d), 1.05 (9H, s), 2.0 (1H, sept), 3.7 (1H, dd), 8.3 (1H, d), 8.4 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.4-8.8 (4H, br), 9.05 (1H, s), 11.2
10 (1H, br) ppm.

LRMS 456, 458 (MH⁺), 478, 480 (MNa⁺).

Anal. Found: C, 46.07; H, 5.67; N, 13.50. Calc for C₁₉H₂₆ClN₅O₄S•1.0HCl•0.5MeOH: C, 46.07; H, 5.75; N, 13.77.
15

1-{{{(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}-D-valine *t*-butyl ester hydrochloride (61 mg, 0.12 mmol) was dissolved in a solution of EtOAc saturated with HCl (10 mL) at 0 °C, and the mixture stirred at room temperature for 4 h. The mixture was
20 concentrated *in vacuo*, the residue extracted with hot EtOAc, and the organic solution was then concentrated *in vacuo* and dried to give 1-{{{(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}-D-valine hydrochloride (24.3 mg, 0.050 mmol) as a pale yellow solid.

25 mp >190 °C (dec).

¹H (TFA-*d*, 400 MHz) δ 0.95 (3H, br s), 1.0 (3H, br s), 2.3 (1H, br s), 4.05 (1H, br s), 8.35 (1H, br s), 8.4 (1H, br s), 8.55 (1H, br s), 9.1 (1H, br s) ppm.


30 LRMS 400 (MH⁺), 417 (MNH₄⁺).

Anal. Found: C, 41.29; H, 4.76; N, 14.16. Calc for C₁₅H₁₈ClN₅O₄S•1.0HCl•0.7H₂O•0.4EtOAc: C, 41.18; H, 4.91; N, 14.46.

35 **Example 27:**

(a) 1-[[[(4-chloro-1-guanidino-7-isoquinoliny)]sulphonyl]amino]-D-tert-leucine *t*-butyl ester hydrochloride

(b) *N*-[[[(4-Chloro-1-guanidino-7-isoquinoliny)]sulphonyl]-D-tert-leucine hydrochloride



5

NaH (58 mg, 80% dispersion by wt in mineral oil, 1.27 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (191 mg, 2.0 mmol) in DMSO (5.0 mL) under N_2 and the mixture was heated at 23 °C for 30 min. A solution of 1-[[[(1,4-dichloro-7-isoquinoliny)]sulphonyl]amino]-D-tert-leucine *t*-butyl ester (225 mg, 0.50 mmol) in DMSO (3.0 mL) was added in one portion and the mixture heated at 90 °C for 9 h. A second portion of guanidine (0.67 mmol)[prepared from guanidine hydrochloride (100 mg) and NaH (20 mg)] in DMSO (1.0 mL) was added and the mixture heated at 90 °C for an additional 8 h. The cooled mixture was poured into water, extracted with EtOAc and the combined organic extracts were washed with water, brine, dried ($MgSO_4$) and evaporated *in vacuo*. The residue was dissolved in Et_2O and a solution of HCl in Et_2O (1.5 mL, 1 M) was added which gave a white precipitate. The solvents were evaporated *in vacuo* and the residue triturated with Et_2O to give 1-[[[(4-chloro-1-guanidino-7-isoquinoliny)]sulphonyl]amino]-D-tert-leucine *t*-butyl ester hydrochloride (222 mg, 0.43 mmol).

20

mp 187-189 °C.

1H (DMSO- d_6 , 400 MHz) δ 0.9 (9H, s), 0.95 (9H, s), 3.6 (1H, d), 8.3 (1H, d), 8.4 (1H, d), 8.4-8.8 (4H, br), 8.5 (1H, s), 9.0 (1H, s), 11.15 (1H, br) ppm.

25

LRMS 470, 472 (MH $^+$).

Anal. Found: C, 46.55; H, 5.78; N, 13.46. Calc for $C_{20}H_{24}ClN_5O_4S \cdot 1.0HCl \cdot 0.5H_2O$: C, 46.60; H, 5.87; N, 13.59.

30

1-[[[(4-Chloro-1-guanidino-7-isoquinoliny)]sulphonyl]amino]-D-tert-leucine *t*-butyl ester hydrochloride (188 mg, 0.36 mmol) was dissolved in a solution of EtOAc saturated with HCl

(30 mL) and the mixture stirred at room temperature for 5 h. The mixture was concentrated *in vacuo* and the residue heated with EtOAc to give a white solid. The hot organic solution was decanted and the solid dried *in vacuo* to give 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-D-tert-leucine hydrochloride (109.3 mg, 0.24 mmol) as a white solid.

mp 234-236 °C (dec).

¹H (TFA-*d*, 400 MHz) δ 1.1 (9H, s), 3.9 (1H, s), 8.35 (1H, d), 8.5 (1H, s), 8.6 (1H, d), 9.1 (1H, s) ppm.

LRMS 414, 416 (MH⁺).


Anal. Found: C, 41.70; H, 4.86; N, 15.01. Calc for C₁₆H₂₀ClN₅O₄S•1.0HCl•0.5H₂O: C, 41.84; H, 4.83; N, 15.25.

Example 28:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-phenylalanine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-phenylalanine

trifluoroacetate



NaH (22 mg, 80% dispersion by wt in mineral oil, 0.73 mmol) was added in one portion to a stirred suspension of guanidine hydrochloride (76.7 mg, 0.80 mmol) in DMSO (5.0 mL) and the mixture was heated at 60 °C under N₂ for 20 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-L-phenylalanine *t*-butyl ester (103 mg, 0.21 mmol) was added and the mixture heated at 95 °C for 17 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 80:20:2) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-phenylalanine *t*-butyl ester (34.7 mg, 0.069 mmol) as a yellow resin.

¹H (DMSO-*d*₆, 300 MHz) δ 1.0 (9H, s), 2.7 (1H, dd), 2.8 (1H, dd), 3.9 (1H, dd), 7.1-7.2 (5H, m), 7.1-7.3 (4H, br s), 7.9 (1H, d), 7.95 (1H, d), 8.1 (s, 1H), 8.5 (1H, br d), 8.95 (1H, s) ppm.

LRMS 504, 506 (MH⁺).

5

N-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-phenylalanine *t*-butyl ester (30 mg, 0.060 mmol) was dissolved in CF₃CO₂H (2.5 mL) and the mixture stirred at room temperature for 2.5 h. The mixture was diluted with CH₂Cl₂ and PhMe, concentrated *in vacuo*, azeotroping with PhMe, and the residue triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-phenylalanine trifluoroacetate (24.4 mg, 0.42 mmol) as a white solid.

10

mp 306 °C (dec).

¹H (DMSO-*d*₆, 300 MHz) δ 2.7 (1H, dd), 3.0 (1H, dd), 3.95 (1H, m), 6.9-7.1 (5H, m), 7.8-8.4 (4H, br), 7.9 (1H, d), 8.05 (1H, d), 8.3 (s, 1H), 8.6 (1H, br s), 8.8 (1H, s) ppm.

15

LRMS 448 (MH⁺).

Anal. Found: C, 44.35; H, 3.78; N, 11.38. Calc for C₁₉H₁₈ClN₅O₄S•1.0CF₃CO₂H•0.5H₂O•0.12Et₂O: C, 44.50; H, 3.69; N, 12.08.


20

Example 29:

(a) 1-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino}-*O*-methyl-D-serine *t*-butyl ester hydrochloride

25

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]-*O*-methyl-D-serine hydrochloride



30

NaH (50 mg, 80% dispersion by wt in mineral oil, 1.66 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (260 mg, 2.72 mmol) in DMSO (4 mL) under N₂

and the mixture was heated at 50 °C for 30 min. 1-[[[1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino]-O-methyl-D-serine *t*-butyl ester (300 mg, 0.689 mmol) was added in one portion and the mixture heated at 90 °C for 8 h. The cooled mixture was poured into water (50 mL), the aqueous solution was extracted with EtOAc (x2) and the combined
5 organic extracts were washed with water, brine, dried (MgSO₄). The solvents were evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant to give the desired product. This material was treated with a solution of HCl in Et₂O (1.0 mL, 1 M), the solvents evaporated *in vacuo*, and the residue triturated with Et₂O (x2) to give 1-[[[4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-O-methyl-D-serine *t*-butyl ester hydrochloride (18 mg,
10 0.036 mmol) as a white solid.

¹H (d4-MeOH, 300 MHz) δ 1.2 (9H,s), 3.2 (3H,s), 3.5-3.6 (1H,m), 3.6-3.7 (1H,m), 4.1-4.2 (1H,m), 8.35-8.5 (3H,m), 8.9 (1H,s) ppm.

15

LRMS 458 (MH).

1-[[[4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-O-methyl-D-serine *t*-butyl ester hydrochloride (18 mg, 0.036 mmol) was dissolved in a solution of EtOAc saturated
20 with HCl (5 mL) and the mixture stirred at room temperature for 3 h. The mixture was concentrated *in vacuo* and the residue triturated with EtOAc (x3) to give 1-[[[4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-L-tert-leucine hydrochloride (9 mg, 0.02 mmol) as an off-white solid.


25 ¹H (d-TFA, 400MHz) 3.6 (3H,s), 4.0-4.2 (2H,m), 4.65 (1H, br s), 8.4 (1H,d), 8.5 (1H,s), 8.65 (1H,d), 9.1 (1H,s) ppm.

LRMS 402 (MH).

30 **Example 30:**

(a) *N*-[[[4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-aspartic acid di-*t*-butyl ester

(b) *N*-[[[4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-aspartic acid hydrochloride



Guanidine hydrochloride (190 mg, 2.0 mmol) was added in one portion to a stirred suspension of NaH (47 mg, 80% dispersion by wt in mineral oil, 1.57 mmol) in DME (7 mL) and the mixture was heated at 60 °C under N₂ for 30 min. 1-[[[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino}-D-aspartic acid di-*t*-butyl ester (250 mg, 0.50 mmol) was added and the mixture heated at reflux for 18 h. The cooled mixture was diluted with EtOAc, washed with water, brine, dried (MgSO₄) and the solvents evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-aspartic acid di-*t*-butyl ester (50 mg, 0.095 mmol) as a yellow solid.

¹H (CDCl₃, 400 MHz) δ 1.2 (9H, s), 1.4 (9H, s), 2.7 (1H, dd), 2.8 (1H, dd), 4.1 (1H, br t), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.3 (1H, s) ppm.

LRMS 528, 530 (MH⁺).

N-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-aspartic acid di-*t*-butyl ester (50 mg, 0.095 mmol) was dissolved in a solution of EtOAc saturated with HCl (10 mL) and the mixture stirred at room temperature for 4 h. The mixture was concentrated *in vacuo* and the residue triturated with PhMe and then Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-aspartic acid hydrochloride (29 mg, 0.062 mmol) as an off-white solid.

¹H (CD₃OD, 400 MHz) δ 2.7 (1H, dd), 2.8 (1H, dd), 4.4 (1H, br t), 8.35 (1H, d), 8.45 (1H, s), 8.45 (1H, d), 8.9 (1H, s) ppm.


LRMS 415 (M⁺).

Anal. Found: C, 36.05; H, 3.72; N, 13.62. Calc for C₁₄H₁₄ClN₅O₆S•1.0HCl•0.8H₂O: C, 36.03; H, 3.59; N, 15.01.

Example 31:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-proline *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-proline hydrochloride



- 5 NaH (35 mg, 80% dispersion by wt in mineral oil, 1.16 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (177 mg, 1.85 mmol) in DME (5 mL) and the mixture was heated at 60 °C under N₂ for 45 min. A solution of 1-[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino]-L-proline *t*-butyl ester (200 mg, 0.46 mmol) in DME (2 mL) was added and the mixture heated at 95 °C for 4 h. The solvents were evaporated *in vacuo*
- 10 and the residue was purified by column chromatography upon silica gel using pentane-EtOAc (80:20 to 0:100) as eluant, followed by azeotrope with CH₂Cl₂, to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-proline *t*-butyl ester (153 mg, 0.32 mmol) as a pale yellow foam.

- 15 ¹H (DMSO-*d*₆, 300 MHz) δ 1.35 (9H, s), 1.6-1.7 (1H, m), 1.7-1.9 (2H, m), 1.9-2.0 (1H, m), 3.15-3.25 (1H, m), 3.35-3.5 (1H, m), 4.1 (1H, dd), 7.15-7.4 (4H, br), 8.05 (1H, d), 8.1 (1H, d), 8.1 (1H, s), 9.05 (1H, s) ppm.

LRMS 454, 456 (MH⁺), 907 (M₂H⁺).

20

Anal. Found: C, 50.02; H, 5.41; N, 14.84. Calc for C₁₉H₂₄ClN₅O₄S•0.1EtOAc•0.05CH₂Cl₂: C, 50.02; H, 5.37; N, 15.00.

- N*-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-proline *t*-butyl ester (60 mg, 0.13 mmol) was dissolved in a solution of EtOAc saturated with HCl (5.0 mL) and the mixture stirred at room temperature for 1 h. The mixture was concentrated *in vacuo*, azeotrope with EtOAc, and the residue triturated with CH₂Cl₂ to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-L-proline hydrochloride (44 mg, 0.095 mmol) as a white powder.

- 30 mp 185-189 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 1.5-1.7 (1H, m), 1.7-2.0 (3H, m), 3.2-3.5 (2H, m), 4.2 (1H, dd), 8.3-8.8 (4H, br), 8.2 (2H, s), 8.5 (1H, s), 8.1 (1H, s), 9.05 (1H, s), 11.2 (1H, br) ppm.

Anal. Found: C, 39.89; H, 4.06; N, 14.93. Calc for


5 C₁₅H₁₆ClN₅O₄S•1.0HCl•1.0H₂O•0.1EtOAc: C, 40.11; H, 4.33; N, 15.19.

Example 32:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline hydrochloride

10



Guanidine hydrochloride (220 mg, 2.3 mmol) was added in one portion to a stirred suspension of NaH (55 mg, 80% dispersion by wt in mineral oil, 1.83 mmol) in DME (8 mL) and the mixture was heated at 60 °C under N₂ for 30 min. 1-[[1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino}-D-proline *t*-butyl ester (250 mg, 0.58 mmol) was added and the mixture heated at reflux for 5 h. The cooled mixture was diluted with EtOAc, washed with water, brine, dried (MgSO₄) and the solvents evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97:3:0.3) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline *t*-butyl ester (200 mg, 0.44 mmol) as a yellow solid.

15

20

mp >170 °C (dec).

¹H (CDCl₃, 400 MHz) δ 1.45 (9H, s), 1.7-1.8 (1H, m), 1.8-2.05 (3H, m), 3.3-3.45 (1H, m), 3.5-3.6 (1H, m), 4.3 (1H, dd), 6.3-6.6 (4H, br), 8.05 (1H, d), 8.1 (1H, d), 8.1 (1H, s), 9.2 (1H, s) ppm.

25

LRMS 454, 456 (MH⁺).

Anal. Found: C, 49.57; H, 5.27; N, 14.95. Calc for C₁₉H₂₄ClN₅O₄S•0.2H₂O•0.04CH₂Cl₂: C, 49.61; H, 5.35; N, 15.19.

30

N-[(4-Chloro-1-guanidino-7-isoquinoliny)sulphonyl]-D-proline *t*-butyl ester (50 mg, 0.11 mmol) was dissolved in a solution of EtOAc saturated with HCl (10 mL) and the mixture stirred at room temperature for 2.5 h. The mixture was concentrated *in vacuo*, azeotroping with CH₂Cl₂, to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-D-proline hydrochloride (40 mg, 0.092 mmol) as a white powder.

mp >200°C (dec).

¹H (CD₃OD, 400 MHz) δ 1.7-1.85 (1H, m), 1.9-2.2 (3H, m), 3.4-3.5 (1H, m), 3.5-3.6 (1H, m), 4.4 (1H, dd), 8.4 (1H, d), 8.45 (1H, s), 8.5 (1H, d), 8.9 (1H, s) ppm.


LRMS 397, 399 (MH⁺)

Anal. Found: C, 40.22; H, 3.92; N, 14.88. Calc for

C₁₅H₁₆ClN₅O₄S•1.0HCl•0.2H₂O•0.25CH₂Cl₂: C, 39.89; H, 3.93; N, 15.25.

It was noted that some racemisation had occurred during repetition of the above preparation in some conditions. An alternative route to Example 32(b) was developed, reversing the guanylation/hydrolysis sequence, as exemplified below:

1. Hydrolysis




tert-Butyl (2*S*)-1-[(1,4-dichloro-7-isoquinoliny)sulfonyl]-2-pyrrolidinecarboxylate (50.0 g, 0.116 mol) was dissolved in conc. HCl (12 M, 200 ml) and stirred for 3.5 h. Water (200 ml) was added over 30 minutes and the resultant white precipitate stirred for a further 0.5 h, filtered and washed with water (3 x 100 ml). Drying under vacuum gave (2*S*)-1-[(1,4-dichloro-7-isoquinoliny)sulfonyl]-2-pyrrolidinecarboxylic acid as a white solid (42.9 g, 0.114 mol).

¹H (d₆-DMSO, 300 MHz) δ 1.6-1.95 (3H, m), 1.95-2.1 (1H, m), 3.25-3.35 (1H, m), 3.35-3.45 (1H, m), 4.3 (1H, dd), 8.35 (2H, s), 8.6 (1H, s), 8.65 (1H, s) ppm.

Chiral analysis was performed using capillary electrophoresis, showing an enantiomeric purity of 97.41%.

2. Guanylation of free acid

5




Potassium t-butoxide (49.0 g, .0437 mol) and guanidine.HCl (42.8 g, 0.448 mol) in DME
 10 (210 ml) was heated to reflux under nitrogen for 20 min. (2S)-1-[(1,4-dichloro-7-
 isoquinoliny)sulfonyl]-2-pyrrolidinecarboxylic acid (42.0 g, 0.112 mol) was added and
 heating continued at reflux for 5.5 h. Water (420 ml) was added and the mixture acidified
 with c. HCl to pH = 5 giving a solid which was removed by filtration, washed with aq. DME
 (1:1, 2 x 75 ml) and water (2 x 75 ml) and dried to yield the title compound (b) as a yellow
 15 solid (40.71 g, 0.102 mol).

¹H (d₆-DMSO, 300 MHz) δ 1.5-1.65 (1H, m), 1.7-2.0 (3H, m), 3.1-3.25 (1H, m), 3.35-4.05
 (1H, m), 4.2 (1H, dd), 7.2-7.7 (4H, br s), 8.0 (1H, d), 8.1-8.2 (2H, m), 9.05 (1H, d).

20 Chiral analysis was performed using capillary electrophoresis, showing an enantiomeric
 purity of 99.76% (n=2).

Example 33:

4-Chloro-1-guanidino-7-[(2R)-(hydroxymethyl)-1-pyrrolidinyl]sulphonylisoquinoline
 25 hydrochloride



NaH (26 mg, 80% dispersion by wt in mineral oil, 0.87 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (126 mg, 1.32 mmol) in DMSO (2 mL) and the mixture was heated at 50 °C under N₂ for 20 min. A solution of 1,4-dichloro-7-[[[(2R)-(hydroxymethyl)-1-pyrrolidinyl]sulphonyl]isoquinoline (120 mg, 0.33 mmol) in DMSO (3 mL) was added in one portion and the mixture heated at 80-90 °C for 1 h. The cooled mixture was poured into water, extracted with EtOAc (2x) and the combined organic extracts were then washed with water (x3), brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 80:20:5) as eluant to give the desired product as an off-white, sticky solid. This material was dissolved in MeOH, a solution of HCl in Et₂O (1 M) was added and the solvents were evaporated *in vacuo*. The residue was recrystallised from MeOH to give 4-chloro-1-guanidino-7-[[[(2R)-(hydroxymethyl)-1-pyrrolidinyl]sulphonyl]isoquinoline hydrochloride (43 mg, 0.10 mmol) as a white solid.

mp 275-276.5 °C.

¹H (CD₃OD, 400 MHz) δ 1.5-1.65 (2H, m), 1.8-1.95 (2H, m), 3.25 -3.35 (2H, m), 3.45-3.55 (1H, m), 3.6-3.65 (1H, m), 3.7-3.85 (2H, m), 8.4 (1H, d), 8.45 (1H, s), 8.5 (1H, d), 8.9 (1H, s) ppm.


LRMS 383 (MH⁺), 405 (MNa⁺), 767 (M₂H⁺).

Anal. Found: C, 42.36; H, 4.54; N, 16.14. Calc for C₁₅H₁₈ClN₅O₃S•1.0HCl•0.25H₂O: C, 42.41; H, 4.63; N, 16.49.

Example 34:

(a) 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]isobutyric acid methyl ester

(b) 2-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]isobutyric acid hydrochloride



NaH (32 mg, 80% dispersion by wt in mineral oil, 1.07 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (167 mg, 1.7 mmol) in DMSO (5 mL) and the mixture was heated at 50 °C under N₂ for 20 min. 1-[[[1,4-Dichloro-7-isoquinolinyl]sulphonyl]amino]isobutyric acid methyl ester (161 mg, 0.43 mmol) was added in one portion and the mixture heated at 80 °C for 6.5 h. The cooled mixture was poured into water (50 mL), extracted with EtOAc (2x100, 2x25 mL) and the combined organic extracts were washed with water, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by repeated column chromatography upon silica gel using (i) CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5), (ii) hexane-EtOAc (70:30), and then (iii) CH₂Cl₂-MeOH-0.880NH₃ (90:10:01), as eluant to give the product as a yellow oil. Trituration with Et₂O gave 1-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]isobutyric acid methyl ester (23 mg, 0.054 mmol) as yellow solid.

mp >170 °C (dec).

¹H (CD₃OD, 300 MHz) δ 1.4 (6H, s), 3.5 (3H, s), 8.15-8.25 (3H, m), 9.1 (1H, s) ppm.

LRMS 400, 402 (MH⁺).

Anal. Found: C, 44.02; H, 4.65; N, 16.29. Calc for C₁₅H₁₈ClN₅O₄S•0.9H₂O•0.1*i*-Pr₂O: C, 43.95; H, 5.01; N, 16.43.

A solution of NaOH (1 mL, 2 M, 2 mmol) was added to a solution of 1-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]isobutyric acid methyl ester (16.5 mg, 0.041 mmol) in MeOH (0.5 mL) and the mixture was heated at 40-50 °C for 16 h. The cooled mixture was neutralised with dilute HCl (0.5 mL, 2 M) to give a precipitate. The solid was collected by filtration, with copious water washing, and then dissolved in conc. HCl. The solvents were evaporated *in vacuo* azeotroping with PhMe, and then dried under high vacuum to give 1-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]-amino]isobutyric acid hydrochloride (12 mg, 0.026 mmol) as a pale cream solid.

mp 258 °C (dec)

¹H (CD₃OD, 400 MHz) δ 1.45 (6H, s), 8.4 (1H, d), 8.4 (1H, s), 8.45 (1H, d), 8.9 (1H, s) ppm.


LRMS 386, 388 (MH⁺).

Anal. Found: C, 37.89; H, 4.33; N, 15.18. Calc for C₁₄H₁₆ClN₅O₄S•1.0HCl•1.5H₂O•0.05Et₂O: C, 37.65; H, 4.56; N, 15.46.

5

Example 35:

2-{{{(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl}amino}-2-methylpropanamide hydrochloride



10

NaH (41 mg, 80% dispersion by wt in mineral oil, 1.36 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (210 mg, 2.2 mmol) in DMSO (10 mL) under N₂ and the mixture was heated at 23 °C for 30 min. 2-{{{(1,4-Dichloro-7-isoquinolinyl)sulphonyl}amino}-2-methylpropanamide (225 mg, 0.50 mmol) was added in one portion and the mixture heated at 90 °C for 8 h. The cooled mixture was partially concentrated *in vacuo* and the residue poured into water. The aqueous solution was extracted with EtOAc (x4) and the combined organic extracts were washed with water, brine, dried (MgSO₄). The solvents were evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant to give the desired product. This material was dissolved in MeOH and treated with a solution of HCl in Et₂O (1.0 mL, 1 M) to furnish 2-{{{(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl}amino}-2-methylpropanamide hydrochloride (86 mg, 0.188 mmol) as an off-white powder.

25 mp 279-281 °C.

¹H (TFA-*d*, 400 MHz) δ 1.6 (6H, s), 8.35 (1H, br s), 8.4 (1H, s), 8.55 (1H, s), 9.1 (1H, br s) ppm.


30 LRMS 385, 387 (MH⁺).

Anal. Found: C, 39.68; H, 4.81; N, 18.18. Calc for C₁₄H₁₇ClN₆O₃S•1.0HCl•1.2 MeOH: C, 39.71; H, 5.00; N, 18.28.

Example 36:

(a) Ethyl 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}cyclobutanecarboxylate

5 (b) 1-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}cyclobutanecarboxylic acid hydrochloride



10 NaH (37 mg, 80% dispersion by wt in mineral oil, 1.24 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (189 mg, 1.98 mmol) in DMSO (6 mL) and the mixture was heated at 60 °C under N₂ for 30 min. Ethyl 1-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino}-cyclobutanecarboxylate (200 mg, 0.50 mmol) was added in one portion and the mixture heated at 80 °C for 10 h. The cooled mixture was poured into

15 water, extracted with EtOAc (2x50 mL) and the combined organic extracts were dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (50:50 to 0:100) as eluant to give ethyl 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}cyclobutanecarboxylate (150 mg, 0.34 mmol) as a yellow powder.

20

mp 165-169 °C

¹H (DMSO-*d*₆, 300 MHz) δ 1.0 (3H, t), 1.6-1.8 (2H, m), 2.05-2.2 (2H, m), 2.25-2.4 (2H, m), 3.8 (2H, q), 7.0-7.4 (4H, br), 8.05 (2H, s), 8.1 (1H, s), 8.6 (1H, s), 9.05 (1H, s) ppm.

25

LRMS 426, 428 (MH⁺).

Anal. Found: C, 46.62; H, 4.62; N, 15.82. Calc for C₁₇H₂₀ClN₅O₄S•0.25CH₂Cl₂: C, 46.45; H, 4.63; N, 15.70.

30

A solution of NaOH (5 mL, 2 M, 10 mmol) was added to a solution of ethyl 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}cyclobutanecarboxylate (100 mg, 0.23 mmol) in

MeOH (5 mL) and the mixture was heated at 55 °C for 6 h. The cooled mixture was neutralised with dilute HCl (5 mL, 2 M) to give a precipitate and the MeOH was evaporated *in vacuo*. The solid was collected by filtration, with copious water washing, and dried under high vacuum to give 1-[[4-chloro-1-guanidino-7-

5 isoquinolinyl)sulphonyl]amino)cyclobutanecarboxylic acid hydrochloride (15 mg, 0.033 mmol).

¹H (DMSO-*d*₆, 400 MHz) δ 1.65-1.8 (2H, m), 2.05-2.2 (2H, m), 2.25-2.4 (2H, m), 8.3 (1H, d), 8.35-8.7 (4H, br), 8.4 (1H, d), 8.5 (1H, s), 8.7 (1H, s), 8.95 (1H, s), 11.0 (1H, br), 12.5
10 (1H, br) ppm.


Anal. Found: C, 40.06; H, 4.34; N, 15.09. Calc for C₁₅H₁₆ClN₅O₄S•1.0HCl•1.0H₂O: C, 39.83; H, 4.23; N, 15.48.

15 Example 37:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cyclo-leucine ethyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cycloleucine

(c) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cycloleucine trifluoroacetate



20

NaH (1.12 g, 80% dispersion by wt in mineral oil, 37.3 mmol) was added portionwise to a stirred suspension of guanidine hydrochloride (5.85 g, 59.4 mmol) in DMSO (320 mL) and the mixture was heated at 30-50 °C under N₂ for 30 min. *N*-[(1,4-Dichloro-1-guanidino-7-
25 isoquinolinyl)sulphonyl]-cycloleucine ethyl ester (6.2 g, 14.9 mmol) was added in one portion and the mixture heated at 80 °C for 8 h. The cooled mixture concentrated *in vacuo* to ca. 160 mL and poured into water (800 mL). The aqueous mixture was extracted with EtOAc (4x150 mL) and the combined organic extracts were then washed with water, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography
30 upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 90:10:1) as eluant and then recrystallised from EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cyclo-leucine ethyl ester (1.43 g, 3.25 mmol) as a yellow solid.

mp 225-226 °C

¹H (DMSO-*d*₆, 300 MHz) δ 1.1 (3H, t), 1.35-1.45 (2H, m), 1.45-1.5 (2H, m), 1.85-1.95 (4H, br), 3.9 (2H, q), 7.1-7.35 (4H, br), 8.0 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 9.1 (1H, s) ppm.

LRMS 440, 442 (MH⁺).

Anal. Found: C, 49.02; H, 4.97; N, 15.61. Calc for C₁₈H₂₂ClN₅O₄S: C, 49.14; H, 5.04; N, 15.92.

A solution of NaOH (75 mL, 2 M, 150 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]cycloleucine ethyl ester (1.39 g, 3.16 mmol) in MeOH (75 mL) and the mixture heated at 40-50 °C for 24 h. The cooled mixture was neutralised with dilute HCl (75 mL, 2 M) to give a precipitate and the MeOH was evaporated *in vacuo*. The solid was collected by filtration, with copious water washing, and dried under high vacuum to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]cycloleucine (1.27 g, 3.08 mmol) as a white powder.

Anal. Found: C, 46.40; H, 4.39; N, 16.66. Calc for C₁₆H₁₈ClN₅O₄S: C, 46.66; H, 4.41; N, 17.00.

N-[(4-Chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]cycloleucine (8 mg) was dissolved in CF₃CO₂H (ca. 1.0 mL) and the mixture was evaporated *in vacuo*, azeotroping with PhMe. The residue was triturated with *i*-Pr₂O and Et₂O to give a white solid. The solid was dissolved in MeOH, filtered and the filtrate evaporated *in vacuo* to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]cycloleucine trifluoroacetate (12 mg).

mp >178 °C (dec).


¹H (DMSO-*d*₆, 400 MHz) δ 1.3-1.45 (2H, m), 1.45-1.55 (2H, m), 1.85-1.95 (4H, br), 8.25-8.6 (4H, br), 8.3 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.85 (1H, s), 10.8 (1H, br), 12.4 (1H, br) ppm.

LRMS 412, 414 (MH⁺).

Anal. Found: C, 39.50; H, 3.62; N, 11.50. Calc for $C_{16}H_{18}ClN_5O_4S \cdot 1.0CF_3CO_2H \cdot 1.0H_2O$: C, 39.75; H, 3.89; N, 12.88.

Example 38:

5 1-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-hydroxyethyl)cyclopentanecarboxamine hydrochloride



10 $(COCl)_2$ (60 μ L, 0.67 mmol) and then DMF (3 drops) were added to a stirred suspension of *N*-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cyclopentyl]carboxamide (150 mg, 0.334 mmol) in CH_2Cl_2 (15 mL) and the mixture was stirred at 23 °C for 30 min. The solvents were evaporated *in vacuo*, azeotroping with PhMe, to give the corresponding acid chloride. This material was redissolved in CH_2Cl_2 (15 mL) and added to a stirred solution of

15 2-hydroxyethylamine (400 μ L) in CH_2Cl_2 (15 mL) and the mixture stirred for 1 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880NH₃ (90:10:1) as eluant to give 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-*N*-(2-hydroxyethyl)cyclopentanecarboxamine. This material was dissolved in EtOAc-EtOH and a solution of HCl in Et₂O (1 M) was added

20 which gave a precipitate. The solvents were decanted and the solid was triturated with Et₂O, collected by filtration and dried to give 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-*N*-(2-hydroxyethyl)cyclopentanecarboxamine hydrochloride (77 mg, 0.155 mmol) as a white solid.

25 mp 244-246 °C.

¹H (CD₃OD, 300 MHz) δ 1.35-1.5 (2H, m), 1.5-1.65 (2H, m), 1.85-2.0 (2H, m), 2.0-2.15 (2H, m), 3.1-3.2 (2H, m), 3.5-3.65 (2H, m), 8.4 (1H, d), 8.45 (1H, s), 8.5 (1H, d), 8.95 (1H, s) ppm.


30

LRMS 455 (MH⁺), 477 (MNa⁺).

Anal. Found: C, 43.63; H, 5.03; N, 16.65. Calc for $C_{18}H_{23}ClN_6O_4S \cdot 1.0HCl \cdot 0.25 H_2O$: C, 43.60; H, 4.98; N, 16.95.

Example 39:

- 5 (a) 1-[[[(4-Chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]amino]-*N*-[2-(dimethylamino)ethyl]cyclopentanecarboxamine
 (b) 1-[[[(4-Chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]amino]-*N*-[2-(dimethylamino)ethyl]cyclopentanecarboxamine dihydrochloride



A solution HCl in Et₂O (0.5 mL, 1 M) was added to a stirred solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]cycloleucine (100 mg, 0.243 mmol) in MeOH. The solvents were evaporated in vacuo and the residue azeotroped with PhMe to give the
 15 corresponding hydrochloride salt.

(COCl)₂ (42 μL, 0.48 mmol) and then DMF (2 drops) were added to a stirred solution of *N*-[[[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]cycloleucine hydrochloride (0.243 mmol) in CH₂Cl₂ (5 mL) and the mixture was stirred at 23 °C for 18 h. The solvents were evaporated
 20 *in vacuo*, the residue redissolved in CH₂Cl₂ (5 mL), and 2-(dimethylamino)ethylamine (60 μL, 0.48 mmol) was added and the mixture stirred for 3 h. The solvents were evaporated *in vacuo* and the residue partitioned between EtOAc and aqueous NaHCO₃ (10 %). The organic phase was dried and evaporated. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5 to 90:10:1) as eluant to give 1-[[[(4-chloro-1-guanidino-7-isoquinoliny)l)sulphonyl]amino]-*N*-[2-(dimethylamino)ethyl]cyclopentanecarboxamine.

LRMS 482 (MH⁺).

30 This material was dissolved in EtOAc, a solution of HCl in Et₂O (1 M) was added and the solvents were evaporated *in vacuo* to give 1-[[[(4-chloro-1-guanidino-7-

isoquinoliny]sulphonyl]amino)-*N*-[2-(dimethylamino)ethyl]cyclopentanecarboxamine dihydrochloride (28 mg, 0.048 mmol) as a white solid.


¹H (TFA-*d*, 400 MHz) δ 1.5 (2H, br s), 1.7 (2H, br s), 2.1 (4H, br s), 3.2 (6H, s), 3.7 (2H, br s), 4.0 (2H, br s), 7.8 (1H, br s), 8.45 (1H, d), 8.5 (1H, s), 8.6 (1H, d), 9.5 (1H, s) ppm.

LRMS 482 (MH⁺).

Anal. Found: C, 41.25; H, 5.63; N, 16.59. Calc for C₂₀H₂₈ClN₇O₃S•2.0HCl•1.5H₂O: C, 41.28; H, 5.72; N, 16.85.

Example 40:

4-Chloro-1-guanidino-*N*-[1-(hydroxymethyl)cyclopentyl]-7-isoquinolinesulphonamide hydrochloride



NaH (30 mg, 80% dispersion by wt in mineral oil, 1.0 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (157 mg, 1.6 mmol) in DMSO (5 mL) and the mixture was heated at 60 °C under N₂ for 20 min. 1,4-Dichloro-*N*-[1-(hydroxymethyl)cyclopentyl]-7-isoquinolinesulphonamide (150 mg, 0.40 mmol) was added in one portion and the mixture heated at 80 °C for 4 h. A second portion of guanidine (0.40 mmol) [prepared from guanidine hydrochloride (38 mg) and NaH (12 mg)] in DMSO (1 mL) was added and the mixture heated at 80 °C for an additional 6 h. The cooled mixture was poured into water (80 mL), extracted with EtOAc (2x50 mL) and the combined organic extracts were then washed with brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (97.5:2.5:0.25 to 80:20:5) as eluant to give the partially purified product (90 mg). This material was converted to the corresponding hydrochloride salt by treatment with a solution of HCl in Et₂O (1 M) and then recrystallised from EtOH to give 4-chloro-1-guanidino-*N*-[1-(hydroxymethyl)cyclopentyl]-7-isoquinolinesulphonamide hydrochloride (16 mg, 0.040 mmol) as a white solid.

mp 245-247 °C.

¹H (CD₃OD, 400 MHz) δ 1.4-1.55 (4H, m), 1.55-1.7 (2H, m), 1.8-1.9 (2H, m), 3.5 (2H, s), 8.4 (1H, d), 8.45 (1H, s), 8.45 (1H, d), 8.9 (1H, s) ppm.

5

LRMS 398, 400 (MH⁺).

Anal. Found: C, 44.17; H, 4.84; N, 15.88. Calc for C₁₆H₂₀ClN₅O₃S•1.0HCl: C, 44.24; H, 4.87; N, 16.12.


10

Example 41:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine ethyl ester dihydrochloride

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-[2-

15 (dimethylamino)ethyl]cycloleucine dihydrochloride



NaH (32 mg, 80% dispersion by wt in mineral oil, 1.05 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (145 mg, 1.52 mmol) in DMSO (4 mL) and the mixture was heated at 50 °C under N₂ for 20 min. *N*-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine ethyl ester hydrochloride (160 mg, 0.305 mmol) was added in one portion and the mixture heated at 90 °C for 1 h. The cooled mixture was poured into water, extracted with EtOAc (2x20 mL) and the combined organic extracts were then washed with brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was dissolved in Et₂O, filtered, and a solution of HCl in Et₂O (1 M) was added which gave a precipitate. The solvents were evaporated *in vacuo* and the residue recrystallised from hot EtOH to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine ethyl ester dihydrochloride (123 mg, 0.20 mmol) as a pale yellow solid.

30

mp 228-230°C.

¹H (TFA-*d*, 400 MHz) δ 1.45 (3H, t), 1.7 (2H, br s), 1.9 (2H, br s), 2.2 (2H, br s), 2.5 (2H, br s), 3.3 (6H, s), 3.75 (2H, br s), 4.3 (2H, br s), 4.4 (2H, q), 8.15 (1H, br s), 8.4 (1H, d), 8.5 (1H, s), 8.65 (1H, d), 9.35 (1H, s) ppm.

5

LRMS 511, 513 (MH⁺).

Anal. Found: C, 43.74; H, 5.88; N, 13.75. Calc for C₂₂H₃₁ClN₆O₄S•2.0HCl•1.0H₂O: C, 43.90; H, 5.86; N, 13.96.

10

A solution of NaOH (5 mL, 5 M) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine ethyl ester dihydrochloride (75 mg, 0.128 mmol) in dioxane (5 mL) and the mixture was heated at 80 °C for 30 h. The cooled mixture was diluted with water (20 mL), the dioxane was evaporated *in vacuo*, and the aqueous residue neutralised with dilute HCl (2 M) to pH 6. The precipitate was collected by filtration with water washing, and then dissolved in MeOH, filtered and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1 to 80:20:5) as eluant to give the desired product. This material was dissolved in MeOH-EtOAc, a solution of HCl in Et₂O (1 M) was added and the solvents were evaporated *in vacuo*. The residue was triturated with EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine dihydrochloride (15.4 mg, 0.025 mmol).

15

20

¹H (TFA-*d*, 400 MHz) δ 1.7 (2H, br s), 1.9 (2H, br s), 2.2 (2H, br s), 2.6 (2H, br s), 3.25 (6H, s), 3.8 (2H, br s), 4.3 (2H, br s), 8.1 (1H, br s), 8.4 (1H, d), 8.5 (1H, s), 8.65 (1H, d), 9.4 (1H, s) ppm.

25

LRMS 483 (MH⁺).


Anal. Found: C, 39.03; H, 5.60; N, 14.02. Calc for C₂₀H₂₇ClN₆O₄S•2HCl•3H₂O: C, 39.38; H, 5.78; N, 13.78.

30

Example 42:

N-(*t*-Butoxycarbonylmethyl)-*N*-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]cycloleucine ethyl ester

35



Anhydrous K_2CO_3 (34 mg, 0.25 mmol) and *t*-butyl bromoacetate (44 μ L, 0.30 mmol) were added to a stirred solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cycloleucine ethyl ester (110 mg, 0.25 mmol) in DMF (1.0 mL) and the mixture was stirred at 23 °C for 18 h. The mixture was diluted with EtOAc (60 mL), washed with water (3x100 mL), dried ($MgSO_4$) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 20:80) as eluant to give *N*-(*t*-butoxycarbonylmethyl)-*N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cycloleucine ethyl ester (95 mg, 0.17 mmol) as a white solid.

1H ($CDCl_3$, 400 MHz) δ 1.3 (3H, t), 1.45 (9H, s), 1.6-1.7 (4H, m), 1.85-1.95 (2H, br), 2.25-2.35 (2H, m), 4.2 (2H, q), 4.5 (2H, s), 8.1 (1H, d), 8.15 (1H, s), 8.3 (1H, dd), 9.3 (1H, d) ppm.


LRMS 554 (MH^+).

Anal. Found: C, 52.31; H, 5.94; N, 13.33. Calc for $C_{24}H_{32}ClN_5O_6S$: C, 52.03; H, 5.82; N, 12.64.

Example 43:

(a) Methyl 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate

(b) 1-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylic acid hydrochloride



NaH (22.3 mg, 80% dispersion by wt in mineral oil, 0.743 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (117 mg, 1.98 mmol) in DMSO (5 mL) and

the mixture was heated at 50-70 °C under N₂ for 25 min. Methyl 1-[[[1,4-dichloro-7-isoquinoliny]sulphonyl]amino]-cyclohexanecarboxylate (124 mg, 0.30 mmol) was added in one portion and the mixture heated at 80 °C for 8 h. The cooled mixture was poured into water (50 mL), extracted with EtOAc (2x50 mL) and the combined organic extracts were washed with water, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was crystallised from a minimum of hot EtOAc to give methyl 1-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]cyclohexanecarboxylate (12 mg, 0.043 mmol) as yellow solid. Evaporation of the mother liquors and trituration of the residue with Et₂O gave a second crop (7 mg).

mp >220 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 1.1-1.35 (6H, m), 1.65-1.75 (2H, m), 1.75-1.85 (2H, m), 3.35 (3H, s), 7.1-7.4 (4H, br), 8.0 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 8.15 (1H, s), 9.0 (1H, s) ppm.

LRMS 440, 442 (MH⁺).

Anal. Found: C, 48.55; H, 5.12; N, 15.73. Calc for C₁₈H₂₂ClN₅O₄S•0.3H₂O: C, 49.14; H, 5.04; N, 15.92.

A solution of NaOH (1 mL, 2 M, 2 mmol) was added to a solution of methyl 1-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]cyclohexanecarboxylate (12 mg, 0.027 mmol) in MeOH (4 mL) and the mixture was heated at 50-60 °C for 4 d. The cooled mixture was neutralised with dilute HCl (1 mL, 2 M) to give a precipitate. The solid was collected by filtration, with copious water washing, and then triturated with EtOAc. The solid was dissolved in conc. HCl, the solvents were evaporated *in vacuo* azeotroping with PhMe, and then dried under high vacuum to give 1-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino]cyclohexanecarboxylic acid hydrochloride (11 mg, 0.021 mmol).

mp 194 °C (dec)

¹H (DMSO-*d*₆, 400 MHz) δ 1.1-1.4 (6H, m), 1.6-1.8 (2H, m), 1.8-1.95 (2H, m), 8.15-8.7 (4H, br), 8.2 (1H, s), 8.3 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.9 (1H, s), 10.9 (1H, br), 12.4 (1H, br) ppm.

LRMS 426 (MH⁺).


Anal. Found: C, 39.87; H, 5.05; N, 13.16. Calc for C₁₇H₂₀ClN₅O₄S•1.0HCl•3.0H₂O: C, 39.54;

5 H, 5.27; N, 13.56.

Example 44:

(a) Methyl 4-[[[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino}tetrahydro-2H-pyran-4-carboxylate

10 (b) 4-[[[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino}tetrahydro-2H-pyran-4-carboxylic acid hydrochloride



15 NaH (33.5 mg, 80% dispersion by wt in mineral oil, 1.12 mmol) was added in one portion to a stirred solution of guanidine hydrochloride (176 mg, 1.84 mmol) in DMSO (3.0 mL) under N₂ and the mixture was heated at 50 °C for 15 min. Methyl 4-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino}tetrahydro-2H-pyran-4-carboxylate (187 mg, 0.446 mmol) was added in one portion and the mixture heated at 80 °C for 8 h. A second portion of

20 guanidine (0.45 mmol)[prepared from guanidine hydrochloride and NaH] in DMSO (1.0 mL) was added and the mixture heated at 90 °C for an additional 4 h. The cooled mixture was poured into water (100 mL), extracted with EtOAc (3x50 mL) and the combined organic extracts were washed with brine, dried (Na₂SO₄). The solvents were evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-

25 0.880NH₃ (95:5:0.5) as eluant, and then crystallised with EtOAc, to give to give methyl 4-[[[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino}tetrahydro-2H-pyran-4-carboxylate (83 mg, 0.186 mmol) as a yellow solid.

mp 245-247 °C.

30

¹H (CDCl₃, 400 MHz) δ 3.3 (3H, s), 3.35-3.45 (8H, m), 7.1-7.4 (4H, br), 8.05 (2H, s), 8.1 (1H, s), 8.4 (1H, s), 9.0 (1H, s) ppm.

LRMS 442, 444 (MH⁺).

Anal. Found: C, 46.18; H, 4.56; N, 15.32. Calc for C₁₇H₂₀ClN₅O₅S•0.2H₂O: C, 45.83; H, 4.62;
 5 N, 15.72.

A solution of NaOH (1 mL, 2 M, 2 mmol) was added to a solution of methyl 4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}tetrahydro-2H-pyran-4-carboxylate (68 mg, 0.153 mmol) in MeOH (12 mL) and the mixture was heated at reflux for 30 h. The cooled
 10 mixture was neutralised with dilute HCl (1 mL, 2 M), partially concentrated by evaporation *in vacuo* to give a precipitate which was collected by filtration, with water washing. The solid was extracted with warm conc. HCl, the solution decanted from insoluble material and the solvents were evaporated *in vacuo*. The solid residue was azeotroped with PhMe and then dried under high vacuum to give 4-[[[(4-chloro-1-guanidino-7-
 15 isoquinolinyl)sulphonyl]amino}tetrahydro-2H-pyran-4-carboxylate acid hydrochloride (30 mg, 0.062 mmol) as a white solid.

mp 190-210 °C (dec).

20 ¹H (DMSO-*d*₆, 400 MHz) δ 3.2-3.5 (8H, m), 8.2-8.7 (4H, br), 8.3 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.95 (1H, s), 11.0 (1H, br s), 12.6 (1H, br s) ppm.


Anal. Found: C, 39.76; H, 4.33; N, 14.12. Calc for C₁₆H₁₈ClN₅O₅S•1.0HCl•1.1H₂O: C, 39.69; H, 4.41; N, 14.47.

25

Example 45:

(a) *t*-Butyl (±)-*cis*-2-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-cyclohexanecarboxylate

(b) (±)-*cis*-2-[[[(4-Chloro-1-guanidino-7-
 30 isoquinolinyl)sulphonyl]amino}cyclohexanecarboxylic acid hydrochloride



Guanidine hydrochloride (325 mg, 3.4 mmol) was added in one portion to a stirred suspension of NaH (89 mg, 80% dispersion by wt in mineral oil, 2.97 mmol) in DME (5 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *t*-butyl (±)-*cis*-2-
5 {[(1,4-dichloro-7-isoquinoliny)sulphonyl]amino}cyclohexanecarboxylate (391 mg, 0.85 mmol) in DME (5 mL) was added and the mixture heated at 90 °C for 6 h. The solvents were evaporated *in vacuo*, the residue was dissolved with EtOAc, washed with aqueous NH₄Cl, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using using toluene-*i*-PrOH-0.880NH₃ (100:0:0 to
10 90:10:0.05) as eluant to give *t*-butyl (±)-*cis*-2-{[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]amino}cyclohexanecarboxylate (75 mg, 0.15 mmol) as a white solid.

¹H (CDCl₃, 400 MHz) δ 1.1-1.8 (7H, m), 1.4 (9H, s), 1.95 (1H, m), 2.55 (1H, dd), 3.45 (1H, br s), 5.9 (1H, d), 6.0-6.5 (4H, br), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.3 (1H, s) ppm.

15 LRMS 482, 484 (MH⁺).

CF₃CO₂H (3.0 mL) was added to a stirred solution of *t*-butyl (±)-*cis*-2-{[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]amino}cyclohexanecarboxylate (66 mg, 0.14 mmol) in
20 CH₂Cl₂ (3.0 mL) and the mixture was stirred at 23 °C for 6 h. The solvents were evaporated *in vacuo*, azeotroping CH₂Cl₂ (x3). The residue was dissolved in EtOAc and a solution of HCl in Et₂O (200 µL, 1.0 M) was added which gave a precipitate. The white solid was collected by filtration and dried to give (±)-*cis*-2-{[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]amino}cyclohexanecarboxylic acid hydrochloride (35 mg, 0.069
25 mmol).


mp 220-223 °C (dec).

¹H (DMSO-*d*₆, 400 MHz) δ 1.1-1.3 (3H, m), 1.4-1.6 (4H, m), 1.7-1.8 (1H, m), 2.5 (1H, m),
30 3.75 (1H, br s), 8.0 (1H, d), 8.25-8.6 (4H, br), 8.35 (2H, s), 8.45 (1H, s), 8.95 (1H, s) ppm.

Anal. Found: C, 42.95; H, 4.96; N, 13.79. Calc for C₁₇H₂₀ClN₅O₄S•1.0HCl•1.25H₂O•0.3Et₂O: C, 43.11; H, 5.27; N, 13.81.

35 **Example 46:**

Ethyl (±)-*trans*-2-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate




- 5 Guanidine hydrochloride (458 mg, 4.8 mmol) was added in one portion to a stirred suspension of NaH (90 mg, 80% dispersion by wt in mineral oil, 2.97 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of ethyl (±)-*cis*-2-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (377 mg, 0.87 mmol) in DMA (5 mL) was added and the mixture heated at 90 °C for 4 h. The solvents were
- 10 evaporated *in vacuo*, the residue was dissolved with EtOAc (200 mL), washed with aqueous NH₄Cl (20 mL), then with water (500 mL), and the combined aqueous washings were extracted with EtOAc (2x50 mL). The combined EtOAc extracts were washed with water (4x100 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using using toluene-*i*-PrOH-0.880NH₃ (100:0:0 to
- 15 90:10:0.05) as eluant to give ethyl (±)-*trans*-2-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (65 mg, 0.14 mmol) as a white solid. [A small amount of ethyl (±)-*cis*-2-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (<20 mg) was also isolated.]

- 20 ¹H (CDCl₃, 400 MHz) δ 1.1-1.8 (6H, mm), 1.1 (3H, t), 1.9 (1H, m), 2.0 (1H, m), 2.25 (1H, td), 3.45 (1H, m), 3.8-4.0 (2H, m), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.3 (1H, s) ppm.

LRMS 454, 456 (MH⁺).

25 **Example 47:**

- (a) *t*-Butyl *cis*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate
- (b) *t*-butyl *trans*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate
- 30 (c) *cis*-4-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylic acid hydrochloride



Guanidine hydrochloride (286 mg, 3.0 mmol) was added in one portion to a stirred suspension of NaH (56 mg, 80% dispersion by wt in mineral oil, 1.82 mmol) in DME (5 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of *t*-butyl *cis*-4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (346 mg, 0.75 mmol) in DME (15 mL) was added and the mixture heated at 90 °C for 2 h. A second portion of guanidine (0.75 mmol)[prepared from guanidine hydrochloride (72 mg) and NaH (22 mg)] in DME (5 mL) was added and the mixture heated at 90 °C for 1 h. DMA (10 mL) was then added to the heterogeneous reaction mixture and the now homogeneous mixture heated for an additional 6 h. The solvents were evaporated *in vacuo*, the residue was quenched aqueous NH₄Cl (10 mL), diluted with water (150 mL) and extracted with EtOAc (2x150 mL). The combined organic extracts were washed with water (100 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by repeated column chromatography upon silica gel using (i), pentane-EtOAc (100:0 to 25:75) and then (ii), PhMe-EtOAc (50:50 to 0:100) as eluant to give *t*-butyl *cis*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (247 mg, 0.51 mmol). [A small amount of *t*-butyl *trans*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (20 mg) was also isolated.]

20

¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 1.5-1.8 (8H, m), 2.3 (1H, m), 3.4 (1H, m), 4.8-4.9 (1H, br), 6.1-6.55 (4H, br), 8.05 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.3 (1H, s) ppm.

LRMS 482 (MH⁺), 963 (M₂H⁺).

25

Anal. Found: C, 52.14; H, 5.92; N, 14.19. Calc for C₂₁H₂₈ClN₅O₄S: C, 52.33; H, 5.86; N, 14.53.

t-Butyl *cis*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (55 mg, 0.121 mmol) was suspended in a solution of EtOAc saturated with HCl (50 mL) and the mixture heated at reflux. The mixture was cooled, the white solid was collected by filtration, with EtOAc washing, and

30

then dried to give *cis*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-cyclohexanecarboxylic acid hydrochloride (110 mg, 0.236 mmol).

mp 287-289 °C.

5

¹H (CDCl₃, 400 MHz) δ 1.5-1.6 (6H, m), 1.8-1.9 (2H, m), 2.35 (1H, m), 3.4 (1H, m), 8.35 (1H, d), 8.45 (1H, s), 8.5 (1H, d), 8.9 (1H, s) ppm


Anal. Found: C, 43.88; H, 4.61; N, 14.69; Calc for C₁₇H₂₀ClN₅O₄S•1.0HCl•0.2H₂O: C, 43.82;

10 H, 4.63; N, 15.03.

Example 48:

(a) Ethyl *trans*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate

15 (b) *trans*-4-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylic acid hydrochloride



20 Guanidine hydrochloride (273 mg, 2.86 mmol) was added in one portion to a stirred suspension of NaH (55 mg, 80% dispersion by wt in mineral oil, 1.82 mmol) in DME (10 mL) and the mixture was heated at 60 °C under N₂ for 30 min. A solution of ethyl *trans*-4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (370 mg, 0.78 mmol) in DMA (10 mL) was added and the mixture heated at 90 °C for 3 h. The solvents
25 were evaporated *in vacuo*, the residue was partitioned between Et₂O (100 mL), aqueous NH₄Cl (10 mL), and water (150 mL). The separated aqueous phase was extracted with Et₂O (3x100 mL) and the combined organic extracts were dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using toluene-*i*-PrOH-0.880NH₃ (100:0:0 to 90:10:0.05) as eluant to give ethyl *trans*-4-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (70 mg, 0.15 mmol).
30

¹H (CDCl₃, 400 MHz) δ 1.1 (3H, s), 1.1-1.3 (4H, mm), 1.6 (2H, br d), 1.8 (2H, br d), 2.1 (1H, m), 2.9 (1H, m), 3.95 (2H, q), 7.1-7.4 (4H, br), 7.8 (1H, d), 8.0 (1H, d), 8.1 (1H, d), 8.1 (1H, s), 9.1 (1H, s) ppm.

5 LRMS 454, 456 (MH⁺).

Anal. Found: C, 50.27; H, 5.56; N, 14.92. Calc for C₁₉H₂₄ClN₅O₄S: C, 50.27; H, 5.32; N, 15.43.

10 A solution of HCl (5 mL, 2 M, 10 mmol) was added to a solution of ethyl *trans*-4-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]cyclohexanecarboxylate (55 mg, 0.121 mmol) in dioxane (5.0 mL) and the mixture was heated at reflux for 2 h. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon MCI gel (CHP 20P) using water-MeOH (100:0 to 20:80) as eluant to give *trans*-4-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]-cyclohexanecarboxylic acid. This material was
15 dissolved in dilute HCl (20 mL, 0.1 M), the solvents were evaporated *in vacuo*, and the residue triturated with Et₂O to give *trans*-4-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]cyclohexanecarboxylic acid hydrochloride (35 mg, 0.067 mmol) as a white solid.


20 mp >205 °C (dec).

¹H (CD₃OD, 400 MHz) δ 1.2-1.4 (4H, mm), 1.8 (2H, br d), 1.9 (2H, br d), 2.1 (1H, m), 3.1 (1H, m), 8.3 (1H, d), 8.45 (1H, s), 8.5 (1H, d), 8.9 (1H, s) ppm.

25 Anal. Found: C, 42.75; H, 5.04; N, 13.35. Calc for C₁₇H₂₀ClN₅O₄S•1.0HCl•1.5H₂O•0.4Et₂O: C, 43.04; H, 5.44; N, 13.49.

Example 49:

- 30 (a) *N*-[[[4-chloro-1-guanidino-7-isoquinolinyl]carbonyl]glycine *t*-butyl ester
(b) *N*-[[[4-Chloro-1-guanidino-7-isoquinolinyl]carbonyl]glycine trifluoroacetate



- NaH (34 mg, 60% dispersion in mineral oil, 0.85 mmol) was added to a stirred solution of guanidine hydrochloride (80 mg, 0.84 mmol) in DMSO (2 mL) at 23 °C. After 30 min, *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]glycine *t*-butyl ester (120 mg, 0.34 mmol) was added and the resultant solution heated at 90 °C for 21 h. After cooling, the mixture was poured into water (30 mL), extracted with EtOAc, and then with CH₂Cl₂, and the combined organic extracts were dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography on silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]glycine *t*-butyl ester (25 mg, 0.07 mmol) as a yellow gum.

LRMS 378 (MH⁺), 756 (M₂H⁺).

- A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]glycine *t*-butyl ester (24 mg, 0.06 mmol) in CF₃CO₂H (0.5 ml) was stirred at 0 °C for 1.5 h. The reaction mixture was diluted with PhMe, evaporated *in vacuo*, azeotroping with PhMe, and the residue triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]glycine trifluoroacetate (21 mg, 0.05 mmol) as a white solid.

mp > 300 °C.


¹H (TFA-*d*, 400 MHz) δ 4.6 (2H, s), 8.4 (1H, d), 8.45 (1H, s), 8.6 (1H, d), 9.3 (1H, s) ppm.

- LRMS 322 (MH⁺).

Anal. Found: C, 40.60; H, 2.91; N, 15.47. Calc for C₁₃H₁₂ClN₅O₃·CF₃CO₂H: C, 40.58; H, 2.93; N, 15.46.

Example 50:

- (a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-β-alanine *t*-butyl ester
 (b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)carbonyl]-β-alanine



NaH (114 mg, 60% dispersion in mineral oil, 2.85 mmol) was added portionwise to a stirred
 5 solution of guanidine hydrochloride (272 mg, 2.85 mmol) in DMSO (8 mL) and the solution
 was heated at 80 °C for 20 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-β-alanine *t*-butyl
 ester (420 mg, 1.14 mmol) was added and the mixture heated at 90 °C overnight. The cooled
 mixture was poured into water, extracted with EtOAc, and the combined organic extracts
 were washed with water, saturated brine, dried (Na₂SO₄) and evaporated *in vacuo*. The
 10 residue was crystallised from *i*-Pr₂O-CH₂Cl₂ to give *N*-[(4-chloro-1-guanidino-7-
 isoquinolinyl)carbonyl]-β-alanine *t*-butyl ester (190 mg, 0.48 mmol).

mp 224-226 °C.

15 ¹H (DMSO-*d*₆, 400 MHz) δ 1.4 (9H, s), 2.55-2.5 (2H, m), 3.5 (2H, dt), 7.0-7.3 (4H, br s),
 7.85 (1H, d), 8.0 (1H, s), 8.1 (1H, d), 8.65 (1H, t), 9.1 (1H, s) ppm.

LRMS 392 (MH⁺), 783 (M₂H⁺).

20 Anal. Found: C, 54.89; H, 5.68; N, 17.94. Calc for C₁₈H₂₂ClN₃O₃: C, 55.17; H, 5.66; N,
 17.87.

A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-β-alanine *t*-butyl ester
 (145 mg, 0.37 mmol) in CF₃CO₂H (1.5 mL) was stirred at 0 °C for 30 min, and then at room
 25 temperature for 1 h. PhMe (15 mL) was added, the mixture evaporated *in vacuo*, and the
 residue triturated with EtOAc and Et₂O to give *N*-[(4-Chloro-1-guanidino-7-
 isoquinolinyl)carbonyl]-β-alanine (117 mg, 0.26 mmol) as a white solid.

mp 235-236 °C.

30

¹H (DMSO-*d*₆, 300 MHz) δ 2.6 (2H, t), 3.55 (2H, dt), 8.25 (1H, d), 8.35-8.4 (2H, m), 8.5 (4H,
 br s), 8.8-8.9 (2H, m) ppm.


LRMS 336 (MH⁺).

Anal. Found: C, 42.72; H, 3.56; N, 14.55. Calc for C₁₄H₁₄ClN₃O₂•0.25EtOAc: C, 42.75; H, 3.57; N, 14.49.

Example 51:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny]carbonyl]cycloleucine ethyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny]carbonyl]cycloleucine



NaH (45 mg, 60% dispersion in mineral oil, 1.13 mmol) was added to *t*-BuOH and the mixture heated at 50 °C for 15 min. Guanidine hydrochloride (105 mg, 1.10 mmol) was added and the mixture heated at 50 °C for an additional 15 min. *N*-[(1,4-Dichloro-7-isoquinoliny]carbonyl]cycloleucine ethyl ester (350 mg, 0.92 mmol) was added and the mixture heated at reflux for 17 h. The solvents were evaporated *in vacuo* and the residue purified by column chromatography on silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant, followed by trituration with CH₂Cl₂-*i*-Pr₂O, to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny]carbonyl]cycloleucine ethyl ester (55 mg, 0.14 mmol) as a pale yellow powder.

¹H (CDCl₃, 300 MHz) δ 1.0 (3H, t), 1.5-1.65 (4H, m), 1.8-2.0 (2H, m), 2.0-2.15 (2H, m), 3.9 (2H, q), 6.7 (4H, br s), 7.5 (1H, s), 7.7 (1H, d), 7.8 (1H, s), 7.9 (1H, d), 8.95 (1H, s) ppm.

LRMS 404 (MH⁺).

Anal. Found: C, 55.94; H, 5.42; N, 16.94. Calc for C₁₉H₂₂ClN₃O₃•0.25 H₂O: C, 55.87; H, 5.55; N, 17.14.

A partly heterogeneous solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny]carbonyl]cycloleucine ethyl ester (45 mg, 0.11 mmol) in dioxane (1.5 mL) was stirred with aqueous NaOH (1 mL, 2 M) for 2.5 h at 23 °C. Dilute HCl (1 mL, 2 M) was

added to give a cream suspension. The solid was collected by filtration and dried *in vacuo* to yield *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]cycloleucine (40 mg, 0.11 mmol).

mp > 275 °C.

5

¹H (TFA-*d*, 400 MHz) δ 1.9-2.1 (4H, m), 2.2-2.4 (2H, m), 2.5-2.7 (2H, m), 8.3 (1H, d), 8.35 (1H, s), 8.45 (1H, d), 9.25 (1H, s) ppm.


LRMS 376 (MH⁺), 751 (M₂H⁺).

10

Anal. Found: C, 51.67; H, 4.92; N, 17.39. Calc for C₁₇H₁₈ClN₅O₃•H₂O: C, 51.84; H, 5.11; N, 17.78.

Example 52:

- 15 (a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylglycine *t*-butyl ester
(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylglycine
trifluoroacetate



20

- A mixture of guanidine hydrochloride (326 mg, 3.41 mmol) and NaH (137 mg, 60% dispersion in oil, 3.43 mmol) in DMSO (5 mL) was heated to 70 °C, a solution of *N*-[(1,4-dichloro-7-isoquinoliny)carbonyl]-DL-phenylglycine *t*-butyl ester (590 mg, 1.37 mmol) in DMSO (3 mL) was added, and the mixture heated at 80-90 °C overnight. After cooling, the reaction mixture was poured into water (50 mL) and extracted with EtOAc (3x30 mL). The combined organic extracts were washed with water, dried (Na₂SO₄), and evaporated *in vacuo*. Purification of the residue by column chromatography on silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant, followed by crystallisation from *i*-Pr₂O, gave *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylglycine *t*-butyl ester (110 mg, 0.24 mmol) as a pale yellow solid.

30

mp 158 °C (foam), 170 °C (dec).

^1H (CDCl_3 , 300 MHz) δ 1.4 (9H, s), 5.7 (1H, d), 6.5 (4H, br s), 7.25-7.4 (3H, m), 7.4-7.5 (3H, m), 8.05 (1H, d), 8.10 (1H, s), 8.15 (1H, d), 9.2 (1H, d) ppm.

5 LRMS 454 (MH^+).

Anal. Found: C, 61.53; H, 5.96; N, 14.27. Calc for $\text{C}_{23}\text{H}_{24}\text{ClN}_5\text{O}_3 \cdot 0.3i\text{-Pr}_2\text{O}$: C, 61.53; H, 5.92; N, 14.27.

10 A solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylglycine *t*-butyl ester (100 mg, 0.22 mmol) in $\text{CF}_3\text{CO}_2\text{H}$ (1.5 mL) was stirred at 0 °C for 30 min, and then at 23 °C for 1 h. The reaction mixture was diluted with PhMe (15 mL) and evaporated *in vacuo*. The residual gum was triturated with EtOAc, and then Et_2O , and the resulting white solid was dried *in vacuo* to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylglycine trifluoroacetate (50 mg, 0.10 mmol).

^1H ($\text{DMSO}-d_6$, 300 MHz) δ 5.6 (1H, d), 7.3-7.45 (3H, m), 7.55 (2H, d), 8.2 (1H, d), 8.2-8.4 (5H, m), 8.45 (1H, d), 8.95 (1H, s), 9.4 (1H, d) ppm.


20 LRMS 398 (MH^+).

Anal. Found: C, 49.72; H, 3.68; N, 14.04. Calc for $\text{C}_{19}\text{H}_{16}\text{ClN}_5\text{O}_3 \cdot 0.95\text{CF}_3\text{CO}_2\text{H}$: C, 49.27; H, 3.35; N, 13.68.

25 Example 53:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-L-phenylglycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-L-phenylglycine trifluoroacetate



NaH (38 mg, 80% dispersion in mineral oil, 1.27 mmol) was added to a stirred solution of guanidine hydrochloride (121 mg, 1.27 mmol) in DMSO (4 mL) at 23 °C, and the mixture heated at 80-85 °C for 15 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-L-phenylglycine *t*-butyl ester (218 mg, 0.51 mmol) was added and the mixture heated at 85 °C for 4 h. The cooled solution was poured into water and extracted with EtOAc (x3). The combined organics were washed with saturated brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was crystallised with *i*-Pr₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-L-phenylglycine *t*-butyl ester (55 mg, 0.12 mmol) as a pale yellow solid.

mp 147 °C (dec).

¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 5.7 (1H, d), 6.2-6.8 (4H, br s), 7.3-7.4 (3H, m), 7.45-7.5 (3H, m), 8.0-8.1 (2H, m), 8.15-8.2 (1H, d), 9.2 (1H, s) ppm.

LRMS 454 (MH⁺), 907 (M₂H⁺).

Anal. Found: C, 61.22; H, 6.01; N, 13.91. Calc for C₂₃H₂₄ClN₅O₃•0.4*i*-Pr₂O: C, 61.21; H, 6.07; N, 14.05.


A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-L-phenylglycine *t*-butyl ester (40 mg, 0.09 mmol) in CF₃CO₂H (1 mL) was stirred at room temperature for 1 h. The reaction mixture was diluted with PhMe, evaporated *in vacuo*, and the residue triturated with EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-L-phenylglycine trifluoroacetate (32 mg, 0.06 mmol) as a white powder.

mp 163 °C (shrinks), > 200 °C (dec).

¹H (TFA-*d*, 400 MHz) δ 5.85 (1H, s), 7.35-7.4 (3H, m), 7.4-7.45 (2H, m), 8.25 (1H, d), 8.3 (1H, s), 8.4 (1H, d), 9.15 (1H, s) ppm.

LRMS 398 (MH⁺), 795 (M₂H⁺).

Anal. Found: C, 48.28; H, 3.74; N, 13.57. Calc for C₁₉H₁₆ClN₅O₃•CF₃CO₂H•0.5H₂O: C, 48.43; H, 3.48; N, 13.45.

Example 54:**(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-D-phenylglycine *t*-butyl ester****(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)carbonyl]-D-phenylglycine****5 trifluoroacetate**

NaH (30 mg, 80% dispersion in mineral oil, 1.0 mmol) was added to a solution of guanidine hydrochloride (97 mg, 1.0 mmol) in DMSO (3 mL) and the solution heated to 80 °C for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-D-phenylglycine *t*-butyl ester (175 mg, 0.41 mmol) was added, the mixture heated at 85 °C for 3.5 h, and then at 23 °C overnight. The mixture was poured into water (25 mL), extracted with EtOAc (3x20 mL), and the combined organics washed with brine, dried (MgSO₄), and evaporated *in vacuo*. The residue was purified by column chromatography on silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5) as eluant, followed by crystallisation from CH₂Cl₂-*i*-Pr₂O, to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-D-phenylglycine *t*-butyl ester (37 mg, 0.08 mmol) as a solid.

mp 154-156 °C (dec).

¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 5.7 (1H, d), 7.3-7.4 (3H, m), 7.4-7.5 (3H, m), 8.05 (1H, d), 8.05 (1H, s), 8.15 (1H, d), 9.2 (1H, s) ppm.

LRMS 454 (MH⁺), 907 (M₂H⁺).

Anal. Found: C, 61.15; H, 6.00; N, 13.87. Calc for C₂₃H₂₄ClN₅O₃•0.45*i*-Pr₂O•0.2 H₂O: C, 61.31; H, 6.15; N, 13.91.

A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-D-phenylglycine *t*-butyl ester (40 mg, 0.09 mmol) in CF₃CO₂H (0.5 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-D-phenylglycine trifluoroacetate (21 mg, 0.04 mmol) as a white powder.

mp 222 °C (dec).

¹H (TFA-*d*, 400 MHz) δ 5.9 (1H, s), 7.4-7.5 (3H, m), 7.5-7.55 (2H, m), 8.3 (1H, d), 8.35
5 (1H, s), 8.4 (1H, d), 9.2 (1H, s) ppm.

LRMS 398 (MH⁺), 795 (M₂H⁺).


Anal. Found: C, 49.02; H, 3.42; N, 13.26. Calc for C₁₉H₁₆ClN₅O₃.CF₃CO₂H•0.25H₂O: C,
10 48.85; H, 3.42; N, 13.56.

Example 55:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-valine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-valine trifluoroacetate

15



NaH (88 mg, 60% dispersion in mineral oil, 2.2 mmol) was added to a stirred solution of
guanidine hydrochloride (210 mg, 2.2 mmol) in DMSO (5 mL) at 70 °C and the solution
20 stirred for 30 min. *N*-[(1,4-Dichloro-7-isoquinoliny)carbonyl]-DL-valine *t*-butyl ester (350
mg, 0.88 mmol) was added and the solution heated at 80-90 °C overnight. The cooled
mixture was poured into water, extracted with EtOAc (3x20 mL), and the combined organic
extracts were dried (MgSO₄) and evaporated *in vacuo*. The residue was crystallised with
CH₂Cl₂-*i*-Pr₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-valine *t*-butyl
25 ester (285 mg, 0.68 mmol) as a yellow solid.

mp 178-180 °C (dec).

¹H (CDCl₃, 300 MHz) shows 1:1 mixture of rotamers, δ 1.0 (1/2 of 6H, d), 1.05 (1/2 of 6H,
30 d), 1.5 (9H, s), 2.2-2.4 (1H, m), 4.7 (1/2 of 1H, d), 4.75 (1/2 of 1H, d), 6.2-6.8 (4H, br s), 6.9
(1H, d), 8.05 (1H, d), 8.1 (1H, s), 8.15 (1H, d), 9.1 (1H, s) ppm.

LRMS 420 (MH⁺), 839 (M₂H⁺).

Anal. Found: C, 56.00; H, 6.35; N, 16.33. Calc for C₂₀H₂₆ClN₃O₃•0.5H₂O: C, 55.71; H, 6.36; N, 16.32.

5

A solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-valine *t*-butyl ester (200 mg, 0.48 mmol) in CF₃CO₂H (1.5 mL) was stirred at 0°C for 30 min, and at 23 °C for 1 h. The reaction mixture was diluted with PhMe, evaporated *in vacuo*, and the residue triturated with EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-valine trifluoroacetate (170 mg, 0.36 mmol) as a white solid.

10

mp 243-245°C (dec).

¹H (DMSO-*d*₆, 300 MHz) shows a 1:1 mixture of rotamers, δ 0.95 (1/2 of 6H, d), 1.0 (1/2 of 6H, d), 2.15-2.3 (1H, m), 4.35 (1H, t), 8.25 (1H, d), 8.4 (1H, s), 8.45 (1H, d), 8.4-8.6 (4H, br s), 8.85 (1H, d), 8.9 (1H, s) ppm.

15

LRMS 364 (MH⁺).

Anal. Found: C, 44.96; H, 3.95; N, 14.56. Calc for C₁₆H₁₈ClN₃O₃•CF₃CO₂H: C, 45.24; H, 4.01; N, 14.65.


20

Example 56:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-proline *t*-butyl ester

(b) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-proline trifluoroacetate

25



NaH (65 mg, 60% dispersion in mineral oil, 1.63 mmol) was added to a stirred solution of guanidine hydrochloride (154 mg, 1.61 mmol) in DMSO (5 mL) at 50 °C and the solution stirred for 15 min. *N*-[(1,4-Dichloro-7-isoquinoliny)carbonyl]-DL-proline *t*-butyl ester (253 mg, 0.64 mmol) was added and the mixture was heated at 80 °C overnight. The mixture was

30

poured into water (20 mL) and extracted with EtOAc (x2). The combined organic extracts were washed with water, brine, dried over (MgSO₄), and evaporated *in vacuo*. The residue was crystallised with CH₂Cl₂-*i*-Pr₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-proline *t*-butyl ester (241 mg, 0.58 mmol).

5

mp 147-149°C (dec).

¹H (CDCl₃, 300 MHz) shows 1:3 mixture of rotamers, δ 1.55 (9H, s), 1.8-2.1 (3H, m), 2.15-2.45 (1H, m), 3.55-3.65 (1H, m), 3.75-3.85 (1H, m), 4.35-4.45 (1H, m), 6.5-7.2 (4H, br m),
10 7.7 (1/4 of 1H, d), 7.85 (3/4 of 1H, d), 7.9-8.1 (2H, m), 8.85 (1/4 of 1H, s), 8.95 (3/4 of 1H, s) ppm.

LRMS 418 (MH⁺), 835 (M₂H⁺).

15 Anal. Found: C, 58.46; H, 6.49; N, 14.95. Calc for C₂₀H₂₄ClN₅O₃•0.4*i*-Pr₂O: C, 58.65; H, 6.50; N, 15.27.

A solution of *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-proline *t*-butyl ester (175 mg, 0.42 mmol) in CF₃CO₂H (1 mL) was stirred at room temperature for 1 h. The
20 solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-proline trifluoroacetate (156 mg, 0.33 mmol) as a white solid.

mp 185 °C (dec).

25

¹H (DMSO-*d*₆ + 1 drop TFA-*d*, 300 MHz) δ 1.8-2.1 (3H, m), 2.25-2.4 (1H, m), 3.45-3.7 (2H, m), 4.4-4.5 (1H, m), 8.0-8.6 (4H, m) ppm.

LRMS 362 (MH⁺).


30

Anal. Found: C, 45.65; H, 3.84; N, 14.43. Calc for C₁₆H₁₆ClN₅O₃•CF₃CO₂H: C, 45.43; H, 3.60; N, 14.72.

Example 57:

35 (a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-phenylalanine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylalanine trifluoroacetate



5

NaH (78 mg, 60% dispersion in mineral oil, 1.95 mmol) was added to a solution of guanidine hydrochloride (188 mg, 1.97 mmol) in DMSO (6 mL) at 50 °C and the solution was stirred for 15 min. *N*-[(1,4-Dichloro-7-isoquinoliny)carbonyl]-DL-phenylalanine *t*-butyl ester (350 mg, 0.79 mmol) was added and the mixture heated at 80 °C overnight. The cooled mixture was poured into water (50 mL) and extracted with EtOAc (2x25 mL). The combined organics were washed with brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was crystallised with CH₂Cl₂-*i*-Pr₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylalanine *t*-butyl ester (172 mg, 0.37 mmol) as a cream coloured solid.

15 mp 201-203 °C (dec).

¹H (CDCl₃, 300 MHz) δ 1.45 (9H, s), 1.5-1.8 (1H, br m), 3.25 (2H, d), 5.0 (1H, dt), 6.0-6.8 (3H, br s), 6.9 (1H, d), 7.15-7.35 (5H, m), 8.0-8.1 (3H, m), 9.1 (1H, s) ppm.

20 LRMS 468 (MH⁺), 935 (M₂H⁺).

Anal. Found: C, 61.60; H, 5.60; N, 14.97. Calc for C₂₄H₂₆ClN₅O₃: C, 61.60; H, 5.76; N, 14.68.

25 A solution of *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylalanine *t*-butyl ester (210 mg, 0.48 mmol) in CF₃CO₂H (1 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-phenylalanine trifluoroacetate (196 mg, 0.37 mmol).

30

mp 192 °C (dec).

^1H (DMSO- d_6 + 1 drop TFA- d , 300 MHz) δ 3.1 (1H, dd), 3.25 (1H, dd), 4.7 (1H, dd), 7.1-7.35 (5H, m), 8.25 (1H, d), 8.35 (1H, s), 8.35 (1H, d), 8.9 (1H, s), 9.15 (1/2H, d partially exchanged amide NH) ppm.


5 LRMS 412 (MH^+).

Anal. Found: C, 50.92; H, 3.81; N, 13.57. Calc for $\text{C}_{20}\text{H}_{18}\text{ClN}_5\text{O}_3 \cdot 0.9\text{CF}_3\text{CO}_2\text{H}$: C, 50.90; H, 3.70; N, 13.61.

10 **Example 58:**

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-leucine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-leucine trifluoroacetate



15

NaH (73 mg, 60% dispersion in mineral oil, 1.83 mmol) was added to a stirred solution of guanidine hydrochloride (174mg, 1.82 mmol) in DMSO (6 mL) at 50°C and the solution stirred for 15 min. *N*-[(1,4-Dichloro-7-isoquinoliny)carbonyl]-DL-leucine *t*-butyl ester (300 mg, 0.73 mmol) was added and the solution heated at 80 °C overnight. The cooled mixture was poured into water (50 mL), extracted with EtOAc (2x25 mL) and the combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was crystallised with CH_2Cl_2 -*i*-Pr₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-leucine *t*-butyl ester (185 mg, 0.43 mmol).

25 mp 210-212°C (dec).

^1H (CDCl_3 , 300 MHz) δ 0.9-1.0 (6H, m), 1.5 (9H, s), 1.6-1.8 (3H, m), 4.7-4.8 (1H, m), 6.4-7.0 (4H, br s), 6.85 (1H, d), 8.05 (1H, d), 8.05 (1H, s), 8.15 (1H, d), 9.15 (1H, s) ppm.

30 LRMS 434 (MH^+), 866 (M_2H^+).

Anal. Found: C, 58.35; H, 6.75; N, 15.51. Calc for $C_{21}H_{28}ClN_5O_3 \cdot 0.15i\text{-Pr}_2O$: C, 58.55; H, 6.75; N, 15.59.

A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-leucine *t*-butyl ester (184 mg, 0.57 mmol) in CF_3CO_2H (1 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with Et_2O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-leucine trifluoroacetate (183 mg, 0.37 mmol).

mp 249 °C.

1H (DMSO- d_6 , 300 MHz) 1:1 mixture of rotamers, δ 0.9 (1/2 of 6H, d), 0.95 (1/2 of 6H, d), 1.6-1.8 (3H, m), 4.45-4.5 (1H, m), 8.35 (1H, d), 8.4 (1H, s), 8.4 (1H, d), 8.3-8.6 (4H, br s), 8.95 (1H, s), 9.0 (1H, d) ppm.


LRMS 378 (MH^+).

Anal. Found: C, 46.31; H, 4.27; N, 14.08. Calc for $C_{17}H_{20}ClN_5O_3 \cdot CF_3CO_2H$: C, 46.39; H, 4.30; N, 14.24.

Example 59:

(a) *t*-butyl DL-3-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]amino}-3-phenylpropanoate

(b) DL-3-[(4-Chloro-1-guanidino-7-isoquinolinyl)carbonyl]amino}-3-phenylpropanoic acid trifluoroacetate



NaH (67 mg, 60% dispersion in oil, 1.68 mmol) was added to a solution of guanidine hydrochloride (161 mg, 1.69 mmol) in DMSO (6 mL) and the solution was heated to 50 °C for 15 mins. *t*-Butyl DL-3-[(1,4-dichloro-7-isoquinolinyl)carbonyl]amino}-3-phenylpropanoate (300 mg, 0.67 mmol) was added and the mixture heated at 80 °C overnight.

The cooled mixture was poured into water (50 mL) and extracted with EtOAc (2x25 mL). The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was crystallised with *i*- Pr_2O to give *t*-butyl DL-3-[[[4-chloro-1-guanidino-7-isoquinolinyl]carbonyl]amino]-3-phenylpropanoate (55 mg, 0.12 mmol) as a yellow solid.

mp 227 °C (dec).

^1H (CDCl_3 , + drop of $\text{DMSO}-d_6$, 300 MHz) δ 1.25 (9H, s), 2.75 (1H, dd), 2.85 (1H, dd), 5.5 (1H, ddd), 6.4-6.8 (4H, br s), 7.1-7.35 (5H, m), 7.8 (1H, d), 7.9 (1H, d), 7.95 (1H, s), 8.05 (1H, d), 9.05 (1H, s) ppm.

LRMS 468 (MH^+).

Anal. Found: C, 61.48; H, 5.62; N, 14.70. Calc for $\text{C}_{24}\text{H}_{26}\text{ClN}_3\text{O}_3$: C, 61.60; H, 5.60; N, 14.97.

A solution of *t*-butyl DL-3-[[[4-chloro-1-guanidino-7-isoquinolinyl]carbonyl]amino]-3-phenylpropanoate (153 mg, 0.33 mmol) in $\text{CF}_3\text{CO}_2\text{H}$ (1 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with Et_2O to give DL-3-[[[4-chloro-1-guanidino-7-isoquinolinyl]carbonyl]amino]-3-phenylpropanoic acid trifluoroacetate (132 mg, 0.25 mmol).

mp. 241-244°C.

^1H ($\text{DMSO}-d_6$ + 1 drop TFA-*d*, 300 MHz) δ 2.8 (1H, dd), 2.95 (1H, dd), 5.5-5.6 (1H, m), 7.2-7.35 (3H, m), 7.4 (2H, d), 8.25 (1H, d), 8.35 (1H, s), 8.4 (1H, d), 8.9 (1H, s) ppm.

LRMS 412 (MH^+).


Anal. Found: C, 49.95; H, 3.64; N, 13.03. Calc for $\text{C}_{20}\text{H}_{18}\text{ClN}_3\text{O}_3 \cdot \text{CF}_3\text{CO}_2\text{H}$: C, 50.25; H, 3.45; N, 13.32.

Example 60:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-aspartic acid α,β -di-*t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-aspartic acid trifluoroacetate

5



NaH (53 mg, 80% dispersion in mineral oil, 1.77 mmol) was added to a solution of guanidine hydrochloride (168 mg, 1.76 mmol) in DMSO (6 mL) and the solution was heated to 50 °C for 30 min. *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-DL-aspartic acid α,β -di-*t*-butyl ester (330 mg, 0.70 mmol) was added and the mixture heated at 80-90 °C overnight. The cooled mixture was poured into water (50 mL) and extracted with EtOAc extract (5x20 mL). The combined organic extracts were washed with water, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by (i), trituration with *i*-Pr₂O (ii), column chromatography on silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5) as eluant, and (iii), crystallisation from *i*-Pr₂O, to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-aspartic acid α,β -di-*t*-butyl ester (145 mg, 0.29 mmol) as a yellow solid.

mp 165-167 °C.

20

¹H (CDCl₃, 300 MHz) δ 1.45 (9H, s), 1.5 (9H, s), 2.9 (1H, dd), 3.0 (1H, dd), 4.95-5.0 (1H, m), 7.5 (1H, d), 7.95 (1H, s), 8.0 (1H, d), 8.15 (1H, d), 9.2 (1H, s) ppm.

LRMS 492 (MH⁺), 983 (M₂H⁺).

25

Anal. Found: C, 56.06; H, 6.28; N, 13.92. Calc for C₂₃H₂₀ClN₅O₅: C, 56.15; H, 6.15; N, 14.24.

A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL-aspartic acid α,β -di-*t*-butyl ester (120 mg, 0.24 mmol) in CF₃CO₂H (1 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was trituated with

30

Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-aspartic acid trifluoroacetate (60 mg, 0.12 mmol).

mp 125 °C (dec).

5

¹H (TFA-*d*, 400 MHz) δ 3.3-3.4 (2H, m), 5.35-5.4 (1H, m), 8.25 (1H, d), 8.3 (1H, s), 8.45 (1H, d), 9.2 (1H, s) ppm.


LRMS 380 (MH⁺), 758 (M₂H⁺).

10

Anal. Found: C, 43.22; H, 3.75; N, 14.31. Calc for C₁₃H₁₄ClN₅O₅•0.8CF₃CO₂H•0.25Et₂O: C, 43.19; H, 3.56; N, 14.31.

Example 61:

- 15 (a) *O*-*t*-butyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-serine *t*-butyl ester
(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-serine trifluoroacetate



- 20 NaH (54 mg, 80% dispersion in mineral oil, 1.80 mmol) was added to a solution of guanidine hydrochloride (173 mg, 1.81 mmol) in DMSO (6 mL) and the solution was heated to 80 °C for 30 min. *O*-*t*-Butyl-*N*-[(1,4-dichloro-7-isoquinoliny)carbonyl]-DL-serine *t*-butyl ester (330 mg, 0.70 mmol) was added and the mixture heated at 80 °C for 3 h. The cooled mixture was poured into water (50 mL) and extracted with EtOAc. The combined organic extracts
- 25 were washed with water, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was crystallised with *i*-Pr₂O to give *O*-*t*-butyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-serine *t*-butyl ester (138 mg, 0.30 mmol) as a yellow solid.

mp 215-219 °C.

30

¹H (CDCl₃, 300 MHz) δ 1.2 (9H, s), 1.5 (9H, s), 1.5-1.7 (1H, br s), 3.75 (1H, dd), 3.95 (1H, dd), 4.8-4.9 (1H, m), 6.2-6.8 (3H, br s), 7.25-7.3 (1H, m), 8.0 (1H, s), 8.05 (1H, d), 8.15 (1H, d), 9.2 (1H, s) ppm.

5 LRMS 464 (MH⁺), 927 (M₂H⁺).

Anal. Found: C, 56.88; H, 6.65; N, 15.10. Calc for C₂₂H₃₀ClN₅O₄•0.25H₂O•0.2*i*-Pr₂O: C, 57.00; H, 6.87; N, 14.32.

10 A solution of *O*-*t*-butyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-serine *t*-butyl ester in CF₃CO₂H (1 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was recrystallised twice from MeOH-EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-serine trifluoroacetate (68 mg, 0.19 mmol) as a white solid.

15

mp 203 °C (dec).

¹H (TFA-*d*, 400 MHz) δ 4.4 (1H, dd), 4.5 (1H, dd), 5.2-5.25 (1H, m), 8.35 (1H, s), 8.4 (1H, d), 8.5 (1H, d), 9.2 (1H, s) ppm.

20

LRMS 352 (MH⁺), 703 (M₂H⁺).

Anal. Found: C, 42.48; H, 3.69; N, 14.21. Calc for C₁₄H₁₄ClN₅O₄•CF₃CO₂H•0.4EtOAc: C, 42.19; H, 3.66; N, 13.98.


25

Example 62:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-α-cyclopentylglycine *t*-butyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinoliny)carbonyl]-DL-α-cyclopentylglycine

30 trifluoroacetate



NaH (30 mg, 80% dispersion in mineral oil, 1.00 mmol) was added to a solution of guanidine hydrochloride (96 mg, 1.01 mmol) in DMSO (3 mL) and the solution was heated at 75-80 °C. *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]- α -cyclopentylglycine *t*-butyl ester (170 mg, 0.40 mmol) was added and the mixture heated at 80 °C for 4.5 h. The cooled mixture was poured into water (25 mL) and extracted with EtOAc (3x20 mL). The combined organic extracts were washed with water, brine, dried (Na₂SO₄) and evaporated *in vacuo* to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL- α -cyclopentylglycine *t*-butyl ester (105 mg, 0.23 mmol) as a yellow solid.

10

An analytical sample was prepared as follows: this yellow solid was extracted with hot *i*-Pr₂O (3x20 mL), the hot solution was filtered, and on cooling gave the title compound as a pale yellow solid (40 mg) which was collected by filtration and dried *in vacuo*.

15 mp 219-221 °C (dec).

¹H (CDCl₃, 300 MHz) δ 1.4-1.8 (18H, m), 2.25-2.4 (1H, m), 4.7 (1H, dd), 6.2-6.9 (3H, br s), 6.95 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 8.15 (1H, d), 9.15 (1H, s) ppm.

20 LRMS 446 (MH⁺), 891 (M₂H⁺).

Anal. Found: C, 58.83; H, 6.39; N, 15.34. Calc for C₂₂H₂₈ClN₃O₃•0.2H₂O: C, 58.78; H, 6.37; N, 15.30.

25 A solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL- α -cyclopentylglycine *t*-butyl ester (65 mg, 0.15 mmol) in CF₃CO₂H (0.5 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was crystallised with EtOAc. This solid was then triturated with Et₂O to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)carbonyl]-DL- α -cyclopentylglycine trifluoroacetate (52 mg, 0.10 mmol) as white powder.

30

mp 235 °C (dec).

¹H (TFA-*d*, 400 MHz) δ 1.4-1.8 (6H, m), 1.85-2.0 (2H, m), 2.4-2.55 (1H, m), 4.8 (1H, d), 8.25 (1H, d), 8.35 (1H, s), 8.45 (1H, d), 9.15 (1H, s) ppm.

35


LRMS 390 (MH^+), 779 (M_2H^+).

Anal. Found: C, 47.34; H, 4.36; N, 13.60. Calc for $C_{18}H_{20}ClN_5O_3 \cdot CF_3CO_2H$: C, 47.67; H, 4.20; N, 13.90.

Example 63:

(a) *N*-Benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]glycine hydrochloride

(b) *N*-Benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]glycine hydrochloride



NaH (16 mg, 80% dispersion in mineral oil, 0.53 mmol) was added to a solution of guanidine hydrochloride (82 mg, 0.86 mmol) in DME (4 mL) and the mixture was heated at 60 °C for 30 min. A solution of *N*-benzyl-*N*-[(1,4-dichloro-7-isoquinoliny)carbonyl]glycine *t*-butyl ester (95 mg, 0.21 mmol) in DME (2 mL) was added and the mixture was heated at 90 °C for 4 h. The cooled mixture was partitioned between Et₂O and water, and the combined organic extracts were dried and evaporated *in vacuo*. The residue was dissolved in Et₂O and a solution of HCl in Et₂O (1 M) was added to give a precipitate of *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]glycine hydrochloride. Evaporation of the ethereal mother liquors gave recovered, unreacted *N*-benzyl-*N*-[(1,4-dichloro-7-isoquinoliny)carbonyl]glycine *t*-butyl ester which was again reacted with guanidine (as above) to give a second batch. Total yield: 70 mg, 0.15 mmol.

mp 130 °C (dec).

¹H (DMSO-*d*₆, 400 MHz)-5:6 mixture of rotamers, δ 1.2 (6/11 of 9H, s), 1.4 (5/11 of 9H, s), 4.0 (6/11 of 2H, s), 4.05 (5/11 of 2H, s), 4.5 (5/11 of 2H, s), 4.75 (6/11 of 2H, s), 7.2-7.5 (5H, m), 7.9-8.0 (1H, m), 8.2-8.3 (1H, m), 8.35 (1H, s), 8.75 (5/11 of 1H, s), 8.85 (6/11 of 1H, s) ppm.

LRMS 468 (MH^+), 934 (M_2H^+).

Anal. Found: C, 56.98; H, 5.71; N, 13.01. Calc for $C_{24}H_{26}ClN_5O_3 \cdot HCl \cdot 0.5H_2O \cdot 0.2i-Pr_2O$: C, 56.70; H, 5.82; N, 13.12.

- 5 A solution of *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]glycine hydrochloride (50 mg, 0.10 mmol) in CF_3CO_2H (1 mL) was stirred at room temperature for 1 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with Et_2O to afford a white solid (41 mg). This solid was dissolved in EtOAc and a solution of HCl in Et_2O was added which gave a precipitate. The mother liquors were decanted and
10 the solid triturated with MeCN to give *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)carbonyl]glycine hydrochloride (16 mg, 0.04 mmol) as an off-white powder.

1H (TFA-*d*, 400 MHz) 1:4 mixture of rotamers, δ 4.2 (1/5 of 2H, s), 4.45 (4/5 of 2H, s), 4.7 (4/5 of 2H, s), 4.95 (1/5 of 2H, s), 7.2 (2H, d), 7.3-7.4 (3H, m), 8.15 (1/5 of 1H, d), 8.2 (4/5 of 1H, d), 8.4 (1H, s), 8.45 (4/5 of 1H, d), 8.5 (1/5 of 1H, d), 8.7 (1/5 of 1H, s), 8.8 (4/5 of 1H, s) ppm.


LRMS 412 (MH^+), 823 (M_2H^+), 845 (M_2Na^+).

- 20 Anal. Found: C, 52.55; H, 4.33; N, 15.10. Calc for $C_{20}H_{18}ClN_5O_3 \cdot HCl \cdot 0.5H_2O$: C, 52.52; H, 4.41; N, 15.32.

Example 64:

- (a) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine *t*-
25 butyl ester
(b) *N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine *t*-butyl ester dihydrochloride
(c) *N*-[(4-Chloro-1-guanidino-7-Isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine trifluoroacetate

30



NaH (21 mg, 80% dispersion in mineral oil, 0.7 mmol) was added to *t*-BuOH (2.5 ml) and heated at 50 °C for 15 min. Guanidine hydrochloride (68 mg, 0.71 mmol) was added and heated at 50 °C for an additional 15 min. *N*-[(1,4-Dichloro-7-isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine *t*-butyl ester (102 mg, 0.24 mmol) was added and the mixture
5 heated at 95 °C for 9.5 h. The cooled mixture was evaporated *in vacuo* and the residue was purified by column chromatography on silica gel using hexane-EtOAc (9:1), and then CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine *t*-butyl ester (26 mg, 0.06 mmol) as a yellow gum. A portion of this material was dissolved in Et₂O, a solution of HCl in Et₂O was
10 added and the resultant precipitate was triturated with hexane and then *i*-Pr₂O to give the corresponding dihydrochloride salt.

¹H (CD₃OD, 400 MHz) free base, δ 1.4 (9H, s), 2.2 (3H, s), 3.7 (1H, d), 3.8 (1H, d), 4.2 (1H, s), 7.3-7.4 (3H, m), 7.5 (2H, d), 7.9 (1H, d), 8.05 (1H, d), 8.05 (1H, s), 8.35 (1H, s) ppm.
15 LRMS 454 (MH⁺).

Anal. Found: C, 51.89; H, 6.01; N, 12.42. Calc for C₂₄H₂₈ClN₅O₂•2HCl•1.5H₂O: C, 52.04; H, 6.01; N, 12.64.

20 A solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine *t*-butyl ester (20 mg, 0.44 mmol) in CH₂Cl₂ (2 mL) was stirred with CF₃CO₂H (2 mL) at room temperature for 4 h. The solvents were evaporated *in vacuo*, and the residue was triturated with Et₂O and then EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]-*N*-
25 methyl-DL-phenylglycine trifluoroacetate (6.5 mg, 0.02 mmol) as a white solid.

mp 180-182 °C.


¹H (TFA-*d*, 400 MHz) 3:5 mixture of rotamers, δ 2.7 (5/8 of 3H, s), 3.05 (3/8 of 3H, s), 3.95-4.05 (3/8 of 1H, m), 4.55-4.7 (5/8 of 1H, m), 4.95-5.1 (1H, m), 5.35 (5/8 of 1H, s), 5.45 (3/8 of 1H, s), 7.4-7.7 (5H, m), 7.95 (3/8 of 1H, d), 8.1 (5/8 of 1H, d), 8.35 (1H, s), 8.4-8.65 (2H, m) ppm.

LRMS 400 (MH⁺).

Anal. Found: C, 50.10; H, 4.27; N, 12.90. Calc for $C_{20}H_{20}ClN_3O_2 \cdot CF_3CO_2H \cdot H_2O$: C, 49.87; H, 4.37; N, 13.22.

Example 65:

- 5 (a) *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]glycine *t*-butyl ester
 (b) *N*-Benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]glycine
 bistrifluoroacetate



10

NaH (48.6 mg, 80% dispersion in mineral oil, 1.62 mmol) was added to *t*-BuOH (5 mL) and heated to 50 °C for 15 min. Guanidine hydrochloride (155 mg, 1.62 mmol) was added and heated at 50 °C for an additional 20 min. *N*-Benzyl-*N*-[(1,4-dichloro-7-isoquinoliny)methyl]glycine *t*-butyl ester (40 mg, 0.09 mmol) added and the mixture was then heated at 95 °C for 20 h. The cooled mixture was evaporated *in vacuo* and the residue purified by column chromatography on silica gel using CH_2Cl_2 -MeOH-0.880NH₃ (95:5:0.5), followed by trituration with hexane and crystallisation with *i*-Pr₂O, to give *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]glycine *t*-butyl ester (5 mg, 0.01 mmol) as a white solid.

20

¹H (CD₃OD, 400 MHz) δ 1.45 (9H, s), 3.15 (2H, s), 3.8 (2H, s), 3.95 (2H, s), 7.2-7.4 (5H, m), 7.85-7.95 (1H, m), 8.0-8.1 (2H, m), 8.5-8.55 (1H, m) ppm.

LRMS 454 (MH⁺), 907 (M₂H⁺).

25

Anal. Found: C, 62.57; H, 6.13; N, 15.17. Calc for $C_{24}H_{28}ClN_3O_2 \cdot 0.4H_2O$: C, 62.51; H, 6.29; N, 15.19.

A solution of *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinoliny)methyl]glycine *t*-butyl ester (16 mg, 0.04 mmol) in CF₃CO₂H (1 mL) was stirred for at room temperature 1.5 h. The solution was diluted with PhMe, evaporated *in vacuo*, and the residue was triturated with

30

Et₂O to give *N*-benzyl-*N*-[(4-chloro-1-guanidino-7-isoquinolinyl)methyl]glycine bistrifluoroacetate (6 mg, 0.02 mmol) as a white solid.

mp 199 °C dec.

5

¹H (TFA-*d*, 400 MHz) δ 4.2 (2H, s), 4.6 (1H, d), 4.75 (1H, d), 4.85 (1H, d), 4.95 (1H, d), 7.3-7.5 (5H, m), 8.0 (1H, d), 8.3 (1H, s), 8.45 (1H, d), 8.55 (1H, s) ppm.

LRMS 398 (MH⁺).

10


Anal. Found: C, 44.50; H, 3.81; N, 10.80. Calc for C₂₀H₂₀ClN₅O₂•2CF₃CO₂H•1.2H₂O: C, 44.52; H, 3.80; N, 10.82.

Example 66:

15

(a) *N*α-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*ε-*tert*-butyloxycarbonyl-L-lysine *tert*-butyl ester

(b) *N*α-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-lysine dihydrochloride.



20

NaH (44 mg, 80% dispersion in mineral oil, 1.47 mmol) was added in a single portion to a solution of guanidine hydrochloride (224 mg, 2.35 mmol) in DMSO (5 ml) and stirred at room temperature until solution occurred. *N*α-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*ε-*tert*-butyloxycarbonyl-L-lysine-*tert*-butyl ester (330 mg, 0.59 mmol) was added and the solution stirred at 100°C for 6 h. After cooling, the reaction mixture was quenched with water (30 ml), extracted with EtOAc (3 x 20 ml) and the combined organic extracts washed with water and brine. The organic solution was evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880 NH₃ (90:10:1) as eluant to give *N*α-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*ε-*tert*-

25

30

butyloxycarbonyl-L-lysine *tert*-butyl ester (152 mg, 0.26 mmol). An analytical sample was obtained by crystallisation from *i*-Pr₂O.

¹H (CDCl₃, 300 MHz) δ 1.15 (9H, s), 1.3-1.5 (13H, m), 1.5-1.8 (2H, m), 3.0-3.1 (2H, m), 3.8-3.9 (1H, m), 4.5-4.6 (1H, m), 5.2-5.4 (1H, m), 6.25-6.6 (3H, m), 8.0 (1H, d), 8.05 (1H, d), 8.1 (1H, s), 9.1 (1H, s) ppm.

5

LRMS 585 (MH⁺).

Anal. Found: C, 51.02; H, 6.32; N, 14.12. Calc for C₂₅H₃₇ClN₆O₆S: C, 51.32; H, 6.37; N, 14.36.

10

*N*α-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-*N*ε-*tert*-butyloxycarbonyl-L-lysine *tert*-butyl ester (119 mg, 0.20 mmol) was dissolved in EtOAc (10 ml) and saturated with gaseous HCl. After 20 min, the resultant white precipitate was obtained by filtration and recrystallised from EtOH to give *N*α-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-L-lysine (13 mg, 0.03 mmol).

15

¹H (DMSO-*d*₆ + CF₃CO₂D, 300 MHz) δ 1.1-1.7 (6H, m), 2.65-2.75 (2H, m), 3.75-3.80 (1H, m), 8.25 (1H, d), 8.35 (1H, d), 8.25 (1H, s), 8.9 (1H, s) ppm.

20


LRMS 429 (MH⁺).

Anal. Found: C, 37.00; H, 4.93; N, 15.72. Calc for C₁₆H₂₁ClN₆O₄S•2HCl • H₂O•0.15 EtOH: C, 37.15; H, 4.95; N, 15.97.

25

Example 67:

*N*α-[(4-Chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-D-lysine dihydrochloride



30

NaH (33 mg, 80% dispersion in mineral oil, 1.1 mmol) was added to a stirred solution of guanidine hydrochloride (170 mg, 1.78 mmol) in DMSO (3 ml) at 50°C. After 30 min, *N*α-

[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*-*tert*-butoxycarbonyl-D-lysine *tert*-butyl ester (250 mg, 0.44 mmol) was added and the solution stirred at 90°C for 8 h. The cooled mixture was poured into water and the precipitate extracted into Et₂O (4 x 15 ml). The combined organic extracts were washed with brine, dried (Na₂SO₄) and treated with 1N ethereal HCl.

- 5 The solution was concentrated *in vacuo*, and the residue triturated with Et₂O and then EtOAc-EtOH to give *N*α-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-lysine dihydrochloride (90 mg, 0.18 mmol).


¹H (DMSO-*d*₆, 400 MHz) δ 1.2-1.4 (2H, m), 1.4-1.7 (4H, m), 2.6-2.75 (2H, m), 3.9-4.0 (1H, m), 7.75-7.85 (3H, br s), 8.3 (1H, d), 8.35 (1H, d), 8.4 (1H, d), 8.4 (1H, s), 8.2-9.0 (3H, br m), 9.1 (1H, s) ppm.

LRMS 429 (MH⁺).

- 15 Anal. Found: C, 36.15; H, 5.10; N, 15.06. Calc for C₁₆H₂₁ClN₆O₄S•2HCl•2H₂O•0.13 EtOAc: C, 36.18; H, 5.16; N, 15.25.

Example 68:

- (a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-glutamine *tert*-butyl ester
20 (b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-glutamine trifluoroacetate



- NaH (25 mg, 80% dispersion in mineral oil, 0.83 mmol) was added to a solution of
25 guanidine hydrochloride (128 mg, 1.34 mmol) in DMSO (2 ml) and stirred at 50°C for 1 h. *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-L-glutamine *tert*-butyl ester (150 mg, 0.32 mmol) was added and the resultant solution stirred at 100°C for 6 h, allowed to cool and then poured into water. The aqueous mixture was extracted with EtOAc (3 x 30 ml) and concentrated *in vacuo*. The residue was purified by column chromatography upon silica gel
30 using CH₂Cl₂-MeOH-0.880 NH₃ (90:10:1) as eluant to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-glutamine *tert*-butyl ester (30 mg, 0.06 mmol) as a buff-coloured powder.

¹H (DMSO-*d*₆, 300 MHz) δ 1.0-1.2 (9H, s), 1.6-1.75 (1H, m), 1.75-1.9 (1H, m), 2.05-2.15 (2H, m), 3.26-3.8 (1H, m), 6.65-6.75 (1H, br s), 7.0-7.45 (5H, br m), 7.95-8.1 (3H, m), 8.35 (1H, d), 9.0 (1H, s) ppm.

5

LRMS 485 (MH⁺).


N-[(4-Chloro-1-guanidino-7-isoquinoliny)sulphonyl]-L-glutamine *tert*-butyl ester (15 mg, 0.03 mmol) was dissolved in trifluoroacetic acid (1 ml) and the resultant solution stirred at room temperature for 1 h, diluted with toluene and concentrated to a residue. Trituration with Et₂O gave a powder to which was added MeOH and the suspension filtered. The filtrate was concentrated and then triturated with EtOAc to give *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-L-glutamine trifluoroacetate (9 mg, 0.02 mmol).

15 ¹H (DMSO-*d*₆ + TFA-*d*, 300 MHz) δ 1.6-1.75 (1H, m), 1.8-2.0 (1H, m), 2.0-2.15 (2H, m), 3.8-3.9 (1H, m), 8.3 (1H, d), 8.35 (1H, d), 8.4 (1H, s), 8.8 (1H, s) ppm.

LRMS 429 (MH⁺).

20 Example 69:

(2*R*)-1-[(4-Chloro-1-guanidino-7-isoquinoliny)sulphonyl]-2-pyrrolidinecarboxamide



25 Oxalyl chloride (136 μl, 1.56 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinoliny)sulphonyl]-D-proline (339 mg, 0.78 mmol) in CH₂Cl₂ (30 ml), followed by DMF (100 μl), and the reaction stirred at room temperature for 10 min. The mixture was evaporated *in vacuo* and azeotroped with toluene, to give an off-white solid. This was suspended in CH₂Cl₂ (15 ml), 0.880 NH₃ (760 μl, 7.8 mmol) added, and the reaction stirred at room temperature for 18 h. The mixture was partitioned between CH₂Cl₂ and water, and the layers separated. The aqueous phase was extracted with CH₂Cl₂ the combined organic

30

solutions dried (MgSO_4) and evaporated *in vacuo*. The crude roduct was purified by column chromatography upon silica gel using an elution gradient of CH_2Cl_2 -MeOH-0.880 NH_3 (100:0:0 to 95:5:0.1) to afford (2*R*)-1-({4-chloro-1-guanidino-7-isoquinolinyl} sulphonyl)-2-pyrrolidinecarboxamide (102mg, 0.26mmol) as a pale yellow solid.

5

^1H (d_4 -MeOH, 400 MHz) δ 1.5-1.6 (1H, m), 1.7-2.0 (3H, m), 3.3-3.4 (1H, m), 3.55-3.65 (1H, m), 4.1-4.2 (1H, m), 8.1-8.2 (3H, m), 9.15 (1H, s) ppm.


10 LRMS 397 (MH^+), 419 (MNa^+).

Anal. Found: C, 44.05; H, 4.42; N, 20.14. Calc for $\text{C}_{13}\text{H}_{17}\text{ClN}_6\text{O}_3\text{S} + 0.15 \text{CH}_2\text{Cl}_2$: C, 44.43; H, 4.26; N, 20.52.

15

Example 70:

(2*R*)-1-({4-Chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-*N*-(2-hydroxyethyl)-2-pyrrolidinecarboxamide.



20

Oxalyl chloride (40 μl , 0.46 mmol) was added to a solution of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline (100 mg, 0.23 mmol) in CH_2Cl_2 (10 ml), followed by DMF (1 drop), and the reaction stirred at room temperature for 30 min. The mixture was evaporated *in vacuo* and azeotroped with toluene. The residue was dissolved in CH_2Cl_2 (5 ml), and added to a solution of ethanolamine (17 μl , 0.28 mmol) in CH_2Cl_2 (5 ml), the reaction stirred at room temperature for 2 h, then concentrated *in vacuo*. The crude product was purified by column chromatography upon silica gel using an elution gradient of CH_2Cl_2 -MeOH-0.880 NH_3 (95:5:0.5 to 90:10:1) to afford (2*R*)-1-({4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-*N*-(2-hydroxyethyl)-2-pyrrolidinecarboxamide (65 mg, 0.147 mmol) as a yellow foam.

30

^1H (DMSO- d_6 , 300 MHz) δ 1.45-1.8 (4H, m), 3.15 (3H, m), 3.35-3.55 (3H, m), 4.1 (1H, m), 4.65 (1H, m), 7.9 (1H, m), 8.0 (1H, d), 8.15 (2H, m), 9.1 (1H, s) ppm.

5 LRMS 441, 443 (MH $^+$)


Anal. Found: C, 43.96; H, 4.89; N, 17.47. Calc. for $\text{C}_{17}\text{H}_{21}\text{ClN}_6\text{O}_4\text{S}\cdot 0.4\text{CH}_2\text{Cl}_2$: C, 44.01; H, 4.63; N, 17.70%.

10 **Example 71:**

(a) *tert*-butyl (2*R*)-1-({4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-2-piperidinecarboxylate

(b) (2*R*)-1-({4-Chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-2-piperidinecarboxylic acid hydrochloride

15



Guanidine hydrochloride (128 mg, 1.34 mmol) was added to a solution of NaH (32 mg, 80% dispersion in mineral oil, 1.07 mmol) in DME (5 ml), and the mixture stirred at 60°C, for 30 min. *tert*-Butyl (2*R*)-1-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-2-piperidinecarboxylate (150 mg, 0.34 mmol) was added and the reaction heated under reflux for 7 h, and stirred for a further 18 h at room temperature. The mixture was diluted with EtOAc, washed with water, brine, dried (MgSO_4), and evaporated *in vacuo*. The residual yellow gum was purified by column chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880 NH_3 (97:3:0.3) as eluant to give *tert*-butyl (2*R*)-1-({4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-2-piperidinecarboxylate, as a yellow solid (126 mg, 0.27 mmol).

mp 157-158°C

30 ^1H (CDCl_3 , 400MHz) δ 1.3 (9H, s), 1.4 (1H, m), 1.6-1.8 (4H, m), 2.15 (1H, m), 3.3 (1, m), 3.85 (1H, m), 4.75 (1H, m), 8.0 (1H, d), 8.1 (1H, d), 8.15 (1H, s), 9.2 (1H, s) ppm.

LRMS 468 (MH⁺)

Anal. Found: C, 51.23; H, 5.68; N, 14.51. Calc. for C₂₀H₂₆ClN₅O₄S: C, 51.33; H, 5.60; N, 14.97%.

5

A solution of *tert*-butyl (2*R*)-1-((4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl)-2-piperidinecarboxylate (50 mg, 0.107 mmol) in EtOAc saturated with HCl (10 ml), was stirred at room temperature for 2 h. The solution was concentrated *in vacuo*, and azeotroped several times with CH₂Cl₂ to give (2*R*)-1-((4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl)-2-piperidinecarboxylic acid hydrochloride (37 mg, 0.083 mmol) as a white solid.

10

mp dec>220°C

¹H (CD₃OD, 400MHz) δ 1.35 (1H, m), 1.5 (1H, m), 1.65-1.8 (3H, m), 2.2 (1H, m), 3.2-3.3 (2H, m), 3.95 (1H, m), 8.3 (1H, d), 8.45 (2H, m), 8.9 (1H, s) ppm.

15


LRMS 412, 414 (MH⁺)

Example 72:

(a) Methyl 4-(((4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl)amino)-1-methyl-4-piperidinecarboxylate

20

(b) 4-(((4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl)amino)-1-methyl-4-piperidinecarboxylic acid hydrochloride



25

Guanidine hydrochloride (270 mg, 2.83 mmol) was added to a solution of NaH (65 mg, 80% dispersion in mineral oil, 2.16 mmol) in DMSO (6 ml), and the solution stirred at 60°C for 30 min. Methyl 4-(((1,4-dichloro-7-isoquinolinyl)sulphonyl)amino)-1-methyl-4-piperidinecarboxylate (300 mg, 0.7 mmol) was added and the reaction stirred at 80°C for 5 h.

30

Additional NaH (30 mg, 1 mmol), and guanidine hydrochloride (135 mg, 1.4 mmol) in DMSO (1 ml) were added, and the reaction heated for a further 2 ½ h. The cooled mixture was poured into water, and extracted with EtOAc. The combined organic extracts were

washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residual yellow solid was purified by column chromatography upon silica gel using an elution gradient of CH_2Cl_2 - MeOH - 0.880 NH_3 (95:5:0.5 to 90:10:1) to afford methyl 4-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-1-methyl-4-piperidinecarboxylate (232 mg, 0.51 mmol).

5

mp dec > 205°C

^1H (CD_3OD , 400MHz) δ 2.05 (4H, m), 2.15 (3H, s), 2.25 (2H, m), 2.4 (2H, m), 3.4 (3H, s), 8.05-8.15 (3H, m), 9.1 (1H, s) ppm.

10

LRMS 455 (MH^+)

Anal. Found: C, 47.17; H, 5.02; N, 17.96. Calc. for $\text{C}_{18}\text{H}_{23}\text{ClN}_6\text{O}_4\text{S} \cdot 0.25\text{H}_2\text{O}$: C, 47.06; H, 5.16; N, 18.29%.

15

A solution of methyl 4-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-1-methyl-4-piperidinecarboxylate (100 mg, 0.22 mmol) in aqueous NaOH (2 ml, 2M, 4mmol) and MeOH (5 ml) was stirred at 60°C for 42 h. The cooled solution was neutralised using 2M HCl, and the mixture concentrated *in vacuo*, until precipitation occurred. The solid was filtered, dried and dissolved in concentrated HCl, and the solution evaporated *in vacuo*. The resulting solid was triturated with Et_2O , then *i*-PrOH, and dried under vacuum, to give 4-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-1-methyl-4-piperidinecarboxylic acid hydrochloride (18 mg, 0.035 mmol).

20


^1H ($\text{DMSO}-d_6$, 400MHz) δ 2.1 (2H, m), 2.3 (2H, m), 2.7 (3H, s), 2.8-3.0 (2H, m), 3.3 (2H, m), 8.25-8.75 (7H, m), 9.1 (1H, s) ppm.

LRMS 441 (MH^+)

30 **Example 73:**

(a) *tert*-butyl *N*-[(1-guanidino-7-isoquinolinyl)sulphonyl]-*D*-prolinecarboxylate

(b) *N*-[(1-Guanidino-7-isoquinolinyl)sulphonyl]-*D*-proline hydrochloride



A mixture of *tert*-butyl *N*-[(4-chloro-1-guanidino-7-isoquinolinylnyl)sulphonyl]-D-prolinecarboxylate (200 mg, 0.44 mmol) and 5% palladium on charcoal (150 mg) in EtOH (30 ml) was hydrogenated at 50psi and 50°C for 24 h. The cooled mixture was filtered through Arbocel®, and the filter pad washed well with EtOH. The combined filtrates were concentrated *in vacuo* and the residue purified by column chromatography upon silica gel using an elution gradient of CH₂Cl₂-MeOH-0.880 NH₃ (97:3:0.3 to 95:5:0.5) to afford *tert*-butyl *N*-[(1-guanidino-7-isoquinolinylnyl)sulphonyl]-D-prolinecarboxylate (143 mg, 0.34 mmol) as an off-white solid.

¹H (CDCl₃, 400MHz) δ 1.45 (9H, s), 1.75 (1H, m), 1.95 (3H, m), 3.4 (1H, m), 3.55 (1H, m), 4.3 (1H, m), 7.1 (1H, d), 7.75 (1H, d), 8.0 (1H, d), 8.15 (1H, d), 9.25 (1H, s) ppm.

LRMS 420 (MH⁺)

A solution of *tert*-butyl *N*-[(1-guanidino-7-isoquinolinylnyl)sulphonyl]-D-prolinecarboxylate (130 mg, 0.31 mmol) in EtOAc saturated with HCl (7 ml) was stirred at room temperature for 1 h. The reaction mixture was evaporated *in vacuo* and azeotroped with CH₂Cl₂, to give *N*-[(1-guanidino-7-isoquinolinylnyl)sulphonyl]-D-proline hydrochloride (118 mg, 0.295 mmol) as a white solid.


mp dec>250°C

¹H (DMSO-*d*₆, 400MHz) δ 1.6 (1H, m), 1.75-1.95 (3H, m), 3.2 (1H, m), 3.4 (1H, m), 4.4 (1H, m), 7.7 (1H, m), 8.2 (2H, m), 8.3 (1H, m), 9.05 (1H, s) ppm.

LRMS 364 (MH⁺)

Example 74:

1-[[{4-Chloro-1-guanidino-7-isoquinolinyl}sulphonyl]amino]-*N*-methyl-*N*-[2-(methylamino)ethyl]cyclopentanecarboxamide hydrochloride



DMF (5 drops) was added to a suspension of 1-[[{1-guanidino-4-chloro-7-isoquinolinyl}sulphonyl]amino]cyclopentanecarboxylic acid hydrochloride (1.1 g, 2.46 mmol) in CH_2Cl_2 (100 ml), followed by oxalyl chloride (319 μl , 3.68 mmol), and the reaction stirred at room temperature for 45 min. Additional oxalyl chloride (106 μl , 1.23 mmol) was added, and stirring continued for a further 30 min. The mixture was evaporated *in vacuo*, triturated with CH_2Cl_2 and the residue then dissolved in CH_2Cl_2 (100 ml). This solution of acid chloride (10 ml) was added to a solution of *N,N'*-dimethylethylenediamine (500 μl , 4.7 mmol) in CH_2Cl_2 (20 ml) and the resultant solution stirred at room temperature for 1 h. After evaporation to dryness, the residue was partitioned between water and CH_2Cl_2 , the aqueous layer separated and extracted with EtOAc. The combined organic extracts were dried (Na_2SO_4), evaporated to a gum and purified by column chromatography upon silica gel eluting with CH_2Cl_2 -MeOH-0.880 NH_3 (90:10:1) as eluant, to give an oil. This was dissolved in EtOAc, treated with ethereal HCl (1N), and the white precipitate, filtered and triturated with Et_2O , *i*-Pr₂O, and EtOH to yield the title compound (28 mg, 0.058 mmol).


mp 206°C (foams).

¹H (DMSO-*d*₆, 400 MHz) δ 1.35 (4H, m), 1.7 (2H, m), 2.0 (2H, m), 2.6 (3H, s), 3.05 (2H, m), 3.2 (3H, s), 3.4 (2H, m), 3.5 (2H, m), 8.35 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.6-8.8 (4H, m), 9.2 (1H, s) ppm.

LRMS 482, 484 (MH⁺).

Example 75:

1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-hydroxyethyl)-N-methylcyclopentanecarboxamide hydrochloride



5

A suspension of 1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino} cyclopentanecarbonyl chloride (110 mg, 0.245 mmol) in CH_2Cl_2 (10 ml) (prepared as described in example 76) was added over a minute to a solution of N-methylethanolamine (500 μl , 6.25 mmol) in CH_2Cl_2 (10 ml), and the resulting yellow solution stirred at room temperature for 72 h. The reaction mixture was evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880 NH_3 (90:10:1) as eluant to give a clear gum. This was dissolved in EtOAc, ethereal HCl (1N) added, the mixture evaporated *in vacuo* and triturated with EtOAc. The resulting solid was filtered and dried under vacuum at 50°C to give 1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-hydroxyethyl)-N-methylcyclopentanecarboxamide hydrochloride.

^1H (DMSO- d_6 , 400MHz) δ 1.4 (4H, m), 1.8 (2H, m), 2.0 (2H, m), 2.6 (1H, m), 3.05-3.2 (4H, m), 3.35-3.6 (4H, m), 8.3 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.55 (4H, m), 9.0 (1H, s), 11.0 (1H, s) ppm.


LRMS 468, 471 (MH^+)

Anal. Found: C, 41.87; H, 5.55; N, 15.40. Calc. for $\text{C}_{19}\text{H}_{25}\text{ClN}_6\text{O}_4\text{S}\cdot\text{HCl}\cdot 2\text{H}_2\text{O}$: C, 42.15; H, 5.58; N, 15.52%.

Example 76:

30

1-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-methoxyethyl)cyclopentanecarboxamide hydrochloride



5

1-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-methoxyethyl)cyclopentanecarboxamide was prepared from 2-methoxyethylamine and 1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino cyclopentanecarbonyl chloride, following the same procedure described in example 76. This product was treated with
 10 etheral HCl (1N) and the mixture evaporated *in vacuo*. The residual solid was dissolved in EtOH, water (1 drop) added, the solution concentrated *in vacuo* until precipitation occurred, and the resulting solid filtered, washed with Et₂O, and dried under vacuum, at 50°C, to afford 1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-methoxyethyl)cyclopentanecarboxamide hydrochloride (35 mg, 28%).

15

¹H (DMSO-*d*₆, 300MHz) δ 1.3-1.5 (4H, m), 1.9 (4H, m), 2.95 (2H, m), 3.2 (5H, m), 7.55 (1H, t), 8.2 (1H, s), 8.35 (2H, m), 8.45 (1H, s), 8.6 (4H, m), 9.1 (1H, s) ppm.

LRMS 469, 471 (MH⁺)


20

Anal. Found: C, 43.33; H, 5.38; N, 15.82. Calc. for C₁₉H₂₅ClN₆O₄S•HCl•1.2H₂O: C, 43.30; H, 5.43; N, 15.95%.

Example 77:

25

- (a) *N*-(2-*tert*-butyl aminoethylcarbamate)-1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclopentanecarboxamide
 (b) *N*-(2-Aminoethyl)-1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclopentane-carboxamide dihydrochloride



A suspension of 1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclopentanecarbonyl chloride (220 mg, 0.49 mmol) was added to a solution of *tert*-butoxy 2-aminoethylcarbamate (250 mg, 1.56 mmol) in CH_2Cl_2 (10 ml), and the reaction stirred at room temperature for 18 h. The mixture was evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880 NH_3 (90:10:1) as eluant to give a yellow oil. This product was crystallised from MeOH-*i*-Pr₂O to afford *N*-(2-*tert*-butyl aminoethylcarbamate)-1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclopentanecarboxamide (27 mg, 0.05 mmol) as a pale yellow solid.

¹H (CDCl₃, 300MHz) δ 1.3 (1H, m), 1.4 (2H, m), 1.8 (2H, m), 1.9 (2H, m), 2.45 (2H, m), 3.05 (4H, m), 5.65 (1H, m), 6.8 (4H, m), 7.1 (1H, m), 7.2 (1H, m), 7.9 (3H, m), 9.1 (1H, s) ppm.

LRMS 576 (MNa⁺)


A solution of *N*-(2-*tert*-butyl aminoethylcarbamate)-1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclopentanecarboxamide (20 mg, 0.036 mmol) in ethereal HCl (1 ml, 1N) was stirred at room temperature for 2 h. The reaction mixture was diluted with MeOH, concentrated *in vacuo*, and the residue triturated with Et₂O, then *i*-Pr₂O, and dried, to give *N*-(2-aminoethyl)-1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]cyclopentanecarboxamide dihydrochloride (16 mg, 0.30 mmol) as an off-white powder

¹H (DMSO-*d*₆, 400MHz) δ 1.6 (4H, m), 1.85 (2H, m), 1.9 (2H, m), 2.8 (2H, m), 3.2 (2H, m), 5.4 (1H, br s), 7.9 (2H, br s), 8.05 (1H, m), 8.2 (1H, s), 8.4 (1H, m), 8.45 (1H, s), 8.55-8.75 (4H, m), 9.25 (1H, s) ppm.

LRMS 454 (MH⁺)

Example 78:

- 5 **4-Chloro-1-guanidino-N-[1-(morpholinocarbonyl)cyclopentyl]-7-isoquinolinesulphonamide hydrochloride**




- 10 The title compound was prepared from 1-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]amino] cyclopentanecarbonyl chloride, and morpholine, following a similar procedure to that described in example 74.

- 15 ¹H (DMSO-*d*₆, 300MHz) δ 1.35 (4H, m), 1.7 (2H, m), 2.0 (2H, m), 3.4-3.65 (8H, m), 8.35-8.65 (8H, m), 8.95 (1H, s) ppm.

LRMS 480, 482 (MH⁺)

Example 79:

- 20 **4-Chloro-1-guanidino-N-{1-[(4-methylpiperazino)carbonyl]cyclopentyl}-7-isoquinolinesulphonamide dihydrochloride**



Triethylamine (1.36 ml, 10.0 mmol) was added to a solution of (1-aminocyclopentyl)(4-methyl-1-piperazinyl)methanone dihydrochloride (567 mg, 2.0 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (592 mg, 2.0 mmol) in CH_2Cl_2 (25 ml), and the reaction stirred at room temperature for 18 h. The mixture was concentrated *in vacuo* and the residue partitioned between EtOAc and water, and the layers separated. The organic phase was washed with water, extracted with HCl (2N), and these combined acidic extracts washed with EtOAc, and re-basified using Na_2CO_3 . This aqueous solution was extracted with EtOAc, the combined organic extracts washed with brine, dried (Na_2SO_4) and evaporated *in vacuo* to give a foam. This was crystallised from CH_2Cl_2 -*i*-Pr₂O to afford 1,4-dichloro-*N*-{1-[(4-methyl-1-piperazinyl)carbonyl]cyclopentyl}-7-isoquinolinesulphonamide (153 mg, 0.33 mmol) as a solid.

¹H (CDCl₃, 300MHz) δ 1.5-1.75 (6H, m), 2.25-2.45 (9H, m), 3.6 (4H, m), 5.1 (1H, s), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

Anal. Found: C, 49.12; H, 5.02; N, 1.06. Calc. for $\text{C}_{20}\text{H}_{24}\text{Cl}_2\text{N}_4\text{O}_3\text{S}\cdot 0.3\text{CH}_2\text{Cl}_2$: C, 49.07; H, 4.99; N, 11.28%.

NaH (22 mg, 80% dispersion in mineral oil, 0.73 mmol) was added to a solution of guanidine hydrochloride (142 mg, 1.49 mmol) in DMSO (2 ml), and the solution stirred at 50°C for 30 min. 1,4-Dichloro-*N*-{1-[(4-methyl-1-piperazinyl)carbonyl]cyclopentyl}-7-isoquinolinesulphonamide (140 mg, 0.28 mmol) was added and the reaction stirred at 90°C for 5 h. The cooled reaction was poured into water, the mixture extracted with EtOAc, and the combined extracts washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residual yellow foam was dissolved in *i*-PrOH, ethereal HCl (1N) was added, the solution evaporated *in vacuo* and the product suspended in ethanol. This mixture was filtered, the filtrate cooled in an ice-bath, and the resulting solid filtered, washed with EtOH, and dried, to give 4-chloro-1-guanidino-*N*-{1-[(4-methyl-1-piperazinyl)carbonyl]cyclopentyl}-7-isoquinolinesulphonamide dihydrochloride (68 mg, 0.12 mmol).


¹H (DMSO-*d*₆, 300MHz) δ 1.35 (4H, m), 1.7 (2H, m), 2.0 (2H, m), 2.75 (3H, s), 3.0 (2H, m), 3.25-3.45 (4H, m), 4.4 (2H, m), 8.3 (1H, d), 8.4 (1H, d), 8.45 (1H, s), 8.6 (4H, m), 8.7 (1H, s), 9.1 (1H, s), 11.15 (2H, br s) ppm.

LRMS 494, 496 (MH⁺)

Example 80:

(a) N-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-N-(methyl)cycloleucine ethyl ester

5 (b) N-[(4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl]-N-(methyl)cycloleucine hydrochloride



10 NaH (31 mg, 80% dispersion in mineral oil, 1.04 mmol) was added to a solution of guanidine hydrochloride (164 mg, 1.67 mmol) in DMSO (4 ml), and the solution heated at 50°C for 1 h. N-[(1,4-Dichloro-7-isoquinoliny]sulphonyl]-N-(methyl)cycloleucine ethyl ester (180 mg, 0.42 mmol) in DMSO (2 ml) was added, and the reaction heated at 80°C for 3 h. The cooled reaction mixture was poured into water, and extracted with EtOAc. The combined organic

15 extracts were washed with brine, dried (MgSO₄), and evaporated *in vacuo*. The residual yellow oil was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880 NH₃ (90:10:1) as eluant, and recrystallised from EtOAc to afford N-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl]-N-(methyl)cycloleucine ethyl ester (105 mg, 0.23 mmol) as a yellow solid.

20

mp 186-188°C

¹H (DMSO-*d*₆, 400MHz) δ 1.1 (3H, t), 1.55 (4H, m), 2.0 (2H, m), 2.2 (2H, m), 2.95 (3H, s), 4.0 (2H, q), 7.2-7.4 (4H, br s), 8.05 (2H, m), 8.15 (1H, s), 9.1 (1H, s) ppm.

25

LRMS 454, 456 (MH⁺)

Anal. Found: C, 50.04; H, 5.38; N, 15.31. Calc. for C₁₉H₂₄ClN₅O₄S•0.2H₂O: C, 49.88; H, 5.38; N, 15.31%.

30

A solution of N-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-N-(methyl)cycloleucine ethyl ester (80 mg, 0.176 mmol) in NaOH (1ml, 2N) and MeOH (10 ml) was stirred at 70°C for 18 h. The cooled mixture was neutralised using HCl (2N), and the MeOH was removed *in vacuo*. The resulting precipitate was filtered off, washed with water and re-dissolved in concentrated HCl. This solution was evaporated *in vacuo*, azeotroped with toluene, the residue dissolved in EtOH and filtered. The filtrate was evaporated *in vacuo* and the resulting solid recrystallised from *i*-PrOH, to give N-[(4-chloro-1-guanidino-7-isoquinoliny)lsulphonyl]-N-(methyl)cycloleucine hydrochloride (18 mg, 0.039 mmol) as a yellow solid.

mp 225°C (dec.).

¹H (DMSO-*d*₆ + TFA-*d*, 400 MHz) δ 1.4-1.6 (4H, m), 1.95-2.0 (2H, m), 2.15-2.25 (2H, m), 3.0 (3H, s), 8.3 (1H, d), 8.35 (1H, d), 8.45 (1H, s), 8.95 (1H, s) ppm.


LRMS 426, 428 (MH⁺).

Anal. Found: C, 41.50; H, 4.79; N, 13.82. Calc for C₁₇H₂₀ClN₅O₄S•HCl•1.8H₂O: C, 41.27; H, 5.01; N, 14.15.

Example 81:

(a) N-[(4-Bromo-1-guanidino-7-isoquinoliny)lsulphonyl]-D-proline *tert*-butyl ester hydrochloride

(b) N-[(4-Bromo-1-guanidino-7-isoquinoliny)lsulphonyl]-D-proline hydrochloride



NaH (48 mg, 80% dispersion in mineral oil, 1.6 mmol) was added to a solution of guanidine hydrochloride (233 mg, 2.43 mmol) in DMSO (8 ml) and the solution stirred at room temperature for 30 min. N-[(4-Bromo-1-chloro-7-isoquinoliny)lsulphonyl]-D-proline *tert*-butyl ester (290 mg, 0.61 mmol), was added and the reaction stirred at 60°C for 2 h, and

allowed to cool to room temperature overnight. The mixture was poured into water, and extracted with EtOAc. The combined organic extracts were washed with brine, dried (MgSO₄) and evaporated *in vacuo*. The residual yellow oil was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880 NH₃ (97.5:2.5:0.25) as eluant, to give a yellow foam. This was dissolved in Et₂O, treated with ethereal HCl, the mixture evaporated *in vacuo* and the residue triturated with Et₂O to give *N*-[(4-bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline *tert*-butyl ester hydrochloride (166 mg, 0.31 mmol) as a white solid.

mp. 203°C

¹H (DMSO-*d*₆, 300MHz) δ 1.4 (9H, s), 1.65 (1H, m), 1.8 (2H, m), 2.0 (1H, m), 3.35 (1H, m), 3.45 (1H, m), 8.35 (2H, m), 8.5-8.8 (5H, m), 9.1 (1H, s), 11.4 (1H, s) ppm.

LRMS 497, 499 (MH⁺)

Anal. Found: C, 41.96; H, 4.65; N, 12.65. Calc. for C₁₉H₂₄BrN₅O₄S•HCl•0.5H₂O: C, 41.96; H, 4.82; N, 12.88%.

N-[(4-Bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline *tert*-butyl ester hydrochloride (150 mg, 0.28 mmol) was treated with an ice-cold solution of HCl in EtOAc (20 ml), and the reaction allowed to warm to room temperature, and stirred for 4 h. The solution was concentrated *in vacuo* and the crude product purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880 NH₃ (90:10:1) as eluant. The product was treated with ethereal HCl, the resulting precipitate filtered, washed with Et₂O and dried to afford *N*-[(4-bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-D-proline hydrochloride (75 mg, 0.156 mmol) as a white powder.

¹H (DMSO-*d*₆, 300MHz) δ 1.6 (1H, m), 1.7-2.0 (3H, m), 3.2-3.45 (2H, m), 4.4 (1H, m), 8.3 (2H, m), 8.5-8.85 (5H, m), 9.15 (1H, s) ppm.


LRMS 443 (MH⁺)

Anal. Found: C, 35.56; H, 3.54; N, 13.52. Calc. for C₁₅H₁₆BrN₅O₄S•HCl•1.5H₂O: C, 35.62; H, 3.99; N, 13.85%.

Example 82:

(2R)-1-({4-Chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-N-[2-(dimethylamino)ethyl]-2-pyrrolidinecarboxamide

5



N-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-L-proline hydrochloride (300 mg, 0.69 mmol) was suspended in a solution of DMF (5 drops) and CH_2Cl_2 (15 ml), and oxalyl chloride (150 μl , 1.72 mmol) added dropwise. The reaction was stirred at room temperature for 3 h, then concentrated *in vacuo* and azeotroped with toluene. The residue was dissolved in CH_2Cl_2 (15 ml), *N*-(2-aminoethyl)-*N,N*-dimethylamine (1 ml, 0.9 mmol) added and the reaction stirred at room temperature for 2 h. The mixture was evaporated *in vacuo*, the residue partitioned between EtOAc and Na_2CO_3 solution, the layers separated, and the organic phase washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residual yellow solid was purified by column chromatography upon silica gel using an elution gradient of CH_2Cl_2 -MeOH-0.880 NH_3 (95:5:0.5 to 90:10:1) to give (2R)-1-({4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-*N*-[2-(dimethylamino)ethyl]-2-pyrrolidinecarboxamide (195 mg, 0.42 mmol) as a yellow solid.


^1H (DMSO- d_6 , 400 MHz) δ 1.55 (1H, m), 1.65 (1H, m), 1.7 (2H, m), 2.15 (6H, s), 2.25 (2H, t), 3.2 (3H, m), 3.5 (1H, m), 4.1 (1H, dd), 7.2-7.4 (4H, br s), 7.8 (1H, m), 8.0 (1H, d), 8.15 (2H, m), 9.1 (1H, s) ppm.

Anal. Found: C, 47.67; H, 5.61; N, 20.31. Calc. for $\text{C}_{19}\text{H}_{26}\text{ClN}_7\text{O}_3\text{S}\cdot 0.5\text{H}_2\text{O}$:
C, 47.84; H, 5.71; N, 20.56%.

Example 83:

1-({(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl}[2-(dimethylamino)ethyl]amino}-*N*-(2-hydroxyethyl)-*N*-methylcyclopentanecarboxamide dihydrochloride

30



- N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]
 5 cycloleucine dihydrochloride (170 mg, 0.31 mmol) was dissolved in DMF (10 μ l) and CH_2Cl_2 (15 ml). Oxalyl chloride (100 μ l, 1.15 mmol) was added and the mixture stirred at room temperature for 3 h. The solvent was removed *in vacuo*, replaced with fresh CH_2Cl_2 , *N*-methylethanolamine (230 μ l, 2.86 mmol) in CH_2Cl_2 (10 ml) added, and the reaction stirred for 2 h. The solvent was removed *in vacuo* and the resultant gum extracted with Et_2O and
 10 EtOAc . These combined organic extracts were concentrated *in vacuo*, and the crude product purified by column chromatography upon silica gel eluting with CH_2Cl_2 -MeOH-0.880 NH_3 (90:10:1). The resulting yellow oil was dissolved in EtOAc , and acidified with ethereal HCl (1N) to give the title compound as a cream solid (17 mg, 0.03 mmol).


- 15 ^1H ($\text{DMSO}-d_6$ + $\text{TFA}-d$, 300MHz) δ 1.55 (4H, m), 2.0 (2H, m), 2.4 (2H, m), 2.6 (3H, s), 2.9 (6H, s), 3.35 (2H, m), 3.5 (3H, m), 3.95 (2H, m), 4.3 (2H, t), 8.4 (3H, m), 8.5 (1H, s), 9.35 (1H, s) ppm.

LRMS 540, 542 (MH^+).

20

Example 84:

- (a) Ethyl *N*-[(4-bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]-cycloleucine dihydrochloride
 (b) *N*-[(4-Bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine dihydrochloride
 25



A mixture of NaH (28 mg, 80% in mineral oil, 0.93 mmol) and guanidine hydrochloride (126 mg, 1.32 mmol) in dry DMSO (3 ml) was heated at 50°C for 30 min. *N*-[(4-Bromo-1-chloro-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine hydrochloride (150 mg, 0.26 mmol) was added and the mixture heated to 90°C for 1 h, cooled, poured into water and
5 extracted with EtOAc (3 x). The combined organic extracts were washed with water and brine, dried (Na₂SO₄) and concentrated *in vacuo* to a yellow gum. After column chromatography on silica gel eluting with CH₂Cl₂- MeOH-0.880 NH₃ (95 : 5: 0.5), the residue was dissolved in EtOAc and acidified with ethereal HCl (1N) to afford a white precipitate. This was filtered, dried and recrystallised from EtOH to give a white solid (20 mg, 0.04
10 mmol). Concentration of the mother liquors afforded a second crop (95 mg, 0.17 mmol) of ethyl *N*-[(4-bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine dihydrochloride.

¹H (DMSO-*d*₆, 300MHz) δ 1.15 (3H, t), 1.6 (4H, m), 2.0 (2H, m), 2.3 (2H, m), 2.9 (6H, s),
15 3.5 (2H, m), 3.95 (2H, m), 4.0 (2H, q), 8.34 (2H, s), 8.6 (1H, s), 9.4 (1H, s), 11.6 (1H, br s) ppm.

LRMS 555, 557 (MH⁺).

20 Anal. Found: C, 39.67; H, 5.61; N, 12.51. Calc. for C₂₂H₃₁BrN₆O₄S•2HCl•2H₂O:
C, 39.77; H, 5.61; N, 12.65%.

Ethyl *N*-[(4-Bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine dihydrochloride (95 mg, 0.17 mmol) in EtOH (3 ml) was
25 treated with NaOH (4N, 8 ml) and the solution stirred at 60°C for 5 h and allowed to stand for 60 h at room temperature. The reaction mixture was acidified using 2N HCl, concentrated *in vacuo* and the residue azeotroped with *i*-PrOH to give an off- white solid. This was extracted into MeOH, the solution evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using CH₂Cl₂- MeOH-0.880 NH₃ (80 : 20: 5) as eluant. The
30 product was suspended in EtOAc, treated with ethereal HCl, the mixture evaporated *in vacuo* and the product triturated with EtOAc to afford *N*-[(4-bromo-1-guanidino-7-isoquinolinyl)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine dihydrochloride (15 mg, 0.027 mmol) as a pale yellow solid.

^1H (DMSO- d_6 , 300MHz) δ 1.45-1.6 (4H, m), 1.95 (2H, m), 2.2 (2H, m), 2.6 (6H, s), 3.1 (2H, m), 3.7 (2H, t), 7.35-7.6 (4H, br s), 8.0 (1H, d), 8.15 (1H, d), 8.25 (1H, s), 9.15 (1H, s) ppm.

LRMS 527, 529 (MH^+)

5

Anal. Found : C, 41.31; H, 5.35; N, 14.14. Calc. for $\text{C}_{20}\text{H}_{27}\text{BrN}_6\text{O}_4\text{S}\cdot\text{HCl}\cdot\text{H}_2\text{O}$:


C, 41.27; H, 5.19; N, 14.44%.

10 Example 85:

(a) Ethyl 3-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-2,2-dimethylpropanoate hydrochloride

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-2,2-dimethyl- β -alanine hydrochloride

15



Ethyl 3-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-2,2-dimethylpropanoate hydrochloride was prepared (29%) as a white solid, from ethyl 3-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]-2,2-dimethylpropanoate, following a similar procedure to that described in example 83.

mp. 183-187°C

25

^1H (DMSO- d_6 , 300MHz) δ 1.1 (6H, s), 1.15 (3H, t), 2.95 (2H, d), 4.0 (2H, q), 7.95 (1H, t), 8.35 (1H, m), 8.4 (1H, m), 8.45 (1H, s), 8.5-8.65 (3H, br s), 9.1 (1H, s), 11.2 (1H, s).

LRMS 428 (MH^+)

30

Anal. Found: C, 43.99; H, 5.01; N, 14.69. Calc. for $\text{C}_{17}\text{H}_{22}\text{ClN}_6\text{O}_4\text{S}\cdot\text{HCl}$:

C, 43.97; H, 4.99; N, 15.08%.

A solution of ethyl 3-[[[4-chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]-2,2-dimethylpropanoate hydrochloride (28 mg, 0.06 mmol) in NaOH solution (2N, 0.5ml), and MeOH (1 ml), was stirred at 75°C for 24 h. The cooled mixture was acidified to pH 6 using HCl (2N), concentrated *in vacuo* to remove the MeOH, and the resulting precipitate filtered, washed with water and dried. The solid was suspended in a MeOH/EtOAc solution, ethereal HCl added, and the mixture evaporated *in vacuo* to afford *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]-2,2-dimethyl-β-alanine hydrochloride as a white solid (22 mg, 0.05 mmol).

mp. Dec>304°C


¹H (DMSO-*d*₆, 300MHz) δ 1.05 (6H, s), 2.9 (2H, d), 7.9 (1H, t), 8.3-8.6 (6H, m), 9.05 (1H, s) ppm.

Example 86:

(a) 1-[[[4-Chloro-1-guanidino-7-isoquinolinyl]sulphonyl]amino]-*N,N*-dimethylcyclopentanecarboxamide

(b) 1-[[[4-Chloro-1-guanidino-7-isoquinolinyl]sulphonyl][2-(tetrahydro-2*H*-pyran-2-yloxy)ethyl]amino]-*N,N*-dimethylcyclopentanecarboxamide

(c) 1-[[[4-Chloro-1-guanidino-7-isoquinolinyl]sulphonyl](2-hydroxyethyl)amino]-*N,N*-dimethylcyclopentanecarboxamide hydrochloride



Oxalyl chloride (3.5 ml, 4.0 mmol) was added to a suspension of *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]cycloleucine hydrochloride (870 mg, 1.94 mmol) in CH₂Cl₂ (100 ml), followed by DMF (5 drops), and the reaction stirred at room temperature for 2 h. The solution was concentrated *in vacuo* and azeotroped with toluene to give a yellow gum. This

was dissolved in CH_2Cl_2 (100 ml), the solution cooled to -20°C , and cooled N,N -dimethylamine (10 ml) added. The reaction was allowed to warm to room temperature with stirring, over 30 min, then concentrated *in vacuo*, and the residue azeotroped with toluene. The crude product was purified by column chromatography upon silica gel using CH_2Cl_2 -
5 MeOH-0.880 NH_3 (95 : 5: 0.5) as eluant, and crystallised from MeOH to afford to afford 1-
[[{4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl]amino]- N,N -dimethylcyclopentanecarboxamide (302 mg, 0.69 mmol) as a yellow solid.

mp. $264-268^\circ\text{C}$.

10

^1H (DMSO- d_6 , 400MHz) δ 1.35 (4H, m), 2.0 (2H, m), 2.2 (2H, m), 3.1 (6H, s), 8.35 (2H, m), 8.4-8.7 (2H, m), 9.1 (1H, s) ppm.

LRMS 439, 441 (MH $^+$)

15

Anal. Found: C, 49.07; H, 5.27; N, 18.51. Calc. for $\text{C}_{18}\text{H}_{23}\text{ClN}_6\text{O}_3\text{S}\cdot 0.3\text{H}_2\text{O}$:
C, 48.66; H, 5.35; N, 18.91%.

K_2CO_3 (113 mg, 0.82 mmol) was added to a solution of 1-[[{4-chloro-1-guanidino-7-
20 isoquinolinyl}sulphonyl]amino]- N,N -dimethylcyclopentanecarboxamide (150 mg, 0.34
mmol) in DMF (2.5 ml), and the mixture heated to 75°C . 2-(2-Bromoethoxy)tetrahydro-2H-
pyran (J.C.S. 1948; 4187) (150 mg, 0.72 mmol) and sodium iodide (3 mg) were then added
and the reaction stirred at 75°C for 3 days. The cooled reaction mixture was poured into
water, and extracted with EtOAc. The combined organic extracts were washed with brine,
25 dried (Na_2SO_4) and evaporated *in vacuo*. The residual yellow oil was purified by column
chromatography upon silica gel using EtOAc as eluant, and triturated with a hexane-EtOAc
(20:1) solution, to give 1-[[{4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl][2-(tetrahydro-
2H-pyran-2-yloxy)ethyl]amino]- N,N -dimethylcyclopentanecarboxamide (56 mg, 0.099
mmol).

30

^1H (CDCl_3 , 400MHz) δ 1.45-1.85 (?H, m), 2.9-3.2 (6H, m), 3.35-3.6 (4H, m), 3.95 (2H, m), 4.1 (1H, m), 4.65 (1H, s), 8.1 (3H, m), 9.25 (1H, s) ppm.

Ethereal HCl was added dropwise to a solution of 1-[[{4-chloro-1-guanidino-7-
35 isoquinolinyl}sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]- N,N -

dimethylcyclopentanecarboxamide (37 mg, 0.065 mmol) in EtOAc (1.5 ml), until no further precipitation occurred. The resulting suspension was stirred at room temperature for 20 min, and then evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880 NH₃ (95:5:0.5) as eluant, and azeotroped with toluene.

- 5 This product was dissolved in a MeOH-CH₂Cl₂ solution, ethereal HCl added (5 ml), and the mixture evaporated *in vacuo*, and triturated with Et₂O to afford 1-[(4-chloro-1-guanidino-7-isoquinoliny]sulphonyl)(2-hydroxyethyl)amino]-*N,N*-dimethylcyclopentanecarboxamide hydrochloride (9mg, 0.017mmol) as a cream/white solid.

- 10 ¹H (DMSO-*d*₆+ TFA-*d*, 300MHz) δ 1.25-1.45 (4H, m), 1.7 (2H, m), 2.25 (2H, m), 2.8-3.0 (6H, m), 3.3 (2H, m), 3.7 (2H, t), 8.35 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.6 (1H, br s), 9.0 (1H, s) ppm.

LRMS 483 (MH⁺)

15


Example 87:

(a) Ethyl 1-[[[4-chloro-1-guanidino-7-isoquinoliny]sulphonyl][2-(tetrahydro-2*H*-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylate

(b) 1-[[[4-Chloro-1-guanidino-7-isoquinoliny]sulphonyl][2-(tetrahydro-2*H*-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylic acid

20

© *N*'-[4-Chloro-7-[(10-oxo-9-oxa-6-azaspiro[4.5]dec-6-yl)sulphonyl]-1-isoquinoliny]guanidine hydrochloride



25

NaH (45 mg, 80% dispersion in mineral oil, 1.5 mmol) was added to a solution of guanidine hydrochloride (231 mg, 2.4 mmol) in DMSO (5 ml), and the solution stirred at 50°C for 20

min. Ethyl 1-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylate (330 mg, 0.6 mmol) was added and the reaction stirred at 70°C for 2 ½ h. The cooled reaction was poured into water, extracted with EtOAc, and the combined organic extracts washed with brine, dried (MgSO₄) and evaporated *in vacuo*. The residual yellow gum was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880 NH₃ (95:5:0.5) as eluant to give ethyl 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylate as an orange oil.

¹H (CDCl₃, 400MHz) δ 1.25 (3H, t), 1.45-1.75 (14H, m), 2.1 (2H, m), 2.35 (2H, m), 3.5 (1H, m), 3.75-3.9 (4H, m), 4.0 (1H, m), 4.2 (2H, q), 4.61 (1H, s), 8.05-8.15 (3H, m), 9.25 (1H, s) ppm.

LRMS 568 (M⁺)

15

A solution of ethyl 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylate in MeOH (5 ml), was heated to 75°C, NaOH solution (1 ml, 2N, 2 mmol) added, and the reaction stirred at 50°C for 48 h. The cooled reaction mixture was concentrated *in vacuo*, to remove the MeOH, and the remaining aqueous solution acidified to pH 6 using 1N HCl. The resulting precipitate was filtered, washed with water, and the filtrate extracted with EtOAc. The combined organic extracts were dried (MgSO₄), and evaporated *in vacuo* to give 1-[[[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylic acid (9 mg, 0.017 mmol) as a pale yellow solid.

25

¹H (CDCl₃, 300MHz) δ 1.4 (4H, m), 1.55 (4H, m), 2.0 (2H, m), 2.2 (2H, m), 3.35 (3H, m), 3.45-3.75 (5H, m), 4.5 (1H, m), 8.0 (1H, d), 8.15 (2H, m), 9.15 (1H, s) ppm.

Anal. Found: C, 49.50; H, 5.50; N, 12.26. Calc. for C₂₃H₃₀ClN₅O₆S•H₂O:

30

C, 49.50; H, 5.78; N, 12.55%.

1-[[[(4-Chloro-1-guanidino-7-isoquinolinyl)sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino]cyclopentanecarboxylic acid (20 mg, 0.037 mmol) was dissolved in EtOAc (20 ml), ethereal HCl (10 ml) added, and the reaction stirred at room temperature for 18 h. The resulting precipitate was filtered, washed with EtOAc and dried under vacuum to

35

give *N'*-{4-Chloro-7-[(10-oxo-9-oxa-6-azaspiro[4.5]dec-6-yl)sulphonyl]-1-isoquinolinyl}guanidine hydrochloride (17 mg, 0.36 mmol).

¹H (CDCl₃, 300MHz) δ 1.6-1.8 (4H, m), 2.25 (4H, m), 3.95 (2H, t), 4.4 (2H, t), 8.35 (2H, m), 8.45 (1H, s), 9.25 (1H, s), 11.5 (1H, s) ppm.


LRMS 437 (M⁺)

Anal. Found: C, 44.04; H, 4.58; N, 14.17. Calc. for, C₁₈H₂₀ClN₅O₄S•HCl•H₂O:
C, 43.91; H, 4.71; N, 14.22%.

Example 88:

(a) *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)methyl]cycloleucine methyl ester

(b) *N*-[(4-Chloro-1-guanidino-7-isoquinolinyl)methyl]cycloleucine dihydrochloride



NaH (52 mg, 80% dispersion in mineral oil, 1.73 mmol) was added to a slurry of guanidine hydrochloride (265 mg, 2.77 mmol) in DMSO (2.5 ml) and the mixture heated to 50°C for 20 mins. *N*-[(1,4-Dichloro-7-isoquinolinyl)methyl]cycloleucine methyl ester (245 mg, 0.69 mmol) in DMSO (2.5 ml) was added and after heating at 90°C for 4 ½ h, the solution was poured into water (50 ml). The mixture was extracted with EtOAc (2 x), the combined organic extracts washed with water, brine and then dried (Na₂SO₄). The residue was purified by column chromatography upon silica gel eluting with CH₂Cl₂-MeOH -0.880 NH₃ (90 : 10 : 1) to give a yellow solid. This was dissolved in a CH₂Cl₂-MeOH solution and acidified with ethereal HCl (1N), concentrated *in vacuo* and the crude product recrystallised from EtOH to give *N*-[(4-chloro-1-guanidino-7-isoquinolinyl)methyl]cycloleucine methyl ester (30 mg, 0.08 mmol) as a cream solid.

mp. 271-275°C

¹H (DMSO-*d*₆, 300MHz) δ 1.25 (3H, t), 1.75 (2H, m), 1.9 (2H, m), 2.1-2.3 (4H, m), 4.25 (2H, q), 4.35 (2H, m), 8.25 (3H, m), 8.4 (1H, s), 9.3 (1H, s), 11.7 (1H, s) ppm.

5 LRMS 390 (MH⁺)

Anal. Found: C, 49.09; H, 5.74; N, 14.71. Calc. For C₁₉H₂₄ClN₅O₂•2HCl•0.2H₂O: C, 48.93; H, 5.71; N, 15.02%.

10 N-[(4-Chloro-1-guanidino-7-isoquinoliny)methyl]cycloleucine methyl ester (100 mg, 0.27 mmol) was dissolved in methanol (4 ml) at 50°C, NaOH (2N, 1 ml) was added, and the reaction mixture heated for 2 days at 50°C. The cooled mixture was basified to pH 6 with NaOH (2N) to give a precipitate which was filtered off and washed with water. The solid
15 to give the title compound (b) as a pale yellow solid (10 mg, 0.03 mmol).

mp 281-289°C

¹H (DMSO-*d*₆+ TFA-*d*, 300MHz) δ 1.8 (2H, m), 1.85 (2H, m), 2.15 (2H, m), 2.25 (2H, m),
20 4.4 (2H, s), 8.2 (1H, d), 8.3 (1H, d), 8.4 (1H, s), 9.15 (1H, s) ppm.


LRMS 362 (MH⁺).

PREPARATIONS

Preparation 1:

7-Bromo-1,4-dichloroisoquinoline

5




A solution of 4-bromocinnamic acid (5.03 g, 22.2 mmol) in SOCl_2 (15 mL) was stirred at 23 °C for 16 h, and then heated at reflux for a further 2 h. The solvents were evaporated *in vacuo* and the residue azeotroped with PhMe (x3) to yield 4-bromocinnamoyl chloride (22 mmol) as an orange-brown solid.

^1H NMR (CDCl_3 , 300 MHz) δ 6.65 (1H, d), 7.4 (2H, d), 7.6 (2H, d), 7.8 (1H, d) ppm.

A solution of NaN_3 (2.2 g, 33.8 mmol) in water (7.5 mL) was added dropwise over 5 min to a stirred solution of 4-bromocinnamoyl chloride (22 mmol) in acetone (22 mL) at -10 °C. The heterogeneous mixture was stirred at 0 °C for 1 h and diluted with water (25 mL). The precipitate was collected by filtration and dried *in vacuo* over P_2O_5 to give 4-bromocinnamoyl azide (5.22 g, 20.7 mmol) as a golden-coloured solid.

20


^1H NMR (CDCl_3 , 300 MHz) δ 6.4 (1H, d), 7.4 (2H, d), 7.5 (2H, d), 7.65 (1H, d) ppm.



A warm solution of 4-bromocinnamoyl azide (5.22 g, 20.7 mmol) in Ph_2O (25 mL) was added dropwise over 15 min to stirred Ph_2O (10 mL) at 270 °C. [CAUTION: Potentially explosive - use a blast screen.] The mixture was heated at 270 °C for 1.5 h, cooled to 23 °C and then poured into hexanes (400 mL). The precipitate was collected by filtration, with hexanes (2x100 mL) rinsing, and purified by column chromatography upon silica gel using hexanes-EtOAc (6:4 to 0:100) as eluant to give 7-bromo-1(2H)-isoquinolone (1.64 g, 7.3 mmol) as a white solid.

30

¹H NMR (DMSO-*d*₆, 300 MHz) δ 6.55 (1H, d), 7.25-7.15 (1H, m), 7.6 (1H, d), 7.8 (1H, d), 8.25 (1H, s), 11.4 (1H, br s) ppm.



5

A mixture of 7-bromo-1(2H)-isoquinolone (1.28 g, 5.69 mmol) and PCl₅ (2.04 g, 9.80 mmol) was heated at 140 °C for 5 h. The cooled mixture was quenched with ice (50 g) and 0.880N H₃ was added until alkaline by litmus paper. The aqueous mixture was extracted with CH₂Cl₂ (3x50 mL) and the combined organic phases were dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (97:3 to 95:5) as eluant to give 7-bromo-1,4-dichloroisoquinoline (1.13 g, 4.08 mmol) as a white solid.

10

mp 133.5-135 °C.

15

¹H (CDCl₃, 300 MHz) δ 7.9 (1H, d), 8.1 (1H, d), 8.35 (1H, s), 8.5 (1H, s).


LRMS 276, 278 (MH⁺).

20

Anal. Found: C, 39.04; H, 1.32; N, 5.06. Calc for C₉H₄BrCl₂N: C, 39.03; H, 1.46; N, 5.06.

Preparation 2:

t-Butyl 2-aminobenzoate



25

A mixture of 2-nitrobenzoyl chloride (15 mL, 110 mmol) and *t*-BuOH (100 mL) were heated at reflux for 3 h. The cooled mixture was poured onto ice-water, basified with Na₂CO₃ and extracted with CH₂Cl₂ (x2). The combined organic extracts were washed with brine, the solvents evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using hexanes-EtOAc (95:5) as eluant to give *t*-butyl 2-nitrobenzoate (4.9 g, 22 mmol) as a yellow oil.

30

^1H (CDCl_3 , 300 MHz) δ 1.6 (9H, s), 7.5 (1H, dd), 7.6 (1H, dd), 7.7 (1H, d), 7.8 (1H, d) ppm.

LRMS 240 (MNH_4^+).

5

A solution of *t*-butyl 2-nitrobenzoate (4.9 g, 22 mmol) in EtOH (160 mL) was stirred with 10% palladium-carbon (700 mg) under an atmosphere of H_2 (60 psi) at 23 °C. After 4 h, the mixture was filtered and evaporated in vacuo to give *t*-butyl 2-aminobenzoate (4.0 g, 20.7 mmol) as a yellow oil.

10


^1H (CDCl_3 , 300 MHz) δ 1.6 (9H, s), 5.6-5.8 (2H, br s), 6.6 (1H, dd), 6.6 (1H, d), 7.2 (1H, dd), 7.8 (1H, d) ppm.

LRMS 194 (MH^+).

15

Preparation 3:

t-Butyl 2-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]benzoate



20

n-Butyllithium (0.88 mL, 2.5 M in hexanes, 2.2 mmol) was added dropwise to a stirred solution of 7-bromo-1,4-dichloroisoquinoline (570 mg, 2.0 mmol) in THF-Et₂O (10 mL, 1:1) under N_2 at -78 °C. After 5 min, the mixture was added to a solution of SO_2Cl_2 (0.35 mL, 4.35 mmol) in hexane (10 mL) at -78 °C under N_2 , and the mixture was slowly warmed to 23 °C and then stirred for 4.5 h. The solvents were evaporated *in vacuo*, azeotroping with CH_2Cl_2 and PhMe, the residue was suspended in CH_2Cl_2 (12 mL) containing NEt_3 (1.15 mL, 8.25 mmol) and *t*-butyl 2-aminobenzoate (520 mg, 2.7 mmol) was added. The mixture was stirred at room temperature for 3 d and then heated at reflux for 6 h. The cooled mixture was diluted with CH_2Cl_2 , washed with aqueous HCl (2 M), brine, and then evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (97:3 to 95:5) as eluant to give, initially, 1,4,7-trichloroisoquinoline (200 mg) followed by *t*-butyl 2-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]benzoate (120 mg, 0.26 mmol) as a yellow resin.


30

¹H (CDCl₃, 400 MHz) δ 1.5 (9H, s), 7.05 (1H, dd), 7.5 (1H, dd), 7.7 (1H, d), 7.8 (1H, d), 8.2 (1H, d), 8.3 (1H, d), 8.4 (1H, s), 8.8 (1H, s), 10.0 (1H, s) ppm.

5 LRMS 454 (MH⁺).

Preparation 4:

t-Butyl 3-aminobenzoate



A mixture of 3-nitrobenzoic acid (5 g, 30 mmol), di-*tert*-butyl dicarbonate (20 g, 92 mmol), and DMAP (0.84 g, 6.9 mmol) in THF (60 mL) was stirred at 23 °C for 2 d. The mixture was poured onto ice-water, basified with Na₂CO₃ and extracted with CH₂Cl₂ (x3). The combined
 15 organic extracts were washed with brine, the solvents evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using hexanes-EtOAc (95:5) as eluant to give *t*-butyl 3-nitrobenzoate (5.4 g, 24 mmol) as a colourless oil.

20 ¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 7.6 (1H, dd), 8.3 (1H, d), 8.4 (1H, d), 8.8 (1H, s) ppm.


A solution of *t*-butyl 3-nitrobenzoate (5.8 g, 26 mmol) in EtOH (260 mL) was stirred with 10% palladium-carbon (1.0 g) under an atmosphere of H₂ (60 psi) at 23 °C. After 4 h, the mixture was filtered and evaporated *in vacuo* to give *t*-butyl 3-aminobenzoate (4.0 g, 20.7
 25 mmol) as a white solid.

¹H (CDCl₃, 400 MHz) δ 1.6 (9H, s), 3.6-3.9 (2H, br s), 6.8 (1H, d), 7.2 (1H, dd), 7.3 (1H, s), 7.4 (1H, d) ppm.

30 LRMS 194 (MH⁺), 387 (M₂H⁺).

Preparation 5:

t-Butyl 3-(((1,4-dichloro-7-isoquinolinyl)sulphonyl)amino)benzoate



n-Butyllithium (0.88 mL, 2.5 M in hexanes, 2.2 mmol) was added dropwise to a stirred solution of 7-bromo-1,4-dichloroisoquinoline (570 mg, 2.0 mmol) in THF-Et₂O (10 mL, 1:1) under N₂ at -78 °C. After 5 min, the mixture was added to a solution of SO₂Cl₂ (0.35 mL, 4.35 mmol) in hexane (10 mL) at -78 °C under N₂, and the mixture was slowly warmed to 23 °C and then stirred for 4.5 h. The solvents were evaporated *in vacuo*, azeotroping with PhMe, the residue was suspended in CH₂Cl₂ (12 mL) and *t*-butyl 3-aminobenzoate (520 mg, 2.7 mmol) followed by NEt₃ (1.15 mL, 8.25 mmol) were added. The mixture was stirred at room temperature for 4 d and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (90:10 to 50:50) as eluant to give, initially, 1,4,7-trichloroisoquinoline (150 mg) followed by *t*-butyl 2-[[[(1,4-dichloro-7-isoquinolinyl)sulfonyl]amino]benzoate (289 mg, 0.63 mmol) as a brown solid which was used without further purification.

¹H (CDCl₃, 400 MHz) selected data: δ 1.5 (9H, s), 7.20-7.25 (1H, m), 7.3-7.45 (1H, m), 7.5 (1H, dd), 7.6 (1H, s), 8.45 (1H, d), 8.5 (1H, d), 8.6 (1H, s), 8.9 (1H, s) ppm.

LRMS 454 (MH⁺).

Preparation 6:

1,4-Dichloro-7-isoquinolinesulphonyl chloride




A solution of *N*-chlorosuccinimide (9.66 g, 72 mmol) in MeCN (80 mL) was added dropwise to a stirred solution of 1-(2*H*)-isoquinolone (10 g, 69 mmol) in MeCN (250 mL) which was being heated under reflux. The mixture was heated under reflux for an additional 1.5 h and then cooled to room temperature. The resulting precipitate was collected by filtration, with MeCN rinsing, and then dried *in vacuo* to give 4-chloro-1-(2*H*)-isoquinolone (11.3 g, 62.9 mmol) as a pale pink solid.

¹H (DMSO-*d*₆, 300 MHz) δ 7.5 (1H, s), 7.6 (1H, dd), 7.8-7.9 (2H, m), 8.25 (1H, d), 11.5 (1H, br s), ppm.

LRMS 180, 182 (MH⁺), 359, 361, 363 (M₂H⁺).

5




4-Chloro-1-(2H)-isoquinolone (20.62 g, 115 mmol) was added portionwise to stirred chlorosulphonic acid (61 mL, 918 mmol) at 0 °C. The mixture was heated at 100 °C for 3.5 d and then cooled to room temperature. The reaction mixture was added in small portions onto ice-water [CAUTION] and the resulting precipitate was collected by filtration. The solid was washed with water, triturated with MeCN and then dried *in vacuo* to give 4-chloro-1-oxo-1,2-dihydro-7-isoquinolinesulphonyl chloride (18.75 g, 67.4 mmol) as a cream solid.

¹H (DMSO-*d*₆, 400 MHz) δ 7.45 (1H, s), 7.8 (1H, d), 8.0 (1H, d), 8.5 (1H, s), 11.5 (1H, br s) ppm.

Anal. Found: C, 39.37; H, 2.09; N, 4.94. Calc for C₉H₅Cl₂NO₃S: C, 38.87; H, 1.81; N, 5.04.

20



POCl₃ (9.65 mL, 103.5 mmol) was added to a stirred suspension of 4-chloro-1-oxo-1,2-dihydro-7-isoquinolinesulphonyl chloride (22.1 g, 79.6 mmol) in MeCN (500 mL) at room temperature and the mixture was then heated at reflux for 15 h. On cooling, the MeCN solution was decanted from the insoluble sludge and evaporated *in vacuo*. The residue was extracted with hot EtOAc and evaporated to leave a solid which was stirred with Et₂O (1.2 L) at room temperature overnight. The ethereal solution was decanted from the insoluble material and evaporated *in vacuo* to give 1,4-dichloro-7-isoquinolinesulphonyl chloride (20 g, 67 mmol) as a pale yellow solid.


30

¹H (DMSO-*d*₆, 400 MHz) δ 8.2 (2H, s), 8.5 (1H, s), 8.55 (1H, s) ppm.

Anal. Found: C, 37.19; H, 1.34; N, 4.77. Calc for $C_{17}H_{10}Cl_2NO_2S$: C, 36.45; H, 1.36; N, 4.72.

Preparation 7:

5 Methyl 3-[[[1,4-dichloro-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoate




Methyl 3-amino-4-methoxybenzoate (212 mg, 1.17 mmol) was added to a stirred solution of
 10 1,4-dichloro-7-isoquinolinesulphonyl chloride (342 mg, 1.15 mmol) in CH_2Cl_2 (10 mL)
 containing 2,6-lutidine (0.135 mL, 1.16 mmol) under N_2 at 0 °C. After 5 min, the mixture was
 warmed to room temperature and stirred for 22 h. The solvents were evaporated *in vacuo* and
 the residue was suspended in EtOAc (50 mL), and then washed with water, brine, dried
 ($MgSO_4$) and evaporated *in vacuo*. The residue was purified by column chromatography
 15 upon silica gel using hexanes-EtOAc (80:20 to 20:80) as eluant to give methyl 3-[[[1,4-
 dichloro-7-isoquinoliny]sulphonyl]amino]-4-methoxybenzoate (365 mg, 0.83 mmol) as an
 off-white solid.

1H ($CDCl_3$, 300 MHz) δ 3.7 (3H, s), 3.9 (3H, s), 6.75 (1H, d), 7.2 (1H, s), 7.8 (1H, dd), 8.15
 20 (1H, dd), 8.25 (1H, s), 8.3 (1H, d), 8.5 (s, 1H), 8.85 (1H, s) ppm.

LRMS 441 (MH^+), 458 (MNH_4^+).

Preparation 8:

25 *N*-[[[1,4-Dichloro-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester



NEt_3 (0.59 mL, 4.24 mmol) was added to a stirred solution of glycine *t*-butyl ester
 30 hydrochloride (340 mg, 2.02 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (500
 mg, 1.68 mmol) in CH_2Cl_2 (25 mL) under N_2 and the mixture was stirred at room
 temperature for 18 h. The mixture was diluted with CH_2Cl_2 (25 mL), washed with dilute HCl

(x2, 1 M), saturated aqueous NaHCO₃, brine, dried (MgSO₄) and evaporated *in vacuo*. The solid was triturated with EtOAc, collected by filtration and dried to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]glycine *t*-butyl ester (435 mg, 1.11 mmol) as a white solid.

5 mp 194-196 °C.

¹H (CDCl₃, 300 MHz) δ 1.3 (9H, s), 3.8 (2H, d), 5.3 (1H, br t), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

10 LRMS 391 (MH⁺), 408, 410 (MNH₄⁺).

Anal. Found: C, 45.58; H, 4.03; N, 7.03. Calc for C₁₅H₁₆Cl₂N₂O₄S: C, 46.04; H, 4.12; N, 7.16.

Preparation 9:

15 *N*-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-β-alanine *t*-butyl ester



NEt₃ (0.60 mL, 4.3 mmol) was added to a stirred solution of β-alanine *t*-butyl ester
20 hydrochloride (331 mg, 1.82 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (510
mg, 1.72 mmol) in CH₂Cl₂ (10 mL) under N₂ and the mixture was stirred at room
temperature for 22 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with half
saturated brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column
chromatography upon silica gel using pentane-EtOAc (90:10 to 60:40) as eluant to give *N*-
25 [(1,4-dichloro-7-isoquinolinyl)sulphonyl]-β-alanine *t*-butyl ester (580 mg, 1.43 mmol) as a
white solid.


¹H (CDCl₃, 300 MHz) δ 1.4 (9H, s), 2.5 (2H, t), 3.25 (2H, dt), 5.5 (1H, br t), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

30

LRMS 405, 407 (MH⁺), 422 (MNH₄⁺).

Anal. Found: C, 47.41; H, 4.46; N, 6.80. Calc for C₁₆H₁₈Cl₂N₂O₄S: C, 47.42; H, 4.48; N, 6.91.

Preparation 10:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-methylglycine *t*-butyl ester


N-Methylglycine *t*-butyl ester hydrochloride (264 mg, 1.45 mmol) was added to a stirred solution of 1,4-dichloro-7-isoquinolinesulphonyl chloride (376 mg, 1.27 mmol) in CH_2Cl_2 (25 mL) containing NEt_3 (0.44 mL, 3.16 mmol) under N_2 at 0 °C, and the mixture was then stirred at room temperature for 22 h. The solvents were evaporated *in vacuo*, the residue dissolved in EtOAc (50 mL), washed with water, brine, dried (MgSO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentanes-EtOAc (80:20) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-methylglycine *t*-butyl ester (485 mg, 1.20 mmol) as a white solid.

^1H (CDCl_3 , 300 MHz) δ 1.35 (9H, s), 3.0 (3H, s), 4.05 (2H, d), 8.2 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.85 (1H, s) ppm.

LRMS 709 (M_2H^+).

Anal. Found: C, 47.37; H, 4.43; N, 6.79. Calc for $\text{C}_{16}\text{H}_{18}\text{Cl}_2\text{N}_2\text{O}_4\text{S}$: C, 47.42; H, 4.48; N, 6.91.

Preparation 11:

N-Phenylglycine *t*-butyl ester

t-Butyl chloroacetate (10 g, 66.3 mmol) was added dropwise to a stirred solution of aniline (11.3 g, 120 mmol) in NEt_3 (10 mL), and the mixture was stirred at room temperature for 24 h and then at 60 °C for 18 h. The cooled mixture was diluted with Et_2O (100 mL), filtered with Et_2O rinsing, and the filtrate was then washed with water, brine, dried (MgSO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel


using hexanes-EtOAc (98:2 to 92:8) as eluant to give *N*-phenylglycine *t*-butyl ester (6.56 g, 31.6mmol) as an oil.

¹H (CDCl₃, 400 MHz) δ 1.5 (9H, s), 3.8 (2H, s), 4.45 (1H, br s), 6.6 (2H, d), 6.7 (1H, t), 7.2 (2H, dd) ppm.

LRMS 208 (MH⁺), 415 (M₂H⁺).

Preparation 12:

N-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N*-phenylglycine *t*-butyl ester



1,4-Dichloro-7-isoquinolinesulphonyl chloride (300 mg, 1.01 mmol) was added to a stirred solution of *N*-phenylglycine *t*-butyl ester (228 mg, 1.10 mmol) in CH₂Cl₂ (5.0 mL) containing NEt₃ (0.35 mL, 2.5 mmol) under N₂ at room temperature, and the mixture stirred for 5 d. The mixture was diluted with CH₂Cl₂ (50 mL), washed with dilute HCl (20 mL, 1 M), saturated aqueous NaHCO₃, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (90:10 to 60:40) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-*N*-phenylglycine *t*-butyl ester (485 mg, 1.20 mmol) as a white solid.


¹H (CDCl₃, 300 MHz) δ 1.4 (9H, s), 4.4 (2H, d), 7.2-7.4 (5H, m), 8.05 (1H, d), 8.3 (1H, d), 8.45 (1H, s), 8.7 (1H, s) ppm.

LRMS 467 (MH⁺).

Preparation 13:

N-(Cyclopentylmethyl)-*N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]glycine *t*-butyl ester

30



PPh₃ (243 mg, 1.5 mmol) and then a solution of DEAD (236 μ L, 1.5 mmol) in THF (2 mL) were added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]glycine *t*-butyl ester (391 mg, 1.00 mmol) and cyclopentanemethanol (130 μ L, 1.2 mmol) in THF (3 mL) under N₂ at 0 °C, and the mixture was stirred at room temperature for 18 h. An additional portion of cyclopentanemethanol (1.2 mmol), PPh₃ (1.5 mmol), and DEAD (1.5 mmol) were added and the mixture stirred at room temperature for a further 2 d. The solvents were evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 95:5) as eluant to give *N*-(cyclopentylmethyl)-*N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]glycine *t*-butyl ester (144 mg, 0.30 mmol) as a white solid.


¹H (CDCl₃, 400 MHz) δ 1.15-1.4 (3H, m), 1.3 (9H, s), 1.5-1.7 (3H, m), 1.7-1.8 (2H, m), 2.1 (1H, m), 3.25 (2H, d), 4.1 (2H, s), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.85 (1H, s) ppm.

LRMS 473 (MH⁺), 490, 492 (MNH₄⁺).

Anal. Found: C, 53.23; H, 5.58; N, 5.86. Calc for C₂₁H₂₆Cl₂N₂O₄S: C, 53.28; H, 5.54; N, 5.92.

Preparation 14:

N-(Cyclohexylmethyl)-*N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]glycine *t*-butyl ester



25

Cyclohexylmethyl bromide (209 μ L, 1.5 mmol) was added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]glycine *t*-butyl ester (391 mg, 1.00 mmol) and anhydrous K₂CO₃ (276 mg, 2.0 mmol) in DMF (5 mL) under N₂ at 23 °C. The mixture was stirred for 2 h and then heated at 50-60 °C for 6 h. The cooled mixture was diluted with EtOAc (200 mL), washed with water (250 mL), dried (MgSO₄), and the solvents were evaporated *in vacuo*. The

30


residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 95:5) as eluant to give *N*-(cyclohexylmethyl)-*N*-[(1,4-dichloro-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester (320 mg, 0.66 mmol).

- 5 ¹H (CDCl₃, 400 MHz) δ 1.15-1.3 (3H, m), 1.3 (9H, s), 1.5-1.8 (8H, m), 3.15 (2H, d), 4.05 (2H, s), 8.2 (1H, d), 8.35 (1H, d), 8.45 (1H, s), 8.85 (1H, s) ppm.

LRMS 487 (MH⁺), 504, 506, 508 (MNH₄⁺).

10 Preparation 15:

N-Benzylglycine *t*-butyl ester




- 15 A solution of *t*-butyl bromoacetate (1.5 mL, 10.1 mmol) in CH₂Cl₂ (10 mL) was added dropwise to a stirred solution of benzylamine (10.9 mL, 100 mmol) in CH₂Cl₂ (40 mL) at 0 °C, the mixture was stirred for 1 h and then warmed to room temperature and stirred for an additional 3 d. The mixture was washed with water (3x50 mL), dilute HCl (1 N) and the combined aqueous washings were extracted with Et₂O. The organic phase was washed with
- 20 saturated aqueous NaHCO₃, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was dissolved in Et₂O, treated with a solution of HCl in ether (0.5 M) and the resulting precipitate was collected and dissolved in EtOAc. This solution was filtered through hyflo, and partially evaporated *in vacuo* to give a thick slurry. The solid was collected by filtration, washed with Et₂O and then dried to give *N*-benzylglycine *t*-butyl ester hydrochloride (1.03 g, 4.00 mmol)
- 25 as a white solid.

¹H (CDCl₃, 300 MHz) δ 1.4 (9H, s), 3.5 (2H, s), 4.4 (2H, s), 7.3-7.4 (3H, m), 7.55-7.65 (2H, m), 10.2-10.3 (2H, br s).

- 30 LRMS 222, (MH⁺), 443 (M₂H⁺).

Preparation 16:

N-[(1,4-Dichloro-7-isoquinoliny]sulphonyl]-*N*-benzylglycine *t*-butyl ester



1,4-Dichloro-7-isoquinolinesulphonyl chloride (300 mg, 1.01 mmol) was added to a stirred solution of *N*-benzylglycine *t*-butyl ester (310 mg, 1.20 mmol) in CH_2Cl_2 (20 mL) containing
 5 NEt_3 (0.35 mL, 2.5 mmol) under N_2 and the mixture was stirred at room temperature for 3 d. The mixture was diluted with CH_2Cl_2 and washed with dilute HCl (2 M), saturated aqueous NaHCO_3 , brine, dried (Na_2SO_4) then and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexanes-EtOAc (90:10) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-benzylglycine *t*-butyl ester (290 mg, 0.60 mmol)
 10 as an off-white solid.

mp 134-136 °C.


^1H (CDCl_3 , 400 MHz) δ 1.3 (9H, s), 3.9 (2H, s), 4.55 (2H, s), 7.25-7.4 (5H, m), 8.25 (1H, d),
 15 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 481 (MH^+), 498 (MNH_4^+).

Anal. Found: C, 54.52; H, 4.50; N, 5.77. Calc for $\text{C}_{22}\text{H}_{22}\text{Cl}_2\text{N}_2\text{O}_4\text{S}$: C, 54.89; H, 4.61; N, 5.82.
 20

Preparation 17:

N-(2-Methylbenzyl)glycine *t*-butyl ester



25

t-Butyl chloroacetate (2.13 g, 14.1 mmol) was added to a stirred solution of 2-methylbenzylamine (1.71 g, 14.1 mmol) in CH_2Cl_2 (20 mL) containing NEt_3 (2.95 mL, 21.2 mmol) under N_2 and the mixture was stirred at room temperature for 17 h. The solvents were evaporated *in vacuo*, the residue suspended in EtOAc and washed with water, brine,
 30 dried (MgSO_4) then and evaporated *in vacuo*. The residue was purified by column


chromatography upon silica gel using pentanes-EtOAc (95:5 to 80:20) as eluant to give *N*-(2-methylbenzyl)glycine *t*-butyl ester (1.29 g, 5.48 mmol).

¹H (CDCl₃, 300 MHz) δ 1.5 (9H, s), 2.35 (3H, s), 3.3 (2H, s), 3.8 (2H, s), 7.1-7.2 (3H, m),
5 7.25-7.3 (1H, m) ppm.

LRMS 236 (MH⁺), 471 (M₂H⁺).

Preparation 18:

10 *N*-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N*-(2-methylbenzyl)glycine *t*-butyl ester



1,4-Dichloro-7-isoquinolinesulphonyl chloride (400 mg, 1.35 mmol) was added to a stirred
15 solution of *N*-(2-methylbenzyl)glycine *t*-butyl ester (380 mg, 1.61 mmol) in CH₂Cl₂ (20 mL)
containing NEt₃ (0.28 mL, 2.5 mmol) under N₂ and the mixture was stirred at room
temperature for 18 h. The mixture was diluted with CH₂Cl₂ and washed with dilute HCl (2
M), saturated aqueous NaHCO₃, brine, dried (MgSO₄) then and evaporated *in vacuo*. The
residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0
20 to 90:10) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-*N*-(2-
methylbenzyl)glycine *t*-butyl ester (480 mg, 0.97 mmol) as a white solid.


mp 96-98 °C.

25 ¹H (CDCl₃, 400 MHz) δ 1.25 (9H, s), 2.3 (3H, s), 3.9 (2H, s), 4.6 (2H, s), 7.1-7.25 (4H, m),
8.3 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 495 (MH⁺), 512 (MNH₄⁺).

30 Anal. Found: C, 55.70; H, 4.86; N, 5.63. Calc for C₂₃H₂₄Cl₂N₂O₄S: C, 55.76; H, 4.88; N, 5.65.

Preparation 19:

N-(2-Methoxybenzyl)glycine *t*-butyl ester

- 5 A solution of *t*-butyl bromoacetate (1.5 mL, 10.2 mmol) in CH₂Cl₂ (30 mL) was added to a stirred solution of 2-methoxybenzylamine (6.88 g, 50.2 mmol) in CH₂Cl₂ (70 mL) under N₂ at 0 °C, and the mixture was then stirred at room temperature for 1 h. The mixture was thoroughly washed with dilute HCl (30 mL, 1 M) and the separated aqueous phase was extracted with in CH₂Cl₂. The combined organic extracts were washed with saturated
- 10 NaHCO₃, brine, dried (Na₂SO₄) then and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using in CH₂Cl₂-MeOH (99:1 to 95:5) as eluant to give *N*-(2-methoxybenzyl)glycine *t*-butyl ester (0.90 g, 3.58 mmol) as a pale yellow oil.


- ¹H (CDCl₃, 400 MHz) δ 1.25 (9H, s), 2.0 (1H, br s), 3.3 (2H, s), 3.8 (2H, s), 3.85 (3H, s), 6.85
- 15 (1H, d), 6.9 (1H, dd), 7.2-7.3 (2H, m) ppm.

LRMS 252 (MH⁺), 503 (M₂H⁺), 525 (M₂Na⁺).

Anal. Found: C, 66.52; H, 8.54; N, 5.54. Calc for C₁₄H₂₁NO₃: C, 66.91; H, 8.42; N, 5.57.

20

Preparation 20:

N-[(1,4-Dichloro-7-isoquinolinesulphonyl)]-*N*-(2-methoxybenzyl)glycine *t*-butyl ester

25

- 1,4-Dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) was added to a stirred solution of *N*-(2-methoxybenzyl)glycine *t*-butyl ester (508 mg, 2.02 mmol) in CH₂Cl₂ (30 mL) containing NEt₃ (0.35 mL, 2.5 mmol) under N₂ and the mixture was stirred at room
- 30 temperature for 21 h. The mixture was diluted with CH₂Cl₂ and washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) then and evaporated *in vacuo*. The

residue was purified by column chromatography upon silica gel using hexane-EtOAc (95:5 to 90:10) as eluant and then triturated with hexane-*i*-Pr₂O to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-(2-methoxybenzyl)glycine *t*-butyl ester (501 mg, 1.02 mmol) as a yellow solid.

mp 106-108 °C.


¹H (CDCl₃, 400 MHz) δ 1.3 (9H, s), 3.7 (3H, s), 4.0 (2H, s), 4.6 (2H, s), 6.8 (1H, d), 6.9 (1H, dd), 7.2 (1H, dd), 7.3 (1H, d), 8.2 (1H, d), 8.3 (1H, d), 8.45 (1H, s), 8.8 (1H, s) ppm.

LRMS 511, 513 (MH⁺), 528 (MNH₄⁺).

Anal. Found: C, 54.09; H, 4.78; N, 5.33. Calc for C₂₃H₂₄Cl₂N₂O₅S: C, 54.01; H, 4.73; N, 5.48.

Preparation 21:

N-(3-Methoxybenzyl)glycine *t*-butyl ester



A solution of *t*-butyl bromoacetate (1.5 mL, 10.1 mmol) in CH₂Cl₂ (30 mL) was added dropwise to a stirred solution of 3-methoxybenzylamine (6.86 g, 50 mmol) in CH₂Cl₂ (20 mL) at 0 °C, and the mixture was then warmed to room temperature and stirred for 1.5 h. Dilute HCl (30 mL, 1 M) was added and the mixture stirred for 15 min. The aqueous phase was extracted with CH₂Cl₂, and the combined organic extracts were washed with water, brine, saturated aqueous NaHCO₃, dried (MgSO₄) then and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH (99:1 to 90:10) as eluant to give the required amine as a colourless oil. Treatment with a solution of HCl in ether (1 M) gave *N*-(3-methoxybenzyl)glycine *t*-butyl ester hydrochloride (0.83 g, 2.88 mmol) as a white solid.

mp 141-142 °C.

^1H (CDCl_3 , 300 MHz) δ 1.45 (9H, s), 3.5 (2H, s), 3.85 (3H, s), 4.35 (2H, s), 6.9 (1H, d), 7.1 (1H, d), 7.3 (1H, s), 7.3-7.35 (1H, m), 10.3 (2H, br s) ppm.

LRMS 252 (MH^+), 503 (M_2H^+).


5

Anal. Found: C, 58.37; H, 7.75; N, 4.83. Calc for $\text{C}_{14}\text{H}_{21}\text{NO}_3 \cdot \text{HCl}$: C, 58.43; H, 7.71; N, 4.87.

Preparation 22:

N-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N*-(3-methoxybenzyl)glycine *t*-butyl ester

10



NEt_3 (0.59 mL, 4.24 mmol) and then 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.68 mmol) were added to a stirred solution of *N*-(3-methoxybenzyl)glycine *t*-butyl ester hydrochloride (582 mg, 2.02 mmol) in CH_2Cl_2 (25 mL) under N_2 and the mixture was stirred at room temperature for 18 h. The mixture was diluted with CH_2Cl_2 (25 mL), washed with dilute HCl (x2, 1 M), saturated aqueous NaHCO_3 , brine, dried (MgSO_4) and evaporated *in vacuo*. The residue was extracted with *i*- Pr_2O which gave a precipitate on standing. The white solid was collected by filtration and dried to give *N*-[(1,4-dichloro-7-

15

20

isoquinoliny)lsulphonyl]-*N*-(3-methoxybenzyl)glycine *t*-butyl ester (262 mg, 0.51 mmol). A second batch (165 mg, 0.32 mmol) was obtained by evaporation of the mother liquors and purification of the residue by column chromatography upon silica gel using hexane-EtOAc (80:20).

25 mp 129-131 °C.


^1H (CDCl_3 , 300 MHz) δ 1.3 (9H, s), 3.75 (3H, s), 3.9 (2H, s), 4.55 (2H, s), 6.8-6.9 (2H, m), 6.85 (1H, s), 7.25 (1H, m), 8.3 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

30 LRMS 511 (MH^+), 528 (MNH_4^+).

Anal. Found: C, 54.03; H, 4.79; N, 5.34. Calc for $\text{C}_{23}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_5\text{S}$: C, 54.01; H, 4.73; N, 5.48.

Preparation 23:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-(3-chlorobenzyl)glycine *t*-butyl ester



5

3-Chlorobenzyl chloride (0.063 mL, 0.50 mmol) was added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]glycine *t*-butyl ester (195.5 mg, 0.50 mmol) in DMF (5 mL) containing K_2CO_3 (83 mg, 0.60 mmol) and the mixture was stirred at room temperature
 10 for 18 h. The mixture was diluted with water (50 mL), extracted with Et_2O (3x30 mL) and with $EtOAc$ (3x30 mL), and the combined organic extracts were then washed with water, brine, dried (Na_2SO_4) and evaporated *in vacuo*. The solid was triturated with hexanes, collected by filtration and dried to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-(3-chlorobenzyl)glycine *t*-butyl ester (212 mg, 0.41 mmol) as a pale yellow solid.

15

mp 141-143 °C.

1H ($CDCl_3$, 400 MHz) δ 1.3 (9H, s), 3.95 (2H, d), 4.5 (2H, s), 7.15-7.3 (4H, m), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.85 (1H, s) ppm.


20

LRMS 515, 517 (MH^+), 532, 534 (MNH_4^+).

Anal. Found: C, 51.14; H, 4.14; N, 5.31. Calc for $C_{22}H_{21}Cl_3N_2O_4S$: C, 51.22; H, 4.10; N, 5.43.

25 Preparation 24:

N-(4-Methoxybenzyl)glycine *t*-butyl ester



A solution of *t*-butyl bromoacetate (1.5 mL, 10.2 mmol) in CH₂Cl₂ (30 mL) was added dropwise to a stirred solution of 4-methoxybenzylamine (6.89 g, 50.2 mmol) in CH₂Cl₂ (70 mL) at 0 °C, and the mixture was then warmed to room temperature and stirred for 1 h. Dilute HCl (30 mL, 1 M) was added and the mixture stirred for 10 min. The aqueous phase was
 5 extracted with CH₂Cl₂ and the combined organic extracts were washed with saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) then and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH (99:1 to 90:10) as eluant to give the required amine as a colourless oil. Treatment with a solution of HCl in ether (1 M) followed by trituration with Et₂O gave *N*-(4-methoxybenzyl)glycine *t*-butyl ester
 10 hydrochloride (148 mg, 0.51 mmol) as an orange solid.

mp 133-134 °C.

¹H (CDCl₃, 400 MHz) δ 1.45 (9H, s), 3.5 (2H, s), 3.8 (3H, s), 4.3 (2H, s), 6.9 (2H, d), 7.5
 15 (2H, d), 10.2 (2H, br s) ppm.


LRMS 252 (MH⁺), 503 (M₂H⁺), 525 (M₂Na⁺).

Anal. Found: C, 58.08; H, 7.71; N, 4.80. Calc for C₁₄H₂₁NO₃·HCl: C, 58.42; H, 7.71; N, 4.87.

20

Preparation 25:

N-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester



25

NEt₃ (0.25 mL, 1.78 mmol) and then 1,4-dichloro-7-isoquinolinesulphonyl chloride (210 mg, 0.71 mmol) were added to a stirred solution of *N*-(4-methoxybenzyl)glycine *t*-butyl ester hydrochloride (245 mg, 0.85 mmol) in CH₂Cl₂ (20 mL) under N₂ and the mixture was stirred at room temperature for 18 h. The mixture was diluted with CH₂Cl₂, washed with dilute HCl
 30 (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (95:5 to 90:10) as eluant and then triturated with hexane-*i*-Pr₂O to give *N*-[(1,4-dichloro-7-

isoquinoliny]sulphonyl]-*N*-(4-methoxybenzyl)glycine *t*-butyl ester (160 mg, 0.31 mmol) as a white solid.

mp 117-118 °C.

5

¹H (CDCl₃, 300 MHz) δ 1.3 (9H, s), 3.8 (3H, s), 3.9 (2H, s), 4.5 (2H, s), 6.85 (2H, d), 7.2 (2H, d), 8.3 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 511 (MH⁺), 528 (MNH₄⁺).


10

Anal. Found: C, 53.90; H, 4.59; N, 5.34. Calc for C₂₃H₂₄Cl₂N₂O₅S: C, 54.01; H, 4.73; N, 5.48.

Preparation 26:

N-[(1,4-Dichloro-7-isoquinoliny]sulphonyl]-*N*-(2-pyridylmethyl)glycine *t*-butyl ester

15



2-(Chloromethyl)pyridine hydrochloride (246 mg, 1.5 mmol) was added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinoliny]sulphonyl]glycine *t*-butyl ester (391 mg, 1.0 mmol) and anhydrous K₂CO₃ (415 mg, 3.0 mmol) in DMF (5 mL) under N₂ at 23 °C and the mixture was stirred for 18 h. The cooled mixture was azeotroped with xylene, diluted with EtOAc, washed with water, and the organic extracts were then dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 50:50) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny]sulphonyl]-*N*-(2-pyridylmethyl)glycine *t*-butyl ester (400 mg, 0.83 mmol) as a white solid.

25


¹H (CDCl₃, 400 MHz) δ 1.3 (9H, s), 4.1 (2H, s), 4.7 (2H, s), 7.1 (1H, m), 7.5 (1H, d), 7.7 (1H, dd), 8.25 (1H, d), 8.35 (1H, d), 8.45 (1H, m), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 482, 484 (MH⁺).

30

Preparation 27:

N-[(1,4-Dichloro-7-isoquinoliny)l]sulphonyl]-*N*-(3-pyridylmethyl)glycine *t*-butyl ester



- 5 3-(Chloromethyl)pyridine hydrochloride (246 mg, 1.5 mmol) was added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinoliny)l]sulphonyl]glycine *t*-butyl ester (391 mg, 1.0 mmol) and anhydrous K_2CO_3 (416 mg, 3.0 mmol) in DMF (5 mL) under N_2 at 23 °C and the mixture was stirred for 18 h. The cooled mixture was azeotroped with xylene, diluted with EtOAc, washed with water, and the organic extracts were then dried ($MgSO_4$) and evaporated *in*
- 10 *vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 50:50) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)l]sulphonyl]-*N*-(3-pyridylmethyl)glycine *t*-butyl ester (400 mg, 0.83 mmol) as a white solid.


1H (CDCl₃, 400 MHz) δ 1.3 (9H, s), 4.1 (2H, d), 4.7 (2H, s), 7.1 (1H, m), 7.5 (1H, d), 7.7 (1H, dd), 8.25 (1H, d), 8.35 (1H, d), 8.45 (1H, m), 8.5 (1H, s), 8.9 (1H, s) ppm.

15

LRMS 482, 484 (MH⁺).

Preparation 28:

- 20 *N*-[(1,4-Dichloro-7-isoquinoliny)l]sulphonyl]-*N*-(4-pyridylmethyl)glycine *t*-butyl ester



- 4-(Chloromethyl)pyridine hydrochloride (246 mg, 1.5 mmol) was added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinoliny)l]sulphonyl]glycine *t*-butyl ester (391 mg, 1.0 mmol) and anhydrous K_2CO_3 (416 mg, 3.0 mmol) in DMF (5 mL) under N_2 at 23 °C and the mixture was stirred for 18 h. The cooled mixture was azeotroped with xylene, diluted with EtOAc, washed with water, and the organic extracts were then dried ($MgSO_4$) and evaporated *in*
- 25 *vacuo*. The residue was purified by column chromatography upon silica gel using pentane-


EtOAc (100:0 to 50:50) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-(4-pyridylmethyl)glycine *t*-butyl ester (397 mg, 0.82 mmol) as a white solid.

¹H (CDCl₃, 400 MHz) δ 1.3 (9H, s), 4.0 (2H, d), 4.6 (2H, s), 7.3 (2H, d), 8.25 (1H, dd), 8.4 (1H, d), 8.5 (1H, s), 8.6 (2H, d), 8.9 (1H, d) ppm.

LRMS 482, 484 (MH⁺).

Preparation 29:

N-[(1*R*)-1-Phenylethyl]glycine *t*-butyl ester



A solution of *t*-butyl bromoacetate (5.0 g, 25.6 mmol) in CH₂Cl₂ (5 mL) was added dropwise to a stirred solution of (+)-(*R*)-α-methylbenzylamine (4.65 g, 38.5 mmol) in CH₂Cl₂ (40 mL) at 0 °C, and the mixture was then warmed to room temperature and stirred for 18 h. The mixture was diluted with CH₂Cl₂, washed with water, with dilute HCl (1 M) and then dried (MgSO₄). The solvents were evaporated *in vacuo* to give *N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester (3.15 g, 13.4 mmol) as a white powder.


mp 193-197 °C.

¹H (CDCl₃, 300 MHz) δ 1.4 (9H, s), 1.95 (3H, d), 3.3 (1H, d), 3.6 (1H, d), 4.6 (1H, q), 5.3 (1H, s), 7.3-7.45 (3H, m), 7.5-7.65 (2H, m).

LRMS 236 (MH⁺).

Preparation 30:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester



A mixture of NEt₃ (0.59 mL, 4.21 mmol), 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) and *N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester (476 mg, 2.02 mmol) in CH₂Cl₂ (8 mL) were stirred under N₂ at room temperature for 18 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-*N*-[(1*R*)-1-phenylethyl]glycine *t*-butyl ester (490 mg, 0.99 mmol) as a colourless oil.

10


¹H (CDCl₃, 300 MHz) δ 1.3 (9H, s), 1.4 (3H, d), 3.9 (1H, d), 4.1 (1H, d), 5.15 (1H, q), 7.1-7.25 (5H, m), 8.4 (1H, d), 8.5 (1H, d), 8.65 (1H, s), 8.7 (1H, d) ppm.

LRMS 495 (MH⁺), 512 (MNH₄⁺).

15

Preparation 31:

N-[(1*S*)-1-Phenylethyl]glycine *t*-butyl ester



20

A solution of *t*-butyl bromoacetate (5.0 g, 25.6 mmol) in CH₂Cl₂ (5 mL) was added dropwise to a stirred solution of (-)-(*S*)-α-methylbenzylamine (4.65 g, 38.5 mmol) in CH₂Cl₂ (40 mL) at 0 °C, and the mixture was then warmed to room temperature and stirred for 18 h. The mixture was diluted with CH₂Cl₂, washed with water, with dilute HCl (1 M) and then dried (MgSO₄). The solvents were evaporated *in vacuo* to give *N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester (2.02 g, 8.6 mmol) as a white powder.

25

mp 197-202 °C.


¹H (CDCl₃, 300 MHz) δ 1.4 (9H, s), 1.9 (3H, d), 3.3 (1H, d), 3.55 (1H, d), 4.5 (1H, q), 5.3 (1H, s), 7.3-7.45 (3H, m), 7.5-7.6 (2H, m) ppm.

30

LRMS 236 (MH⁺).

Preparation 32:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester



5


A mixture of NEt_3 (0.59 mL, 4.21 mmol), 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) and *N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester (476 mg, 2.02 mmol) in CH_2Cl_2 (8 mL) were stirred under N_2 at room temperature for 24 h. The mixture was diluted with CH_2Cl_2 (50 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO_3 , brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-[(1*S*)-1-phenylethyl]glycine *t*-butyl ester (420 mg, 0.85 mmol) as a colourless oil.

15 ^1H (CDCl_3 , 300 MHz) δ 1.3 (9H, s), 1.4 (3H, d), 3.9 (1H, d), 4.1 (1H, d), 5.15 (1H, q), 7.1-7.25 (5H, m), 8.4 (1H, d), 8.5 (1H, d), 8.65 (1H, s), 8.7 (1H, d) ppm.

LRMS 495 (MH^+), 512 (MNH_4^+).

20 Preparation 33:

N-Benzyl-L-alanine *t*-butyl ester



25 Benzaldehyde (2.69 mL, 26.4 mmol) was added to a stirred slurry of L-alanine *t*-butyl ester (4.0 g, 22.0 mmol) and NEt_3 (3.07 mL, 22.0 mmol) in CH_2Cl_2 (70 mL) at 23 °C and the mixture was stirred for 10 min. $\text{NaBH}(\text{OAc})_3$ (6.44 g, 30.4 mmol) was added portionwise and the mixture stirred at 23 °C for 24 h. The mixture was washed with water, dried (MgSO_4) and the solvents were evaporated *in vacuo*. The residue was purified by column chromatography


upon silica gel using CH_2Cl_2 -MeOH (99:1 to 95:5) as eluant to give to give *N*-benzyl-L-alanine *t*-butyl ester (3.97 g, 16.9 mmol) as a colourless oil.

^1H (CDCl_3 , 300 MHz) δ 1.3 (3H, d), 1.5 (9H, s), 2.1 (1H, s), 3.25 (1H, q), 3.7 (1H, d), 3.8 (1H, d), 7.2-7.4 (5H, m) ppm.

LRMS 236 (MH^+), 258 (MNa^+).

Preparation 34:

10 *N*-Benzyl-*N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-L-alanine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinesulphonyl chloride (600 mg, 2.02 mmol) in CH_2Cl_2 (3 mL) was added to a stirred solution of *N*-benzyl-L-alanine *t*-butyl ester (571 mg, 2.43 mmol) and NEt_3 (0.70 mL, 5.06 mmol) in CH_2Cl_2 (3 mL) and the mixture was stirred at room temperature for 24 h. The mixture was diluted with CH_2Cl_2 (50 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO_3 , brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (95:5 to 85:15) as eluant to give *N*-benzyl-*N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-L-alanine *t*-butyl ester (470 mg, 0.95 mmol) as a colourless solid.


mp 92-96 °C.

25 ^1H (CDCl_3 , 300 MHz) δ 1.3 (9H, s), 1.35 (3H, d), 4.4 (1H, d), 4.7 (1H, q), 4.8 (1H, d), 7.1-7.3 (3H, m), 7.3-7.4 (2H, m), 8.15 (1H, d), 8.3 (1H, d), 8.45 (1H, s), 8.7 (1H, s) ppm.

LRMS 495 (MH^+).

30 Preparation 35:

N-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-L-alanine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) in CH_2Cl_2 (3 mL) was added to a stirred solution of L-alanine *t*-butyl ester (322 mg, 1.77 mmol) and NEt_3 (0.82 mL, 5.9 mmol) in CH_2Cl_2 (6 mL) and the mixture was stirred at 23 °C for 17 h. The mixture was diluted with CH_2Cl_2 , washed with dilute HCl (2 M), saturated aqueous NaHCO_3 , brine, dried (MgSO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10 to 50:50) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinesulfonyl)]-L-alanine *t*-butyl ester (500 mg, 1.23 mmol) as a white powder.

mp 115-119 °C.

^1H (CDCl_3 , 300 MHz) δ 1.2 (9H, s), 1.4 (3H, d), 4.0 (1H, dq), 5.4 (1H, d), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 405 (MH^+).

Anal. Found: C, 47.57; H, 4.39; N, 6.72. Calc for $\text{C}_{16}\text{H}_{18}\text{Cl}_2\text{N}_2\text{O}_4\text{S}$: C, 47.42; H, 4.48; N, 6.91.

Preparation 36:

N-[(1,4-Dichloro-7-isoquinolinesulfonyl)]-D-alanine methyl ester



A solution of 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) in CH_2Cl_2 (3 mL) was added to a stirred solution of D-alanine methyl ester (247 mg, 1.77 mmol) and NEt_3 (0.82 mL, 5.9 mmol) in CH_2Cl_2 (6 mL) and the mixture was stirred at 23 °C for 16 h. The mixture was diluted with CH_2Cl_2 , washed with dilute HCl (2 M), saturated aqueous NaHCO_3 , brine, dried (MgSO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10 to 50:50) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinesulfonyl)]-D-alanine methyl ester (500 mg, 1.23 mmol) as a white powder.

[(1,4-dichloro-7-isoquinoliny]sulphonyl]-D-alanine methyl ester (420 mg, 1.16 mmol) as a white powder.

mp 150-152 °C.

5

¹H (CDCl₃, 300 MHz) δ 1.45 (3H, d), 3.55 (3H, s), 4.15 (1H, dq), 5.4 (1H, d), 8.2 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 363, 365 (MH⁺).


10

Anal. Found: C, 42.97; H, 3.29; N, 7.42. Calc for C₁₃H₁₂Cl₂N₂O₄S: C, 42.99; H, 3.33; N, 7.71.

Preparation 37:

N-[(1,4-Dichloro-7-isoquinoliny]sulphonyl]-L-valine *t*-butyl ester

15



NEt₃ (0.59 mL, 4.2 mmol) was added to a stirred mixture of 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) and L-valine *t*-butyl ester (354 mg, 1.69 mmol) and in CH₂Cl₂ (25 mL) and the mixture was stirred at 23 °C for 3 d. The mixture was washed with dilute HCl (2x20 mL, 1 M), saturated aqueous NaHCO₃, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was extracted with hexane, which crystallised on standing, to give *N*-[(1,4-dichloro-7-isoquinoliny]sulphonyl]-L-valine *t*-butyl ester (463 mg, 1.07 mmol) as a white solid.

25

mp 127-129 °C.


¹H (CDCl₃, 300 MHz) δ 0.9 (3H, d), 1.0 (3H, d), 1.1 (9H, s), 2.0-2.2 (1H, m), 3.8 (1H, dd), 5.25 (1H, d), 8.2 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

30

LRMS 433, 435 (MH⁺), 450, 452 (MNH₄⁺).

Anal. Found: C, 49.86; H, 5.13; N, 6.40. Calc for C₁₈H₂₂Cl₂N₂O₄S: C, 49.89; H, 5.18; N, 6.46.

Preparation 38:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-D-valine *t*-butyl ester

D-Valine *t*-butyl ester has been prepared previously, see: Shepel, E. N.; Iodanov, S.; Ryabova, I. D.; Miroshnikov, A. I.; Ivanov, V. T.; Ovchinnikov, Yu A. *Bioorg. Khim.* 1972, 2, 581-593.

10

D-Valine *t*-butyl ester (354 mg, 1.69 mmol) and then NEt₃ (0.59 mL, 4.2 mmol) were added to a stirred solution of 1,4-dichloro-7-isoquinoline sulphonyl chloride (500 mg, 1.69 mmol) and in CH₂Cl₂ (20 mL) and the mixture was stirred at 23 °C for 16 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with saturated aqueous NaHCO₃, water, aqueous citric acid (1 M), water, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was dissolved in *i*-Pr₂O and hexane was added which gave a precipitate. The solvents were evaporated *in vacuo* and the solid was triturated with hexane to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-D-valine *t*-butyl ester (532 mg, 1.22 mmol) as a white solid. An analytical sample was obtained by recrystallisation from hexane.

20

mp 117-119 °C.

¹H (CDCl₃, 400 MHz) δ 0.9 (3H, d), 1.0 (3H, d), 1.1 (9H, s), 2.0-2.2 (1H, m), 3.8 (1H, dd), 5.3 (1H, d), 8.2 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

25


LRMS 433, 435 (MH⁺).

Anal. Found: C, 49.99; H, 5.28; N, 6.34. Calc for C₁₈H₂₂Cl₂N₂O₄S: C, 49.89; H, 5.12; N, 6.46.

30

Preparation 39:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-D-tert-leucine *t*-butyl ester



A mixture of D-tert-leucine *t*-butyl ester hydrochloride (250 mg, 1.12 mmol), NEt₃ (0.40 mL, 2.87 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (330 mg, 1.11 mmol) in CH₂Cl₂ (20 mL) was stirred at 23 °C for 16 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with water, aqueous citric acid (1 M), water, saturated aqueous NaHCO₃, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (90:10) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinesulphonyl)-D-tert-leucine *t*-butyl ester (250 mg, 0.56 mmol) as a white foam.

mp 140-142 °C.


¹H (CDCl₃, 400 MHz) δ 1.0 (9H, s), 1.05 (9H, s), 3.6 (1H, d), 5.35 (1H, d), 8.2 (1H, d), 8.35 (1H, d), 8.45 (1H, s), 8.85 (1H, s).

LRMS 447, 449, 451 (MH⁺).

Anal. Found: C, 51.03; H, 5.41; N, 6.13. Calc for C₁₉H₂₄Cl₂N₂O₄S: C, 51.01; H, 5.41; N, 6.26.

Preparation 40:

N-[(1,4-Dichloro-7-isoquinolinesulphonyl)-L-phenylalanine *t*-butyl ester



A mixture of L-phenylalanine *t*-butyl ester (352 mg, 1.37 mmol), NEt₃ (0.41 mL, 2.97 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (399 mg, 1.35 mmol) in CH₂Cl₂ (10 mL) was stirred at 23 °C for 20 h. The solvents were evaporated *in vacuo* and the residue suspended in EtOAc. This solution was washed with water, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10 to 70:30) as eluant to give *N*-[(1,4-dichloro-7-

isoquinoliny)sulphonyl]-L-phenylalanine *t*-butyl ester (450 mg, 0.94 mmol) as a white crystallised foam.

¹H (CDCl₃, 300 MHz) δ 1.2 (9H, s), 2.95 (1H, dd), 3.1 (1H, dd), 4.1 (1H, m), 5.3 (1H, d), 7.0-7.2 (5H, m), 8.1 (1H, d), 8.25 (1H, d), 8.5 (1H, s), 8.75 (1H, d) ppm.

LRMS 481 (MH⁺), 498 (MNH₄⁺).

Preparation 41:

10 *N*-(Benzyloxycarbonyl)-*O*-methyl-D-serine *t*-butyl ester




Condensed isobutylene gas (35 mL) was added to a solution of *N*-(benzyloxycarbonyl)-*O*-methyl-D-serine dicyclohexylamine salt (2.5 g, 5.76 mmol) in CH₂Cl₂ (35 mL) at -78 °C in a steel bomb. Conc. H₂SO₄ (0.5 mL) was added, the vessel was sealed and the mixture allowed to warm to 23 °C [CAUTION: Pressure]. The mixture was stirred at 23 °C for 6 d, the vessel was vented and excess isobutylene was allowed to evaporate. The mixture then poured into aqueous NaHCO₃ (30 mL, 10 %), extracted with CH₂Cl₂ (3x30 mL), and the combined organic extracts were dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20) as eluant to give *N*-(benzyloxycarbonyl)-*O*-methyl-D-serine *t*-butyl ester (1.2 g, 3.88 mmol) as a colorless oil.

¹H (CDCl₃, 400 MHz) δ 1.45 (9H, s), 3.35 (3H, s), 3.6 (1H, dd), 3.75 (1H, dd), 4.35 (1H, br d), 5.1 (2H, s), 5.6 (1H, br d), 8.4-8.9 (5H, m) ppm.

LRMS 310 (MH⁺), 327 (MNH₄⁺).

Preparation 42:

30 *O*-Methyl-D-serine *t*-butyl ester



A solution of *N*-(benzyloxycarbonyl)-*O*-methyl-D-serine *t*-butyl ester (1.15 g, 3.72 mmol) in MeOH (20 mL) was hydrogenated over 10% Pd/C (150 mg) under an atmosphere of H₂ (15 psi) at 23 °C for 18 h. The mixture was filtered and the filtrate evaporated *in vacuo*. The residue was dissolved in Et₂O, a solution of HCl in Et₂O (1 M) was added, the solvents were evaporated *in vacuo* to give a white solid and this material was triturated with hexane to give *O*-methyl-D-serine *t*-butyl ester hydrochloride (0.62 g, 2.90 mmol).

mp 167-169 °C (dec).


¹H (CDCl₃, 400 MHz) δ 1.5 (9H, s), 1.8-2.2 (1H, br s), 3.4 (3H, s), 3.9 (1H, dd), 4.0 (1H, dd), 4.2 (1H, t), 8.4-8.9 (3H, br s) ppm.

LRMS 176 (MH⁺).

Anal. Found: C, 45.26; H, 8.59; N, 6.39. Calc for C₈H₁₇NO₃•HCl: C, 45.39; H, 8.57; N, 6.62.

Preparation 43:

N-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*O*-methyl-D-serine *t*-butyl ester



A mixture of *O*-methyl-D-serine *t*-butyl ester hydrochloride (300 mg, 1.42 mmol), NEt₃ (0.50 mL, 3.6 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (420 mg, 1.42 mmol) in CH₂Cl₂ (20 mL) was stirred at 23 °C for 3 d. The mixture was diluted with CH₂Cl₂ (30 mL), washed with water, aqueous citric acid (1 M), water, saturated aqueous NaHCO₃, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20) as eluant to give *N*-[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-*O*-methyl-D-serine *t*-butyl ester (356 mg, 0.82 mmol) as a white solid.

mp 135-137 °C.

^1H (CDCl_3 , 400 MHz) δ 1.25 (9H, s), 3.3 (3H, s), 3.6 (1H, dd), 3.7 (1H, dd), 4.1 (1H, br s), 5.6 (1H, br d), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 435, 437 (MH^+), 452, 454 (MNH_4^+).


5

Anal. Found: C, 47.04; H, 4.62; N, 6.42. Calc for $\text{C}_{17}\text{H}_{20}\text{Cl}_2\text{N}_2\text{O}_5\text{S}$: C, 46.90; H, 4.63; N, 6.44.

Preparation 44:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-D-aspartic acid di-*t*-butyl ester

10



A mixture of D-aspartic acid di-*t*-butyl ester (462 mg, 1.64 mmol), NEt_3 (0.50 mL, 3.6 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (400 mg, 1.35 mmol) in CH_2Cl_2 (30 mL) was stirred at 23 °C for 18 h. The mixture was diluted with CH_2Cl_2 (30 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO_3 , brine, dried (MgSO_4) and evaporated *in vacuo* to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-D-aspartic acid di-*t*-butyl ester (520 mg, 1.03 mmol) as a white solid.

15

mp 106-110 °C.

^1H (CDCl_3 , 400 MHz) δ 1.2 (9H, s), 1.4 (9H, s), 2.7-2.8 (1H, dd), 2.8-2.9 (1H, dd), 4.15 (1H, m), 8.2 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 507 (MH^+).

25

Preparation 45:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-L-proline *t*-butyl ester



30

A mixture of L-proline *t*-butyl ester hydrochloride (335 mg, 1.61 mmol), NEt₃ (0.53 mL, 3.78 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (449 mg, 1.51 mmol) in CH₂Cl₂ (10 mL) was stirred at 23 °C for 20 h. The solvents were evaporated *in vacuo* and the residue suspended in EtOAc. This solution was washed with water, brine, dried (MgSO₄) and
5 evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10 to 70:30) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-L-proline *t*-butyl ester (543 mg, 1.26 mmol) as a white solid.

¹H (CDCl₃, 300 MHz) δ 1.45 (9H, s), 1.8-2.1 (3H, m), 2.1-2.3 (1H, m), 3.4-3.6 (2H, m), 4.4
10 (1H, dd), 8.3 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, d) ppm.

LRMS 431 (MH⁺), 448, 450 (MNH₄⁺).

Anal. Found: C, 50.09; H, 4.62; N, 6.37. Calc for C₁₈H₂₀Cl₂N₂O₄S: C, 50.12; H, 4.67; N, 6.49.

15

Preparation 46:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-D-proline *t*-butyl ester



20

A mixture of D-proline *t*-butyl ester hydrochloride (340 mg, 1.64 mmol), NEt₃ (0.50 mL, 3.6 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (400 mg, 1.35 mmol) in CH₂Cl₂ (30 mL) was stirred at 23 °C for 20 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (MgSO₄) and evaporated *in*
25 *vacuo* to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-D-proline *t*-butyl ester (550 mg, 1.28 mmol) as a white solid.

mp 80-82 °C.


¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 1.9-2.0 (3H, m), 2.2 (1H, m), 3.4-3.6 (2H, m), 4.4 (1H,
30 m), 8.3 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 431 (MH⁺), 448 (MNH₄⁺).

Anal. Found: C, 49.76; H, 4.75; N, 6.39. Calc for $C_{18}H_{20}Cl_2N_2O_4S$: C, 50.12; H, 4.67; N, 6.49.

Preparation 47:

5 1,4-Dichloro-7-[[[(2R)-(hydroxymethyl)-1-pyrrolidinyl]sulphonyl]isoquinoline



A mixture of (*R*)-2-pyrrolidinemethanol (1.1 mL, 11.0 mmol), NEt_3 (1.5 mL, 20 mmol) and
 10 1,4-dichloro-7-isoquinolinesulphonyl chloride (3.0 g, 10 mmol) in CH_2Cl_2 (50 mL) was
 stirred at 23 °C for 30 min. The mixture was diluted with CH_2Cl_2 (50 mL), washed with
 aqueous citric acid (1 N), water, brine, dried ($MgSO_4$) and evaporated *in vacuo* to give 1,4-
 dichloro-7-[[[(2R)-(hydroxymethyl)-1-pyrrolidinyl]sulphonyl]isoquinoline (4.0 g, 11 mmol)
 as a white solid.

15

mp 167.5-168.5 °C.

1H ($CDCl_3$, 400 MHz) δ 1.5-1.55 (1H, m), 1.6-2.0 (3H, m), 2.5 (1H, br t), 3.3-3.4 (1H, m),
 3.5-3.6 (1H, m), 3.7-3.8 (3H, m), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.


20

LRMS 361, 363 (MH^+), 378 (MNH_4^+), 383 (MNa^+).

Anal. Found: C, 46.65; H, 3.91; N, 7.61. Calc for $C_{14}H_{14}Cl_2N_2O_3S$: C, 46.55; H, 3.91; N, 7.75.

25 Preparation 48:

Methyl 2-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino]isobutyrate



30 A mixture of methyl 2-aminoisobutyrate (310 mg, 2.02 mmol), NEt_3 (0.70 mL, 5.05 mmol)
 and 1,4-dichloro-7-isoquinolinesulphonyl chloride (500 mg, 1.69 mmol) in CH_2Cl_2 (30 mL)

was stirred at 23 °C for 17 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (70:30) as eluant to give methyl 2-[[[1,4-dichloro-7-

5 isoquinolinyl)sulphonyl]amino]isobutyrate (210 mg, 0.56 mmol) as a white solid.

mp 159.5-161 °C.

¹H (CDCl₃, 400 MHz) δ 1.5 (6H, s), 3.7 (3H, s), 5.55 (1H, s), 8.25 (1H, d), 8.35 (1H, d), 8.5
10 (1H, s), 8.9 (1H, s) ppm.


LRMS 377 (MH⁺).

Anal. Found: C, 44.24; H, 3.72; N, 7.29. Calc for C₁₄H₁₄Cl₂N₂O₄S: C, 44.57; H, 3.74; N, 7.43.

15

Preparation 49:

2-[[[1,4-Dichloro-7-isoquinolinyl)sulphonyl]amino]-2-methylpropanamide



20

A mixture of 2-amino-2-methylpropanamide (200 mg, 1.96 mmol), NEt₃ (0.69 mL, 5.0 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (580 mg, 1.96 mmol) in CH₂Cl₂ (20 mL) was stirred at 23 °C for 17 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with water, aqueous citric acid (1 N), water, brine, dried (MgSO₄) and evaporated *in vacuo*.
25 The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (90:10:1) as eluant to give 2-[[[1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]-2-methylpropanamide (228 mg, 0.62 mmol) as a white solid.

mp 220-222 °C.

30

¹H (*d*₇-MeOH, 400 MHz) δ 1.4 (6H, s), 3.3 (2H, s), 8.4 (1H, dd), 8.45 (1H, d), 8.55 (1H, d), 8.9 (1H, s).

LRMS 362, 364 (MH⁺), 379, 381 (MNH₄⁺).

Anal. Found: C, 42.81; H, 3.70; N, 11.15. Calc for C₁₃H₁₃Cl₂N₃O₃S•0.25H₂O: C, 42.58; H, 3.71; N, 11.46.

5

Preparation 50:

Ethyl 1-aminocyclobutanecarboxylate



10

A solution 1-aminocyclobutanecarboxylic acid (500 mg, 4.34 mmol) in EtOH (10 mL) was saturated with HCl gas, and the mixture was stirred at 23 °C for 4 d. The solvents were evaporated *in vacuo*, azeotroping with PhMe and CH₂Cl₂, to give ethyl 1-aminocyclobutanecarboxylate hydrochloride (754 mg, 4.20 mmol) as an off-white solid.

15


¹H (DMSO-*d*₆, 300 MHz) δ 1.25 (3H, t), 1.9-2.1 (2H, m), 2.3-2.5 (4H, m), 4.2 (2H, q), 8.8 (2H, br s) ppm.

LRMS 287 (M₂H⁺).

20

Preparation 51:

Ethyl 1-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclobutanecarboxylate



25

A mixture of ethyl 1-aminocyclobutanecarboxylate hydrochloride (382 mg, 2.12 mmol), NEt₃ (1.04 mL, 7.43 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (630 mg, 2.12 mmol) in CH₂Cl₂ (8 mL) was stirred at 23 °C for 18 h. The mixture was diluted with CH₂Cl₂, washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (90:10 to 80:20) as eluant to give ethyl 1-[[[(1,4-dichloro-7-

30

isoquinolinyl)sulphonyl]amino}cyclobutanecarboxylate (480 mg, 1.19 mmol) as a white powder.

mp 123-125 °C.

5

¹H (CDCl₃, 300 MHz) δ 1.2 (3H, t), 1.9-2.1 (2H, m), 2.4-2.6 (4H, m), 4.0 (2H, q), 5.5 (1H, br s), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 403, 405 (MH⁺), 420 (MNH₄⁺).

10

Preparation 52:

Cycloleucine ethyl ester




- 15 A solution of cycloleucine (8.94 g, 69.2 mmol) in EtOH (100 mL) was saturated with HCl gas, and the mixture was stirred at 23 °C for 2 d. The solvents were evaporated *in vacuo*, the residue was dissolved in water (200 mL) and the solution basified with solid NaHCO₃. The aqueous solution was extracted with EtOAc (3x100 mL) and the combined extracts were washed with brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was dissolved in
- 20 hexane-Et₂O (1:1) and a solution of HCl in Et₂O-dioxane (0.5 M, 1:1) was added which gave a precipitate. This off-white solid was collected by filtration and dried to give cycloleucine ethyl ester hydrochloride (6.57 g, 33.9 mmol).

- ¹H (d₆-DMSO, 400 MHz) δ 1.2 (3H, t), 1.6-1.8 (2H, m), 1.8-2.0 (4H, m), 2.05-2.15 (2H, m),
- 25 4.15 (2H, q), 8.6-8.7 (3H, br s) ppm.

Preparation 53:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]cycloleucine ethyl ester



30

A mixture of cycloleucine ethyl ester hydrochloride (5.56 g, 28.7 mmol), NEt₃ (9.9 mL, 72 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (7.10 g, 24.0 mmol) in CH₂Cl₂ (480 mL) was stirred at 23 °C for 3 d. The mixture was diluted with CH₂Cl₂, washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*.

- 5 The residue was purified by column chromatography upon silica gel using pentane-EtOAc (80:20 to 70:30) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]cycloleucine ethyl ester (6.36 g, 15.2 mmol) as a white solid.

mp 127-129 °C.

10

¹H (CDCl₃, 400 MHz) δ 1.2 (3H, t), 1.6-1.8 (4H, m), 1.9-2.0 (2H, m), 2.1-2.2 (2H, m), 4.1 (2H, q), 5.25 (1H, s), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 417, 419 (MH⁺).


15

Anal. Found: C, 48.57; H, 4.35; N, 6.58. Calc for C₁₇H₁₈Cl₂N₃O₄S: C, 48.93; H, 4.35; N, 6.71.

Preparation 54:

1,4-Dichloro-*N*-[1-(hydroxymethyl)cyclopentyl]-7-isoquinolinesulphonamide

20



- A mixture of 1-amino-1-cyclopentylmethanol (559 mg, 4.86 mmol), NEt₃ (0.85 mL, 6.0 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (1.2 g, 4.05 mmol) in CH₂Cl₂ (80 mL) was stirred at 23 °C for 16 h. The mixture was diluted with CH₂Cl₂ (50 mL), washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5) as eluant, followed by trituration with Et₂O, to give to give 1,4-dichloro-*N*-[1-(hydroxymethyl)cyclopentyl]-7-isoquinolinesulphonamide (0.62 g, 1.65 mmol) as a white solid.
- 25
- 30

mp 148-150 °C.


^1H (CDCl_3 , 400 MHz) δ 1.5-1.6 (4H, m), 1.6-1.7 (2H, m), 1.7-1.8 (2H, m), 2.2 (1H, br t), 3.65 (2H, d), 5.1 (1H, s), 8.3 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 375 (MH^+).

5

Preparation 55:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine ethyl ester



10

2-(Dimethylamino)ethyl chloride (140 mg, 1.3 mmol) was added to a stirred solution of *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]cycloleucine ethyl ester (200 mg, 0.48 mmol) and anhydrous K_2CO_3 (80 mg, 0.58 mmol) in DMF (4 mL) under N_2 at 23 °C and the mixture was stirred for 21 h. The cooled mixture was diluted with EtOAc, washed with water, dried (Na_2SO_4), and the solvents were evaporated *in vacuo*. The residue was dissolved in Et_2O and a solution of HCl in Et_2O (1 M) was added which gave a precipitate. This off-white solid was collected by filtration and dried to give to give *N*-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-*N*-[2-(dimethylamino)ethyl]cycloleucine ethyl ester (170 mg, 0.32 mmol).

15

mp 238-240 °C.

^1H ($\text{DMSO}-d_6$, 300 MHz) δ 1.15 (3H, t), 1.55-1.7 (4H, m), 2.0-2.1 (2H, m), 2.2-2.35 (2H, m), 2.8 (6H, s), 3.35-3.45 (2H, m), 3.75-3.85 (2H, m), 4.0 (2H, q), 8.45 (1H, d), 8.5 (1H, d), 8.7 (1H, s), 8.7 (1H, s) ppm.

25


LRMS 488, 490 (MH^+).

Anal. Found: C, 47.53; H, 5.37; N, 7.96. Calc for $\text{C}_{21}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}_4\text{S}\cdot 0.25\text{H}_2\text{O}$: C, 47.65; H, 5.43; N, 7.94.

30

Preparation 56:

Methyl 1-(((1,4-dichloro-7-isoquinolinyl)sulphonyl]amino)cyclohexanecarboxylate



- 5 Methyl 1-aminocyclohexanecarboxylate has been prepared previously, see: Didier, E.; Horwell, D. C.; Pritchard, M. C. *Tetrahedron*, 1992, 48, 8471-8490.

A mixture of methyl 1-aminocyclohexanecarboxylate (325 mg, 1.68 mmol), NEt₃ (0.49 mL, 3.5 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (415 mg, 1.40 mmol) in
 10 CH₂Cl₂ (30 mL) was stirred at 23 °C for 16 h. The mixture was diluted with CH₂Cl₂, washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20 to 70:30) as eluant, followed by trituration with *i*-Pr₂O, to give to give methyl
 15 1-(((1,4-dichloro-7-isoquinolinyl)sulphonyl]amino)-cyclohexanecarboxylate (132 mg, 0.32 mmol) as a white solid.

mp 185-186 °C.

¹H (CDCl₃, 300 MHz) δ 1.2-1.5 (6H, m), 1.8-2.0 (4H, m), 3.6 (3H, s), 4.95 (1H, s), 8.25 (1H,
 20 d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 418 (MH⁺).

Anal. Found: C, 48.94; H, 4.43; N, 6.42. Calc for C₁₇H₁₈Cl₂N₂O₄S: C, 48.93; H, 4.35; N, 6.71.

25

Preparation 57:

Methyl 4-aminotetrahydro-2H-pyran-4-carboxylate



30

4-Aminotetrahydro-2H-pyran-4-carboxylic acid has been prepared previously, see: Palacin, S.; Chin, D. N.; Simanek, E. E.; MacDonald, J. C.; Whitesides, G. M.; McBride, M. T.; Palmore, G. *J. Am. Chem. Soc.*, 1997, 119, 11807-11816.

- 5 A solution 4-aminotetrahydro-2H-pyran-4-carboxylic acid (0.50 g, 3.4 mmol) in MeOH (10 mL) was saturated with HCl gas at 0-5 °C, and the mixture was then heated at reflux for 3.5 h. The solvents were evaporated *in vacuo*, the residue was dissolved in saturated aqueous NaHCO₃ and the aqueous solution was extracted with CH₂Cl₂ (2x50 mL). The combined extracts were dried (MgSO₄) and evaporated *in vacuo* to give methyl 4-aminotetrahydro-2H-
10 pyran-4-carboxylate (410 mg, 2.58 mmol).


¹H (CDCl₃, 300 MHz) δ 1.4-1.6 (4H, m), 2.05-2.2 (2H, m), 3.6-3.7 (2H, m), 3.75 (3H, s), 3.8-3.9 (2H, m) ppm.

- 15 LRMS 160 (MH⁺).

Preparation 58:

Methyl 4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino] tetrahydro-2H-pyran-4-carboxylate

20



- A mixture of methyl 4-aminotetrahydro-2H-pyran-4-carboxylate (400 mg, 2.51 mmol), NEt₃ (0.44 mL, 3.14 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (621 mg, 2.09
25 mmol) in CH₂Cl₂ (30 mL) was stirred at 23 °C for 20 h. The mixture was diluted with CH₂Cl₂, washed with dilute HCl (2 M), saturated aqueous NaHCO₃, brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20) and then CH₂Cl₂-MeOH-0.880NH₃ (95:5:0.5) as eluant, followed by trituration with *i*-Pr₂O, to give to give methyl 4-[[[(1,4-dichloro-7-
30 isoquinolinyl)sulphonyl]amino] tetrahydro-2H-pyran-4-carboxylate (197 mg, 0.47 mmol) as a white solid.

mp 168-170 °C.


¹H (CDCl₃, 400 MHz) δ 1.8-1.95 (2H, m), 2.1-2.2 (2H, m), 3.5 (3H, s), 3.5-3.7 (4H, m), 5.4 (1H, s), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

5 LRMS 419 (MH⁺).

Anal. Found: C, 45.97; H, 3.85; N, 6.36. Calc for C₁₆H₁₆Cl₂N₂O₅S: C, 45.83; H, 3.85; N, 6.68.

Preparation 59:

10 *t*-Butyl (±)-*cis*-2-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino} cyclohexanecarboxylate



t-Butyl (±)-*cis*-2-aminocyclohexanecarboxylate has been prepared previously, see: Xie, J.;

15 Soleilhac, J. M.; Renwart, N.; Peyroux, J.; Roques, B. P.; Fournie-Zaluski, M. C. *Int. J. Pept. Protein Res* 1989, 34, 246-255.

A mixture of *t*-butyl (±)-*cis*-2-aminocyclohexanecarboxylate hydrochloride (282 mg, 1.20 mmol), NEt₃ (0.33 mL, 2.37 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (282 mg, 0.95 mmol) in CH₂Cl₂ (10 mL) was stirred at 23 °C for 1 h. The solvents were
20 evaporated *in vacuo* and the residue suspended in EtOAc (100 mL). This solution was washed with dilute HCl (10 mL, 1 M), water, dried (MgSO₄) and evaporated *in vacuo* to give *t*-butyl (±)-*cis*-2-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino} cyclohexanecarboxylate (395 mg, 0.86 mmol) as a white solid.

25

¹H (CDCl₃, 300 MHz) δ 1.1-1.8 (16H, m), 1.95-2.1 (1H, m), 2.5-2.6 (1H, m), 3.4-3.55 (1H, m), 6.1 (1H, d), 8.25 (1H, d), 8.35 (1H, d), 8.45 (1H, s), 8.9 (1H, s).


LRMS 459, 461 (MH⁺).

30

Anal. Found: C, 51.99; H, 5.28; N, 6.01. Calc for C₂₀H₂₄Cl₂N₂O₄S: C, 52.29; H, 5.27; N, 6.10.

Preparation 60:

Ethyl (±)-*cis*-2-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate



- 5 A mixture of ethyl (±)-*cis*-2-aminocyclohexanecarboxylate hydrochloride (251 mg, 1.20 mmol), NEt₃ (0.33 mL, 2.4 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (296 mg, 1.00 mmol) in CH₂Cl₂ (10 mL) were stirred at 23 °C for 1 h. The mixture was diluted with CH₂Cl₂ (100 mL), washed with dilute HCl (30 mL, 1 M), water, dried (MgSO₄) and evaporated *in vacuo* to give ethyl (±)-*cis*-2-[[[(1,4-dichloro-7-
- 10 isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (385 mg, 0.89 mmol) as a white solid.

¹H (CDCl₃, 400 MHz) δ 1.2 (3H, t), 1.2-1.4 (3H, m), 1.4-1.7 (3H, m), 1.75-1.85 (1H, m), 2.0-2.1 (1H, m), 2.65 (1H, q), 3.5-3.6 (1H, m), 3.95-4.0 (1H, m), 4.05-4.15 (1H, m), 5.9 (1H, d),

15 8.2 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s).


LRMS 431, 433 (MH⁺).

Anal. Found: C, 50.45; H, 4.79; N, 6.31. Calc for C₁₈H₂₀Cl₂N₂O₄S: C, 50.12; H, 4.67; N, 6.49.

20

Preparation 61:

t-Butyl *cis*-4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate



25

t-Butyl *cis*-4-aminocyclohexanecarboxylate has been prepared previously, see: Barnish, I. T.; James, K.; Terrett, N. K.; Danilewicz, J. C.; Samuels, G. M. R.; Wythes, M. J. *Eur. Patent*, 1988, EP 274234.

- 30 A mixture of *t*-butyl *cis*-4-aminocyclohexanecarboxylate (282 mg, 1.20 mmol), NEt₃ (0.33 mL, 2.37 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (296 mg, 1.00 mmol) in CH₂Cl₂ (10 mL) was stirred at 0 °C for 1 h. The mixture was diluted with CH₂Cl₂ (150 mL),

was washed with dilute HCl (30 mL, 1 M), water, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using pentane-EtOAc (100:0 to 75:25) to give *t*-butyl *cis*-4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (360 mg, 0.78 mmol) as a white solid.


¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 1.5-1.65 (6H, m), 1.75-1.85 (2H, m), 2.3 (1H, m), 3.45 (1H, m), 4.75 (1H, d), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

LRMS 459, 461 (MH⁺), 476 (MNH₄⁺).

Anal. Found: C, 52.34; H, 5.28; N, 5.98. Calc for C₂₀H₂₄Cl₂N₂O₄S: C, 52.29; H, 5.27; N, 6.10.

Preparation 62:

Ethyl *trans*-4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate



Ethyl *trans*-4-aminocyclohexanecarboxylate has been prepared previously, see: Skaric, V.; Kovacevic, M.; Skaric, D. *J. Chem. Soc., Perkin Trans. 1* 1976, 1199-1201.

A mixture of ethyl *trans*-4-aminocyclohexanecarboxylate (168 mg, 0.81 mmol), NEt₃ (0.22 mL, 1.6 mmol) and 1,4-dichloro-7-isoquinolinesulphonyl chloride (200 mg, 0.67 mmol) in CH₂Cl₂ (8 mL) was stirred at 0 °C for 1 h. The mixture was diluted with CH₂Cl₂ (100 mL), was washed with dilute HCl (50 mL, 1 M), water, dried (MgSO₄) and evaporated *in vacuo* to give ethyl *trans*-4-[[[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino]cyclohexanecarboxylate (232 mg, 0.54 mmol) as a white solid.

¹H (CDCl₃, 400 MHz) δ 1.15-1.3 (5H, m), 1.4-1.55 (2H, m), 1.9-2.0 (4H, m), 2.1-2.2 (1H, m), 3.2-3.3 (1H, m), 4.1 (2H, t), 4.55 (1H, d), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s)

LRMS 431 (MH⁺).

Preparation 63:

1,4-Dichloro-7-isoquinolinecarbonyl chloride



5

A solution of *N*-chlorosuccinimide (4.13 g, 31 mmol) in MeCN (50 mL) was added dropwise to a stirred solution of 7-bromo-1-(2*H*)-isoquinolone (6.6 g, 29.5 mmol) in MeCN (150 mL) which was heating under reflux. The mixture was heated under reflux for an additional 3 h and then cooled to room temperature. The resulting precipitate was collected by filtration,
10 with MeCN rinsing, and then dried *in vacuo* to give 7-bromo-4-chloro-1(2*H*)-isoquinolone (6.72 g, 26.0 mmol) as a white solid.

mp 241-243 °C.

15 ¹H (DMSO-*d*₆, 300 MHz) δ 7.5 (1H, s), 7.73 (1H, d), 7.8 (1H, dd), 8.3 (1H, s) ppm.

LRMS 259 (MH⁺), 517 (M₂H⁺).

Anal. Found: C, 41.69; H, 1.90; N, 5.37. Calc for C₉H₅BrClNO: C, 41.80; H, 1.95; N, 5.42.

20



25 A mixture of 7-bromo-4-chloro-1(2*H*)-isoquinolone (1.0 g, 3.87 mmol) and bis(triphenylphosphine) palladium (II) chloride (100 mg, 0.14 mmol) in EtOH (15 mL) and NEt₃ (2 mL) was heated to 100 °C in a pressure vessel under an atmosphere of CO (100 psi) for 48 h. After cooling and venting the vessel, the catalyst was removed by filtration, and the filtrate was evaporated *in vacuo*. The residue was purified by column chromatography upon
30 silica gel using hexane-EtOAc (50:50) as eluant, and then by crystallisation from *i*-Pr₂O. This


material was combined with CH_2Cl_2 washings of the catalyst residues to give ethyl 4-chloro-1-oxo-1,2-dihydro-7-isoquinolinecarboxylate (743 mg, 2.95 mmol) as a white solid.

mp 184-186 °C.

^1H (CDCl_3 , 300 MHz) δ 1.45 (2H, t), 4.45 (2H, q), 7.4 (1H, s), 7.95 (1H, d), 8.4 (1H, d), 9.05 (1H, s) ppm.

LRMS 252 (MH^+), 269 (MNH_4^+), 503 (M_2H^+).

Anal. Found: C, 57.02; H, 3.99; N, 5.53. Calc for $\text{C}_{12}\text{H}_{10}\text{ClNO}_3$: C, 57.27; H, 4.01; N, 5.57.



Ethyl 4-chloro-1-oxo-1,2-dihydro-7-isoquinolinecarboxylate (500 mg, 1.99 mmol) was warmed in POCl_3 (3 mL) until a clear solution formed, and was then allowed to stand at 23 °C for 18 h. The reaction mixture was poured into warm water, extracted with EtOAc (3x20 mL), and the combined organic extracts washed with water and saturated brine, dried (MgSO_4), and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (90:10) as eluant followed by crystallisation from *i*- Pr_2O to give ethyl 1,4-dichloro-7-isoquinolinecarboxylate (377 mg, 1.40 mmol) as a pale pink solid.

mp 92-94 °C.

^1H (CDCl_3 , 300 MHz) δ 1.45 (2H, t), 4.45 (2H, q), 8.25 (1H, d), 8.4-8.45 (2H, m), 9.05 (1H, s) ppm.

LRMS 270 (MH^+).

Anal. Found: C, 53.27; H, 3.48; N, 5.14. Calc for $\text{C}_{12}\text{H}_9\text{Cl}_2\text{NO}_2$: C, 53.36; H, 3.36; N, 5.19.



Ethyl 1,4-dichloro-7-isoquinolinecarboxylate (500 mg, 1.85 mmol) in THF (2 mL) was treated with an aqueous solution of NaOH (3.7 mL, 1 M) and EtOH (few drops) added to give a single phase mixture. After stirring at room temperature overnight, HCl (3.7 mL, 1 M) was added to give a thick slurry which was filtered off, washed with water, and crystallised from *i*-PrOH. The fluffy white crystalline solid was triturated with hexane and dried to afford 1,4-dichloro-7-isoquinolinecarboxylic acid (240 mg, 0.99 mmol).

mp 226-228 °C.

¹H (DMSO-*d*₆, 300 MHz) δ 8.3 (1H, d), 8.4 (1H, d), 8.55 (1H, s), 8.8 (1H, s) ppm.

LRMS 242 (MH⁺).


Anal. Found: C, 49.59; H, 2.08; N, 5.74. Calc for C₁₀H₅Cl₂NO₂: C, 49.62; H, 2.08; N, 5.78.



Oxalyl chloride (144 μL, 1.65 mmol) was added to a suspension of 1,4-dichloro-7-isoquinolinecarboxylic acid (200 mg, 0.83 mmol) at room temperature in CH₂Cl₂ (10 mL), followed by DMF (1 drop). After 30 min the resultant clear solution was evaporated *in vacuo* to afford 1,4-dichloro-7-isoquinolinecarbonyl chloride which was used without further purification.

Preparation 64:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]glycine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (213 mg, 0.8 mmol) in CH_2Cl_2 (10 mL) was added to a stirred suspension of glycine *t*-butyl ester hydrochloride (166 mg, 0.99 mmol) and NEt_3 (253 μL , 1.82 mmol) in CH_2Cl_2 (5 mL). The reaction mixture was stirred at room temperature overnight, quenched with a drop of water and then evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (70:30) as eluant to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]glycine *t*-butyl ester (140 mg, 0.39 mmol). An analytical sample was prepared by crystallisation from *i*- Pr_2O - CH_2Cl_2 .

mp 162-164 °C.


^1H (CDCl_3 , 300 MHz) δ 1.5 (9H, s), 4.15-4.2 (2H, m), 6.9 (1H, s), 8.25-8.3 (2H, m), 8.4 (1H, s), 8.75 (1H, s) ppm.

LRMS 355 (MH^+).

Anal. Found: C, 53.98; H, 4.36; N, 7.83. Calc for $\text{C}_{16}\text{H}_{16}\text{Cl}_2\text{N}_2\text{O}_3$: C, 54.10; H, 4.54; N, 7.89.

Preparation 65:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]- β -alanine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (450 mg, 1.7 mmol) in CH_2Cl_2 (20 mL) was added to a stirred solution of β -alanine *t*-butyl ester hydrochloride (376 mg, 2.07 mmol) and NEt_3 (530 μL , 3.81 mmol) in CH_2Cl_2 (10 mL) and the mixture was stirred at room temperature for 3 h. The mixture was washed with HCl (2x30mL, 1 M), aqueous NaHCO_3 (10%, 30 mL), dried (Na_2SO_4), and evaporated *in vacuo*. The residue was crystallised from *i*- Pr_2O to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]- β -alanine *t*-butyl ester (440 mg, 1.19 mmol) as a white solid.

mp 131-133 °C.


^1H (CDCl_3 , 400 MHz) δ 1.5 (9H, s), 2.6 (2H, t), 3.7-3.8 (2H, m), 7.15 (1H, br s), 8.2-8.3 (2H, m), 8.4 (1H, s), 8.65 (1H, s) ppm.

5 LRMS 369 (MH^+), 740 (M_2H^+).

Anal. Found: C, 55.11; H, 4.88; N, 7.48. Calc for $\text{C}_{17}\text{H}_{18}\text{Cl}_2\text{N}_2\text{O}_3$: C, 55.29; H, 4.91; N, 7.59.

Preparation 66:

10 *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]cycloleucine ethyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (270 mg, 1.04 mmol) in CH_2Cl_2 (12 mL) was added to a stirred solution of cycloleucine ethyl ester hydrochloride (300 mg, 1.55 mmol) and NEt_3 (415 μL , 2.98 mmol) in CH_2Cl_2 (20 mL) and the mixture was stirred at room temperature for 1h. The mixture was washed with dilute HCl (2 M), aqueous NaHCO_3 (10 %), dried (Na_2SO_4), and evaporated *in vacuo*. The residue was crystallised from *i*- Pr_2O to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]cycloleucine ethyl ester (372 mg, 0.98 mmol) as a white solid.

mp 178-180 $^\circ\text{C}$.


^1H (CDCl_3 , 300 MHz) δ 1.3 (3H, t), 1.8-2.05 (4H, m), 2.1-2.3 (2H, m), 2.3-2.45 (2H, m), 4.25 (2H, q), 6.95 (1H, br s), 8.2-8.25 (2H, m), 8.4 (1H, s), 8.7(1H, s) ppm.

LRMS 382 (MH^+), 398 (MNH_4^+), 763 (M_2H^+).

Anal. Found: C, 56.71; H, 4.77; N, 7.27. Calc for $\text{C}_{18}\text{H}_{18}\text{Cl}_2\text{N}_2\text{O}_3$: C, 56.70; H, 4.76; N, 7.35.

Preparation 67:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-DL-phenylglycine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (450 mg, 1.73 mmol) in CH_2Cl_2 (20 mL) was added to a stirred solution of DL-phenylglycine *t*-butyl ester hydrochloride (505 mg, 2.07 mmol) and NEt_3 (530 μL , 3.81 mmol) in CH_2Cl_2 (30 mL) and the mixture was stirred at room temperature for 3 h. The mixture was washed with dilute HCl (2x30 mL, 1 M), aqueous NaHCO_3 (10%), dried (Na_2SO_4), and evaporated *in vacuo* to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-phenylglycine *t*-butyl ester (600 mg, 1.39 mmol) as a waxy solid. An analytical sample was prepared by the slow evaporation of a solution in CH_2Cl_2 to give a fluffy white solid.

mp 146-149 °C.


^1H (CDCl_3 , 300 MHz) δ 1.5 (9H, s), 5.7 (1H, d), 7.3-7.5 (6H, m), 8.2-8.3 (2H, m), 8.4 (1H, s), 8.8 (1H, s) ppm.

LRMS 431 (MH^+), 861 (M_2H^+).

Anal. Found: C, 60.57; H, 4.76; N, 6.42. Calc for $\text{C}_{22}\text{H}_{20}\text{Cl}_2\text{N}_2\text{O}_3 \cdot 0.25\text{H}_2\text{O}$: C, 60.63; H, 4.74; N, 6.43

Preparation 68:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-L-phenylglycine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (148 mg, 0.57 mmol) in CH_2Cl_2 (6 mL) was added to a stirred solution of *S*-(+)-phenylglycine *t*-butyl ester hydrochloride (138 mg, 0.57 mmol) and NEt_3 (200 μL , 1.44 mmol) in CH_2Cl_2 (5 mL), and the mixture was stirred at room temperature overnight. The mixture was diluted with CH_2Cl_2 (25 mL), washed with dilute HCl (0.5 M), aqueous NaHCO_3 (10%), brine, dried (Na_2SO_4), and evaporated *in*

vacuo to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-*L*-phenylglycine *t*-butyl ester (218 mg, 0.51 mmol) as a gum. An analytical sample was prepared by trituration with hexane yielding a solid.

5 mp 173-175 °C.


¹H (CDCl₃, 300 MHz) δ 1.45 (9H, s), 5.7 (1H, d), 7.3-7.5 (6H, m), 8.25 (2H, s), 8.4 (1H, s), 8.8 (1H, s) ppm.

10 LRMS 431 (MH⁺), 448 (MNH₄⁺), 861 (M₂H⁺), 883 (M₂Na⁺).

Anal. Found: C, 58.83; H, 4.88; N, 5.90. Calc for C₂₂H₂₀Cl₂N₂O₃•H₂O: C, 58.80; H, 4.93; N, 6.23

15 Preparation 69:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-*D*-phenylglycine *t*-butyl ester



20 A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (148 mg, 0.57 mmol) in CH₂Cl₂ (6 mL) was added to a stirred solution of *R*-(+)-phenylglycine *t*-butyl ester hydrochloride (138 mg, 0.57 mmol) and NEt₃ (200 μL, 1.44 mmol) in CH₂Cl₂ (5 mL), and the mixture was stirred at room temperature overnight. The mixture was diluted with CH₂Cl₂ (25 mL), washed with dilute HCl (0.5 M), aqueous NaHCO₃ (10 %), brine, dried (Na₂SO₄), and evaporated *in vacuo*. Trituration of the residue with hexane gave *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-*D*-phenylglycine *t*-butyl ester (203 mg, 0.47 mmol) as a white solid.


¹H (CDCl₃, 300 MHz) δ 1.4 (9H, s), 5.7 (1H, d), 7.3-7.5 (6H, m), 8.25 (2H, s), 8.4 (1H, s), 8.8 (1H, s) ppm.

30

LRMS 431 (MH⁺), 448 (MNH₄⁺), 861 (M₂H⁺), 883 (M₂Na⁺).

Anal. Found: C, 61.17; H, 4.70; N, 6.37. Calc for C₂₂H₂₀Cl₂N₂O₃: C, 61.26; H, 4.67; N, 6.50

Preparation 70:

N-[(1,4-Dichloro-7-isoquinoliny)carbonyl]-DL-valine *t*-butyl ester


A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (450 mg, 1.73 mmol) in CH_2Cl_2 (20 mL) was added to a stirred solution of DL-valine *t*-butyl ester hydrochloride (435 mg, 2.07 mmol) and NEt_3 (530 μL , 3.81 mmol) in CH_2Cl_2 (10 mL) and the mixture was stirred at room temperature for 3 h. The mixture was washed with dilute HCl (1 M), aqueous NaHCO_3 (10%), dried (Na_2SO_4), and evaporated *in vacuo*. The residue was crystallised with *i*- Pr_2O to give *N*-[(1,4-dichloro-7-isoquinoliny)carbonyl]-DL-valine *t*-butyl ester (390 mg, 0.98 mmol) as a white solid.

15 ^1H (CDCl_3 , 400 MHz) δ 1.0-1.05 (6H, m), 1.5 (9H, s), 2.3-2.4 (1H, m), 4.7-4.8 (1H, m), 6.85 (1H, d), 8.25-8.3 (2H, m), 8.4 (1H, s), 8.75 (1H, s) ppm.

LRMS 397 (MH^+), 793 (M_2H^+).

20 Anal. Found: C, 57.20; H, 5.53; N, 6.99. Calc for $\text{C}_{19}\text{H}_{22}\text{Cl}_2\text{N}_2\text{O}_3$: C, 57.44; H, 5.58; N, 7.05.

Preparation 71:

N-[(1,4-Dichloro-7-isoquinoliny)carbonyl]-DL-proline *t*-butyl ester

DL-Proline *t*-butyl ester hydrochloride (320 mg, 1.54 mmol) and then NEt_3 (513 μL , 3.69 mmol) were added to a stirred solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (270 mg, 1.04 mmol) in CH_2Cl_2 (32 mL) and the cloudy solution was then stirred at room temperature for 4 h. The mixture was diluted with CH_2Cl_2 (20 mL), washed with dilute HCl (1 M), saturated brine, dried (Na_2SO_4), and evaporated *in vacuo*. The residue was crystallised

with *i*-Pr₂O to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-proline *t*-butyl ester (395 mg, 1.00 mmol) as a white solid.

mp 144-146 °C.

5

¹H (CDCl₃, 300 MHz) shows a 3:1 mixture of rotamers δ 1.15 (1/4 of 9H, s), 1.55 (3/4 of 9H, s), 1.8-2.15 (3H, m), 2.2-2.4 (1H, m), 3.45-3.9 (2H, m), 4.2-4.3 (1/4 of 1H, m), 4.6-4.7 (3/4 of 1H, m), 7.9 (1/4 of 1H, d), 8.05 (3/4 of 1H, d), 8.2-8.3 (1H, m), 8.4 (1H, s), 8.55 (1H, s) ppm.


10

LRMS 395 (MH⁺), 789 (M₂H⁺).

Anal. Found: C, 57.79; H, 5.11; N, 6.97. Calc for C₁₉H₂₀Cl₂N₂O₃: C, 57.73; H, 5.10; N, 7.09.

15 Preparation 72:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-DL-phenylalanine *t*-butyl ester



- 20 A mixture of NEt₃ (330 μL, 2.37 mmol), DL-phenylalanine *t*-butyl ester hydrochloride (293 mg, 1.14 mmol) and 1,4-dichloro-7-isoquinolinecarbonyl chloride (247 mg, 0.95 mmol) in CH₂Cl₂ (20 mL) was stirred at room temperature for 18 h. The solvents were evaporated *in vacuo* and the residue partitioned between dilute HCl (1M) and EtOAc. The organic phase was washed with brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residue was crystallised
- 25 with *i*-Pr₂O to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-phenylalanine *t*-butyl ester (384 mg, 0.86 mmol) as a white solid.

mp 156-157 °C.


- 30 ¹H (CDCl₃, 300 MHz) δ 1.5 (9H, s), 3.2-3.3 (2H, m), 5.0 (1H, dt), 6.8 (1H, d), 7.2-7.49 (5H, m), 8.2 (1H, d), 8.25 (1H, d), 8.4 (1H, s), 8.6 (1H, s) ppm.

LRMS 445 (MH⁺).

Anal. Found: C, 62.02; H, 4.98; N, 6.28. Calc for $C_{23}H_{22}Cl_2N_2O_3$: C, 62.03; H, 4.98; N, 6.29.

Preparation 73:

5 *N*-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-DL-leucine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (247 mg, 0.95 mmol) in CH_2Cl_2
 10 (10 mL) was added to a solution of DL-leucine *t*-butyl ester hydrochloride (255 mg, 1.14 mmol) and NEt_3 (330 μ L, 2.37 mmol) in CH_2Cl_2 (10 mL) and the mixture was stirred at room temperature overnight. The solvents were evaporated *in vacuo* and the residue was partitioned between dilute HCl (1 M) and EtOAc. The organic phase was washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was crystallised with *i*-Pr₂O to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-leucine *t*-butyl ester (285 mg, 0.69 mmol).
 15

mp 183-184 °C.

¹H (CDCl₃, 300 MHz) δ 1.0-1.1 (6H, m), 1.5 (9H, s), 1.65-1.85 (3H, m), 4.75-4.85 (1H, m),
 20 6.8 (1H, d), 8.2 (2H, s), 8.4 (1H, s), 8.7 (1H, s) ppm.


LRMS 411 (MH⁺).

Anal. Found: C, 58.39; H, 5.84; N, 6.76. Calc for $C_{20}H_{24}Cl_2N_2O_3$: C, 58.40; H, 5.88; N, 6.81.

25

Preparation 74:

t-Butyl DL-3-[[[(1,4-dichloro-7-isoquinolinyl)carbonyl]amino]-3-phenylpropanoate



30

A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (247 mg, 0.95 mmol) in CH_2Cl_2 (10 mL) was added to a solution of DL-3-amino-3-phenylpropionic acid *t*-butyl ester (252 mg, 1.14 mmol) and NEt_3 (260 μL , 1.87 mmol) in CH_2Cl_2 (10 mL) and the mixture was stirred at room temperature overnight. The solvents were evaporated *in vacuo* and the residue was partitioned between dilute HCl (1 M) and EtOAc. The organic phase was washed with brine, dried (Na_2SO_4) and evaporated *in vacuo* to give *t*-butyl DL-3-[[[(1,4-dichloro-7-isoquinolinyl)carbonyl]amino]-3-phenylpropanoate (323 mg, 0.73 mmol). An analytical sample was prepared by crystallisation with *i*-Pr₂O-hexane to yield a white powder.

mp 153-155 °C.


¹H (CDCl₃, 300 MHz) δ 1.4 (9H, m), 2.9-3.05 (2H, m), 5.6 (1H, dt), 7.2-7.4 (5H, m), 7.9 (1H, d), 8.2 (2H, s), 8.4 (1H, s), 8.7 (1H, s) ppm.

LRMS 445 (MH⁺).

Anal. Found: C, 61.99; H, 5.07; N, 6.15. Calc for $\text{C}_{23}\text{H}_{22}\text{Cl}_2\text{N}_2\text{O}_3$: C, 62.03; H, 4.98; N, 6.29.

Preparation 75:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-DL-aspartic acid α,β -di-*t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (247 mg, 0.95 mmol) in CH_2Cl_2 (10 mL) was added to a solution of aspartic acid α,β -di-*t*-butyl ester hydrochloride (321 mg, 1.14 mmol) and NEt_3 (330 μL , 2.37 mmol) in CH_2Cl_2 (10 mL) and the mixture was stirred at room temperature overnight. The mixture was diluted with CH_2Cl_2 (30 mL), washed with dilute HCl (3x30 mL, 1 M), saturated aqueous Na_2CO_3 , brine, dried (MgSO_4) and evaporated *in vacuo*. The residue was crystallised from hexane to give, in two crops, *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-aspartic acid α,β -di-*t*-butyl ester (298 + 88 mg, 0.63 + 0.19 mmol) as a fluffy white solid.

mp 112-114 °C.


^1H (CDCl_3 , 300 MHz) δ 1.45 (9H, m), 1.55 (9H, m), 2.9 (1H, dd), 3.05 (1H, dd), 4.9-5.0 (1H, m), 7.45 (1H, d), 8.25-8.35 (2H, m), 8.45 (1H, s), 8.75 (1H, s) ppm.

5 LRMS 469 (MH^+), 491 (MNa^+), 959 (M_2Na^+).

Anal. Found: C, 56.20; H, 5.57; N, 5.88. Calc for $\text{C}_{22}\text{H}_{26}\text{Cl}_2\text{N}_2\text{O}_5$: C, 56.29; H, 5.58; N, 5.97.

Preparation 76:

10 *O*-*t*-Butyl-*N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-serine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarboxyl chloride (247 mg, 0.95 mmol) in CH_2Cl_2 (10 mL) was added to a solution of *O*-*t*-butyl-DL-serine *t*-butyl ester hydrochloride (288 mg, 1.14 mmol) and NEt_3 (330 μL , 2.37 mmol) in CH_2Cl_2 (10 mL) and the mixture was stirred at room temperature for 3 h. The mixture was diluted with CH_2Cl_2 (30 mL), washed with HCl (1 M), saturated aqueous Na_2CO_3 , saturated brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was crystallised from hexane to give *O*-*t*-butyl-*N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL-serine *t*-butyl ester (378 mg, 0.86 mmol) as a white solid.

20

mp 116-117 $^\circ\text{C}$.

^1H (CDCl_3 , 300 MHz) δ 1.1 (9H, m), 1.5 (9H, m), 3.7 (1H, dd), 3.9 (1H, dd), 4.8-4.9 (1H, m), 7.15 (1H, d), 8.25-8.35 (2H, m), 8.4 (1H, s), 8.75 (1H, s) ppm.

25


LRMS 441 (MH^+), 881 (M_2H^+), 903 (M_2Na^+).

Anal. Found: C, 57.15; H, 5.94; N, 6.27. Calc for $\text{C}_{21}\text{H}_{26}\text{Cl}_2\text{N}_2\text{O}_4$: C, 57.15; H, 5.94; N, 6.35.

30

Preparation 77:

N-[(1,4-Dichloro-7-isoquinolinyl)carbonyl]-DL- α -cyclopentylglycine *t*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinecarbonyl chloride (148 mg, 0.57 mmol) in CH_2Cl_2 (6 mL) was added to a solution of DL- α -cyclopentylglycine *t*-butyl ester hydrochloride (134 mg, 0.57 mmol) and NEt_3 (200 μL , 1.44 mmol) in CH_2Cl_2 (5 mL) and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with CH_2Cl_2 (25 mL), washed with dilute HCl (0.5 M), saturated aqueous Na_2CO_3 , brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was crystallised from *i*- Pr_2O -hexane to give *N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]-DL- α -cyclopentylglycine *t*-butyl ester (198 mg, 0.47 mmol) as a white solid.


^1H (CDCl_3 , 300 MHz) δ 1.4-1.9 (17H, m), 2.3-2.5 (1H, m), 4.8 (1H, dd), 6.85 (1H, d), 8.2-8.3 (2H, m), 8.4 (1H, s), 8.7 (1H, s) ppm.

LRMS 423 (MH^+), 440 (MNH_4^+), 445 (MNa^+), 845 (M_2H^+), 867 (M_2Na^+).

Anal. Found: C, 59.56; H, 5.72; N, 6.57. Calc for $\text{C}_{21}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_3$: C, 59.58; H, 5.72; N, 6.62.

Preparation 78:

N-Benzyl-*N*-[(1,4-dichloro-7-isoquinolinyl)carbonyl]glycine *t*-butyl ester



Oxalyl chloride (95 μL , 1.09 mmol) and then DMF (2 drops) were added to a stirred suspension of 1,4-dichloro-7-isoquinolinecarboxylic acid (130 mg, 0.54 mmol) in CH_2Cl_2 (10 mL), and the mixture was stirred for 30 min. to give a clear solution of the corresponding acid chloride. The solvents were evaporated *in vacuo* and the residue redissolved in CH_2Cl_2 (10 mL). *N*-Benzylglycine *t*-butyl ester hydrochloride (152 mg, 0.59 mmol) and NEt_3 (200 μL , 1.44 mmol) were added and the mixture stirred at room temperature overnight. The solvents were evaporated *in vacuo*, and the residue was partitioned between Et_2O and dilute HCl (1 M). The organic phase was washed with dilute HCl (1 M), aqueous Na_2CO_3 (10 %, 20

mL), saturated brine, dried (Na_2SO_4), and evaporated *in vacuo*. The residue was extracted with hot hexane, and the organic solution was decanted from the insoluble material. The organic solution was evaporated *in vacuo* and the residue purified by column chromatography upon silica gel using hexane-EtOAc (80:20) as eluant to give *N*-benzyl-*N*-[(1,4-dichloro-7-isoquinoliny)carbonyl]glycine *t*-butyl ester (130 mg, 0.29 mmol) as an oil.

^1H (CDCl_3 , 400 MHz) shows a 1:2 mixture of rotamers δ 1.4 (1/3 of 9H, s), 1.5 (2/3 of 9H, s), 3.75 (1/3 of 2H, s), 4.1 (2/3 of 2H, s), 4.6 (2/3 of 2H, s), 4.85 (1/3 of 2H, s), 7.2-7.45 (5H, m), 7.9-8.05 (1H, m), 8.2-8.5 (3H, m) ppm.

LRMS 445 (MH^+), 467 (MNa^+), 889 (M_2H^+), 911 (M_2Na^+).

Preparation 79:

7-(Chloromethyl)-1,4-dichloro-isoquinoline




LiBH_4 (530 mg, 24.3 mmol) was added portionwise to a stirred solution of ethyl 4-chloro-1-oxo-1,2-dihydro-7-isoquinolinecarboxylate (3.06 g, 12.2 mmol) in THF (100 mL) and the mixture was stirred at room temperature for 1 h. The heterogeneous mixture was quenched with dilute HCl (2 M), and extracted with CH_2Cl_2 (2x100 mL) and EtOAc (5x100 mL). The remaining solid was taken up in hot EtOH, and allowed to cool to yield a white fluffy solid. This solid was combined with the combined organic extracts, evaporated *in vacuo* and crystallised with EtOH to give 4-chloro-7-(hydroxymethyl)-1(2*H*)-isoquinolone (2.19 g, 10.49 mmol) as a white solid.

mp 266-268 °C.

^1H ($\text{DMSO}-d_6$, 300 MHz) δ 4.6 (2H, d), 5.4 (1H, t), 7.4 (1H, s), 7.7-7.8 (2H, m), 8.2 (1H, s) ppm.

LRMS 210 (MH^+), 419 (M_2H^+).

Anal. Found: C, 57.11; H, 3.81; N, 6.54. Calc for $C_{10}H_8ClNO_2$: C, 57.29; H, 3.85; N, 6.68.



5

A solution of 4-chloro-7-(hydroxymethyl)-1(2H)-isoquinolone (1.00 g, 4.77 mmol) in $POCl_3$ was stirred at 50 °C for 19 h. The reaction mixture was cooled in an ice-bath, quenched by the dropwise addition of dilute HCl (1 M) (reaction temperature < 30°C) and then partitioned between water and EtOAc. The aqueous phase was reextracted with EtOAc and the combined organic extracts were dried (Na_2SO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using hexane-EtOAc (80:20) as eluant to give 7-(chloromethyl)-1,4-dichloroisoquinoline (870 mg, 3.53 mmol).

10

mp 139-141°C.


15

1H ($CDCl_3$, 400 MHz) δ 4.8 (2H, s), 7.9 (1H, d), 8.1 (1H, d), 8.3-8.4 (2H, m) ppm.

LRMS 241 [$C_{11}H_8Cl_2ON \cdot H^+$; product of MeO (from MeOH) substitution of Cl]

20 Preparation 80:

N-[(1,4-Dichloro-7-isoquinoliny)methyl]-*N*-methyl-DL-phenylglycine *t*-butyl ester



25 7-(Chloromethyl)-1,4-dichloroisoquinoline (230 mg, 0.93 mmol) was added to a solution of *N*-methyl-DL-phenylglycine *t*-butyl ester (248 mg, 0.96 mmol) and NEt_3 (187 μ L, 1.34 mmol) in CH_2Cl_2 (5 mL), and the mixture heated at reflux for 15 h. [TLC indicated incomplete reaction]. The solvent was evaporated *in vacuo*, THF (30 mL) and NEt_3 (100 μ L, 0.72 mmol) were added, and the mixture heated at reflux for 24 h. Although the reaction was still incomplete, the solvent was evaporated *in vacuo*, and the residue purified by column chromatography upon silica gel using hexane-Et₂O (98:2) as eluant to give *N*-[(1,4-dichloro-

30

7-(chloromethyl)-1,4-dichloroisoquinoline (120 mg, 0.28 mmol) as a colourless oil.

The corresponding dihydrochloride salt was prepared as follows: a solution of the amine in
5 hexane was stirred with a solution of HCl in Et₂O (0.5 M). The resulting white precipitate was collected by filtration and dried.

mp 120-122 °C.

10 ¹H (CDCl₃, 400 MHz) δ 1.5 (9H, s), 2.25 (3H, s), 3.8 (1H, d), 3.9 (1H, d), 4.3 (1H, s), 7.3-7.4 (3H, m), 7.45-7.5 (2H, m), 7.95 (1H, d), 8.15 (1H, d), 8.2 (1H, s), 8.3 (1H, s) ppm.


LRMS 432 (MH⁺).

15 Anal. Found: C, 56.62; H, 5.58; N, 5.63. Calc for C₂₃H₂₄Cl₂N₂O₂•HCl•H₂O: C, 56.86; H, 5.60; N, 5.77.

Preparation 81:

N-Benzyl-*N*-[(1,4-dichloro-7-isoquinolinyl)methyl]glycine *t*-butyl ester

20



7-(Chloromethyl)-1,4-dichloroisoquinoline (378 mg, 1.53 mmol) was added to a stirred solution of *N*-benzyl glycine *t*-butyl ester (340 mg, 1.53 mmol) and NEt₃ (256 μL, 1.84
25 mmol) in THF (20 mL) and the mixture heated at reflux for 18 h. The solvent was evaporated *in vacuo* and the residue was purified by column chromatography upon silica gel using hexane-EtOAc (95:5 to 90:10) as eluant to give *N*-benzyl-*N*-[(1,4-dichloro-7-isoquinolinyl)methyl]glycine *t*-butyl ester (245 mg, 0.57 mmol).

30 The corresponding dihydrochloride salt was prepared as follows: a solution of the amine in Et₂O was stirred with a solution of HCl in dioxane (0.5 M). The resulting white precipitate was collected by filtration and dried.

mp 140-143 °C.

¹H (CDCl₃, 400 MHz) δ 1.4 (9H, s), 3.3 (2H, s), 4.6 (2H, s), 4.8 (2H, s), 7.4-7.45 (3H, m),
 5 7.75-7.8 (2H, m), 8.35 (1H, d), 8.4 (1H, s), 8.45 (1H, s), 8.8 (1H, d) ppm.


LRMS 433 (MH⁺).

Anal. Found: C, 58.91; H, 5.38; N, 5.90. Calc for C₂₃H₂₄Cl₂N₂O₂•HCl: C, 59.05; H, 5.39; N,
 10 5.99.

Preparation 82:

*N*α-[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N*ε-*tert*-butyloxycarbonyl-L-lysine *tert*-butyl
 ester

15



A solution of 1,4-dichloro-7-isoquinolinylsulphonyl chloride (250 mg, 0.84 mmol), *N*ε-*tert*-
 butyloxycarbonyl-L-lysine *tert*-butyl ester hydrochloride (286 mg, 0.84 mmol) and
 20 triethylamine (235 μl, 1.69 mmol) in CH₂Cl₂ (25 ml) was stirred at 23°C for 3h. The reaction
 mixture was washed with water (2 x 20 ml), dried (MgSO₄) and concentrated *in vacuo* to a
 residue which upon trituration with hexane and then *i*-Pr₂O gave *N*α-[(1,4-dichloro-7-
 isoquinoliny)lsulphonyl]-*N*ε-*tert*-butyloxycarbonyl-L-lysine *tert*-butyl ester as a white
 powder (270 mg, 0.48 mmol).

25


¹H (CDCl₃, 300 MHz) δ 1.1 (9H, s), 1.35-1.5 (13H, m), 1.6-1.85 (2H, m), 3.0-3.2 (2H, m),
 3.8-3.95 (1H, m), 4.45-4.6 (1H, br m), 5.35 (1H, d), 8.2 (1H, dd), 8.35 (1H, d), 8.45 (1H, s),
 8.8 (1H, d) ppm.

30 LRMS 562 (MH⁺), 584 (MNa⁺).

Anal. Found: C, 51.04; H, 5.96; N, 7.42. Calc for $C_{24}H_{33}Cl_2N_3O_6S$: C, 51.24; H, 5.91; N, 7.47.

Preparation 83:

- 5 $N\alpha$ -[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-*N* ϵ -*tert*-butyloxycarbonyl-D-lysine *tert*-butyl ester



- 10 A solution of 1,4-dichloro-7-isoquinolinylsulphonyl chloride (250 mg, 0.84 mmol), *N* ϵ -*tert*-butyloxycarbonyl-D-lysine *tert*-butyl ester hydrochloride (286 mg, 0.84 mmol) and triethylamine (235 μ l, 1.69 mmol) in CH_2Cl_2 (25 ml) was stirred at 23°C for 18 h. The reaction mixture was concentrated *in vacuo* and the residue purified by column chromatography upon silica gel using hexane-EtOAc (70:30) as eluant. Crystallisation from
- 15 *i*-Pr₂O gave $N\alpha$ -[(1,4-dichloro-7-isoquinoliny)lsulphonyl]-*N* ϵ -*t*-butyloxycarbonyl-D-lysine *tert*-butyl ester (285 mg, 0.51 mmol).

- ¹H (CDCl₃, 400 MHz) δ 1.15 (9H, s), 1.2-1.55 (13H, m), 1.55-1.8 (2H, m), 3.05-3.15 (2H, m), 3.85-3.9 (1H, m), 4.5-4.6 (1H, m), 5.4 (1H, br d), 8.2 (1H, d), 8.35 (1H, d), 8.45 (1H, s),
- 20 8.8 (1H, s) ppm.


LRMS 584 (MNa⁺).

Anal. Found: C, 51.18; H, 5.89; N, 7.33. Calc for $C_{24}H_{33}Cl_2N_3O_6S$: C, 51.24; H, 5.91; N, 7.47.

25

Preparation 84:

N -[(1,4-Dichloro-7-isoquinoliny)lsulphonyl]-L-glutamine *tert*-butyl ester



A solution of 1,4-dichloro-7-isoquinolinyl sulphonylchloride (250 mg, 0.84 mmol), L-glutamine *tert*-butyl ester hydrochloride (201 mg, 0.84 mmol) and triethylamine (235 μ l, 1.69 mmol) in CH_2Cl_2 (25 ml) was stirred at 23°C for 18 h. The reaction mixture was washed with water (2 x 20 ml) and the solvent removed *in vacuo* to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-L-glutamine *tert*-butyl ester (309 mg, 0.67 mmol). An analytical sample was obtained following crystallisation from EtOAc.


¹H (CDCl₃, 300 MHz) δ 1.05-1.15 (9H, s), 1.8-1.95 (1H, m), 2.1-2.25 (1H, m), 2.35-2.55 (2H, m), 3.9-4.0 (1H, m), 5.4-5.6 (1H, br s), 5.6-5.8 (1H, br s), 5.85 (1H, d), 8.2 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.8 (1H, s) ppm.

LRMS 462 (MH⁺), 479 (MNH₄⁺).

Anal. Found: C, 46.66; H, 4.54; N, 8.96. Calc for C₁₈H₂₁Cl₂N₃O₅S: C, 46.75; H, 4.58; N, 9.09.

Preparation 85:

N-[(1,4-Dichloro-7-isoquinolinyl)sulphonyl]-cyclopentylamin



1,4-Dichloro-7-isoquinolinylsulphonyl chloride (250 mg, 0.84 mmol) was added to a solution of cyclopentylamine (100 μ l, 1.0 mmol) and triethylamine (170 μ l, 1.22 mmol) in CH_2Cl_2 (15 ml), and the reaction stirred at room temperature for 18 h. The solution was diluted with CH_2Cl_2 , washed with 2M hydrochloric acid, saturated aqueous Na₂CO₃ solution and then brine. This solution was dried (MgSO₄), and evaporated *in vacuo*, to give *N*-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-cyclopentylamine (250 mg, 0.72 mmol) as a white crystalline solid.

^1H (CDCl_3 , 300MHz) δ 1.4 (2H, m), 1.5-1.7 (4H, m), 1.85 (2H, m), 3.75 (1H, m), 4.6 (1H, d), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.95 (1H, s) ppm.


LRMS 346 (MH^+)

5

Anal. Found: C, 48.68; H, 4.02; N, 7.97. Calc. for $\text{C}_{14}\text{H}_{14}\text{Cl}_2\text{N}_2\text{O}_2\text{S}$: C, 48.71; H, 4.09; N, 8.11%.

Preparation 86:

10 1,4-Dichloro-7-(1-pyrrolidinylsulphonyl)isoquinoline



Pyrrolidine (96 mg, 1.35 mmol) was added to a solution of 1,4-dichloro-7-
15 isoquinolinylsulphonyl chloride (20 mg, 0.67 mmol) in CH_2Cl_2 (5 ml), and the reaction
stirred at room temperature for 72 h. The mixture was concentrated *in vacuo*, and the residual
solid triturated with water, filtered and dried. The crude product was purified by column
chromatography upon silica gel using EtOAc-hexane (50:50) as eluant, and recrystallised
from $i\text{-Pr}_2\text{O}$, to give 1,4-dichloro-7-(1-pyrrolidinylsulphonyl)isoquinoline (67 mg, 0.20
20 mmol) as a white solid,


^1H (CDCl_3 , 300MHz) δ 1.8 (4H, m), 3.35 (4H, m), 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.85
(1H, s) ppm.

25 LRMS : 331, 333 (MH^+)

Anal. Found: C, 47.23; H, 3.60; N, 8.32. Calc. for $\text{C}_{13}\text{H}_{12}\text{N}_2\text{Cl}_2\text{O}_2\text{S}$: C, 47.14; H, 3.65; N,
8.46%.

30 Preparation 87:

tert-Butyl (2*R*)-1-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-2-piperidinecarboxylate



Concentrated H_2SO_4 (2.0 ml) was added to an ice-cold solution of 2-(R)-piperidine
 carboxylic acid (415 mg, 3.21 mmol) in dioxan (10 ml). Condensed isobutylene (40 ml) was
 5 carefully added, and the reaction stirred at room temperature in a sealed vessel for 21 h. The
 reaction mixture was poured into an ice-cooled solution of Et_2O (100 ml) and 5N NaOH (20
 ml), the mixture allowed to warm to room temperature with stirring, and then diluted with
 water. The phases were separated, the organic layer washed with 1N NaOH, then
 concentrated *in vacuo*, to half the volume, and extracted with 2N HCl. The combined acidic
 10 extracts were basified using 1N NaOH, and extracted with CH_2Cl_2 , the combined organic
 solutions dried (MgSO_4) and evaporated *in vacuo* to afford *tert*-butyl 2(R)-piperidine
 carboxylate (210 mg, 1.14 mmol) as an oil.

^1H (CDCl_3 , 300MHz) δ 1.4-1.6 (11H, m), 1.75 (3H, m), 1.9 (1H, m), 2.65 (1H, m), 3.1 (1H,
 15 m), 3.2 (1H, m) ppm.

LRMS 186 (MH^+).

1,4-Dichloro-7-isoquinolinesulphonyl chloride (245 mg, 0.83 mmol) was added to a solution
 20 of *tert*-butyl 2(R)-piperidine carboxylate (153 mg, 0.83 mmol) and triethylamine (170 μl ,
 1.22 mmol) in CH_2Cl_2 (15 ml), and the reaction stirred at room temperature for 18 h. The
 solution was diluted with CH_2Cl_2 , washed with 2M hydrochloric acid, saturated Na_2CO_3
 solution and then brine, dried (MgSO_4), and evaporated *in vacuo*. The residual oil was
 purified by column chromatography upon silica gel using an elution gradient of pentane-
 25 EtOAc (100:0 to 90:10), to give *tert*-butyl 2(R)-1-[(1,4-dichloro-7-isoquinolinesulphonyl)]-
 2-piperidinecarboxylate, (290 mg, 0.65 mmol) as a colourless film.

^1H (CDCl_3 , 400MHz) δ 1.3 (9H, s), 1.55 (2H, m), 1.7-1.85 (3H, m), 2.2 (1H, m), 3.3 (1H, dd),
 3.9 (1H, dd), 4.75 (1H, d), 8.15 (1H, d), 8.35 (1H, dd), 8.45 (1H, s), 8.8 (1H, s) ppm.


30

LRMS 462, 464 (MNH_4^+)

Anal. Found: C, 50.99; H, 4.95; N, 6.10. Calc. For $C_{19}H_{22}Cl_2N_2O_4S$; C, 51.24; H, 4.98; N, 6.29%.

Preparation 88:

- 5 Methyl 4-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino]-1-methyl-4-piperidinecarboxylate



A solution of 4-amino-1-methyl-4-piperidinecarboxylic acid (4.0 g, 15.6 mmol) in
 10 methanolic HCl (100 ml) was stirred under reflux for 20 h. The cooled mixture was
 concentrated *in vacuo* and azeotroped with CH_2Cl_2 to give an oil. This was dissolved in ice-
 cold Na_2CO_3 solution and extracted with CH_2Cl_2 (2 x). The combined organic extracts were
 dried ($MgSO_4$) and evaporated *in vacuo* to afford 4-amino-1-methyl-4-piperidinecarboxylate
 (1.6g, 9.3 mmol) as an oil.

15

1H ($CDCl_3$, 400MHz) δ 1.4-1.65 (4H, m), 2.1-2.25 (2H, m), 2.35 (3H, s), 2.4-2.55 (4H, m),
 3.75 (3H, s) ppm.

LRMS 173 (MH^+)

20


1,4-Dichloro-7-isoquinoliny]sulphonyl chloride (1.0 g, 3.37 mmol) was added to a solution of
 methyl 4-amino-1-methyl-4-piperidinecarboxylate (700 mg, 4.0 mmol) and triethylamine
 (700 μ l, 1.0 mmol) in CH_2Cl_2 (60 ml), and the reaction stirred at room temperature for 18 h.
 The mixture was concentrated *in vacuo*, and the residue purified by column chromatography
 25 upon silica gel using an elution gradient of CH_2Cl_2 -MeOH-0.880 NH_3 (97:3:0.3 to 95:5:0.5)
 to give methyl 4-[[[(1,4-dichloro-7-isoquinoliny]sulphonyl]amino]-1-methyl-4-
 piperidinecarboxylate (700 mg, 1.62 mmol) as a white solid.

1H ($CDCl_3$, 400MHz) δ 2.05 (2H, m), 2.25 (6H, m), 2.4 (2H, m), 2.55 (2H, m), 3.5 (3H, s),
 30 8.25 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.85 (1H, s) ppm.

LRMS 432, 434 (MH^+)

Preparation 89:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-N-(methyl)cycloleucine ethyl ester



K₂CO₃ (238 mg, 1.73 mmol) was added to a solution of N-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-cycloleucine ethyl ester (300 mg, 0.72 mmol) in DMF (5 ml), and the mixture stirred at room temperature for 40 min. Methyl iodide (47 µl, 0.76 mmol) was added and the reaction stirred for a further 30 min. at room temperature. The mixture was poured into water, extracted with EtOAc, and the combined organic extracts washed with water, then brine, dried (Na₂SO₄) and evaporated *in vacuo*. The residual yellow solid was purified by column chromatography upon silica gel using EtOAc-hexane (20:80) as eluant to give N-[(1,4-dichloro-7-isoquinoliny)sulphonyl]-N-(methyl)cycloleucine ethyl ester (204 mg, 0.47 mmol) as a white solid.


¹H (CDCl₃, 400MHz) δ 1.25 (3H, t), 1.75 (4H, m), 2.1 (2H, m), 2.4 (2H, m), 3.05 (3H, s), 4.2 (2H, q), 8.25 (1H, d), 8.35 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.

20 LRMS 431, 433 (MH⁺)

Anal. Found: C, 50.12; H, 4.66; N, 6.43. Calc. for C₁₈H₂₀Cl₂N₂O₄S: C, 50.12; H, 4.67; N, 6.49%.

25 Preparation 90:

4-Bromo-1-chloro-7-isoquinolinesulphonyl chloride



A suspension of isoquinolinol (10 g, 68.9 mmol) in MeCN (250 ml) at 50°C, was treated with *N*-bromosuccinimide (12.6 g, 70.8 mmol) whereupon almost complete solution occurred before a thick white precipitate was formed. After heating under reflux for 3 h, the reaction mixture was cooled in ice and the solid filtered, washed with MeCN, and dried to afford 4-bromo-1-(2*H*)-isoquinolone (7.6 g, 34.0 mmol).

¹H (DMSO-*d*₆, 300MHz) δ 7.55 (1H, s), 7.6 (1H, m), 7.75 (1H, d), 7.85 (1H, m), 8.2 (1H, d), 11.55 (1H, br s) ppm.

LRMS 223, 225 (MH⁺).

4-Bromo-1-(2*H*)-isoquinolone (7.5 g, 33.0 mmol) was added portionwise to chlorosulphonic acid (23 ml, 346 mmol) and the resultant solution heated to 100°C for 2 ½ days. After cooling, the reaction mixture was poured carefully onto ice to give a white solid which was filtered, washed with water, MeCN, and Et₂O and air-dried to give a cream solid. 4-Bromo-1-oxo-1,2-dihydro-7-isoquinolinesulphonyl chloride (~13.5 g) was immediately used without further drying.

mp >300°C.

¹H (DMSO-*d*₆, MHz) δ 7.45 (1H, s), 7.7 (1H, d), 8.0 (1H, d), 8.45 (1H, s), 11.55 (1H, br s) ppm.

To a stirred solution of 4-bromo-1-oxo-1,2-dihydro-7-isoquinolinesulphonyl chloride (~13.5 g) in acetonitrile (200 ml) was added portionwise POCl₃ (10 ml, 110 mmol). The resultant heterogeneous mixture was heated under reflux for 24 h, allowed to cool, and the supernatant decanted from the brown oily residues and concentrated to a solid. Extraction of the solid into EtOAc gave, after solvent removal, a sticky solid which was triturated with Et₂O to afford the title compound (3.83 g, 11.0 mmol) as a white solid.

mp 120.5-121°C.

¹H (DMSO-*d*₆, 300MHz) δ 8.2 (2H, m), 8.5 (1H, s), 8.6 (1H, s) ppm.


Anal. Found: C, 31.21; H, 1.27; N, 4.08. Calc for C₉H₄BrCl₂NO₂S•0.25H₂O:

C, 31.29; H, 1.31; N, 4.05.

Preparation 91:

N-[(4-Bromo-1-chloro-7-isoquinoliny)lsulphonyl]-D-proline *tert*-butyl ester

5



4-Bromo-1-chloro-7-isoquinolinesulphonyl chloride (400 mg, 1.17 mmol) in CH_2Cl_2 (20 ml) was treated with (D)-proline *tert*-butyl ester hydrochloride (250 mg, 1.20 mmol) and triethylamine (410 μl , 2.94 mmol) and stirred at room temperature for 2 h. The reaction was diluted with CH_2Cl_2 , washed consecutively with water, 10% aqueous citric acid and brine, and then dried (MgSO_4) and concentrated *in vacuo* to give an off-white solid.

10

This was purified by column chromatography upon silica gel eluting with EtOAc - hexane (16:84) to give *N*-[(4-bromo-1-chloro-7-isoquinoliny)lsulphonyl]-D-proline *tert*-butyl ester (350 mg, 0.74 mmol) as a white solid.

15

mp 128.5-129.5°C.

^1H (CDCl_3 , 300MHz) δ 1.1 (9H, s), 1.85-2.0 (3H, m), 2.2 (1H, m), 3.5 (2H, m), 4.4 (1H, dd), 8.3 (2H, m), 8.6 (1H, s), 8.9 (1H, s) ppm.

20


LRMS 475, 477 (MH^+).

Anal. Found: C, 45.41; H, 4.21; N, 5.83. Calc for $\text{C}_{18}\text{H}_{20}\text{BrClN}_2\text{O}_4\text{S}$: C, 45.44; H, 4.24; N, 5.89.

25

Preparation 92:

N-{[(4-Bromo-1-chloro-7-isoquinoliny)lsulphonyl]-N-[2-(dimethylamino)ethyl]cycloleucine ethyl ester hydrochloride



Triethylamine (1.02 ml, 7.33 mmol) was added to a solution of 4-bromo-1-chloroisoquinolinesulphonyl chloride (1.0 g, 2.93 mmol) in CH_2Cl_2 (25 ml) and the reaction stirred at room temperature for 2 h. The reaction was washed consecutively with 1N HCl, Na_2CO_3 solution, and brine, then dried (Na_2SO_4) and evaporated *in vacuo*. The residual oil was crystallised from CH_2Cl_2 -*i*- Pr_2O to give N-[[[4-bromo-1-chloro-7-isoquinoliny]sulphonyl]cycloleucine ethyl ester (380 mg, 0.82 mmol) as a solid.

^1H (CDCl_3 , 300MHz) δ 1.2 (3H, t), 1.6-1.8 (4H, m), 2.0 (2H, m), 2.15 (2H, m), 4.05 (2H, q), 8.25 (1H, d), 8.35 (1H, d), 8.6 (1H, s), 8.9 (1H, s) ppm.

LRMS 484 (MNa^+)

K_2CO_3 (157 mg, 1.14 mmol) was added to a solution of N-[[[4-bromo-1-chloro-7-isoquinoliny]sulphonyl]cycloleucine ethyl ester (300 mg, 0.65 mmol) in DMF (5 ml), and the solution stirred for 5 min. N,N-dimethylaminoethyl chloride hydrochloride (112 mg, 0.78 mmol) was added and the reaction stirred at room temperature for 36 h. The reaction mixture was partitioned between water and EtOAc, the layers separated, and the aqueous phase extracted with EtOAc. The combined organic solutions were washed with brine, dried (Na_2SO_4) and evaporated *in vacuo*. The residue was purified by column chromatography upon silica gel using CH_2Cl_2 -MeOH-0.880 NH_3 (95:5:0.5) as eluant, to give a gum. This was dissolved in an Et_2O -EtOAc solution, ethereal HCl added and the mixture evaporated *in vacuo*. The resulting solid was triturated with water, filtered and dried to give N-[[[4-bromo-1-chloro-7-isoquinoliny]sulphonyl]-N-(2-(dimethylamino)ethyl)cycloleucine ethyl ester hydrochloride (90 mg, 0.16 mmol) as a solid.


^1H (CDCl_3 , 300MHz) δ 1.3 (3H, t), 1.65 (2H, m), 1.8 (2H, m), 2.15 (2H, m), 2.4 (2H, m), 2.9 (6H, m), 3.6 (2H, m), 4.0 (2H, m), 4.2 (2H, q), 8.2 (1H, d), 8.4 (1H, d), 8.65 (1H, s), 8.80 (1H, s) ppm.

LRMS 534 (MH^+)

Anal Found: C, 44.17; H, 4.97; N, 7.24. Calc. for $C_{21}H_{27}BrClN_3O_4S \cdot HCl$: C, 44.30; H, 4.96; N, 7.38%.

5 Preparation 93:

Ethyl 3-[(1,4-dichloro-7-isoquinoliny)sulphonyl]amino}-2,2-dimethylpropanoate hydrochloride



10

The title compound was obtained as a white solid (86%) from 1,4-dichlorosulphonyl chloride and ethyl 3-amino-2,2-dimethylpropanoate hydrochloride, following a similar procedure to that described in preparation 90.

15 1H ($CDCl_3$, 300MHz) δ 1.25 (9H, m), 3.0 (2H, d), 4.1 (2H, q), 5.4 (1H, t), 8.2 (1H, d), 8.4 (1H, d), 8.5 (1H, s), 8.9 (1H, s) ppm.


LRMS 404, 406 (MH^+)

20 Anal. found : C, 47.39; H, 4.44; N, 6.73. Calc. for $C_{16}H_{18}Cl_2N_2O_4S$: C, 47.42; H, 4.48; N, 6.91%.

Preparation 94:

N-[(1,4-Dichloro-7-isoquinoliny)sulphonyl]-N-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]cycloleucine ethyl ester

25



K₂CO₃ (238 mg, 1.73 mmol) was added to a solution of N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]cycloleucine ethyl ester (600 mg, 1.44 mmol) in DMF (10 ml), and the suspension stirred at room temperature for 30 min. A solution of 2-(2-bromoethoxy)tetrahydro-2H-pyran (J.C.S. 1948; 4187) (316 mg, 1.44 mmol) in DMF (4 ml) was added, followed by sodium iodide (10 mg), and the reaction stirred at 70°C for 23 h. The cooled mixture was poured into water, and extracted with EtOAc. The combined organic extracts were washed with brine, dried (MgSO₄), and evaporated *in vacuo*. The residual yellow oil was purified by column chromatography upon silica gel using hexane-Et₂O (75:25) as eluant, azeotroped with CH₂Cl₂ and dried under vacuum to afford N-[(1,4-dichloro-7-isoquinolinyl)sulphonyl]-N-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]cycloleucine ethyl ester (341 mg, 0.63 mmol) as a solid.


¹H (CDCl₃, 400MHz) δ 1.3 (3H, t), 1.55 (4H, m), 1.65-1.8 (6H, m), 2.15 (2H, m), 2.4 (2H, m), 3.5 (1H, m), 3.7 (3H, m), 3.8 (1H, m), 3.95 (1H, m), 4.2 (2H, q), 4.55 (1H, m), 8.35 (2H, s), 8.45 (1H, s), 8.9 (1H, s) ppm.

LRMS 545 (MH⁺), 562 (MNH₄⁺)

Anal. Found: C, 52.31; H, 5.58; N, 4.84. Calc. for C₂₄H₃₀Cl₂N₂O₆S•0.3H₂O: C, 52.33; H, 5.60; N, 5.09%.

Preparation 95:

N-[(1,4-dichloro-7-isoquinolinyl)methyl]cycloleucine methyl ester



7-Chloromethyl-1,4-dichloro-isoquinoline (400 mg, 1.62 mmol) was added to a suspension of cycloleucine methyl ester (255 mg, 1.78 mmol), K₂CO₃ (500 mg, 3.62 mmol) and sodium iodide (15 mg) and the resultant mixture heated to 75°C for 2 ½ h. After cooling, the reaction mixture was poured into water and extracted with CH₂Cl₂ (2 x 60 ml). The organic extracts were washed with water, brine, dried (Na₂SO₄) and concentrated *in vacuo* to give an oil. This

was purified by column chromatography upon silica gel eluting with hexane - EtOAc (85 : 15) to give N-[(1,4-dichloro-7-isoquinoliny)methyl]cycloleucine methyl ester (414 mg, 1.17 mmol) as a yellow oil.


A sample of this oil was treated with ethereal HCl, and the mixture evaporated to give the hydrochloride salt of the title compound as a white solid.

^1H (CDCl₃, 300MHz) δ 1.4-1.8 (5H, m), 2.0 (3H, m), 3.75 (3H, s), 4.15 (2H, s), 8.25 (3H, m), 8.5 (1H, s), 10.5 (2H, br s) ppm.

Anal. found: C, 52.53; H, 4.99; N, 6.84. Calc. for C₁₇H₁₈Cl₂N₂O₂•HCl: C, 52.39; H, 4.91; N, 7.19%.

Preparation 96:

(1-Aminocyclopentyl)(4-methyl-1-piperazinyl)methanone dihydrochloride



1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.49 g, 13.0 mmol) was added portionwise to a cooled (4°C) solution of hydroxybenzotriazole hydrate (1.49 g, 11.0 mmol) and 1-[(*tert*-butoxycarbonyl)amino]cyclopentanecarboxylic acid (2.29 g, 10.0 mmol) in DMF (15 ml), and the mixture stirred for 30 min. N-Methylpiperazine (1.10 g, 11.0 mmol) was added, the reaction stirred for 30 min. allowed to warm to room temperature and stirring continued for a further 17 h. The reaction mixture was evaporated *in vacuo*, and the residual yellow oil partitioned between saturated Na₂CO₃ solution and EtOAc. The layers were separated, the aqueous phase extracted with EtOAc, and the combined organic solutions dried (MgSO₄) and concentrated *in vacuo*. The residual solid was pre-adsorbed onto silica gel and purified by column chromatography upon silica gel using an elution gradient of CH₂Cl₂-MeOH-0.880 NH₃ (97.5:2.5:0.25 to 90:10:1) and triturated with Et₂O to afford *tert*-butyl 1-[(4-methyl-1-piperazinyl)carbonyl]cyclopentylcarbamate (2.31 g, 7.4 mmol) as a crystalline solid.

mp 171-175°C

¹H (CDCl₃, 300MHz) δ 1.4 (9H, s), 1.7 (6H, m), 2.25 (3H, s), 2.4 (6H, m), 3.65 (4H, m), 4.7 (1H, br s).

LRMS 312 (MH⁺)

5

A suspension of *tert*-butyl 1-[(4-methyl-1-piperazinyl)carbonyl]cyclopentylcarbamate (2.2 g, 7.06 mmol) in EtOAc (120 ml) at 4°C was saturated with HCl gas, and the reaction then stirred for 4 h. The mixture was azeotroped with EtOAc, then dry Et₂O, and dried under vacuum to afford (1-aminocyclopentyl)(4-methyl-1-piperazinyl)methanone dihydrochloride (2.1 g) as a white solid.

10

mp 267-270°C (Decomp)


Anal. Found: C, 43.29; H, 7.99; N, 13.84. Calc. for C₁₁H₂₁N₃O•2HCl•H₂O: C, 43.71; H, 8.34; N, 13.90%.

15

LRMS 212 (MH⁺)

CLAIMS

1. A compound of formula (I) :-



(I)

5

and pharmaceutically acceptable salts thereof, wherein:

G is $\text{N}=\text{C}(\text{NH})_2$ or $\text{NHC}(=\text{NH})\text{NH}_2$;

10 R^1 is H or halo;

X is CO, CH_2 or SO_2 ;

15 R^2 is H, aryl, heteroaryl, C_{3-7} cycloalkyl or C_{1-6} alkyl each of which C_{3-7} cycloalkyl and C_{1-6} alkyl is optionally substituted by one or more substituents independently selected from halo, aryl, het, C_{3-7} cycloalkyl, C_{5-7} cycloalkenyl, OH, C_{1-6} alkoxy, O-het¹, C_{1-3} alkyl, CO_2R^7 and NR^4R^5 ;


20 X^1 is arylene, C_{1-6} alkylene optionally substituted by one or more R^6 group, or cyclo(C_{4-7})alkylene optionally substituted by R^6 , which cyclo(C_{4-7})alkylene ring can optionally contain a hetero moiety selected from O, $\text{S}(\text{O})_p$ or NR^7 ;

or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring;


25 R^3 is CO_2R^7 , CH_2OH , CONR^8R^9 or $\text{CH}_2\text{NR}^8\text{R}^9$;

or, when X^1 is taken independently from R^2 and is methylene optionally substituted by one or more R^6 group, or is a 1,1-cyclo(C_{4-7})alkylene optionally containing a hetero moiety selected from O, S(O)_p, or NR⁷ and optionally substituted by R^6 ,

then R^2 and R^3 can be taken together with the N and X^1 groups to which they are attached, as a group of formula (IA) or (IB):



(IA)



(IB)

wherein X^2 is ethylene, n-propylene or n-butylene;

R^4 and R^5 are each independently H, aryl or C_{1-6} alkyl optionally substituted by aryl;

R^6 is halo, OH, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{3-7} cycloalkyl, SH, aryl, CO_2R^7 , $CONHR^8$, or C_{1-6} alkyl optionally substituted by aryl, C_{1-6} alkoxy, CO_2H , OH, $CONR^8R^9$ or by NR^8R^9 ;

R^7 is H or C_{1-6} alkyl;

R^8 and R^9 are either each independently H, or C_{1-6} alkyl optionally substituted by OH, CO_2R^7 , C_{1-6} alkoxy or by NR^4R^5 ;

or R^8 and R^9 can be taken together with the N atom to which they are attached, to form a 4- to 7-membered ring optionally incorporating an additional hetero- group selected from O, S and NR⁷;

p is 0, 1 or 2;

"aryl" is phenyl optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, or halo;

"het" is a saturated or partly or fully unsaturated 5- to 7-membered heterocycle containing up to 3 hetero-atoms independently selected from O, N and S, and which is optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, CO_2R^7 or halo;

"heteroaryl" is a fully unsaturated 5- to 7-membered heterocycle containing up to 3 hetero-atoms independently selected from O, N and S, and which is optionally substituted by one or more substituents independently selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, CO₂R⁷ or halo;

5 "het¹" is tetrahydropyran-2-yl (2-THP);

and "arylene" is phenylene optionally substituted by one or more substituents independently selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, CO₂R⁷ or halo.

10 2. A compound or salt according to any previous claim wherein R¹ is halo.

3. A compound or salt according to any previous claim wherein X is SO₂.

15 4. A compound or salt according to any previous claim wherein R² is H, C₃₋₇ cycloalkyl or C₁₋₆ alkyl each of which C₃₋₇ cycloalkyl and C₁₋₆ alkyl is optionally substituted by aryl, het, C₃₋₇ cycloalkyl, OH, Ohet¹, C₁₋₆ alkoxy, CO₂H, CO₂(C₁₋₆ alkyl) or by NR⁴R⁵, or R² and X¹ can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.

20 5. A compound or salt according to any previous claim wherein X¹ is phenylene optionally substituted by one or two substituents independently selected from methoxy and halo, or is C_{1,3} alkylene optionally substituted by one or more group selected from aryl or (C₁₋₆ alkyl optionally substituted by aryl, C₁₋₆ alkoxy, CO₂H, OH, NH₂ or CONH₂), or is cyclo(C₄₋₇)alkylene optionally containing a hetero moiety selected from O or NR⁷, which ring is optionally substituted by R⁶,
25 or is taken together with R² and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.

6. A compound or salt according to any previous claim wherein R³ is CO₂R⁷ or CONR⁸R⁹.

30 7. A compound or salt according to any previous claim wherein preferably R¹ is chloro or bromo.

8. A compound or salt according to any previous claim wherein R² is H, C₁₋₃ alkyl optionally substituted by aryl or by optionally substituted pyridyl or by NR⁴R⁵ or by HO or by Ohet¹, or R² and

X¹ can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring.

9. A compound or salt according to any previous claim wherein X¹ is methylene optionally substituted
5 by one or more group selected from aryl or (C₁₋₄ alkyl optionally substituted by OH, NH₂ or CONH₂),
or is cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, tetrahydropyranylene,
piperidinylene substituted by R⁷,
or is taken together with R² and with the N atom to which they are attached to form an azetidine,
pyrrolidine, piperidine or homopiperidine ring.

10

10. A compound or salt according to any previous claim wherein R³ is CO₂H, CONH₂,
CON(CH₃)(CH₂)₂OH, CON(CH₃)(CH₂)₂NHCH₃, CO₂(C₁₋₃alkyl), CONH(CH₂)₂OH,
CONH(CH₂)₂OCH₃, (morpholino)CO or (4-methylpiperazino)CO.

15

11. A compound or salt according to any previous claim wherein R¹ is chloro.

12. A compound or salt according to any previous claim wherein R² is H, CH₂CH₂N(CH₃)₂, CH₃,
CH₂CH₂OH, CH₂CH₂O(2-THP), pyridinylmethyl, benzyl or methoxybenzyl, or R² and X¹ can be
taken together with the N atom to which they are attached to form an azetidine, pyrrolidine,
20 piperidine or homopiperidine ring linked to the R³ moiety via the 2-position of said ring.

13. A compound or salt according to any previous claim wherein X¹ is C(CH₃)₂, 1,1-cyclopentylene,
4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, CH₂, CH(CH(CH₃)₂), CH(CH₂)₄NH₂,
CH(CH₂)₃NH₂, CH(CH₂)CONH₂, 1,1-cyclobutylene, 1,1-cyclopentylene, 1,1-cyclohexylene, 1,1-
25 cycloheptylene, or is taken together with R² and with the N atom to which they are attached to form
an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R³ moiety via the 2-
position.


14. A compound or salt according to any previous claim wherein R³ is CO₂H.

30


15. A compound or salt according to any previous claim wherein R² is H, CH₂CH₂N(CH₃)₂, CH₃,
CH₂CH₂OH, CH₂CH₂O(2-THP) or R² and X¹ are taken together with the N atom to which they are
attached to form a pyrrolidine ring linked to the R³ moiety via the 2-position.

16. A compound or salt according to any previous claim wherein X^1 is $C(CH_3)_2$, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, or is taken together with R^2 and with the N atom to which they are attached to form an azetidine, pyrrolidine, or piperidine ring linked to the R^3 moiety via the 2-position.

17. A compound or salt according to claim 1 where X is SO_2 in which the $R^3-X^1-NR^2$ - moiety is, where X^1 is taken independently from R^2 and is methylene optionally substituted by one or more R^6 group, or is a 1,1-cyclo(C_{4-7})alkylene optionally containing a hetero moiety selected from O, $S(O)_p$, or NR^7 and optionally substituted by R^6 , and R^2 and R^3 can be taken together with the N and X^1 groups to which they are attached, a group of formula (IA) or (IB):



(IA)



(IB)

wherein X^2 is ethylene, n-propylene or n-butylene.

15

18. A compound or salt according to claim 17 wherein X^1 is $C(CH_3)_2$, 1,1-cyclobutylene, 1,1-cyclopentylene, 1,1-cyclohexylene, 4,4-tetrahydropyranylene or *N*-methyl-4,4-piperidinylene.
19. A compound or salt according to claim 17 or 18 wherein X^2 is ethylene.
20. A compound or salt according to claim 1 wherein the substituents R^1 , X, R^2 , X^1 and R^3 have the values as described by the Examples.
21. A compound or salt according to claim 1 wherein R^1 is chloro or bromo; X is SO_2 ;
- 25 R^2 is H, $CH_2CH_2N(CH_3)_2$, CH_3 , CH_2CH_2OH , $CH_2CH_2O(2-THP)$, pyridinylmethyl, benzyl or methoxybenzyl, or R^2 and X^1 can be taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R^3 moiety via the 2-position of said ring;
- X^1 is $C(CH_3)_2$, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, *N*-methyl-4,4-piperidinylene, CH_2 ,
- 30 $CH(CH(CH_3)_2)$, $CH(CH_2)_4NH_2$, $CH(CH_2)_3NH_2$, $CH(CH_2)CONH_2$, 1,1-cyclobutylene, 1,1-

cyclopentylene, 1,1-cyclohexylene, 1,1-cycloheptylene, N-methyl-4,4-piperidinylenes, 4,4-tetrahydropyranylene, or is taken together with R² and with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine or homopiperidine ring linked to the R³ moiety via the 2-position;

- 5 and R³ is CO₂H, CONH₂, CON(CH₃)(CH₂)₂OH, CON(CH₃)(CH₂)₂NHCH₃, CO₂(C₁₋₃alkyl), CONH(CH₂)₂OH, CONH(CH₂)₂OCH₃, (morpholino)CO or (4-methylpiperazino)CO.

22. A compound or salt according to claim 1 wherein R¹ is chloro; X is SO₂;

R² if taken independently, is H, CH₂CH₂N(CH₃)₂, CH₃, CH₂CH₂OH, CH₂CH₂O(2-THP);

- 10 X¹ when taken independently, is C(CH₃)₂, 1,1-cyclopentylene, 4,4-tetrahydropyranylene, N-methyl-4,4-piperidinylenes,

or X¹ and R² are taken together with the N atom to which they are attached to form an azetidine, pyrrolidine, piperidine ring linked to the R³ moiety via the 2-position;

and R³ is CO₂H.

15

23. A compound or salt selected from the compounds of the Examples and the salts thereof.

24. A compound or salt selected from:

N-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-D-proline;

- 20 2-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]isobutyric acid;

1-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]cyclobutanecarboxylic acid;

N-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]cycloleucine;

N-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]cycloleucine;

1-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]-N-(2-

- 25 hydroxyethyl)cyclopentanecarboxamine;

1-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]-N-[2-(dimethylamino)ethyl]cyclopentanecarboxamine;

1-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]-N-[2-(dimethylamino)ethyl]cyclopentanecarboxamine;

- 30 N-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-N-[2-(dimethylamino)ethyl]cycloleucine;


1-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]cyclohexanecarboxylic acid;

4-[[[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]amino]tetrahydro-2H-pyran-4-carboxylic acid;

tert-butyl (2R)-1-[(4-chloro-1-guanidino-7-isoquinoliny)l]sulphonyl]-2-piperidinecarboxylate;

- (2R)-1-({4-chloro-1-guanidino-7-isoquinolinyl}sulphonyl)-2-piperidinecarboxylic acid;
1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-hydroxyethyl)-N-methylcyclopentanecarboxamide;
1-[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino]-N-(2-methoxyethyl)cyclopentanecarboxamide;
4-chloro-1-guanidino-N-[1-(morpholinocarbonyl)cyclopentyl]-7-isoquinolinesulphonamide;
4-chloro-1-guanidino-N-[1-[(4-methylpiperazino)carbonyl]cyclopentyl]-7-isoquinolinesulphonamide;
N-({4-bromo-1-guanidino-7-isoquinolinyl}sulphonyl)-N-[2-(dimethylamino)ethyl]cycloleucine;
1-[[{(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl][2-(tetrahydro-2H-pyran-2-yloxy)ethyl]amino}cyclopentanecarboxylic acid; and
N"-{4-chloro-7-[(10-oxo-9-oxa-6-azaspiro[4.5]dec-6-yl)sulphonyl]-1-isoquinolinyl}guanidine;
and the pharmaceutically acceptable salts thereof.
- 15 25. A pharmaceutical composition comprising a compound or salt according to any previous claim and a pharmaceutically acceptable adjuvant, diluent or carrier.
26. A compound or salt according to any one of claims 1 to 24 for use as a medicament.
- 20 27. The use of a compound or salt according to any one of claims 1 to 24 in the manufacture of a medicament for the treatment of a uPA-mediated condition or process.
28. A method of treating a condition or process mediated by uPA which comprises administering an effective amount of a compound or salt according to any one of claims 1 to 24, or composition
25 according to claim 25.
29. A process to make a compound of formula (I) or salt thereof according to claim 1, which comprises reaction of the corresponding 1-aminoisoquinoline derivative (II):


218




with cyanamide (NH_2CN) or a reagent which acts as a " $\text{NHC}^+=\text{NH}$ " synthon, wherein R^1 , R^2 , R^3 , X and X^1 are as defined in claim 1.

5


30. A process to make a compound of formula (I) or salt thereof according to claim 1, which comprises reaction of the corresponding 1-aminoisoquinoline derivative (II):



10 wherein R^1 , R^2 , R^3 , X and X^1 are as defined in claim 1, with a reagent which acts as a protected amidine(2+) synthon (III):



to give an intermediate of formula (IV):




15

where G^1 is a protected guanidine moiety $N=C(NHP)(NHP_1)$ or tautomer thereof, where P and P_1 are nitrogen-protecting groups such as t-butoxycarbonyl ("Boc"), benzyl, benzyloxycarbonyl, etc., which can conveniently be deprotected to give the compound of formula (I) or a salt thereof.

5

31. A process to make a compound of formula (I) or salt thereof according to claim 1, which comprises reaction of the corresponding compound of formula (V):




wherein R^1 , R^2 , R^3 , X and X^1 are as defined in claim 1, and Z is a suitable leaving group such as Cl,

10

Br or OPh, by displacement of the leaving group by the free base of guanidine.

32. A compound of formula (II):




15

wherein R^1 , R^2 , R^3 , X and X^1 are as defined in claim 1, or salt thereof.

33. A compound of formula (IV):

220




(IV)

where R^1 , R^2 , R^3 , X and X^1 are as defined in claim 1, and G^1 is a protected guanidine moiety $N=C(NHP)(NHP_1)$ or tautomer thereof, where P and P_1 are nitrogen-protecting groups

5

34. A compound of formula (V):



(V)

10 where R^1 , R^2 , R^3 , X and X^1 are as defined in claim 1, and Z is a leaving group.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 February 2000 (03.02.2000)

PCT

(10) International Publication Number
WO 00/05214 A3

(51) International Patent Classification⁷: C07D 217/22,
401/12, 403/12, A61K 31/435

Paul, Vincent [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(21) International Application Number: PCT/IB99/01289

(74) Agent: SPIEGEL, Allen, J.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(22) International Filing Date: 15 July 1999 (15.07.1999)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:
9816228.2 24 July 1998 (24.07.1998) GB
9908829.6 16 April 1999 (16.04.1999) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except GB, US*):
PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(71) Applicant (*for GB only*): PFIZER LIMITED [GB/GB];
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

Published:

— With international search report.


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BARBER, Christopher, Gordon [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DICKINSON, Roger, Peter [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). FISH,

(88) Date of publication of the international search report:
31 May 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ISOQUINOLINES AS UROKINASE INHIBITORS



(57) Abstract: Isoquinolinylguanidine compounds of formula (I): wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.

WO 00/05214 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/01289

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D217/22 C07D401/12 C07D403/12 A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 99 20608 A (PFIZER LIMITED) 29 April 1999 (1999-04-29) the whole document ---	1,25,32
P,A	WO 99 05096 A (ABBOTT LABORATORIES) 4 February 1999 (1999-02-04) page 213 -page 225; claims 1-16 ---	1,25,32
A	WO 98 11089 A (FUJISAWA PHARMACEUTICAL CO. LTD.) 19 March 1998 (1998-03-19) the whole document ---	1,25
A	EP 0 568 289 A (EISAI CO. LTD.) 3 November 1993 (1993-11-03) the whole document ---	1,25
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 January 2000

Date of mailing of the international search report

01/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/IB 99/01289

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCHNEUR RACHLIN ET AL.: "Basic antiinflammatory Compounds. N,N', N''-Trisubstituted guanidines"</p> <p>J. MED. CHEM., vol. 23, 1980, page 13-20 XP002059265 columbus ohio the whole document</p> <p>-----</p>	1,25,32

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 99/01289

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 28
is are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01289

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9920608 A	29-04-1999	AU 1150899 A	10-05-1999
WO 9905096 A	04-02-1999	AU 8587498 A	16-02-1999
WO 9811089 A	19-03-1998	EP 0927177 A	07-07-1999
EP 568289 A	03-11-1993	US 5340833 A	23-08-1994
		CA 2094332 A	02-11-1993
		JP 6049058 A	22-02-1994